CN1114834A - Quinoxaline derivative as antidiabetic agent - Google Patents

Quinoxaline derivative as antidiabetic agent Download PDF

Info

Publication number
CN1114834A
CN1114834A CN94190719A CN94190719A CN1114834A CN 1114834 A CN1114834 A CN 1114834A CN 94190719 A CN94190719 A CN 94190719A CN 94190719 A CN94190719 A CN 94190719A CN 1114834 A CN1114834 A CN 1114834A
Authority
CN
China
Prior art keywords
group
lower alkyl
substituted
optionally
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94190719A
Other languages
Chinese (zh)
Inventor
小松真
佐藤英昭
平良伸一
三宅将仁
曲田清彦
吉田英浩
植山笃则
西孝夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN1114834A publication Critical patent/CN1114834A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Quinoxaline derivatives of following formula, and salts thereof, which have excellent antidiabetic activity, and an antidiabetic agent comprising as an active ingredient the quinoxaline derivative or a pharmaceutically acceptable salt thereof.

Description

Antidiabetic agent
Technical Field
The present invention relates to antidiabetic agents.
Background
Different quinoxaline derivatives are known. For example, BE-764998 (JP- ｃA-46-4377) discloses the following sulfonylureas as hypoglycemic agents:wherein R is a group of the formula:
Figure A9419071900432
R2alkyl, alkenyl, cycloalkyl, and the like. The compounds are similar to the compounds of the present invention in basic structure and pharmacological activity, but are different from the compounds of the present invention in that a substituent on the benzene ring, i.e., a substituent-CONR at the 2-position of quinoxaline3R4。
DD-273254-A discloses the process for the selective reduction of quinoxaline-di-N-oxide derivatives of the formula to the corresponding N-4-monooxides, the products being useful as medicamentsAnd intermediates of pesticides:wherein R is1H, Cl, methyl or methoxy;
R2is OH, alkoxy or β -hydroxyethylamino.
DT-2410852(═ JP-A-50-29583) discloses N-tetrazolyl-quinoxaline-2-carboxamides of the formulｃA which are useful in the treatment of asthmｃA, hay fever, urticariｃA, eczemｃA or atopic dermatitis,
Figure A9419071900442
wherein A is-N ═ CR2-etc. R2Is H, halogen, alkyl, OR3、NR4R5Etc. R6And R7Is H, halogen, alkyl, OR3、NR4R5And the like.
EP-23785 discloses substituted alkoxy-phenoxy-quinoxalines of the formula:
Figure A9419071900443
wherein A, B, D, E, J, U and V are hydrogen, halogen, nitro, CN, amino, mono-or di-substituted amino, alkyl, alkoxy, carbamoyl, etc.;
y and X are O or S;
R1and R2H, alkyl, alkenyl, etc.; and
w is CN, CSNH2And the like. EP-26622 also discloses a similar quinoxalinyl-amino-phenoxyalkanoic acid compound useful as a pre-and post-emergent selective herbicide.
Substituted 2-quinoxaline carboxamides of the formula:wherein R is H or methyl, n is 0 or an integer of 1 to 4, and l and m are 0 or 1, but the pharmacological activity of these compounds is not mentioned.
Chem. eng.data, volume 29, phase 2, page 229-231 (1984) disclose quinoxaline compounds of the formula:wherein l and m are 0 or 1, and R is 2-imidazolyl, 3-indolyl, etc.
DD-284585-A discloses quinoxaline-1, 4-di-N-oxides of the formula which are useful as medicinal feeds for the prevention and treatment of stomach and bowel diseases in piglets:
Figure A9419071900461
wherein R is1Is H or optionally substituted alkyl, R2Is H, optionally substituted alkyl, or hydroxyethylcarbamoyl.
BE-721725 discloses 3-carboxamido (carboxamido) quinoxaline-di-N- (1, 4) -oxides of the formula:
Figure A9419071900462
wherein R is1Is H, alkyl, alkoxy or Cl; r2And R3Is H, optionally substituted alkyl, or may also form a 5-or 6-membered heterocyclic ring with N; x is O or S: r4Is optionally substituted alkyl or optionally substituted phenyl. Analogous compounds are also found in many documents, for example BE-721726, BE-721728, BE-738246, BE-742970, DT-2012743, NL-7305048, BE-846532, GB-1308370, JP-B-46-23264, JP-B-45-24988 and JP-B-45-24989.
NL-7206031 discloses 2-formyl-3-carbamoyl-quinoxaline-1, 4-dioxides of the formula:
Figure A9419071900471
wherein R is1And R2Is H, an optionally substituted aliphatic or cycloaliphatic radical, or forms an optionally O-or S-containing 5-to 7-membered ring, Z is NOH or NNHC (Y) R3. Analogous compounds are also found in many documents, such as BE-856771, DT-2639429, DT-2656783, EP-1618, EP-73390, DE-3230273-A, BE-824065, DT-2501492, BE-828745, US-3948911, US-4039540, DD-268127, DD-268942-A, JP-A-62-120371, JP-A-62-123178, EP-288628-A, JP-A-60-120815, BE-856771 and BE-753582.
DE-3324908-A discloses 2- (N- (2-hydroxyethyl) carbamoyl) -3-methylquinoxaline-1, 4-di-N-oxides of the formula:
Figure A9419071900472
it can be used as an animal growth promoter. Similar compounds can be found in many documents, e.g. EP-142093-A, DT-2907174, JP-A-50-082217, GB-2038824, JP-A-62-174061 and JP-A-62-149670.
NL-7206601 discloses 2, 3-disubstituted quinoxaline-1, 4-dioxides of the formula:
Figure A9419071900481
wherein R is1Is substituted by alkyl, alkoxy, halogen or CF3Optionally substituted phenyl, R2is-CONR3R4Wherein R is3And R4Are H or alkyl, or together form an alkylene group optionally containing O, S, N heteroatoms, which are useful as fungicides and deformatocides. Similar compounds can also BE found in BE-763377, DT-2228802 and BE-904482.
EP-12725 discloses quinoxaline-di-N-oxides of the formula which are useful as broad spectrum microbicides, particularly in veterinary medicine and animal growth promoters:
Figure A9419071900482
wherein R is1Is H or alkyl; r2And R3Is alkyl or NR2R3Form a substituted alkyl groupSubstituted heterocycle of 4-5 carbons, R4Is H, methoxy, methylthio, OH, F, Cl, Br or CN, and similar compounds can also be found in DT-2701707.
CH-619456 discloses 6-thiophenyl-quinoxaline-1, 4-dioxide derivatives of the formula useful as animal growth promoters:wherein one of A and B is methyl and the other is-CONHCH2CH2And (5) OH. Similar compounds can be found in CH-619457 and CH-630908.
DT-2052359 discloses quinoxaline-1, 4-dioxides of the formula:
Figure A9419071900492
wherein R is1And R2Each H, alkyl or alkoxy, or together form methylenedioxy; r3Is H, an optionally unsaturated aliphatic group (optionally substituted with CN, COOH, carbamoyl, alkylamino, etc.), 5-orA 6-membered cycloaliphatic (optionally substituted with alkyl), aralkyl or furfuryl group; r4Is H, or NR3R4Is optionally unsaturated and optionally substituted by alkylA 5-or 6-membered heterocyclic ring; r5Is an optionally substituted and optionally unsaturated aliphatic, cycloaliphatic, araliphatic or heterocyclic radical. Similar compounds can be found in DT-2052279.
DT-2120501 discloses 3-substituted quinoxaline-2-carboxamido-1, 4-dioxides of the formula which are useful as broad-spectrum antibacterial agents, growth promoters, in particular for pigs and poultry:
Figure A9419071900501
wherein X is H, methyl, methoxy, CF3F, Cl or Br; y is alkylthio, alkylsulfinyl or alkylsulfonyl; r' is H or alkyl; r' is H or alkyl optionally substituted with amino, alkylamino, dialkylamino, pyrrolidino, piperidino, and the like. Analogous compounds are found in BE-764088, BE-773396 and DT-2212932.
US-3185688 discloses quinoxaline derivatives of the formula:wherein Z is NR (CH)2)nNR1R2、NR(CH2) nO alkyl, NR (CH)2) -nS alkyl; x and R are H or alkyl; r1And R2Is alkyl, or NR1R2Morpholino, piperidino, pyrrolidino; n is 2 to 4. Similar compounds can also be found in US-3192212And FR-2211006.
Specification
The antidiabetic agent of the present invention comprises at least one quinoxaline derivative of the formula (1) or a salt thereof as an active ingredient:
Figure A9419071900511
wherein R is1Is hydrogen atom, halogen atom, lower alkyl, lower alkoxy, optionally having lower alkyl
Amino group as a substituent or amino group optionally having a lower alkyl substituentA carbonyl group; r2Is hydrogen atom, lower alkyl optionally having halogen substituent, phenyl, morpholinyl
Lower alkyl or imidazolyl-substituted lower alkyl of (a); n and m are each 0 or 1; r is 1 or 2; r3And R4Which may be the same or different, are each a) a hydrogen atom, b) a lower alkyl group; c)
phenyl-lower alkoxycarbonyl, d) lower alkanoyloxy-substituted lower alkyl, e) lower
A lower alkanoyl group; f) lower alkoxycarbonyl, g) lower alkoxy-lower alkyl, h)
Phenoxycarbonyl, i) lower alkanoyl substituted lower alkyl, j) lower alkoxycarbonyloxy
Substituted lower alkyl, k) benzoyl optionally containing halogen substituents on the phenyl ring
Lower alkyl substituted by radicals, l) formula-E-N (R)52)(R53) A group of (1), whereinR52And R53Identical or different, are each a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl group or a phenyl group, or R52And R53A5-or 6-membered saturated heterocyclic group which may be interrupted with or without additional nitrogen or oxygen atoms, together with the nitrogen atom to which they are attached, E is lower alkylene, A group of formulA-CO-or A group of formulA-CO-A (wherein A is lower alkylene), m) A group of formulA:
Figure A9419071900521
whereinR is54Is a hydrogen atom or a lower alkyl group, A is as defined above, n) a group of the formula,
Figure A9419071900522
wherein A is as defined above;
p is an integer of 1 to 3;
R5is hydrogen atom, lower alkoxy substituted by lower alkoxy, lower alkoxy,
Amino optionally having a lower alkyl substituent, halogen atom, nitro, hydroxyl,
Optionally substituted by lower alkyl, lower alkenyloxy, carboxyl
Lower alkoxy, lower alkoxy substituted by lower alkoxycarbonyl, lower alkoxycarbonyl-,
lower alkoxy substituted by halogen, lower alkoxy substituted by hydroxy, in the phenyl moiety
Optionally substituted by a substituent selected from the group consisting of lower alkyl and lower alkoxy
Oxy, 1, 3-dioxolanyl optionally having lower alkyl substituent, lower alkyl
Acyl, lower alkoxy substituted by morpholinyl, lower alkyl substituted by morpholinyl, and morpholine
A quinolinylcarbonyl group or of the formula-Y-A1-CONR6R7Group (wherein A)1Is a lower alkylene
Y is a group of formula-O-or of formula-NH-, R6And R7Is the same as or
Different from each other, each is a hydrogen atom, a lower alkyl group optionally having a hydroxy substituent, or a salt thereof
Phenyl-lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, furol
Lower alkyl substituted with furyl or lower alkyl substituted with lower alkoxy, or R6
And R7With or without additional formation together with the adjacent nitrogen atom to which they are attached
5-or 6-membered saturated heterocyclic group having nitrogen atom or oxygen atom inserted therein, said heterocyclic group
Optionally having 1-3 substituents selected from hydroxy, lower alkyl and phenyl-lower alkyl
And (b)) o) phenyl-lower alkenyl, which optionally contains in its phenyl moiety a group selected from
The substituent (b): lower alkoxy, halogen, optionally with a substituent selected from lower alkanoyl
And phenyl-lower alkenylcarbonyl-substituted amino, lower alkoxy
Tetrazole of lower alkoxy, optionally containing lower alkyl substituents on the tetrazole moiety
A radical, A hydroxyl radical, of the formulA-O-A4-CO-NR40R41A group of (wherein A)4Is composed of
Lower alkylene, R40And R41Identical or different, each being a hydrogen atom or lower
Lower alkyl, or R40And R41Together with the adjacent nitrogen atom to which they are attached
With or without additional nitrogen or oxygen atoms inserted in 5-or 6-membered saturated
Heterocyclyl), lower alkenyloxy, nitro and optionally halogen-containing substituents
A lower alkyl group; p) an alkenyl group; q) cycloalkyl-lower alkyl; r) naphthyl-lower alkyl; s) lower alkyl substituted by phenylthio, optionally having lower alkoxy in the phenyl moiety
A substituent group; t) Phenylsulfinyl-substituted lower alkyl optionally having lower in the phenyl moiety thereof
An alkoxy substituent; u) phenylsulfonyl-substituted lower alkyl optionally having lower alkyl in the phenyl moiety thereof
An oxy substituent; v) phenoxy-substituted lower alkyl; w) a group of the formula:wherein q is an integer of 1 to 3, formula
Figure A9419071900542
Is lower alkyl which is substituted by a 5-to 14-membered saturated or unsaturated heteromonocyclic, heterobicyclic or heterotricyclic group containing 1 to 4 heteroatoms selected from N, O and S, R8Substituted on the above heterocyclic group and is hydrogen atom, oxo (oxo group), lower alkyl optionally having a hydroxy substituent, halogen atom, nitro group, lower alkoxy, cyano group, lower alkoxycarbonyl, phenyl-lower alkoxy optionally having an amino substituent on the phenyl moiety, lower alkoxy substituted by carboxyl, lower alkoxy substituted by lower alkoxycarbonyl, hydroxy, lower alkoxy substituted by lower alkoxy, lower alkenyloxy, lower alkyl substituted by lower alkanoyloxy, lower alkyl substituted by halogen, lower alkanoyl,or optionally having on the phenyl moiety a substituent selected from the group consisting of lower alkyl,Lower alkoxy substituted with lower alkoxy, hydroxy, a halogen atom, and lower alkoxy, or lower alkenyl, morpholinylcarbonyl-lower alkoxy, lower alkylsulfinyl, lower alkyl substituted with amino optionally substituted with a substituent selected from the group consisting of lower alkylsulfonyl and lower alkanoyl, lower alkylthio, lower alkylsulfonyl, lower alkanoyloxy, lower alkyl substituted with 1, 3-dioxolanyl optionally having lower alkyl substituent, lower alkyl substituted with lower alkanoyl, lower alkyl substituted with aminocarbonyl optionally having lower alkyl substituent, lower alkenyl substituted with lower alkoxycarbonyl, lower alkenyl substituted with aminocarbonyl optionally having lower alkyl substituent, lower alkenyl substituted with carboxy, lower alkenyl substituted with benzoyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl, lower alkoxy-, lower alkoxycarbonyl-, lower alkoxy-, lower alkoxycarbonyl-, or a combination thereof, A radical of the formula(wherein s is an integer of 1 to 3, formulaThe radical being a 5-or 6-membered saturated or unsaturated heterocyclic radical containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, R45A lower alkyl group, a lower alkoxy-substituted lower alkyl group, a phenyl group or an oxo group) bonded to the heterocyclic group, a group of the formula
(wherein t is an integer of 1 to 3, formula
Figure A9419071900561
The radicals being 1 to
5-to 6-membered saturated or unsaturated with 4 heteroatoms selected from N, O and S
Lower alkyl substituted by heterocyclic radical, R46Bonded to said heterocyclic radical and being hydrogen atom
Lower alkyl or oxo), or of the formula- (C ═ O)1NR9R10Group (it)
Wherein l is 0 or 1, R9And R10Are different or the same and are each a hydrogen atom,
Lower alkanoyl, lower alkyl, morpholinylcarbonyl-lower alkyl, cycloalkylcarbonyl,
Phenyl-lower alkenylcarbonyl, lower alkylsulfonyl, optionally with lower alkyl
Substituted aminocarbonyl, benzene optionally having lower alkyl substituents in the phenyl moiety
Phenylsulfonyl, phenyl-lower alkenyl, or each optionally containing in the phenyl moiety
Having 1 to 3 substituents selected from halogen atoms, lower alkoxy groups, optionally having lower alkanoyl substituents
Benzoyl groups being substituents of the amino and hydroxy radicals of the substituent, or each being optionally substituted by a group
Lower alkanoyl substituted with amino of lower alkanoyl substituent, optionally with lower alkane
Amino-substituted sulphonyl, phenyl-lower alkyl, phenyl or optionally substituted sulphonyl
Amino having a lower alkanoyl substituent, or R9And R10To and by bonding with them
With or without interposition of other nitrogen or oxygen atoms, formed together with adjacent nitrogen atoms
A 5-or 6-membered saturated heterocyclic group)); x) formula-A5-CR42R43R44A group of (wherein A)5Is lower alkylene,
R42And R43Together form a group of the formula ═ O or ═ N-OH or lower alkylenedioxy
Radical, R44Is phenyl optionally containing lower alkoxy substituents on the phenyl moiety); y)2, 3-dihydro-1H-indenyl-substituted lower alkyl in 2, 3-bis
hydrogen-1H-indenyl ring optionally having an oxo group, hydroxy group or having a lower alkyl group
Siloxy for radical substituents; orz) a group of the formula
Figure A9419071900571
Wherein u is an integer of 1 to 3, formula
Figure A9419071900572
The group being lower alkenyl substituted by a 5-to 14-membered saturated or unsaturated heteromonocyclic, heterobicyclic or heterotricyclic group containing 1 to 4 heteroatoms selected from nitrogen, oxygen andsulfur, R47A lower alkyl group substituted with halogen, an oxo group, a halogen atom, a lower alkoxy group, a lower alkyl group, a lower alkoxycarbonyl group, a carboxyl group, an aminocarbonyl group optionally having a lower alkyl substituent, an amino group optionally having a lower alkanoyl substituent, a phenyl group optionally having a substituent selected from the group consisting of a lower alkoxy group and a halogen atom in the phenyl moiety, or a group of the formula:
(wherein、R45And s is as previously defined)); or R3And R4May form together with the adjacent nitrogen atom to which they are bonded a 1, 2, 3, 4-tetrahydroisoquinoline derivative
Quinolinyl, said heterocyclyl optionally containing lower alkoxy substituents.
The present invention also provides novel quinoxaline derivatives of the above formula (1) or salts thereof, wherein each symbol is as defined above, but wherein n is 0 and R is5Excluding hydrogen atoms, and further provided that when R is1Is a hydrogen atom, R2Is methyl, R3R is a hydrogen atom and m is 04Is not 2- (imidazol-2-yl) ethyl, 2- (indol-3-yl) ethyl or sec-butyl.
According to the definition of the disease by the World Health Organization (WHO), diabetes is caused by an absolute deficiency of insulin secretion and occurs in an acute or subacute manner, and includes insulin-dependent diabetes mellitus (IDDM) requiring treatment with insulin, non-insulin dependent diabetes mellitus (NIDDM) not always requiring insulin treatment, diabetes associated with malnutrition (MRDM), and other complications accompanying other diseases.
Among the above various glycourents, one of the causes of IDDM is considered to be destruction of pancreatic β -cells by the autoimmune system, it is considered that pancreatic β -cells can be destroyed by HLA antigens, cytokine viruses, etc. (refer to Koji NAKANISHI, Tetsuro KOBAYASHI, MitsuruHARA; Tonyobagaku (diabetes) 1989; Mikinori KOSAKA. Yasuoakanuma eds., Shindato Chiryo Sha, 1989, p. 226) whereas the cause of NIDDM is considered to be (i) congenital abnormality of pancreatic enzymes, i.e., abnormality in adaptability to increase in insulin consumption, or (ii) insulin activity disorder due to various factors such as aging, stress, obesity, etc. (HiroIMURA; Tonyobyogaku-Diego-shinpin Japan, Shisane.9, Shisanyo-19812).
However, the risk of diabetes is not simple but occurs in a complex situation involving, for example, genetic factors, environmental factors, etc., and the risk is still unclear.
From the tissues of NIDDM patients, the most important causes of hyperglycemia are thought to be a decrease in glucose uptake in the surrounding tissues, particularly muscle, and an increase in glucose secretion in the liver. To date, the most common medical treatments for diabetes have been treatment with insulin or sulfonylurea agents (agents that promote insulin secretion), both based on insulin supplementation, but these treatments have difficulty in tightly controlling blood glucose levels and sometimes lead to high insulin serum or hypoglycemia. Thus, a compound is considered which can, for example, promote the absorption of glucose in muscle without promoting insulin secretion. Then the compound will be a new hypoglycemic agent that will not cause hyperinsulinemia and hypoglycemia phenomena and will be useful in the treatment of diabetes.
The quinoxaline derivatives of the aforementioned formula (1) and their salts (hereinafter referred to as the compounds of the present invention) promote the absorption of 2-deoxyglucose (2DG) in L6 cells (rat striated muscle cell line (muscle cells)) and also promote the consumption of glucose, thereby exhibiting hypoglycemic activity. In particular, the compounds of the invention show hypoglycaemic activity in db/db mice and KK-Ay mice (both animals are animal models of diabetes, see L.Herberg, D.L.Coleman: Metabolism, Vol.26, stage 1 (Yuan-month), 1977, pages 59-99). The compounds of the present invention promote glucose absorption in muscle without affecting insulin secretion and glucose release in the liver, so that they do not exhibit acute hypoglycemic activity, nor do they affect oral glucose tolerance tests.
Therefore, the antidiabetic agent of the present invention is useful for treating diabetes and diabetic complications such as diabetic vascular disorder, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy and the like.
Each group in the above formula (1) specifically means the following group.
The lower alkyl group includes a straight or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl, hexyl and the like.
The halogen atom is fluorine atom, chlorine atom, bromine atom or iodine atom.
The lower alkyl group optionally having halogen substituents includes, for example, a straight-chain or branched alkyl group of 1 to 6 carbon atoms optionally having 1 to 3 halogen substituents, such as trifluoromethyl, trichloromethyl, chloromethyl, bromomethyl, fluoromethyl, iodomethyl, difluoromethyl, dibromomethyl, 2-chloro-ethyl, 2, 2, 2-trifluoroethyl, 2, 2, 2-trichloroethyl, 3-chloropropyl, 2, 3-dichloropropyl, 4, 4, 4-trichlorobutyl, 4-fluorobutyl, 5-chloropentyl, 3-chloro-2-methylpropyl, 5-bromohexyl, 5, 6-dichlorohexyl and the like, in addition to the above-mentioned lower alkyl groups.
Morpholinyl-substituted lower alkyl includes morpholinyl-substituted alkyl wherein the alkyl moiety is a straight or branched chain alkyl containing 1 to 6 carbon atoms, such as morpholinomethyl, 2-morpholinoethyl, 1-morpholinoethyl, 3- (2-morpholinyl) propyl, 4- (3-morpholinyl) butyl, 1-dimethyl-2- (2-morpholinyl) ethyl, 5-morpholinopentyl, 6-morpholinohexyl, 2-methyl-3-morpholinopropyl, and the like.
The imidazolyl-substituted lower alkyl group includes imidazolyl-substituted alkyl groups in which the alkyl moiety is a straight-chain or branched alkyl group having 1 to 6 carbon atoms, such as (1-imidazolyl) methyl, 2- (1-imidazolyl) ethyl, 1- (2-imidazolyl) ethyl, 3- (4-imidazolyl) propyl, 4- (5-imidazolyl) butyl, 1-dimethyl-2- (2-imidazolyl) ethyl, 5- (4-imidazolyl) pentyl, 6- (1-imidazolyl) hexyl, 2-methyl-3- (1-imidazolyl) propyl, and the like.
The lower alkylene group includes a linear or branched alkylene group having 1 to 6 carbon atoms, such as methylene, ethylene, 1, 3-propylene, 2-methyl-1, 3-propylene, 2-dimethyl-1, 3-propylene, 1-methyl-1, 3-propylene, methylmethylene, ethylmethylene, 1, 4-butylene, 1, 5-pentylene, 1, 6-hexylene, and the like.
Lower alkoxy includes straight or branched chain alkoxy groups containing 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy.
The amino group optionally substituted with a lower alkyl group includes amino groups which may be optionally substituted with 1 to 2 straight-chain or branched-chain alkyl substituents having 1 to 6 carbon atoms, such as amino, methylamino, ethylamino, propylamino, isopropylamino, butylamino, tert-butylamino, pentylamino, hexylamino, dimethylamino, diethylamino, dipropylamino, dibutylamino, dipentylamino, dihexylamino, N-methyl-N-ethylamino, N-ethyl-N-propylamino, N-methyl-N-butylamino, N-methyl-N-hexylamino and the like.
Lower alkyl optionally having hydroxyl substituent(s) includes straight or branched chain alkyl of 1 to 6 carbon atoms optionally having 1 to 3 hydroxyl substituents, for example, hydroxymethyl, 2-hydroxyethyl, 1-hydroxyisopropyl, 3-hydroxypropyl, 2, 3-dihydroxypropyl, 4-hydroxybutyl, 1-dimethyl-2-hydroxyethyl, 5, 4-trihydroxypentyl, 5-hydroxypentyl, 6-hydroxyhexyl, 2-methyl-3-hydroxypropyl, 2, 3-dihydroxyethyl, 3, 4-dihydroxybutyl, 5, 6-dihydroxyhexyl and the like.
The lower alkenyloxy group includes straight-chain or branched alkenyloxy groups having 2 to 6 carbon atoms, such as allyloxy, 2-butenyloxy, 3-butenyloxy, 1-methylallyloxy, 2-pentenyloxy, 2-hexenyloxy and the like.
The lower alkoxy group substituted with a carboxyl group includes a carboxyalkoxy group in which the alkoxy moiety is a linear or branched alkoxy group having 1 to 6 carbon atoms, such as carboxymethoxy group, 2-carboxyethoxy group, 1-carboxyethoxy group, 3-carboxypropoxy group, 4-carboxybutoxy group, 5-carboxypentyloxy group, 6-carboxyhexyloxy group, 1-dimethyl-2-carboxyethoxy group, 2-methyl-3-carboxypropoxy group and the like.
Lower alkoxy substituted by lower alkoxycarbonyl includes straight-chain or branched alkoxy having 1 to 6 carbon atoms substituted by straight-chain or branched alkoxycarbonyl having 1 to 6 carbon atoms in the alkoxy moiety, such as methoxycarbonylmethoxy, 3-methoxycarbonylpropoxy, ethoxycarbonylmethoxy, 3-ethoxycarbonylpropoxy, 4-ethoxycarbonylbutoxy, 5-isopropoxycarbonylpentoxy, 6-propoxycarbonylhexyloxy, 1-dimethyl-2-butoxycarbonylethoxy, 2-methyl-3-tert-butoxycarbonylpropoxy, 2-pentoxycarbonylethoxy, hexyloxycarbonylmethoxy and the like.
The lower alkoxycarbonyl group includes a straight or branched alkoxycarbonyl group having 1 to 6 carbon atoms in the alkoxy moiety, such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl and the like.
Halogen-substituted lower alkoxy includes straight-chain or branched alkoxy groups of 1 to 6 carbon atoms having 1 to 3 halogen substituents, such as trifluoromethoxy, trichloromethoxy, chloromethoxy, bromomethoxy, fluoromethoxy, iodomethoxy, difluoromethoxy, dibromomethoxy, 2-chloroethoxy, 2, 2, 2-trifluoroethoxy, 2, 2, 2-trichloroethoxy, 3-chloropropoxy, 2, 3-dichloropropoxy, 4, 4, 4-trichlorobutoxy, 4-fluorobutoxy, 5-chloropentyloxy, 3-chloro-2-methylpropoxy, 5-bromohexyloxy, 5, 6-dichlorohexyloxy and the like.
The lower alkoxy group substituted with a hydroxyl group includes a straight or branched alkoxy group having 1 to 6 carbon atoms substituted with 1 to 3 hydroxyl groups, such as a hydroxymethoxy group, a 2-hydroxyethoxy group, a 1-hydroxypropoxy group, a 3-hydroxypropoxy group, a 2, 3-dihydroxypropoxy group, a 4-hydroxybutoxy group, a 1, 1-dimethyl-2-hydroxyethoxy group, a 5, 5, 4-trihydroxypentyloxy group, a 5-hydroxypentyloxy group, a 6-hydroxyhexyloxy group, a 1-hydroxyisopropoxy group, a 2-methyl-3-hydroxypropoxy group, a 2, 3-dihydroxyethoxy group, a 3, 4-dihydroxybutyloxy group, a 5, 6-dihydroxyhexyloxy group and the like.
Phenyl-lower alkoxy optionally having substituents selected from lower alkyl and lower alkoxy in the phenyl moiety includes phenylalkoxy in which the alkoxy moiety is a straight or branched alkoxy having 1 to 6 carbon atoms, said phenyl-lower alkoxy optionally having 1 to 3 substituents selected from straight or branched alkyl having 1 to 6 carbon atoms and straight or branched alkoxy having 1 to 6 carbon atoms in the phenyl moiety, and examples of such phenyl-lower alkoxy are: benzyloxy, 2-phenethyloxy, 1-phenethyloxy, 3-phenylpropyloxy, 4-phenylbutoxy, 1-dimethyl-2-phenylethoxy, 5-phenylpentyloxy,6-phenylhexyloxy, 2-methyl-3-phenylpropyloxy, 2- (3-methoxyphenyl) ethoxy, 1- (4-methoxyphenyl) ethoxy, 2-methoxybenzyloxy, 3- (2-ethoxyphenyl) propoxy, 4- (3-ethoxyphenyl) butoxy, 1-dimethyl-2- (4-ethoxyphenyl) ethoxy, 5- (4-isopropoxyphenyl) pentyloxy, 6- (4-hexyloxyphenyl) hexyloxy, 3, 4-dimethoxybenzyloxy, benzyoxyethoxy, benzyoxy, 2-methoxy-2-ethoxy, 2-methyl-3-phenylpropyloxy, 2- (3, 3, 4, 5-trimethoxybenzyloxy group, 2, 5-dimethoxybenzyloxy group, 3-methoxybenzyloxy group, 4-methoxybenzyloxy group, 2, 4-diethoxybenzyloxy group, 2, 3-dimethoxybenzyloxy group, 2, 4-dimethoxybenzyloxy group, 2, 6-dimethoxybenzyloxy group, 2-methylbenzyloxy group, 4-ethylbenzyloxy group, 2- (3-tolyl) ethoxy group, 1- (4-tolyl) ethoxy group, 3- (2-ethylphenyl) propoxy group, 4- (3-ethylphenyl) butoxy group, 1-dimethyl-2- (4-ethylphenyl) ethoxy group, 5- (4-isopropylphenyl) pentyloxy group, 6- (4-hexylphenyl) hexyloxy group, p-hexyloxy, 3, 4-dimethylbenzyloxy, 3, 4, 5-trimethylbenzyloxy, 2, 5-dimethylbenzyloxy, 2-methoxy-3-methylbenzyloxy, and the like.
The 1, 3-dioxolanyl group optionally having a lower alkyl substituent includes a 1, 3-dioxolanyl group which may be optionally substituted with 1 to 3 straight-chain or branched alkyl groups having 1 to 6 carbon atoms, for example, 1, 3-dioxolanyl group, 2-methyl-1, 3-dioxolanyl group, 4-ethyl-1, 3-dioxolanyl group, 2-propyl-1, 3-dioxolanyl group, 4-butyl-1, 3-dioxolanyl group, 2-pentyl-1, 3-dioxolanyl group, 4-hexyl-1, 3-dioxolanyl group, 2, 4-dimethyl-1, 3-dioxolanyl group, 2, 4, 5-trimethyl-1, 3-dioxolanyl group and the like.
The lower alkanoyl group includes straight or branched alkanoyl groups having 1 to 6 carbon atoms, such as formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, tert-butylcarbonyl, hexanoyl and the like.
Morpholinyl-substituted lower alkoxy includes morpholinyl-substituted alkoxy in which the alkoxy moiety is a straight or branched chain alkoxy group containing 1 to 6 carbon atoms, such as morpholinomethoxy, 2-morpholinoethoxy, 1-morpholinoethoxy, 3- (2-morpholinyl) propoxy, 4- (3-morpholinyl) butoxy, 1-dimethyl-2- (2-morpholinyl) ethoxy, 5-morpholinopentyloxy, 6-morpholinohexyloxy, 2-methyl-3-morpholinopropoxy and the like.
Phenyl-lower alkyl includes phenyl-alkyl wherein the alkyl moiety is a linear or branched alkyl of 1 to 6 carbon atoms, such as benzyl, 2-phenylethyl, 1-phenylethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, 6-phenylhexyl, 1-dimethyl-2-phenylethyl, 2-methyl-3-phenylpropyl, and the like.
Examples of phenyl-lower alkyl groups which include phenyl-lower alkyl groups wherein the phenyl moiety optionally has a lower alkoxy substituent, the alkyl moiety of which is a straight-chain or branched alkyl group having 1 to 6 carbon atoms, and which may optionally have 1 to 3 straight-chain or branched alkoxy substituents having 1 to 6 carbon atoms in the phenyl moiety include, in addition to the above-mentioned phenyl-lower alkyl groups, 2- (3-methoxyphenyl) ethyl, 1- (4-methoxyphenyl) ethyl, 2-methoxybenzyl, 3-methoxybenzyl, 4-methoxybenzyl, 3- (2-ethoxyphenyl) propyl, 4- (3-ethoxyphenyl) butyl, 1-dimethyl-2- (4-ethoxyphenyl) ethyl, 5- (4-isopropoxyphenyl) pentyl, 6- (4-hexyloxyphenyl) hexyl, 3, 4-dimethoxybenzyl, 2, 4-dimethoxybenzyl, 3, 4, 5-trimethoxybenzyl and the like.
Furyl-substituted lower alkyl groups include furyl-substituted alkyl groups in which the alkyl moiety is a linear or branched alkyl group having 1 to 6 carbon atoms, such as (2-furyl) methyl group, 2- (3-furyl) ethyl group, 1- (2-furyl) ethyl group, 3- (2-furyl) propyl group, 4- (3-furyl) butyl group, 5- (2-furyl) pentyl group, 6- (3-furyl) hexyl group, 1-dimethyl-2- (2-furyl) ethyl group, 2-methyl-3- (3-furyl) propyl group, and the like.
Lower alkoxy-lower alkyl includes straight or branched chain alkyl groups of 1 to 6 carbon atoms substituted with straight or branched chain alkoxy groups of 1 to 6 carbon atoms, such as methoxymethyl, 2-ethoxyethyl, 1-methoxyethyl, 3-methoxypropyl, 4-ethoxybutyl, 6-propoxyhexyl, 5-isopropoxypentyl, 1-dimethyl-2-butoxyethyl, 2-methyl-3-tert-butoxypropyl, 2-pentoxyethyl, hexyloxymethyl and the like.
Optionally having in the phenyl moiety A substituent selected from the group consisting of lower alkoxy, halogen atom, amino optionally having A substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having A lower alkyl substituent on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41(A4、R40And R41A group as defined above), lower alkenyloxy group, nitro group and lower alkyl group optionally containing halogen substituent) includes phenylalkenyl groups in which the alkenyl moiety is a straight-chain or branched alkenyl group having 2 to 6 carbon atoms and having 1 to 2 double bonds, and the phenyl moiety may be optionally substituted with 1 to 3 substituents selected from the group consisting of the following. The substituents are: a linear or branched alkoxy group having 1 to 6 carbon atoms; a halogen atom; (ii) amino optionally having 1 to 2 substituents selected from the group consisting of a straight or branched chain alkanoyl group having 1 to 6 carbon atoms and a phenylalkenylcarbonyl group in which the alkenylcarbonyl moiety is a straight or branched chain alkenylcarbonyl group having 3 to 6 carbon atoms in the alkenylcarbonyl moiety; a linear or branched alkoxy group having 1 to 6 carbon atoms substituted with a linear or branched alkoxy group having 1 to 6 carbon atoms; tetrazolyl optionally containing a linear or branched alkyl group having 1 to 6 carbon atoms on the tetrazole ring; a hydroxyl group; formulA-O-A4-CO-NR40R41Group (A)4Is a linear or branched alkylene radical having from 1 to 6 carbon atoms, R40And R41Identical or different and are each a hydrogen atom or a linear or branched alkyl group having from 1 to 6 carbon atoms, or R40And R41And bondable theretoAdjacent nitrogen atoms together form a 5-or 6-membered saturated heterocyclic ring with or without the interposition of other nitrogen atoms or oxygen atoms); a linear or branched alkenyloxy group containing 2 to 6 carbon atoms; a nitro group; straight or branched chain alkyl containing 1 to 6 carbon atoms and optionally containing 1 to 3 halogen substituents. Of the typeExamples of phenyl-lower alkenyl groups are styryl, cinnamyl, 4-phenyl-3-butenyl, 4-phenyl-2-butenyl, 5-phenyl-4-pentenyl, 5-phenyl-3-pentenyl, 5-phenyl-2-pentenyl, 6-phenyl-5-hexenyl, 6-phenyl-4-hexenyl, 6-phenyl-3-hexenyl, 6-phenyl-2-hexenyl, β -methyl-4-phenyl-3-butenyl, β -methyl-cinnamyl, γ -methyl-cinnamyl, 5-phenyl-2, 4-pentadienyl, 4-phenyl-1, 3-butadienyl, 6-phenyl-2, 4-hexadienyl, 6-phenyl-3, 5-hexadienyl, 6-phenyl-1, 3-hexadienyl, 5-phenyl-1, 3-pentadienyl, 3-methoxycinnamyl, 4-methoxy-cinnamyl, 2-methoxy-3-cinnamyl, 4-methoxy-3-hexenyl, 4-phenyl-3, 5-hexadienyl, 6-phenyl-1, 3-hexadienyl, 3-ethoxyphenyl-3-cinnamyl, 3-methoxycinnamyl, 3-nitro-3-methoxy-3, 3-methoxy-3, 6-dimethyl-3, 6-3, 3-methoxy-3, 3-dimethyl-3, 3-3, 3-methoxy-3, 3-methoxy-ethoxy, 3-3, 3-dimethyl-3, 3-dimethyl-3, 3-3, 3-dimethyl-3, 3-3, 3-3, 3-3, 3-methoxy-ethoxy, 3-3, 3-3, 3-dimethyl-3, 3-dimethyl-3, 3Cinnamyl, 3, 4, 5-trimethyl cinnamyl, 2, 5-dimethyl cinnamyl2-chlorocinnamyl, 3-chlorostyryl, 2-fluorocinnamyl, 4-chlorocinnamyl, 2-fluorostyryl, 4- (3-fluorophenyl) -2-butenyl, 5- (4-fluorophenyl) -2-pentenyl, α -dimethyl-2-bromocinnamyl, 6- (3-bromophenyl) -2-hexenyl, 4-bromostyryl, 2-iodocinnamyl, 3, 4-dichlorocinnamyl, 3, 5-dichlorocinnamyl, 2, 6-dichlorocinnamyl, 2, 3-dichlorocinnamyl, 2, 4-dichlorostyryl, 3, 4-difluorocinnamyl, 3, 5-dibromocinnamyl, 3, 4, 5-trichlorocinnamyl, 2-methoxy-3-chlorocinnamyl, 3- (4-acetamidophenyl) -2-butenyl, 3- (2-trifluoromethylphenyl) -2-butenyl, 3- [4- (1-methyltetrazol-5-yl) phenyltetrazol-5-yl]-2-butenyl, 3- (4-cinnamoylaminophenyl) -2-butenyl, 3- (3-methoxymethylphenyl) -2-butenyl, 3- (2-methoxyphenyl) -2-butenyl, 3- (3-methoxyphenyl) -2-butenyl, 3- (4-trifluoromethylphenyl) -2-butenyl, 3- (3-acetamidophenyl) -2-butenyl, 3- (3-hydroxyphenyl) -2-butenyl, 3- (3-morpholinocarbonylmethoxyphenyl) -2-butenyl, 3- (3-diethylaminocarbonylmethoxyphenyl) 2-butenyl, and a salt thereof, 3- [3- (2-methyl-2-propenyloxy) phenyl]-2-butenyl, 4-chloromethylstyryl, 3-bromomethylcinnamyl, 4- (2-iodomethylphenyl) -3-butenyl, 4- [4- (2, 2, 2-trichloroethyl) phenyl) -2-butenyl, 5- (4-aminophenyl) -4-pentenyl, 5- (3-propionylaminophenyl) -2-pentenyl, 6- (2-butyrylaminophenyl) -5-hexenyl, 6- (4-valerylaminophenyl) -4-hexenyl, 6- (3-hexanoylaminophenyl) -3-hexenyl, 6- (2, 4-diaminophenyl) -2-hexenyl, methyl ethyl acetate, ethyl acetate, 2, 4, 6-triaminocinnamyl, 4- (3-butenamido) styryl, 3-(2-pentenoylamino) cinnamyl, 4- [2- (4-hexenoylamino) phenyl]-3-butenyl, 4- [4- (4-ethoxybutoxy) phenyl]-2-butenyl, 3- [4- (N-acetyl-N-cinnamoylamino) phenyl]-2-butenyl, 5- [2- (6-propoxyhexyloxy) phenyl]-4-pentenyl, 6- [3- (2-pentyloxyethoxy) phenyl]-2-pentenyl, 6- (4-hexyloxymethoxyphenyl) -5-hexenyl, 6- [2- (1, 1-dimethyl-2-butoxyethoxy) phenyl]-3-hexenyl, 3- (2, 4-dimethoxymethoxyphenyl) -2-butenyl, 3- (2, 4, 6-trimethoxyphenyl) -2-butenyl, 3- [4- (1-ethyl-phenyl)Tetrazol-5-yl) phenyl]-2-butenyl, 3- [3- (2-propyltetrazol-5-yl) phenyl]-2-butenyl, 3- [2- (1-butyltetrazol-5-yl) phenyl]-2-butenyl, 3- [4- (2-pentyltetrazol-5-yl) phenyl]-2-butenyl, 3- [3- (1-hexyltetrazol-5-yl) phenyl]-2-butenyl, 2-hydroxycinnamyl, 3-hydroxycinnamyl, 4- (2-hydroxyphenyl) -3-butenyl, 5- (2-hydroxyphenyl) -2-pentenyl, 6- (3-hydroxyphenyl) -3-hexenyl, 2, 4-dihydroxycinnamyl, 3, 4, 5-trihydroxycinnamyl, 4-hydroxycinnamyl, 4-allyloxystyryl, 3- (2-butenyloxy) cinnamyl, 4- [2- (3-butenyloxy) phenyl]-3-butenyl, 5- [3- (2-pentenyloxy) phenyl]-2-pentenyl, 6- [4- (2-hexenyloxy) phenyl]-4-hexenyl, 2, 4-diallyloxycinnamyl, 2, 4, 6-triallyloxystyrene, 3- (2-dimethylaminocarbonylethoxyphenyl) -2-butenyl, 4- [4- (3-butylaminocarbonylpropoxy) phenyl]-3-butenyl, 5- [2- (4-pentylaminocarbonylbutoxy) phenyl]-3-pentenyl, 6- [3- (5-hexanaminocarbonylpentyloxy) phenyl]-5-hexenyl, 4- [6- (N-methyl-N-propylamino) -carbonylRadical hexyloxy]Styryl, 4-methylaminocarbonylmethoxycinnamyl, 4- (1-piperidyl) carbonylmethoxycinnamyl, 3- (1-piperazinyl) carbonylmethoxystyryl, 4- [3- (1-pyrrolidinyl) carbonylmethoxyphenyl]-3-butenyl, 3- (2-methoxy-5-chlorophenyl) -2-butenyl, 3- (2-methoxymethoxy-5-chlorophenyl) -2-butenyl, 3- (2-hydroxy-5-chlorophenyl) -2-butenyl, and the like.
Alkenyl includes straight-chain or branched alkenyl having 1 to 3 double bonds and having 2 to 12 carbon atoms, such as vinyl, allyl, 3-methyl-2-butenyl, 3-butenyl, 1-methylallyl, 2-pentenyl, 2-hexenyl, 1-heptenyl, 1-octenyl, 1-nonenyl, 1-decenyl, 1-undecenyl, 2-dodecenyl, 2-heptenyl, 3-methyl-4-heptenyl, 2-methyl-5-heptenyl, 4-methyl-2-heptenyl, 3-methyl-1-heptenyl, 1, 3-heptadienyl, 1, 4-heptadienyl, 1-heptadienyl, 1, 5-heptadienyl, 1, 6-heptadienyl, 2, 4-heptadienyl, 2-methyl-2, 4-heptadienyl, 2, 6-dimethyl-2, 4-heptadienyl, 2, 5-dimethyl-1, 3-heptadienyl, 2, 4, 6-trimethyl-2, 4-heptadienyl, 2-octenyl, 3-octenyl, 4-octenyl, 2-methyl-5-octenyl, 3-methyl-6-octenyl, 2-methyl-7-octenyl, 1, 3-octadienyl, 1, 4-octadienyl, 1, 5-octadienyl, 1, 6-octadienyl, 1, 7-octadienyl, 2, 4-octadienyl, 3, 7-octadienyl, 4, 8-dimethyl-3, 7-octadienyl, 2, 4, 6-trimethyl-3, 7-octadienyl, 3, 4-dimethyl-2, 5-octadienyl, 3, 7-dimethyl-2, 6-octadienyl, 4, 8-dimethyl-2, 6-octadienyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 2-methyl-5-nonenyl, 2-methyl-6-nonenyl, 2-methyl-7-nonenyl, 2-methyl-8-nonenyl, 1, 3-nonenyl, 1, 4-nonenyl, 1, 5-nonenyl, 1, 6-nonadienyl, 1, 7-nonadienyl, 1, 8-nonadienyl, 2, 4-nonadienyl, 3, 7-nonadienyl, 4, 8-dimethyl-3, 7-nonadienyl, 2, 4, 6-trimethyl-3, 7-nonadienyl, 3, 4-dimethyl-2, 5-nonadienyl, 4, 8-dimethyl-2, 6-nonadienyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 2-methyl-6-decenyl, 3-methyl-7-decenyl, 4-methyl-8-decenyl, 5-methyl-9-decenyl, 1, 3-decadienyl, 1, 8-nonadienyl, 3, 7-nonadienyl, 4, 8-dimethyl-2, 5-nonadienyl, 4, 8-dimethyl-2, 6-dece, 1, 4-decadienyl, 1, 5-decadienyl, 1, 6-decadienyl, 1, 7-decadienyl, 1, 8-decadienyl, 1, 9-decadienyl, 2-methyl-2, 4-decadienyl, 3-methyl-2, 5-decadienyl, 4, 8-dimethyl-2, 6-decadienyl, 2, 4, 6-trimethyl-3, 7-decadienyl, 2, 9-dimethyl-3, 7-decadienyl, 2-undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 2-methyl-6-undecenyl, 3-methyl-7-undecenyl, 4-methyl-8-undecenyl, 5-methyl-9-undecenyl group, 2-methyl-10-undecenyl group, 1, 3-undecenyl group, 1, 4-undecenyl group, 1, 5-undecenyl group, 1, 6-undecenyl group, 1, 7-undecenyl group, 1, 8-undecenyl group, 1, 9-undecenyl group, 1, 10-undecenyl group, 2-methyl-2, 4-undecenyl group, 3-methyl-2, 5-undecenyl group, 4, 8-dimethyl-2, 6-undecenyl group, 2, 4, 6-trimethyl-3, 8-undecenyl group, 2, 9-dimethyl-3, 8-undecenyl group, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl, 2-methyl-7-dodecenyl, 3-methyl-8-dodecenyl, 4-methyl-9-dodecenyl, 5-methyl-10-dodecenyl, 6-methyl-11-dodecenyl, 2-methyl-2, 4-dodecenyl, 3-methyl-2, 5-dodecenyl, 4, 8-dimethyl-2, 6-dodecenyl, 2, 4, 6-trimethyl-2, 7-dodecenyl, 2, 10-dimethyl-2, 8-dodecenyl, 2, 4-dimethyl-2, 8-dodecenyl, 2, 5-dimethyl-3, 7-dodecadienyl, 4, 8, 12-trimethyl-3, 7, 11-dodecatrienyl, 1, 3, 5-heptatrienyl, 2, 4, 6-octatrienyl, 1, 3, 6-nonatrienyl, 2, 6, 8-dodecatrienyl, 1, 5, 7-undecadrienyl, and the like.
Cycloalkyl-lower alkyl includes straight-chain or branched alkyl groups of 1 to 6 carbon atoms substituted with cycloalkyl groups of 3 to 8 carbon atoms, and examples of such cycloalkyl-lower alkyl groups are cyclohexylmethyl, 2-cyclopropylethyl, 1-cyclobutylethyl, 3-cyclopentylpropyl, 4-cyclohexylbutyl, 2-dimethyl-3-cycloheptylpropyl, 5-cyclooctylpentyl, 6-cyclohexylhexyl and the like.
Naphthyl-lower alkyl includes naphthyl-alkyl in which the alkyl moiety is a straight or branched chain alkyl of 1 to 6 carbon atoms, such as α -naphthylmethyl, β -naphthylmethyl, 2- (α -naphthyl) ethyl, 1- (β -naphthyl) ethyl, 3- (β -naphthyl) propyl, 4- (α -naphthyl) butyl, 2-methyl-3- (α -naphthyl) propyl, 5- (β -naphthyl) pentyl, 6- (α -naphthyl) hexyl, 1-dimethyl-2- (β -naphthyl) ethyl, and the like.
Among the phenylthio-alkyl groups included in the phenylthio-substituted lower alkyl group optionally having a lower alkoxy substituent in the phenyl moiety, the alkyl moiety thereof is a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms, and the phenyl moiety thereof may optionally have 1 to 3 straight-chain or branched-chain alkoxy substituents having 1 to 3 carbon atoms, and examples of the phenylthio-substituted lower alkyl group are phenylthiomethyl, 2-phenylthioethyl, 1-phenylthioethyl, 3-phenylthiopropyl, 4-phenylthiobutyl, 5-phenylthiopentyl, 6-phenylthiohexyl, 1-dimethyl-2-phenylthioethyl, 2-methyl-3-phenylthiopropyl, (2-methoxyphenylthio) methyl, (3-methoxyphenylthio) methyl, 2- (4-methoxyphenylthio) ethyl, 1- (2-ethoxyphenylthio) ethyl group, 3- (4-isopropoxyphenylthio) propyl group, 4- (3-pentyloxyphenylthio) butyl group, 5- (4-hexyloxyphenylthio) pentyl group, 6- (2-butoxyphenylthio) hexyl group, (3, 4-dimethoxyphenylthio) methyl group, (3-ethoxy-4-methoxyphenylthio) methyl group, 2- (2, 3-dimethoxyphenylthio) ethyl group, 1- (2, 6-dimethoxyphenylthio) ethyl group, 2- (3, 4, 5-trimethoxyphenylthio) ethyl group and the like.
Among the phenylsulfinylalkyls included in a phenylsulfinylsubstituted lower alkyl group optionally having a lower alkoxy substituent onthe phenyl moiety, the alkyl moiety thereof is a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms, and the phenyl moiety may optionally have 1 to 3 straight-chain or branched-chain alkoxy substituents having 1 to 6 carbon atoms, such as phenylsulfinylmethyl, 2-phenylsulfinylethyl, 1-phenylsulfinylethyl, 3-phenylsulfinylpropyl, 4-phenylsulfinylbutyl, 5-phenylsulfinylpentyl, 6-phenylsulfinylhexyl, 1-dimethyl-2-phenylsulfinylethyl, α -methyl-3-phenylsulfinylpropyl, (2-methoxyphenylsulfinyl) methyl, (3-methoxyphenylsulfinyl) methyl, 2- (4-methoxyphenylsulfinyl) ethyl, 1- (2-ethoxyphenylsulfinyl) ethyl, 3- (4-isopropoxyphenylsulfinyl) propyl, 4- (3-pentyloxyphenylsulfinyl) butyl, 5- (4-hexyloxyphenylsulfinyl) pentyl, 6- (2-butoxyphenylsulfinyl) hexyl, 3- (4-dimethoxyphenylsulfinyl) ethyl, 3-dimethoxyphenylsulfinyl) ethyl, and the like.
Phenylsulfonyl-alkyl which is included in phenylsulfonyl-substituted lower alkyl whose phenyl moiety optionally contains a lower alkoxy substituent, the alkyl moiety thereof being a straight-chain or branched alkyl having 1 to 6 carbon atoms and the phenyl moiety thereof optionally containing 1 to 3 substituents of straight-chain or branched alkoxy having 1 to 6 carbon atoms, such as phenylsulfonylmethyl, 2-phenylsulfonylethyl, 1-phenylsulfonylethyl, 3-phenylsulfonylpropyl, 4-phenylsulfonylbutyl, 5-phenylsulfonylpentyl, 6-phenylsulfonylhexyl, 1-dimethyl-2-phenylsulfonylethyl, 2-methyl-3-phenylsulfonylpropyl, (2-methoxyphenylsulfonyl) methyl, p-toluenesulfonyl, (3-methoxyphenylsulfonyl) methyl, 2- (4-methoxyphenylsulfonyl) ethyl, 1- (2-ethoxyphenylsulfonyl) ethyl, 3- (4-isopropoxyphenylsulfonyl) propyl, 4- (3-pentyloxyphenylsulfonyl) butyl, 5- (4-hexyloxyphenylsulfonyl) pentyl, 6- (2-butoxyphenylsulfonyl) hexyl, 3, 4-dimethoxyphenylsulfonylmethyl, 3-ethoxy-4-methoxyphenylsulfonyl) methyl, 2- (2, 3-dimethoxyphenylsulfonyl) ethyl, 1- (2, 6-dimethoxyphenylsulfonyl) ethyl, 2- (3, 4, 5-trimethoxyphenylsulfonyl)ethyl and the like.
5-to 14-membered saturated or unsaturated heteromonocyclic, heterobicyclic, or heterotricyclic groups containing 1 to 4 heteroatoms selected from N, O, S include, for example: pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyridinyl, thienyl, quinolinyl, 1, 4-dihydroquinolinyl, benzothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinolonyl, 3, 4-dihydroquinolonyl, 1, 2, 3, 4-tetrahydroquinolyl, indolyl, isoindolyl, indolinyl, benzimidazolyl, benzoxazolyl, imidazolidinyl, isoquinolyl, quinazolinyl, quinoxalinyl, 1, 2-naphthyridinyl (cinnonyl), 2, 3-naphthyridinyl, chromanyl, isoindolinyl, isochromanyl, pyrazolyl, imidazolyl, pyrazolidinyl, 2, 3-dihydrobenzofuranyl, perhydrobenzofuranyl, benzofuranyl, benzothienyl, 4H-benzopyranyl, 1, 3, 4-oxadiazolyl, 1, 2, 4-triazolyl, 1, 2, 3, 4-tetrazolyl, 1, 3, 4-triazolyl, 1, 2, 4-oxadiazolyl, 2, 3-dihydrobenzofuranyl, perhydrobenzofuranyl, 5-1H-indazolyl, furanyl, pyrrolinyl, nolyl, oxazolyl, isoxazolyl, thiazolyl, thiazolidinyl, 1, 2, 3, 5-oxathiadiazolyl, isothiazolyl, pyranyl, pyrazolidinyl, quinuclidinyl, 1, 4-benzoxazinyl, 3, 4-dihydro-2H-1, 4-benzoxazinyl, 1, 4-benzothiazinyl, 1, 2, 3, 4-tetrahydroquinoxalinyl, 1, 3-dithia-2, 4-dihydronaphthyl, 1, 4-naphthylheteroaphthyl, 1, 4-thianaphtyl, oxanaphtyl, oxathiadiazolyl, oxadiazinyl, thiadiazolyl, thia, Furo [3, 2-c]pyridyl, furo [2, 3-g]quinolyl' 3, 4-dihydrofuro [2, 3-g]quinolyl, 1, 2, 3, 4-tetrahydrofuro [2, 3-g]quinolyl, 1, 4-benzodioxanyl, 1, 2, 4-triazinyl, naphtho [2, 1-b]furyl, imidazo [1, 2-a]pyridyl, and the like.
Lower alkyl substituted by a 5-to 14-membered saturated or unsaturated heteromonocyclic, heterobicyclic or heterotricyclic group containing 1 to 4 heteroatoms selected from N, O, S includes, for example, pyrrolidinylmethyl, 2-piperidinylethyl, 3-piperazinylpropyl, 4-morpholinobutyl, (2-pyridyl) methyl, (3-pyridyl) methyl, (2-thienyl) methyl, (3-quinolyl) methyl, 5- (6-quinolyl) pentyl, 6- (1, 4-dihydro-2-quinolyl) hexyl, (2-benzothiazolyl) methyl, 2- (3-pyrazinyl) ethyl, 1- (2-pyrimidinyl) ethyl, 3- (3-pyridazinyl) propyl, 4- (2-pyrrolyl) butyl, 5- (3-quinolonyl) -pentyl, 6- (3, 4-dihydroquinolon-6-yl) hexyl, (1, 2, 3, 4-tetrahydroquinolin-8-yl) methyl, (2-indolyl) methyl, (3-indolyl) methyl, 2- (3-indolyl) ethyl, (4-isoindolyl) methyl, 2- (3- (indolinyl) ethyl, (2-benzimidazolyl) methyl, 3- (5- (benzoxazolyl) propyl, 4- (4-imidazolidinyl) butyl, 5- (1-isoquinolinyl) pentyl, 6- (7-quinazolinyl) hexyl, (8-quinazolinyl) methyl, 1- (4-cinnolinyl) ethyl, hexyl, and the like, 3- (5-naphthyridinyl) propyl, 4- (6-chromanyl) butyl, 5- (4-isoindolyl) pentyl, 6- (7-isochromanyl) hexyl, (3-pyrazolyl) methyl, 2- (2-imidazolyl) ethyl, 3- (3-pyrazolidinyl) propyl, (2-benzofuranyl) methyl, (3-benzofuranyl) methyl, 4- (6-benzofuranyl) butyl, (2-benzothienyl) methyl, (3-benzothienyl) methyl, 5- (5-benzothienyl) pentyl, [6- (4H-benzopyranyl)]methyl, (2, 3-dihydro-2-benzofuranyl) methyl, benzyl, (2-perhydrobenzofuranyl) methyl, (5-1H-dihydroindazolinyl) methyl, thienylmethyl, 1- (5-isoindolinyl) ethyl, 3- (2-imidazolinyl) propyl, 4- (2-pyrrolinyl) butyl, (2-furyl) methyl, (4-oxazolyl) methyl, (5-oxazolyl) methyl, 5- (4-oxazolyl) pentyl, 6- (3-isoxazolyl) hexyl, (4-thiazolyl) methyl, (2-thiazolyl) methyl, 2- (3-isothiazolyl) ethyl, (2-pyranyl) methyl, 3- (3-pyrazolidinyl) propyl, 4- (2-pyrazolinyl) butyl, 5- (2-quinuclidinyl) pentyl, (1, 4-benzoxazin-6-yl) methyl group, (3, 4-dihydro-2H-1, 4-benzoxazin-2-yl) methyl group, (1, 3-benzothiazin-5-yl) methyl group, (1, 2, 3, 4-tetrahydroquinoxalin-6-yl) methyl group, (1, 3-dithia-2, 4-dihydronaphthalen-6-yl) methyl group, (1, 4-dithiin-7-yl) methyl group, (5-thiazolyl) methyl group, (1, 3, 4-oxadiazolin-5-yl) methyl group, (1, 2, 4-triazol-5-yl) methyl group, (1, 2, 3, 4-tetrazol-5-yl) methyl group, (1, 3, 4-triazol-5-yl) methyl, (1, 2, 4-oxadiazol-5-yl) methyl, (1, 2, 4-triazin-3-yl) methyl, (thiazolidin-5-yl) methyl, (1, 2, 3, 5-oxathiadiazolin-4-yl) methyl, (3-furyl) methyl, (2-imidazolyl) methyl, 2- (5-thiazolyl) ethyl, 1- (1, 3, 4-oxadiazolin-2-yl) ethyl, 3- (1, 2, 4-triazol-3-yl) propyl, 4- (1, 2, 3, 4-tetrazol-5-yl) butyl, 6- (1, 3, 4-triazol-2-yl) hexyl, 2- (1, 2, 4-oxadiazol-3-yl) ethyl, 1- (1, 2, 4-triazin-5-yl) ethyl, 3- (thiazolidin-2-yl) propyl, 4- (1, 2, 3, 5-oxathiadiazol-4-yl) butyl, 5- (furo [3, 2-c]pyridin-2-yl]pentyl, 6- (furo [2, 3-g quinolin-7-yl) hexyl, (3, 4-dihydrofuro [2, 3-g]quinolin-8-yl) methyl, 2- (1, 2, 3, 4-tetrahydrofuro [2, 3-g]quinolin-4-yl) ethyl, methyl, ethyl, 2- (1, 2, 4-triazin-5-yl) ethyl, 3- (thiazolidin-2, (1, 4-benzodioxan-2-yl) methyl, 1- (1, 4-benzodioxadin-3-yl) ethyl, (2, 3-dihydrobenzofuran-2-yl) methyl, (perhydrobenzofuran-2-yl) methyl, naphtho [2, 1-b]furylmethyl, 4- (naphtho [2, 1-b]furyl) pentyl, imidazo [1, 2-a]pyridylmethyl, 2- (imidazo [1, 2-a]pyridyl) ethyl, 1- (imidazo [1, 2-a]pyridyl) ethyl, and the like.
The phenoxy-substituted lower alkyl group includes phenoxyalkyl groups in which the alkyl moiety is a straight-chain or branched alkyl group having 1 to 6 carbon atoms, such as phenoxymethyl, 2-phenoxyethyl, 1-phenoxyethyl, 3-phenoxypropyl, 4-phenoxybutyl, 5-phenoxypentyl, 6-phenoxyhexyl, 1-dimethyl-2-phenoxyethyl, 2-methyl-3-phenoxypropyl and the like.
Among the phenylalkoxy groups included in the phenyl-lower alkoxy group optionally having an amino substituent optionally having a lower alkanoyl substituent, the alkoxy group thereof is a straight-chain or branched alkoxy group having 1 to 6 carbon atoms, and may optionally have 1 to 3 amino substituents on the phenyl group, and the amino substituent may optionally have a straight-chain or branched alkanoyl group having 1 to 6 carbon atoms. Examples of the phenylalkoxy group include benzyloxy group, 2-phenylethoxy group, 1-phenylethoxy group, 3-phenylpropyloxy group, 4-phenylbutoxy group,5-phenylpentyloxy group, 6-phenylhexyloxy group, 1-dimethyl-2-phenylethoxy group, 2-methyl-3-phenylpropyloxy group, 4-acetamidobenzyloxy group, 2- (2-propionylaminophenyl) ethoxy group, 1- (3-butyrylaminophenyl) ethoxy group, 3- (4-valerylaminophenyl) propoxy group, 4- (3-tert-butylcarbonylaminophenyl) butoxy group, 5- (4-hexanoylaminophenyl) pentyloxy group, 6- (3, 4-diacetylaminophenyl) hexyloxy group, 3, 4, 5-triacetylaminobenzyloxy group, and the like, 2, 4-diacetoxybenzyloxy, 4-aminobenzyloxy, 2, 3-diaminobenzyloxy, 2, 4, 6-triaminobenzyloxy, 2- (3-aminophenyl) ethoxy, 3- (2-aminophenyl) propoxy and the like.
Lower alkoxy-substituted lower alkoxy includes straight or branched alkoxy having 1 to 6 carbon atoms substituted with straight or branched alkoxy having 1 to 6 carbon atoms, such as methoxymethoxy, 3-methoxypropoxy, 4-ethoxybutoxy, 6-propoxyhexoxy, 5-isopropoxypentyloxy, 1-dimethyl-2-butoxyethoxy, 2-methyl-3-tert-butoxypropoxy, 2-pentyloxyethoxy, hexyloxymethoxy and the like.
The lower alkyl group substituted with a lower alkanoyloxy group includes a straight or branched alkyl group having 1 to 6 carbon atoms substituted with a straight or branched alkanoyloxy group having 2 to 6 carbon atoms, for example, acetoxymethyl, 2-dimethylpropionyloxymethyl, propionyloxymethyl, 2-propionyloxyethyl, 1-acetoxyethyl, 1-butyryloxyethyl, 3-acetoxypropyl, 4-isobutyryloxybutyl, 5-valeryloxypentyl, 6-tert-butylcarbonyloxyhexyl, 1-dimethyl-2-hexanoyloxyethyl, 2-methyl-3-acetoxypropyl and the like.
The lower alkyl group substituted with halogen includes a straight or branched alkyl group having 1 to 6 carbon atoms substituted with 1 to 3 halogen atoms, such as trifluoromethyl, trichloromethyl, chloromethyl, bromomethyl, fluoromethyl, iodomethyl, difluoromethyl, dibromomethyl, 2-chloroethyl, 2, 2, 2-trifluoroethyl, 2, 2, 2-trichloroethyl, 3-chloropropyl, 2, 3-dichloropropyl, 4, 4, 4-trichlorobutyl, 4-fluorobutyl, 5-chloropentyl, 3-chloro-2-methylpropyl, 5-bromohexyl, 5, 6-dichlorohexyl and the like.
Tetrazolyl optionally having a lower alkyl substituent on the tetrazole ring includes tetrazolyl optionally having a straight or branched alkyl group of 1 to 6 carbon atoms on the tetrazole ring, such as tetrazolyl, 1-methyltetrazolyl, 2-methyltetrazolyl, 5-ethyltetrazolyl, 5-propyltetrazolyl, 1-butyltetrazolyl, 2-pentyltetrazolyl, 1-hexyltetrazolyl, and the like.
The phenyl group optionally having a substituent selected from the group consisting of a lower alkyl group, a lower alkoxy group substituted with a lower alkoxy group, a hydroxyl group, a halogen atom and a lower alkoxy group includes a phenyl group which may optionally have 1 to 3 substituents selected from the group consisting of: a straight-chain or branched alkyl group having 1 to 6 carbon atoms, a straight-chain or branched alkoxy group having 1 to 6 carbon atoms substituted with a straight-chain or branched alkoxy group having 1 to 6 carbon atoms, a hydroxyl group, a halogen atom and a straight-chain or branched alkoxy group having 1 to 6 carbon atoms, and examples of such phenyl groups are phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 3-isopropylphenyl, 4-hexylphenyl, 3, 4-dimethylphenyl, 2, 5-dimethylphenyl, 3, 4, 5-trimethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl, 4-isopropoxyphenyl group, 4-pentyloxyphenyl group, 2, 4-dimethoxyphenyl group, 4-hexyloxyphenyl group, 3, 4-dimethoxyphenyl group, 3-ethoxy-4-methoxyphenyl group, 2, 3-dimethoxyphenyl group, 3, 4-diethoxyphenyl group, 2, 5-dimethoxyphenyl group, 2, 6-dimethoxyphenyl group, 3, 5-dimethoxyphenyl group, 3, 4-dipentyloxyphenyl group, 3, 4, 5-trimethoxyphenyl group, 2-chlorophenyl group, 3-chlorophenyl group, 4-chlorophenyl group, 2-fluorophenyl group, 3-fluorophenyl group, 4-fluorophenyl group, 2-bromophenyl group, 3-bromophenyl group, 4-bromophenyl group, 2-iodophenyl group, 3-iodophenyl group, 4-iodophenyl, 3, 4-dichlorophenyl, 3, 5-dichlorophenyl, 2, 6-dichlorophenyl, 2, 3-dichlorophenyl, 2, 4-dichlorophenyl, 3, 4-difluorophenyl, 3, 5-dibromophenyl, 3, 4, 5-trichlorophenyl, 2-methoxy-5-chlorophenyl, 3-chloro-4-methoxyphenyl, 3-methoxy-5-iodophenyl, 3, 4-dimethoxy-5-bromophenyl, 3, 5-diiodo-4-methoxyphenyl, 2-hydroxy-5-chlorophenyl, 2-methoxymethoxy-5-chlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 3, 5-dichlorophenyl, 2, 3-dichlorophenyl, 3, 5-dichlorophenyl, 2, 6-dichlorophenyl, 2, 3-dichlorophenyl, 2-methoxy-5-chlorophenyl, 2-methoxyphenyl, 3-chlorophenyl, 4, 2, 3-dihydroxyphenyl, 3, 4, 5-trihydroxyphenyl, 2-methoxymethoxyphenyl, 3- (3-methoxypropoxy) phenyl, 4- (4-ethoxybutoxy) phenyl, 2- (6-propoxyhexoxy) phenyl, 3- (5-isopropoxypentyloxy) phenyl, 4- (1, 1-dimethyl-2-butoxyethoxy) phenyl, 2- (2-methyl-3-tert-butoxypropoxy) phenyl, 3- (2-pentyloxyethoxy) phenyl, 4-hexyloxymethoxyphenyl, 2, 3-dimethoxymethoxyphenyl, 3, 4, 5-trimethoxymethoxyphenyl, and the like.
Lower alkenyl groups include straight or branched chain alkenyl groups having 2 to 6 carbon atoms, such as vinyl, allyl, 2-butenyl, 3-butenyl, 1-methylallyl, 2-pentenyl, 2-hexenyl, and the like.
Morpholinocarbonyl-lower alkoxy includes morpholinocarbonylalkoxy in which the alkoxy moiety is a straight or branched chain alkoxy group having 1 to 6 carbon atoms, such as morpholinocarbonylmethoxy, 2-morpholinocarbonylethoxy, 1-morpholinocarbonylethoxy, 3- (2-morpholinocarbonyl) propoxy, 4- (3-morpholinocarbonyl) butoxy, 1-dimethyl-2- (2-morpholinocarbonyl) ethoxy, 5-morpholinocarbonylpentyloxy, 6-morpholinocarbonylhexyloxy, 2-methyl-3-morpholinocarbonylpropoxy and the like.
Morpholinocarbonyl-lower alkyl includes morpholinocarbonylalkyl wherein the alkyl moiety is a straight or branched alkylgroup having 1 to 6 carbon atoms, such as morpholinocarbonylmethyl, 2-morpholinocarbonylethyl, 1-morpholinocarbonylethyl, 3- (2-morpholinocarbonyl) propyl, 4- (3-morpholinocarbonyl) butyl, 1-dimethyl-2- (2-morpholinocarbonyl) ethyl, 5-morpholinocarbonylpentyl, 6-morpholinocarbonylhexyl, 2-methyl-3-morpholinocarbonylpropyl and the like.
Cycloalkylcarbonyl includes cycloalkylcarbonyl groups containing 3 to 8 carbon atoms in the cycloalkyl moiety, such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, cycloheptylcarbonyl, cyclooctylcarbonyl and the like.
Phenyl-lower alkenylcarbonyl includes phenyl-alkenylcarbonyl in which the alkenylcarbonyl moiety is a straight-chain or branched alkenylcarbonyl group having 3 to 6 carbon atoms, such as cinnamoyl, 4-phenyl-2-butenoyl, 4-phenyl-3-butenoyl, 5-phenyl-4-pentenoyl, 5-phenyl-3-pentenoyl, 5-phenyl-2-pentenoyl, 6-phenyl-5-hexenoyl, 6-phenyl-4-hexenoyl, 6-phenyl-3-hexenoyl, 6-phenyl-2-hexenoyl, 2-methyl-4-phenyl-3-butenoyl, 2-methyl-cinnamoyl, 2-methyl-butenoyl, 4-butenoyl, 5-phenyl-2-pentenoyl, 5-phenyl-3-pentenoyl, 5-phenyl-2-pentenoyl, 6-phenyl-, 1-methyl-cinnamoyl, and the like.
From R6And R7、R9And R10、R40And R41Or R52And R53The 5-to 6-membered saturated heterocyclic group with or without other nitrogen atom or oxygen atom intervening, which is formed together with the adjacent nitrogen atom to which they are bonded, includes, for example, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and the like.
The aforementioned heterocyclic group having 1 to 3 substituents selected from the group consisting of hydroxy, lower alkyl and phenyl-lower alkyl includes the above-mentioned heterocyclic group having 1 to 3 substituents selected from the group consisting of: a hydroxyl group, a linear or branched alkyl group having 1 to 6 carbon atoms, a phenylalkyl group in which the alkyl moiety is a linear or branched alkyl group having 1 to 6 carbon atoms. Such heterocyclic radicals are, for example: 3-hydroxypyrrolidinyl, 2-hydroxypyrrolidinyl, 4-hydroxypiperidinyl, 3-hydroxypiperidinyl, 2-hydroxypiperidinyl, 3-hydroxypiperazinyl, 2-hydroxypiperazinyl, 3-hydroxymorpholinyl, 2-hydroxymorpholinyl, 4-benzylpiperazinyl, 3- (2-phenylethyl) pyrrolidinyl, 2- (3-phenylpropyl) pyrrolidinyl, 4- (4-phenylbutyl) piperidinyl-, 3- (5-phenylpentyl) morpholinyl, 2- (6-phenylhexyl) piperazinyl, 4-methylpiperazinyl, 3, 4-dimethylpiperazinyl, 3-ethylpyrrolidinyl, 2-propylpyrrolidinyl, 3, 4, 5-trimethylpiperidinyl, 4-butylpiperidinyl, piperidinyl, 3-pentylmorpholinyl, 2-hexylpiperazinyl, 3-methyl-4-benzylpiperazinyl, 3-ethyl-4-hydroxypiperidinyl, 3-methyl-4-benzylpyrrolidinyl, and the like.
Amino optionally containing a substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl includes amino optionally containing 1 to 2 substituents selected from the group consisting of: straight or branched alkanoyl of 1 to 6 carbon atoms, and phenylalkenylcarbonyl wherein the alkenylcarbonyl moiety is a straight or branched alkenylcarbonyl of 3 to 6 carbon atoms, said amino group being for example: amino, formylamino, acetylamino, propionylamino, butyrylamino, isobutyrylamino, pentanoylamino, tert-butylcarbonylamino, hexanoylamino, cinnamoylamino, 4-phenyl-3-butenoylamino, 4-phenyl-2-butenoylamino, 5-phenyl-5-butenoylamino, 5-phenyl-3-pentenoylamino, 5-phenyl-2-pentenoylamino, 6-phenyl-5-hexenoylamino, 6-phenyl-4-hexenoylamino, 6-phenyl-3-hexenoylamino, 6-phenyl-2-hexenoylamino, 2-methyl-4-phenyl-3-butenoylamino, 2-methyl-cinnamoylamino, 1-methyl cinnamamido, N-acetyl-N-cinnamamido, and the like.
The amino group optionally having a lower alkanoyl substituent includes an amino group optionally having a straight-chain or branched alkanoyl substituent having 1 to 6 carbon atoms, such as amino, formylamino, acetylamino, propionylamino, butyrylamino, isobutyrylamino, pentanoylamino, tert-butylcarbonylamino, hexanoylamino and the like.
The alkylsulfinyl group includes a straight-chain or branched alkylsulfinyl group having 1 to 6 carbon atoms, such as methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, butylsulfinyl, t-butylsulfinyl, pentylsulfinyl, hexylsulfinyl, and the like.
The lower alkylthio group includes a straight or branched alkylthio group having 1 to 6 carbon atoms, such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, tert-butylthio, pentylthio, hexylthio and the like.
The lower alkylsulfonyl group includes a straight or branched alkylsulfonyl group containing 1 to 6 carbon atoms, such as methylsulfonyl group, ethylsulfonyl group, isopropylsulfonyl group, butylsulfonyl group, t-butylsulfonyl group, pentylsulfonyl group, hexylsulfonyl group and the like.
The lower alkanoyloxy group includes a straight or branched alkanoyloxy group having 1 to 6 carbon atoms, for example, formyloxy, acetyloxy, propionyloxy, butyryloxy, isobutyryloxy, valeryloxy, tert-butyryloxy, hexanoyloxy and the like.
The lower alkyl group optionally substituted with an amino group selected from the group consisting of a lower alkylsulfonyl group and a lower alkanoyl group includes a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms which is substituted with an amino group optionally having 1 to 2 substituents selected from the group consisting of a straight-chain or branched-chain alkylsulfonyl group having 1 to 6 carbon atoms and a straight-chain or branched-chain alkanoyl group having 1 to 6 carbon atoms, and the amino-substituted lower alkyl group is, for example, aminomethyl, 2-aminoethyl, 1-aminoethyl, 2-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 1-dimethyl-2-aminoethyl, 2-methyl-3-aminopropyl, formylaminomethyl, 1-acetylaminoethyl, 2-propionylaminoethyl, 3-butyrylaminopropyl, 4-valerylaminopentyl, 5-hexanoylaminohexyl, 6-isobutyrylaminohexyl, 1-dimethyl-2-acetamidoethyl, 2-methyl-3-formylaminopropyl, methylsulfonylaminomethyl, 2-ethylsulfonylaminoethyl, 1-isopropylsulfonylaminoethyl, 3-butylsulfonylaminopropyl, 4-tert-butylsulfonylaminobutyl, 5-pentylsulfonylaminopentyl, 6-hexylsulfonylaminohexyl, 1-dimethyl-2-methylsulfonylaminoethyl, 2-methyl-3-ethylsulfonylaminopropyl, N-methylsulfonylamino-N-acetamidomethyl and the like.
Lower alkyl substituted with a 1, 3-dioxolanyl group optionally having a lower alkyl substituent includes an alkyl substituted with a 1, 3-dioxolanyl group which may optionally have 1 to 3 straight-chain or branched alkyl substituents having 1 to 6 carbon atoms and in which the alkyl moiety is a straight-chain or branched alkyl group having 1 to 6 carbon atoms, such as (1, 3-dioxolan-2-yl) methyl, 2- (1, 3-dioxolan-4-yl) ethyl, 1- (1, 3-dioxolan-2-yl) ethyl, 3- (1, 3-dioxolan-4-yl) propyl, 4- (1, 3-dioxolan-2-yl) butyl, 2- (1, 3-dioxolan-2-yl) propyl, lower alkyl substituted with a 1, 3-dioxolan group optionally having a lower alkyl substituent, 5- (1, 3-dioxolan-2-yl) pentyl, (4-hexyl-1, 3-dioxolan-2-yl) methyl, (2, 4-dimethyl-1, 3-dioxolan-2-yl) methyl, 6- (1, 3-dioxolan-3-yl) hexyl, 4- (2-propyl-1, 3-dioxolan-2-yl) butyl, 5- (4-butyl-1, 3-dioxolan-2-yl) pentyl, 6- (2-pentyl-1, 3-dioxolan-2-yl) hexyl, 1-dimethyl-2- (1, 3-dioxolan-2-yl) ethyl, 2-methyl-3- (1, 3-dioxolan-2-yl) propyl, (2-methyl-1, 3-dioxolan-2-yl) methyl, 2- (4-ethyl-1, 3-dioxolan-2-yl) ethyl, 3- (2, 4, 5-trimethyl-1, 3-dioxolan-2-yl) propyl, and the like.
The lower alkyl substituted with an alkanoyl group includes an alkanoyl alkyl group wherein the alkanoyl moiety is a straight-chain or branched-chain alkanoyl group having 1 to 6 carbon atoms and the alkanoyl moiety is a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms, such as formylmethyl, acetylmethyl, 2-propionylethyl, 1-butyrylethyl, 3-isobutyrylpropyl, 4-valerylbutyl, 5-hexanoylhexyl, 6-tert-butylcarbonylhexyl, 1-dimethyl-2-acetylethyl, 2-methyl-3-acetylmethyl and the like.
Lower alkyl optionally substituted with aminocarbonyl having a lower alkyl substituent includes straight-chain or branched-chain alkyl having 1 to 6 carbon atoms which is substituted with aminocarbonyl optionally having 1 to 2 straight-chain or branched-chain alkyl substituents having 1 to 6 carbon atoms, such as aminocarbonylmethyl, 2-aminocarbonylethyl, 1-aminocarbonylethyl, 3-aminocarbonylpropyl, 4-aminocarbonylbutyl, 5-aminocarbonylpentyl, 6-aminocarbonylhexyl, 1-dimethyl-2-aminocarbonylethyl, 2-methyl-3-aminocarbonylpropyl, methylaminocarbonylmethyl, 1-ethylaminocarbonylethyl, 2-propylaminocarbonylethyl, 3-isopropylaminocarbonylpropyl, 4-butylaminocarbonylbutyl, 5-pentylaminocarbonylpentyl group, 6-hexylaminocarbonylhexyl group, dimethylaminocarbonylmethyl group, 2-diethylaminocarbonylethyl group, 2-dimethylaminocarbonylethyl group, (N-ethyl-N-propylamino) carbonylmethyl group, 2- (N-methyl-N-hexylamino) carbonylmethyl group and the like.
Lower alkoxy-carbonyl-substituted lower alkenyl group includes straight-chain or branched-chain alkenyl groups having 2 to 6 carbon atoms substituted with a straight-chain or branched-chain alkoxy-carbonyl group having 1 to 6 carbon atoms in the alkoxy moiety, such as 2-methoxycarbonylvinyl, 2-ethoxycarbonylvinyl, 3-propoxycarbonylallyl, 4-butoxycarbonyl-2-butenyl, 4-pentoxycarbonyl-3-butenyl, 3-hexyloxycarbonyl-1-methylallyl, 5-isopropoxycarbonyl-2-pentenyl, 6-tert-butoxycarbonyl-2-hexenyl and the like.
Lower alkenyl which may be optionally substituted by lower alkyl-substituted aminocarbonyl includes straight-chain or branched alkenyl having 2 to 6 carbon atoms which is substituted by aminocarbonyl optionally having 1 to 2 straight-chain or branched alkyl substituents having 1 to 6 carbon atoms, such as 2-aminocarbonylvinyl, 3-aminocarbonylallyl, 4-aminocarbonyl-2-butenyl, 4-aminocarbonyl-3-butenyl, 3-aminocarbonyl-1-methylallyl, 5-aminocarbonyl-2-pentenyl, 6-aminocarbonyl-2-hexenyl, 2-methylaminocarbonylvinyl, 3-ethyl-aminocarbonylallyl, 4-propylaminocarbonyl-2-butenyl, 4-isopropylaminocarbonyl-3-butenyl, 4-isopropylaminocarbonyl-2-butenyl, 3-butylaminocarbonyl-1-methylallyl, 5-pentylaminocarbonyl-2-pentenyl, 6-hexylaminocarbonyl-2-hexenyl, 2-dimethylaminocarbonylvinyl, 2-diethylaminocarbonylvinyl, 3- (N-ethyl-N-propylaminocarbonyl) allyl, 4- (N-methyl-N-hexylaminocarbonyl) -butenyl, and the like.
Carboxy-substituted lower alkenyl groups include straight or branched chain alkenyl groups having 2 to 6 carbon atoms, such as 2-carboxyvinyl, 2-carboxyallyl, 4-carboxy-2-butenyl, 4-carboxy-3-butenyl, 3-carboxy-1-methylallyl, 5-carboxy-2-pentenyl, 6-carboxy-2-hexenyl, and the like.
Aminocarbonyl optionally containing a lower alkyl substituent includes aminocarbonyl which may optionally have 1 to 2 straight-chain or branched-chain alkyl groups containing 1 to 6 carbon atoms, such as aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, butylaminocarbonyl, tert-butylaminocarbonyl, pentylaminocarbonyl, hexylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, dipropylaminocarbonyl, dibutylaminocarbonyl, dipentylaminocarbonyl, dihexylaminocarbonyl, N-methyl-N-ethylaminocarbonyl, N-ethyl-N-propylaminocarbonyl, N-methyl-N-butylaminocarbonyl, N-methyl-N-hexylaminocarbonyl and the like.
Phenylsulfonyl optionally having lower alkyl substituents includes phenylsulfonyl optionally having 1 to 3 linear or branched alkyl substituents having 1 to 6 carbon atoms, such as phenylsulfonyl, 2-methylphenylsulfonyl, 3-methylphenylsulfonyl, 4-methylphenylsulfonyl, 2-ethylphenylsulfonyl, 3-ethylphenylsulfonyl, 4-ethylphenylsulfonyl, 3-isopropylphenylsulfonyl, 4-hexylphenylsulfonyl, 3, 4-dimethylphenylsulfonyl, 2, 5-dimethylphenylsulfonyl, 3, 4, 5-trimethylphenylsulfonyl and the like.
Phenyl-lower alkenyl includes phenylalkenyl wherein the alkenyl moiety is a straight or branched chain alkenyl group having 2 to 6 carbon atoms, for example, styryl, cinnamyl, 4-phenyl-3-butenyl, 4-phenyl-2-butenyl, 5-phenyl-4-pentenyl, 5-phenyl-3-pentenyl, 5-phenyl-2-pentenyl, 6-phenyl-5-hexenyl, 6-phenyl-4-hexenyl, 6-phenyl-3-hexenyl, 6-phenyl-2-hexenyl, 2-methyl-4-phenyl-3-butenyl, 2-methylcinnamyl, 1-methylcinnamyl and the like.
The benzoyl group which may optionally have 1 to 3 substituents selected from the group consisting of a lower alkoxy group, a halogen atom, an amino group optionally having a lower alkanoyl group, a hydroxyl group in the phenyl moiety includes benzoyl group which may optionally have 1 to 3 substituents selected from the group consisting of: an amino group having a linear or branched alkoxy group of 1 to 6 carbon atoms, a halogen atom, and optionally a linear or branched alkanoyl substituent of 1 to 6 carbon atoms, a hydroxyl group. Such benzoyl groups are, for example, benzoyl, 2-chlorobenzoyl, 3-chlorobenzoyl, 4-chlorobenzoyl, 2-fluorobenzoyl, 3-fluorobenzoyl, 4-fluorobenzoyl, 2-bromobenzoyl, 3-bromobenzoyl, 4-bromobenzoyl, 2-iodobenzoyl, 4-iodobenzoyl, 3, 5-dichlorobenzoyl, 2, 6-dichlorobenzoyl, 3, 4-difluorobenzoyl, 3, 5-dibromobenzoyl, 3, 4, 5-trichlorobenzoyl, 2-methoxybenzoyl, 3-methoxybenzoyl, 4-methoxybenzoyl, 2-ethoxybenzoyl, 3-ethoxybenzoyl, 4-iodobenzoyl, 3, 5-dichlorobenzoyl, 3, 6-dichlorobenzoyl, 3, 4-trichlorobenzoyl, 2-methoxybenzoyl, 3-methoxybenzoyl, 4-methoxybenzoyl, 2-, 4-ethoxybenzoyl, 4-isopropoxybenzoyl, 4-hexyloxybenzoyl, 3, 4-dimethoxybenzoyl, 3, 4-diethoxybenzoyl, 3, 4, 5-trimethoxybenzoyl, 2, 5-dimethoxybenzoyl, 3-methoxy-4-chlorobenzoyl, 2-chloro-6-methoxybenzoyl, 2-methoxy-5-chlorobenzoyl, 2-aminobenzoyl, 3-aminobenzoyl, 4-aminobenzoyl, 2-hydroxybenzoyl, 3-hydroxybenzoyl, 4-hydroxybenzoyl, 2, 5-diaminobenzoyl, 3, 4, 5-triaminobenzoyl, 2-formylaminobenzoyl, 4-hexyloxybenzoyl, 3, 4-dimethoxybenzoyl, 3, 4-chlorobenzoyl, 2-chloro-6-methoxybenzoyl, 2-methoxy-5-chlorobenzoyl, 2-aminobenzoyl, 2-formylcarbamoyl, 2-methoxybenzoyl, 2-methoxybenz, 3-acetylaminobenzoyl, 4-acetylaminobenzoyl, 2-acetylaminobenzoyl, 3-propionylaminobenzoyl, 4-butyrylaminobenzoyl, 2-isobutyrylaminobenzoyl, 3-valerylaminobenzoyl, 3-tert-butylcarbonylaminobenzoyl, 4-hexanoylaminobenzoyl, 2, 6-diacetylaminobenzoyl, 2, 4-dihydroxybenzoyl, 2, 4, 6-trihydroxybenzoyl, 2-hydroxy-5-chlorobenzoyl and the like.
The lower alkanoyl group optionally substituted with an amino group having a lower alkanoyl substituent includes a straight-chain or branched-chain alkanoyl group having 2 to 6 carbon atoms which is substituted with an amino group optionally containing 1 to 2 straight-chain or branched-chain alkanoyl substituents having 1 to 6 carbon atoms, such as 2-aminoacetyl group, 3-aminopropionyl group, 2-aminopropionyl group, 4-aminobutyryl group, 5-aminopentanoyl group, 6-aminocaproyl group, 2-dimethyl-3-aminopropionyl group, 2-methyl-3-aminopropionyl group, 2-acetylaminoacetyl group, 2-acetylaminopropionyl group, 3-propionylaminopropionyl group, 3-isopropanoylaminopropionyl group, 4-butyrylaminobutyryl group, 5-valerylaminopentanoyl group, 6-hexanoylaminohexanoyl group, 2-formylaminoacetyl and the like.
Amino-substituted sulfonyl optionally containing lower alkyl substituents includes aminosulfonyl which may optionally contain 1 to 2 straight or branched alkyl substituents containing 1 to 6 carbon atoms, for example, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, butylaminosulfonyl, tert-butylaminosulfonyl, pentylaminosulfonyl, hexylaminosulfonyl, dimethylaminosulfonyl, diethylaminosulfonyl, dipropylaminosulfonyl, dibutylaminosulfonyl, dipentylaminosulfonyl, dihexylaminosulfonyl, N-methyl-N-ethylaminosulfonyl, N-ethyl-N-propylaminosulfonyl, N-methyl-N-butylaminosulfonyl, N-methyl-N-hexylaminosulfonyl and the like.
The lower alkylenedioxy group includes straight-chain or branched alkylenedioxy groups having 1 to 4 carbon atoms, such as methylenedioxy, ethylenedioxy, 1, 3-propylenedioxy, 1, 4-butylenedioxy and the like.
The phenyl group optionally having a lower alkoxy substituent includes phenyl groups which may optionally have 1 to 3 straight-chain or branched alkoxy substituents having 1 to 6 carbon atoms, such as phenyl, 2-dimethoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-isopropoxyphenyl, 4-pentyloxyphenyl, 2, 4-dimethoxyphenyl, 4-hexyloxyphenyl, 3-ethoxy-4-methylphenyl, 2, 3-dimethoxyphenyl, 3, 4-diethoxyphenyl, 2, 5-dimethoxyphenyl, 2, 6-dimethoxyphenyl, 3, 5-dimethoxyphenyl, n, 3, 4-dipentyloxyphenyl, 3, 4, 5-trimethoxyphenyl and the like.
The lower alkyl group substituted with 2, 3-dihydro-1H-indenyl group optionally having a substituent selected from oxo group, hydroxy group and siloxy group having a lower alkyl group on the 2, 3-dihydro-1H-indenyl ring includes a linear or branched alkyl group having 1 to 6 carbon atoms and substituted with 2, 3-dihydro-1H-indenyl group optionally having 1 to 3 substituents selected from: oxo, hydroxy and siloxy having 3 straight or branched alkyl substituents containing 1 to 6 carbon atoms, examples of said substituted lower alkyl being: (2, 3-dihydro-1H-inden-2-yl) methyl, 2- (2, 3-dihydro-1H-inden-1-yl) ethyl, 1- (2, 3-dihydro-1H-inden-3-yl) ethyl, 3- (2, 3-dihydro-1H-inden-4-yl) propyl, 4- (2, 3-dihydro-1H-inden-5-yl) butyl, 5- (2, 3-dihydro-1H-inden-6-yl) pentyl, 6- (2, 3-dihydro-1H-inden-7-yl) hexyl, (1-oxo-2, 3-dihydro-1H-inden-2-yl) methyl, (1-hydroxy-2, 3-dihydro-1H-inden-2-yl) methyl, (1-dimethyl-tert-butylsiloxy-2, 3-dihydro-1H-inden-2-yl) methyl, (1, 3-dihydroxy-2, 3-dihydro-1H-inden-2-yl) methyl, [1, 3-bis (trimethylsilyloxy) -2, 3-dihydro-1H-inden-2-yl]methyl, (1, 3, 7-trihydroxy-2, 3-dihydro-1H-inden-2-yl) methyl, (1, 3, 4-tris (dimethylethylsiloxy) -2, 3-dihydro-1H-inden-2-yl) methyl, and the like.
The siloxy group having a lower alkyl substituent includes siloxy groups substituted with 3 straight or branched chain alkyl groups having 1 to 6 carbon atoms, such as trimethylsiloxy, triethylsiloxy, triisopropylsiloxy, tributylsiloxy, tri-tert-butylsiloxy, tripentylsiloxy, trihexylsiloxy, dimethyl-tert-butylsiloxy and the like.
The phenyl group optionally having a substituent selected from the group consisting of a lower alkoxy group and a halogen atom on the phenyl ring includes a phenyl group which may be optionally substituted by 1 to 3 substituents selected from the group consisting of a linear or branched alkoxy group having 1 to 6 carbon atoms and a halogen atom, such as phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-isopropoxyphenyl, 4-pentyloxyphenyl, 2, 4-dimethoxyphenyl, 4-hexyloxyphenyl, 3, 4-dimethoxyphenyl, 3-ethoxy-4-methoxyphenyl, 2, 3-dimethoxyphenyl, 3, 4-diethoxyphenyl, 2, 5-dimethoxyphenyl, 2, 6-dimethoxyphenyl, 3, 5-dimethoxyphenyl group, 3, 4-dipentyloxyphenyl group, 3, 4, 5-trimethoxyphenyl group, 2-chlorophenyl group, 3-chlorophenyl group, 4-chlorophenyl group, 2-fluorophenyl group, 3-fluorophenyl group, 4-fluorophenyl group, 2-bromophenyl group, 3-bromophenyl group, 4-bromophenyl group, 2-iodophenyl group, 3-iodophenyl group, 4-iodophenyl group, 3, 4-dichlorophenyl group, 3, 5-dichlorophenyl group, 2, 6-dichlorophenyl group, 2, 3-dichlorophenyl group, 2, 4-dichlorophenyl group,3, 4-difluorophenyl group, 3, 5-dibromophenyl group, 3, 4, 5-trichlorophenyl group, 2-methoxy-5-chlorophenyl group, 3-chloro-4-methoxyphenyl group, 3-methoxy-5-iodophenyl, 3, 4-dimethoxy-5-bromophenyl, 3, 5-diiodo-4-methoxyphenyl, and the like.
5-to 6-membered saturated or unsaturated heterocyclic groups containing 1 to 4 heteroatoms selected from N, O, S include, for example, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyridinyl, thienyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, imidazolidinyl, pyrazolyl, imidazolyl, pyrazolidinyl, 1, 3, 4-oxadiazolyl, 1, 2, 4-triazolyl, 1, 2, 3, 4-tetrazolyl, 1, 3, 4-triazolyl, 1, 2, 4-oxadiazolyl, furyl, pyrrolinyl, oxazolyl, isoxazolyl, thiazolyl, thiazolidinyl, 1, 2, 3, 5-oxathiadiazolyl, isothiazolyl, pyranyl, pyrazolidinyl, 1, 2, 4-triazinyl and the like.
Lower alkyl substituted by a 5-to 6-membered saturated or unsaturated heterocyclic group containing 1 to 4 heteroatoms selected from N, O, S includes straight-chain or branched alkyl groups containing 1 to 6 carbon atoms substituted by the aforementioned heterocyclic group, for example, pyrrolidinylmethyl, 2-piperidinylethyl, 3-piperazinylpropyl, 4-morpholinobutyl, (2-pyridyl) methyl, (3-pyridyl) methyl, (2-thienyl) methyl, 2- (3-pyrazinyl) ethyl, 1- (2-pyrimidinyl) ethyl, 3- (3-pyridazinyl) propyl, 4- (2-pyrrolyl) butyl, 4- (4-imidazolidinyl) butyl, (2-imidazolyl) methyl, (3-pyrazolyl) methyl, 2- (2-imidazolyl) ethyl, lower alkyl substituted by a 5-to 6-membered saturated or unsaturated heterocyclic group containing 1 to 4 heteroatoms selected from N, O, S heteroatoms, such as pyrrolidinylmethyl, 2-piperidinylethyl, piperazinylpropyl, 4- (2, 3- (3-pyrazolyl) propyl, thienylmethyl, 3- (2-imidazolinyl) propyl, 4- (2-pyrrolinyl) butyl, (2-furyl) methyl, (4-oxazolyl) methyl, (5-oxazolyl) methyl, 5- (4-oxazolyl) pentyl, 6- (3-isoxazolyl) hexyl, (4-thiazolyl) methyl, (2-thiazolyl) methyl, 2- (3-isothiazolyl) ethyl, (2-pyranyl) methyl, 3- (3-pyrazolidinyl) propyl, 4- (2-pyrazolinyl) butyl, (5-thiazolyl) methyl, (1, 3, 4-oxadiazolinyl-5-yl) methyl, (1, 2, 4-triazol-5-yl) methyl, (1, 2, 3, 4-tetrazol-5-yl) methyl, (1, 3, 4-triazol-5-yl) methyl, (1, 2, 4-oxadiazol-5-yl) methyl, (1, 2, 4-triazin-3-yl) methyl, (thiazolidin-5-yl) methyl, (1, 2, 3, 5-oxathiadiazolin-4-yl) methyl, (2-furyl) methyl, (3-furyl) methyl, 2- (5-thiazolyl) ethyl, 1- (1, 3, 4-oxadiazolin-2-yl) ethyl, 3- (1, 2, 4-triazol-3-yl) propyl, 4- (1, 2, 3, 4-tetrazol-5-yl) butyl, 6- (1, 3, 4-triazol-2-yl) hexyl, 2- (1, 2, 4-oxadiazol-3-yl) ethyl, 1- (1, 2, 4-triazin-5-yl) ethyl, 3- (thiazolidin-2-yl) propyl, 4- (1, 2, 3, 5-oxathiadiazolin-4-yl) butyl and the like.
Lower alkenyl substituted with 1 to 4 hetero atoms selected from N, O, S hetero atoms includes alkenyl substituted with the above-mentioned heterocyclic group, such as 2-furyl [ 4-furyl-3-hexenyl]furyl [ 3-furyl-4-hexenyl]furyl [ 3-hexenyl]furyl [ 2-3-hexenyl]furyl [ 3-hexenyl]furyl [ 2-5-3-5-hexenyl]furyl [ 2-3-5-hexenyl]furyl [ 1-3-hexenyl]furyl [ 1-3-5-hexenyl]furyl-2-furyl-3-hexenyl, 2-3-furyl-2-furyl-3-2-furyl-3-5-hexenyl, 2-3-furyl-3-5-hexenyl]furyl [ 1-3-5-3-hexenyl, 2-furyl-3-hexenyl]furyl [ 1-3-5-3-2-furyl-2-hexenyl]furyl [ 2-3-5-3-hexenyl]2-3-hexenyl, 2-3-furyl-3-5-3-furyl-2-3-hexenyl, 3-5-3-methyl-3-hexenyl, 2-furyl-3-furyl-2-6-furyl-2-furyl-2-3-furyl-3-2-3-6-2-furyl-2-3-furyl-2-furyl-butenyl, 2-3-2-3-furyl-2-6-furyl-3-2-3-2-6-2-pentyl-furyl-pentyl-3-pentyl-3-2-3-2-pentyl-2-pentyl, 3-pentyl, 3-pentyl, 3-pentyl-3-pentyl, 3-pentyl-3-6-3-pentyl-6-pentyl, 3-pentyl, 3-pentyl, 3-pentyl, 3-pentyl, 3-pentyl, 3-pentyl, 3-pentyl-3-pentyl, 3-pentyl, 3-6-3-pentyl-3-6-pentyl-6-pentyl-6-pentyl, 3-pentyl-6-pentyl, 3-pentyl, 3-pentyl, 3-pentyl, 3-pentyl-6-pentyl, 3-pentyl-6-pentyl, 3-6-pentyl-6-3-pentyl-3-pentyl-6-pentyl,3-6-pentyl-6-pentyl, 3-6-3-pentyl, 3-6-pentyl, 3-6-pentyl, 3-6-pentyl, 3-6-pentyl, 3-6-pentyl, 3-6-pentyl, 3-6-pentyl-6-3-6-pentyl, 3-6-pentyl, 3-6-pentyl, 3-6-pentyl, 3-6-pentyl, 3-6-pentyl, 3-pentyl, 2-pentyl, 3-6-pentyl, 3-6-3-pentyl, 3-6-pentyl, 3-6-pentyl, 3-6-pentyl, 3-pentyl, 2-pentyl, 3-6-pentyl, 3-6-pentyl, 3-pentyl, 2-pentyl, 3-6-pentyl, 3-6-pentyl, 2-6-pentyl, 3-6-pentyl, 3-6-3-6-pentyl, 3-6-pentyl, 3-6-2-3-6-3-6-pentyl, 3-pentyl, 2-6-pentyl, 3-6-pentyl, 2-pentyl, 3-pentyl, 2-6-pentyl, 3-pentyl, 2-pentyl, 3-pentyl, 2-pentyl, 3-6-pentyl, 3-6-pentyl, 2-6-pentyl, 3-6-pentyl, 3-6-pentyl, 2-6-pentyl, 2-6-pentyl, 3-6-pentyl, 2-6-pentyl, 3-6-pentyl, 3-pentyl, 2-pentyl, 3-6-pentyl, 3-6-pentyl, 2-pentyl, 3-6-pentyl, 3-pentyl, 2-pentyl, 3-6-pentyl, 2-pentyl, 3-6-pentyl, 2-6-pentyl, 2-6-pentyl, 2-6-pentyl, 2-6-pentyl, 2-6-pentyl, 3-6-pentyl, 3-pentyl, 2-6-pentyl, 2-6-pentyl, 3-2-3-pentyl, 3-6-pentyl, 2-6-2-6-2-6-pentyl, 2-6-pentyl, 3-6-2-pentyl, 2-6-pentyl, 2-6-pentyl, 3-pentyl, 2-6-pentyl, 2-6-pentyl, 2-pentyl, 2-6-2-3-pentyl, 2-3-6-2-pentyl, 3-pentyl, 2-6-2-pentyl, 3-6-pentyl, 3-6-pentyl, 3-pentyl, 2-pentyl, 3-pentyl, 2-pentyl, 3-pentyl, 2-6-pentyl, 2-6-3-pentyl, 2-pentyl, 3-6-pentyl, 2-6-pentyl, 3-pentyl, 2-pentyl, 3-6-pentyl, 2-6-pentyl, 2-pentyl, 3-pentyl, 2-.
Phenyl-lower alkoxycarbonyl includes phenyl-lower alkoxycarbonyl wherein the alkoxycarbonyl moiety is a linear or branched alkoxycarbonyl having 1 to 6 carbon atoms in the alkoxy moiety, such as: benzyloxycarbonyl, 2-phenylethoxycarbonyl, 1-phenylethoxycarbonyl, 3-phenylpropoxycarbonyl, 4-phenylbutoxycarbonyl, 5-phenylpentoxycarbonyl, 6-phenylhexyloxycarbonyl, 1-dimethyl-2-phenylethoxycarbonyl, 2-methyl-3-phenylpropoxycarbonyl and the like.
The lower alkyl group substituted with a lower alkoxycarbonyloxy group includes a linear or branched alkyl group having 1 to 6 carbon atoms which is substituted with an alkoxycarbonyloxy group in which the alkoxy moiety has a linear or branched alkoxy group having 1 to 6 carbon atoms, such as methoxycarbonyloxymethyl, ethoxycarbonyloxymethyl, 2-ethoxycarbonyloxyethyl, 1-ethoxycarbonyloxyethyl, 3-methoxycarbonyloxypropyl, 4-ethoxycarbonyloxybutyl, 6-propoxycarbonyloxyhexyl, 5-isopropoxycarbonyloxypentyl, 1-dimethyl-2-butoxycarbonyloxyethyl, 2-methyl-3-tert-butoxycarbonyloxypropyl, 2-pentyloxycarbonyloxyethyl, hexyloxycarbonyloxymethyl and the like.
Lower alkyl substituted with benzoyl optionally having halogen substituents on the phenyl ring includes straight-chain or branched alkyl groups having 1 to 6 carbon atoms substituted with benzoyl in which the phenyl ring may optionally have 1 to 3 halogen substituents, such as benzoylmethyl, 1- (2-chlorobenzoyl) ethyl, 2- (3-chlorobenzoyl) ethyl, 3- (4-chlorobenzoyl) propyl, 4- (2-fluorobenzoyl) butyl, 1-dimethyl-2- (3-fluorobenzoyl) ethyl, 5- (4-fluorobenzoyl) pentyl, 6- (2-bromobenzoyl) hexyl, 2-methyl-3- (3-bromobenzoyl) propyl, (4-bromobenzoyl) methyl, ethyl, 2- (2-iodobenzoyl) ethyl group, 1- (4-iodobenzoyl) ethyl group, (3, 5-dichlorobenzoyl) methyl group, 2- (2, 6-dichlorobenzoyl) ethyl group, 1- (3, 4-dichlorobenzoyl) ethyl group, 3- (3, 4-difluorobenzoyl) propyl group, (3, 5-dibromobenzoyl) methyl group, (3, 4, 5-trichlorobenzoyl) methyl group and the like.
The amino group optionally substituted with a lower alkanoyl group includes amino groups which may optionally contain a straight or branched alkanoyl substituent having 1 to 6 carbon atoms, such as amino, formylamino, acetylamino, propionylamino, butyrylamino, isobutyrylamino, pentanoylamino, tert-butylcarbonylamino, hexanoylamino and the like.
The invention specifically includes the following compounds:
(1) quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R2、R3、R4M, n and r are as defined above.
(2) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom, R2、R3、R4M, n and r are as defined above.
(3) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkyl, R2、R3、R4M, n and r are as defined above.
(4) Quinoxaline derivatives of formula (1) or salts thereof, wherein R2Is a hydrogen atom, R1、R3、R4M, n and r are as defined above.
(5) Quinoxaline derivatives of formula (1) or salts thereof, wherein R2Is lower alkyl optionally containing halogen substituents, R1、R3、R4M, n and r are as defined above.
(6) Quinoxaline derivatives of formula (1) or salts thereof, wherein R2Is phenyl, R1、R3、R4M, n and r are as defined above.
(7) Quinoxaline derivatives of formula (1) or salts thereof, wherein R2Is lower alkyl substituted by morpholinyl, R1、R3、R4M, n and r are as defined above.
(8) Quinoxaline derivatives of formula (1) or salts thereof, wherein R2Lower alkyl substituted by imidazolyl, R1、R3、R4M, n and r are as defined above.
(9) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a hydrogen atom, R4Is a group of the formula(wherein A, R5And p is as defined above), R1、R2M, n and r are as defined above.
(10) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl, R4Is a group of the formula
Figure A9419071900982
(wherein A, R5And p is as defined above), R1、R2m, n and r are as defined above.
(11) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a hydrogen atom, R4Is a phenyl-lower alkene which may optionally have a substituent on the phenyl moiety selected fromBase: lower alkoxy, halogen, optionally containing a substituent selected from the group consisting ofAmino substituted by lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, R1、R2M, n and r are as defined above.
(12) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, R1、R2M, n and r are as defined above.
(13) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a hydrogen atom, R4Is lower alkenyl, R1、R2M, n and r are as defined above.
(14) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl, R4Is lower alkenyl, R1、R2M, n and r are as defined above.
(15) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a hydrogen atom, R4Is cycloalkyl-lower alkyl, R1、R2M, n and r are as defined above.
(16) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl, R4Is cycloalkyl-lower alkyl, R1、R2M, n and r are as defined above.
(17) Formula (A), (B) and1) wherein R is3Is a hydrogen atom, R4Is naphthyl-lower alkyl, R1、R2M, n and r are as defined above.
(18) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl, R4Is naphthyl-lower alkyl, R1、R2M, n and r are as defined above.
(19) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a hydrogen atom, R4Is lower alkyl which may be substituted in the phenyl moiety by phenylthio optionally containing lower alkoxy substituents, R1、R2M, n and r are as defined above.
(20) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl, R4Is lower alkyl which may be substituted in the phenyl moiety by phenylthio optionally containing lower alkoxy substituents, R1、R2M, n and r are as defined above.
(21) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a hydrogen atom, R4Is a phenylsulfinyl-substituted lower alkyl group which may optionally contain a lower alkoxy substituent in the phenyl moiety, R1、R2M, n and r are as defined above.
(22) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl, R4Is a phenylsulfinyl-substituted lower alkyl group which may optionally contain a lower alkoxy substituent in the phenyl moiety, R1、R2M, n and r are as defined above.
(23) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a hydrogen atom, R4Is lower alkyl substituted by phenylsulfonyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(24) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl, R4Is lower alkyl substituted by phenylsulfonyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(25) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a hydrogen atom, R4Is lower alkyl substituted by phenoxy, R1、R2M, n and r are as defined above.
(26) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl, R4Is lower alkyl substituted by phenoxy, R1、R2M, n and r are as defined above.
(27) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a hydrogen atom, R4Is a group of the formula
Figure A9419071901011
(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(28) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl, R4Is a group of the formula(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(29) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a hydrogen atom, R4Is of the formula-A5-CR42R43R44Group (A)5、R42、R43And R44As defined above), R1、R2M, n and r are as defined above.
(30) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl, R4Is of the formula-A5-CR42R43R44Group (A)5、R42、R43And R44As defined above), R1、R2M, n and r are as defined above.
(31) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a hydrogen atom, R4Is a methyl group which may optionally have a lower alkyl group selected from oxo, hydroxy, and the like on the 2, 3-dihydro-1H-indenyl ring2, 3-dihydro-1H-indenyl-substituted lower alkyl of a siloxy substituent, R1、R2M, n and r are as defined above.
(32) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from oxo, hydroxy, and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, R1、R2M, n and r are as defined above.
(33) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a hydrogen atom, R4Is a group of the formula
Figure A9419071901021
(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(34) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl, R4Is a group of the formula(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(35) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3And R4Together with the nitrogen atom, form a 1, 2, 3, 4-tetrahydroisoquinolinyl radical, R, optionally containing lower alkoxy1、R2M, n and r are as defined above.
(36) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is a radical of the formula(wherein A, R5And p is as defined above), m, n and r are as defined above.
(37) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkenyl group, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is optionally provided on the phenyl moiety with a substituent selected from the group consisting ofPhenyl-lower alkenyl of substituents of (1): lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl andphenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, and m, n and r are as defined above.
(38) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is lower alkenyl, and m, n and r are as defined above.
(39) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(40) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is naphthyl-lower alkyl, and m, n and r are as defined above.
(41) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is naphthyl-Lower alkyl, m, n and r are as defined above.
(42) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, and m, n and r are as defined above.
(43) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group，R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is a phenylsulfinyl-substituted lower alkyl group which may optionally have a lower alkoxy substituent on the phenyl moiety, and m, n and r are as defined above.
(44) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, and m, n and r are as previously defined.
(45) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is phenoxy-substituted lower alkyl, and m, n and r are as defined above.
(46) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is a group of the formula
Figure A9419071901041
(wherein each symbol is as defined above), and m, n and r are as defined above.
(47) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is of the formula-A5-CR43R43R44Group (A)5、R42、R43And R44As defined above), m, n and r are asdefined above.
(48) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group which may optionally have a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, and m, n and r are as defined above.
(49) Formula (II)(1) Wherein R is1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is a group of the formula
Figure A9419071901051
(wherein each symbol is as defined above), and m, n and r are as defined above.
(50) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3And R4Together with the nitrogen atom, form a 1, 2, 3, 4-tetrahydroisoquinolinyl group which may optionally contain lower alkoxy groups, and m, n and r are as defined above.
(51) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally containing halogen substituents, R3Is a hydrogen atom or lowerLower alkyl radical, R4Is a group of the formula:
Figure A9419071901061
(wherein A, R5And p is as defined above), m, n and r are as defined above.
(52) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally containing halogen substituents, R3Is hydrogen or lower alkyl,R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, and m, n and r are as defined above.
(53) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally containing halogen substituents, R3Is a hydrogen atom or lowerLower alkyl radical, R4Is lower alkenyl, and m, n and r are as defined above.
(54) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally containing halogen substituents, R3Is hydrogen atom or lower. Lower alkyl radical, R4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(55) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally containing halogen substituents, R3Is hydrogen or lower alkyl, R4Is naphthyl-lower alkyl, and m, n and r are as defined above.
(56) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom orLower alkyl, R2Is lower alkyl optionally containing halogen substituents, R3Is hydrogen or lower alkyl, R4Is lower alkyl which may be substituted in the phenyl moiety by phenylthio optionally containing lower alkoxy substituents, and m, n and r are as defined above.
(57) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally containing halogen substituents, R3Is hydrogen or lower alkyl, R4Is a phenylsulfinyl-substituted lower alkyl group which may optionally have a lower alkoxy substituent on the phenyl moiety, and m, n and r are as defined above.
(58) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally containing halogen substituents, R3Is hydrogen or lower alkyl, R4Is lower alkyl substituted by phenylsulfonyl which may optionally contain lower alkoxy substituents on the phenyl moiety, and m, n and r are as defined above.
(59) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally containing halogen substituents, R3Is hydrogen or lower alkyl, R4Is phenoxy-substitutedThe alkyl, m, n and r are as defined above.
(60) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally containing halogen substituents, R3Is hydrogen or lower alkyl, R4Is a group of the formula
Figure A9419071901071
(wherein each symbol is as defined above) and m, n and r are as defined above.
(61) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom orLower alkyl, R2Is lower alkyl optionally containing halogen substituents, R3Is hydrogen or lower alkyl, R4Is of the formula-A5-CR43R43R44A group of (wherein A)5、R42、R43And R44As defined above), m, n and r are as defined above.
(62) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally containing halogen substituents, R3Is hydrogen or lower alkyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group which may optionally have substitution at the 2, 3-dihydro-1H-indenyl ring selected from oxo, hydroxy and lower alkyl-containing siloxy, and m, n and r are as defined above.
(63) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally containing halogen substituents, R3Is hydrogen or lower alkyl, R4Is a group of the formula
Figure A9419071901081
(wherein each symbol is as defined above) and m, n and r are as defined above.
(64) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally containing halogen substituents, R3And R4Together with the nitrogen atom, form a 1, 2, 3, 4-tetrahydroisoquinolinyl group which may optionally contain lower alkoxy groups, and m, n and r are as defined above.
(65) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula
Figure A9419071901091
(wherein A, R5And p is as defined above), m, n and r are as defined above.
(66) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, and m, n and r are as defined above.
(67) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is lower alkenyl, and m, n and r are as defined above.
(68) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(69) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is naphthyl-lower alkyl, and m, n and r are as defined above.
(70) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is hydrogen or lower alkyl, R4At the phenyl partLower alkyl optionally substituted by phenylthio containing lower alkoxy substituents, and m, n and r are as defined above.
(71) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is a phenylsulfinyl-substituted lower alkyl group which may optionally have a lower alkoxy substituent on the phenyl moiety, and m, n and r are as defined above.
(72) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, and m, n and r are as previously defined.
(73) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is phenoxy-substituted lower alkyl, and m, n and r are as defined above.
(74) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula
Figure A9419071901101
(wherein each symbol is as defined above) and m, n and r are as defined above.
(75) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above),m, n and r are as defined above.
(76) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom orLower alkyl, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group which may optionally have a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, and m, n and r are as defined above.
(77) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula(wherein each symbol is as defined above) and m, n and r are as defined above.
(78) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3And R4Together with the nitrogen atom, form a 1, 2, 3, 4-tetrahydroisoquinolinyl group which may optionally contain lower alkoxy groups, and m, n and r are as defined above.
(79) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula
Figure A9419071901112
(wherein A, R5And p is as defined above), m, n and r are as defined above.
(80) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenesOxy, nitro and lower alkyl optionally having halogen substituents, and m, n and r are as defined above.
(81) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is lower alkenyl, and m, n and r are as defined above.
(82) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(83) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is naphthyl-lower alkyl, and m, n and r are as defined above.
(84) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Ishydrogen or lower alkyl, R4Lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, and m, n and r are as defined above.
(85) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is a hydrogen atom or a lower alkyl group,R4is a phenylsulfinyl-substituted lower alkyl group which may optionally have a lower alkoxy substituent on the phenyl moiety, and m, n and r are as defined above.
(86) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, and m, n and r are as previously defined.
(87) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is phenoxy-substituted lower alkyl, and m, n and r are as defined above.
(88) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula
Figure A9419071901131
(wherein each symbol is as defined above) and m, n and r are as defined above.
(89) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), m, n and r are as defined above.
(90) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is a hydrogen atom or a lower alkyl group,R4is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group which may optionally have a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, and m, n and r are as defined above.
(91) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula
Figure A9419071901141
(wherein each symbol is as defined above) and m, n and r are as defined above.
(92) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group，R2Is lower alkyl substituted by morpholinyl, R3And R4Together with the nitrogen atom, form a 1, 2, 3, 4-tetrahydroisoquinolinyl group which may optionally contain lower alkoxy groups, and m, n and r are as defined above.
(93) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula
Figure A9419071901142
(wherein A, R5And p is as defined above), m, n and r are as defined above.
(94) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, and m, n and r are as defined above.
(95) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is lower alkenyl, and m, n and r are as defined above.
(96) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(97) Quinoxaline derivatives of formula (1) or salts thereof, whereinR1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is naphthyl-lower alkyl, and m, n and r are as defined above.
(98) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, and m, n and r are as defined above.
(99) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3Is a hydrogen atom or a lower alkyl group,R4is a phenylsulfinyl-substituted lower alkyl group which may optionally have a lower alkoxy substituent on the phenyl moiety, and m, n and r are as defined above.
(100) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, and m, n and r are as previously defined.
(101) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is phenoxy-substituted lower alkyl, and m, n and r are as defined above.
(102) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula(wherein each symbol is as defined above) and m, n and rare as defined above.
(103) Quinoxaline derivatives of formula (1)Or a salt thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), m, n and r are as defined above.
(104) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3Is a hydrogen atom or a lower alkyl group,R4is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group which may optionally have a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, and m, n and r are as defined above.
(105) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula(wherein each symbol is as defined above) and m, n and r are as defined above.
(106) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is imidazolyl-substituted lower alkyl, R3And R4Together with the nitrogen atom, form a 1, 2, 3, 4-tetrahydroisoquinolinyl group which may optionally contain lower alkoxy groups, and m, n and r are as defined above.
(107) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is a hydrogen atom, R4Is a group of the formula
Figure A9419071901172
(wherein A, R5And p is as defined above), R2M, n and r are as defined above.
(108) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl, R4Is a group of the formula
Figure A9419071901181
(wherein A, R5And p is as defined above), R2M, n and r are as defined above.
(109) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is a hydrogen atom, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, R2M, n and r are as defined above.
(110) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, R2M, n and r are as defined above.
(111) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is a hydrogen atom, R4Is lower alkenyl, R2M, n and r are as defined above.
(112) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl, R4Is lower alkenyl, R2M, n and r are as defined above.
(113) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is a hydrogen atom, R4Is cycloalkyl-lower alkyl, R2M, n and r are as defined above.
(114) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl, R4Is cycloalkyl-lower alkyl, R2M, n and r are as defined above.
(115) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is a hydrogen atom, R4Is naphthyl-lower alkyl, R2M, n and r are as defined above.
(116) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl, R4Is naphthyl-lower alkyl, R2M, n and r are as defined above.
(117) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is a hydrogen atom, R4Is lower alkyl substituted by phenylthiowhich may optionally contain lower alkoxy substituents in the phenyl moiety, R2M, n and r are as defined above.
(118) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl, R4Is lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, R2M, n and r are as defined above.
(119) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is a hydrogen atom, R4Is benzene which may optionally contain lower alkoxy substituents in the phenyl moietyLower alkyl substituted by sulfinyl, R2M, n and r are as defined above.
(120) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl, R4Is a phenyl moiety which may optionally contain a lower alkoxy groupPhenylsulfinyl-substituted lower alkyl of a substituent R2M, n and r are as defined above.
(121) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is a hydrogen atom, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R2M, n and r are as defined above.
(122) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R2M, n and r are as defined above.
(123) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Isa hydrogen atom, R4Is lower alkyl substituted by phenoxy, R2m, n and r are as defined above.
(124) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl, R4Is lower alkyl substituted by phenoxy, R2M, n and r are as defined above.
(125) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is a hydrogen atom, R4Is a group of the formula
Figure A9419071901201
(wherein each symbol is as defined above), R2M, n and r are as defined above.
(126) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl, R4Is a group of the formula
Figure A9419071901211
(wherein each symbol is as defined above), R2M, n and r are as defined above.
(127) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is a hydrogen atom, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), R2M, n and r are as defined above.
(128) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), R2M, n and r are as defined above.
(129) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is a hydrogen atom, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from the group consisting of oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, R2M, n and r are as defined above.
(130) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from the group consisting of oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, R2M, n and r are as defined above.
(131) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is a hydrogen atom, R4Is a group of the formula
Figure A9419071901221
(wherein each symbol is as defined above), R2M, n and r are as defined above.
(132) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl, R4Is a group of the formula
Figure A9419071901222
(wherein each symbol is as defined above), R2M, n and r are as defined above.
(133) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3And R4Together with the nitrogen atom form a 1, 2, 3, 4-tetrahydroisoquinolinyl radical optionally containing lower alkoxy, R2M, n and r are as defined above.
(134) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, R2、R3、R4M, n and r are as defined above.
(135) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is amino optionally substituted with lower alkyl, R2、R3、R4M, n and r are as defined above.
(136) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is aminocarbonyl optionally having lower alkyl substituents, R2、R3、R4M, n and r are as defined above.
(137) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenyl-lower alkoxycarbonyl, R4Is a group of the formula
Figure A9419071901231
(wherein A, R5And p is as defined above), R1、R2M, n and r are as defined above.
(138) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyloxy-substituted lower alkyl, R4Is a group of the formula(wherein A, R5And p is as defined above), R1、R2M, n and r are as defined above.
(139) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenyl-lower alkoxycarbonyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above),Lower alkenyloxy, nitro and lower alkyl optionally containing halogen substituents, R1、R2M, n and r are as defined above.
(140) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyloxy-substituted lower alkyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, R1、R2M, n and r are as defined above.
(141) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenyl-lower alkoxycarbonyl, R4Is lower alkenyl, R1、R2M, n and r are as defined above.
(142) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyloxy-substituted lower alkyl, R4Is lower alkenyl, R1、R2M, n and r are as defined above.
(143) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenyl-lower alkoxycarbonyl, R4Is cycloalkyl-lower alkyl, R1、R2M, n and r are as defined above.
(144) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyloxy-substituted lower alkyl, R4Is cycloalkyl-lower alkyl, R1、R2M, n and r are as defined above.
(145) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenyl-lower alkoxycarbonyl, R4Is naphthyl-lower alkyl, R1、R2M, n and r are as beforeThe above definitions are provided.
(146) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyloxy-substituted lower alkyl, R4Is naphthyl-lower alkyl, R1、R2M, n and r are as defined above.
(147) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenyl-lower alkoxycarbonyl, R4Is lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, R1、R2M, n and r are as defined above.
(148) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyloxy-substituted lower alkyl, R4Is lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, R1、R2M, n and r are as defined above.
(149) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenyl-lower alkoxycarbonyl, R4Is phenylsulfinyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(150) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyloxy-substituted lower alkyl, R4Is phenylsulfinyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(151) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenyl-lower alkoxycarbonyl, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(152) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyloxy-substituted lower alkyl, R4Is a phenyl moiety which may optionally contain lower alkoxyLower alkyl substituted by phenylsulfonyl of the substituent R1、R2M, n and r are as defined above.
(153) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenyl-lower alkoxycarbonyl, R4Is lower alkyl substituted by phenoxy, R1、R2M, n and r are as defined above.
(154) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyloxy-substituted lower alkyl, R4Is lower alkyl substituted by phenoxy, R1、R2M, n and r are as defined above.
(155) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenyl-lower alkoxycarbonyl, R4Is a group of the formula(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(156) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyloxy-substituted lower alkyl, R4Is a group of the formula
Figure A9419071901262
(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(157) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenyl-lower alkoxycarbonyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), R1、R2M, n and r are as defined above.
(158) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyloxy-substituted lower alkyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), R1、R2M, n and r are as defined above.
(159) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenyl-lower alkoxycarbonyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from the group consisting of oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, R1、R2M, n and r are as defined above.
(160) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyloxy-substituted lower alkyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from the group consisting of oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, R1、R2M, n and r are as defined above.
(161) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenyl-lower alkoxycarbonyl, R4Is a group of the formula
Figure A9419071901271
(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(162) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyloxy-substituted lower alkyl, R4Is a group of the formula(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(163) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyl, R4Is a group of the formula
Figure A9419071901282
(wherein A, R5And p is as defined above), R1、R2M, n and r are as defined above.
(164) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxycarbonyl, R4Is a group of the formula
Figure A9419071901283
(wherein A, R5And p is as defined above), R1、R2、m、n and r are as defined above.
(165) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, R1、R2M, n and r are as defined above.
(166) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxycarbonyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, R1、R2M, n and r are as defined above.
(167) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyl, R4Is lower alkenyl, R1、R2M, n and r are as defined above.
(168) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxycarbonyl, R4Is lower alkenyl, R1、R2M, n and r are as defined above.
(169) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyl, R4Is cycloalkyl-lower alkyl, R1、R2M, n and r are as defined above.
(170) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxycarbonyl, R4Is cycloalkyl-lower alkyl, R1、R2M, n and r are as defined aboveAnd (5) defining.
(171) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyl, R4Is naphthyl-lower alkyl, R1、R2M, n and r are as defined above.
(172) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxycarbonyl, R4Is naphthyl-lower alkyl, R1、R2M, n and r are as defined above.
(173) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyl, R4Is lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, R1、R2M, n and r are as defined above.
(174) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxycarbonyl, R4Is lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, R1、R2M, n and r are as defined above.
(175) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyl, R4Is phenylsulfinyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(176) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxycarbonyl, R4Is phenylsulfinyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(177) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lowLower alkanoyl radical, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(178) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxycarbonyl, R4Is phenylsulfonyl-substituted lower alkyl whichmay optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(179) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoylRadical, R4Is lower alkyl substituted by phenoxy, R1、R2M, n and r are as defined above.
(180) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxycarbonyl, R4Is lower alkyl substituted by phenoxy, R1、R2M, n and r are as defined above.
(181) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyl, R4Is a group of the formula(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(182) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxycarbonyl, R4Is a group of the formula
Figure A9419071901312
(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(183) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), R1、R2M, n and r are as defined above.
(184) Quinoxaline derivatives of formula (1) or salts thereofWherein R is3Is lower alkoxycarbonyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), R1、R2M, n and r are as defined above.
(185) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from the group consisting of oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, R1、R2M, n and r are as defined above.
(186) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxycarbonyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from the group consisting of oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, R1、R2M, n and r are as defined above.
(187) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoyl, R4Is a group of the formula
Figure A9419071901321
(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(188) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxycarbonyl, R4Is a group of the formula
Figure A9419071901322
(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(189) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxy-lower alkyl, R4Is a group of the formula
Figure A9419071901331
(wherein A, R5P is as defined above), R1、R2M, n and r are as defined above.
(190) Quinoxaline derivatives of formula (1)Or a salt thereof, wherein R3Is phenoxycarbonyl, R4Is a group of the formula(wherein A, R5P is as defined above), R1、R3M, n and r are as defined above.
(191) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxy-lower alkyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, R1、R2M, n and r are as defined above.
(192) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenoxycarbonyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents,R1、R2M, n and r are as defined above.
(193) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxy-lower alkyl, R4Is lower alkenyl, R1、R2M, n and r are as defined above.
(194) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenoxycarbonyl, R4Is lower alkenyl, R1、R2M, n and r are as defined above.
(195) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxy-lower alkyl, R4Is cycloalkyl-lower alkyl, R1、R2M, n and r are as defined above.
(196) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenoxycarbonyl, R4Is cycloalkyl-lower alkyl, R1、R2M, n and r are as defined above.
(197) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxy-lower alkyl, R4Is naphthyl-lower alkyl, R1、R2M, n and r are as defined above.
(198) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenoxycarbonyl, R4Is naphthyl-lower alkyl, R1、R2M, n and r are as defined above.
(199) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxy-lower alkyl, R4Is lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, R1、R2M, n and r are as defined above.
(200) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenoxycarbonyl, R4Is lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, R1、R2M, n and r are as defined above.
(201) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxy-lower alkyl, R4Is phenylsulfinyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(202) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenoxycarbonyl, R4Is phenylsulfinyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(203) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxy-lower alkyl, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(204) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenoxycarbonyl, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(205) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxy-lower alkyl, R4Is lower alkyl substituted by phenoxy, R1、R2M, n and r are as defined above.
(206) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenoxycarbonylRadical, R4Is lower alkyl substituted by phenoxy, R1、R2M, n and r are as defined above.
(207) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxy-lower alkyl, R4Is a group of the formula
Figure A9419071901361
(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(208) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenoxycarbonyl, R4Is a group of the formula
Figure A9419071901362
(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(209) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxy-lower alkyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), R1、R2M, n and r are as defined above.
(210) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenoxycarbonyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), R1、R2M, n and r are as defined above.
(211) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxy-lower alkyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from the group consisting of oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, R1、R2M, n and r are as defined above.
(212) Quinoxaline derivativesof formula (1) or salts thereof, wherein R3Is phenoxycarbonyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from the group consisting of oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, R1、R2M, n and r are as defined above.
(213) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxy-lower alkyl, R4Is a group of the formula(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(214) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is phenoxycarbonyl, R4Is a group of the formula(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(215) A quinoline of the formula (1)An oxinoid derivative or a salt thereof, wherein R3Is lower alkyl substituted by lower alkanoyl, R4Is a group of the formula(wherein A, R5And p is as defined above), R1、R2And m, n, r are as defined above.
(216) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxycarbonyloxy-substituted lower alkyl, R4Is a group of the formula
Figure A9419071901382
(wherein A, R5And p is as defined above), R1、R2And m, n, r are as defined above.
(217) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkanoyl,R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, a compound of formula (la)-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, R1、R2And m, n, r are as defined above.
(218) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkoxycarbonyloxy, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro andlower alkyl optionally substituted by halogen, R1、R2And m, n, r are as defined above.
(219) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkanoyl, R4Is lower alkenyl, R1、R2And m, n, r are as defined above.
(220) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkoxycarbonyloxy, R4Is lower alkenyl, R1、R2And m, n, r are as defined above.
(221) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkanoyl, R4Is cycloalkyl-lower alkyl, R1、R2And m, n, r are as defined above.
(222) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkoxycarbonyloxy, R4Is cycloalkyl-lower alkyl, R1、R2And m, n, r are as defined above.
(223) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkanoylLower alkyl substituted by radicals R4Is naphthyl-lower alkyl, R1、R2And m, n, r are as defined above.
(224) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkoxycarbonyloxy, R4Is naphthyl-lower alkyl, R1、R2And m, n, r are as defined above.
(225) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkanoyl, R4Is lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, R1、R2And m, n, r are as defined above.
(226) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkoxycarbonyloxy, R4Is lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, R1、R2And m, n, r are as defined above.
(227) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkanoyl, R4Is phenylsulfinyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2And m, n, r are as defined above.
(228) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkoxycarbonyloxy, R4Is phenylsulfinyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2And m, n, r are as defined above.
(229) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkanoyl, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2And m, n, r are as defined above.
(230) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkoxyLower alkyl substituted by alkylcarbonyloxy, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2And m, n, r are as defined above.
(231) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkanoyl, R4Is lower alkyl substituted by phenoxy, R1、R2And m, n, r are as defined above.
(232) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkoxycarbonyloxy, R4Is lower alkyl substituted by phenoxy, R1、R2And m, n, r are as defined above.
(233) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is loweralkyl substituted by lower alkanoyl, R4Is a group of the formula(wherein each symbol is as defined above), R1、R2And m, n, r are as defined above.
(234) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkoxycarbonyloxy, R4Is a group of the formula(wherein each symbol is as defined above), R1、R2And m, n, r are as defined above.
(235) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkanoyl, R4Is of the formula-A5-CR42R43R44A group of (a); group (wherein A)5、R42、R43And R44As defined above), R1、R2And m, n, r are as defined above.
(236) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkoxycarbonyloxy, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), R1、R2And m, n, r are as defined above.
(237) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkanoyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from the group consisting of oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, R1、R2And m, n, r are as defined above.
(238) Quinoxaline derivatives of formula(1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkoxycarbonyloxy, R4Is 2, 3-dihydro-1H-indenyl optionally having a substituent on the 2, 3-dihydro-1H-indenyl ring selected from oxo, hydroxy and lower alkyl-containing siloxyLower alkyl of sub-group, R1、R2And m, n, r are as defined above.
(239) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkanoyl, R4Is a group of the formula
Figure A9419071901421
(wherein each symbol is as defined above) R1、R2And m, n, r are as defined above.
(240) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is lower alkyl substituted by lower alkoxycarbonyloxy, R4Is a group of the formula
Figure A9419071901431
(wherein each symbol is as defined above), R1、R2And m, n, r are as defined above.
(241) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a benzoyl-substituted lower alkyl group which may optionally have a halogen substituent on the phenyl ring, R4Is a group of the formula
Figure A9419071901432
(wherein A, R5And p is as defined above), R1、R2M, n and r are as defined above.
(242) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is of the formula-E-NR52R53Group (wherein E, R)52And R53As defined above), R4Is a group of the formula(wherein A, R5And p is as defined above), R1、R2M, n and rare as defined above.
(243) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a benzoyl-substituted lower alkyl group which may optionally have a halogen substituent on the phenyl ring, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, lower alkoxy substituted by lowerTetrazolyl optionally having lower alkyl substituent(s), hydroxy, formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, R1、R2M, n and r are as defined above.
(244) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is of the formula-E-NR52R53Group (wherein E, R)52And R53As defined above), R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, R1、R2M, n and r are as defined above.
(245) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a benzoyl-substituted lower alkyl group which may optionally have a halogen substituent on the phenyl ring, R4Is a lower chainAlkenyl radical, R1、R2M, n and r are as defined above.
(246) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is of the formula-E-NR52R53Group (wherein E, R)52And R53As defined above), R4Is lower alkenyl, R1、R2M, n and r are as defined above.
(247) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a benzoyl-substituted lower alkyl group which may optionally have a halogen substituent on the phenyl ring, R4Is cycloalkyl-lower alkyl, R1、R2M, n and r are as defined above.
(248) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is of the formula-E-NR52R53Group (wherein E, R)52And R53As defined above), R4Is cycloalkyl-lower alkyl, R1、R2M, n and r are as defined above.
(249) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a benzoyl-substituted lower alkyl group which may optionally have a halogen substituent on the phenyl ring, R4Is naphthyl-lower alkyl, R1、R2M, n and r are as defined above.
(250) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is of the formula-E-NR52R53Group (wherein E, R)52And R53As defined above), R4Is naphthyl-lower alkyl, R1、R2M, n and r are as defined above.
(251) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a benzoyl-substituted lower alkyl group which may optionally have a halogen substituent on the phenyl ring, R4Is lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, R1、R2M, n and r are as defined above.
(252) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is of the formula-E-NR52R53Group (wherein E, R)52And R53As defined above), R4Is lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, R1、R2M, n and r are as defined above.
(253) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a benzoyl-substituted lower alkyl group which may optionally have a halogen substituent on the phenyl ring, R4Is phenylsulfinyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(254) Quinoxaline derivatives of formula (1)An organism or a salt thereof, wherein R3Is of the formula-E-NR52R53Group (wherein E, R)52And R53As defined above), R4Is phenylsulfinyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(255) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a benzoyl-substituted lower alkyl group which may optionally have a halogen substituent on the phenyl ring, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(256) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is of the formula-E-NR52R53Group (wherein E, R)52And R53As defined above), R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(257) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a benzoyl-substituted lower alkyl group which may optionally have a halogen substituent on the phenyl ring, R4Is lower alkyl substituted by phenoxy, R1、R2M, n and r are as defined above.
(258) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is of the formula-E-NR52R53Group (wherein E, R)52And R53As defined above), R4Is lower alkyl substituted by phenoxy, R1、R2M, n and r are as defined above.
(259) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a benzoyl-substituted lower alkyl group which may optionally have a halogen substituent on the phenyl ring, R4Is a base of the following formulaBall
Figure A9419071901471
(wherein each symbol is as defined above), R1、R2M, n and r are as beforeThe above definitions are provided.
(260) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is of the formula-E-NR52R53Group (wherein E, R)52And R53As defined above), R4Is a group of the formula
Figure A9419071901472
(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(261) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a benzoyl-substituted lower alkyl group which may optionally have a halogen substituent on the phenyl ring, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), R1、R2M, n and r are as defined above.
(262) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is of the formula-E-NR52R53Group (wherein E, R)52And R53As defined above), R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), R1、R2M, n and r are as defined above.
(263) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a benzoyl-substituted lower alkyl group which may optionally have a halogen substituent on the phenyl ring, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from the group consisting of oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, R1、R2M, n and r are as defined above.
(264) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is of the formula-E-NR52R53Group (wherein E, R)52And R53As defined above), R4Is optionally provided with a substituent selected from oxo, hydroxy and lower alkyl on the 2, 3-dihydro-1H-indenyl ring2, 3-dihydro-1H-indenyl-substituted lower alkyl with a siloxy substituent of (A), R1、R2M, n and r are as defined above.
(265) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a benzoyl-substituted lower alkyl group which may optionally have a halogen substituent on the phenyl ring, R4Is a group of the formula(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(266) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is of the formula-E-NR52R53Group (wherein E, R)52And R53As defined above), R4Is a group of the formula
Figure A9419071901491
(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(267) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a group of the formula:(wherein A and R54As defined above), R4Is a group of the formula(wherein R, R5And p is as defined above), R1、R2M, n and r are as defined above.
(268) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a group of the formula:
Figure A9419071901494
(wherein A and R54As defined above), R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, R1、R2M, n and r are as defined above.
(269) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a group of the formula:
Figure A9419071901501
(wherein A and R54As defined above), R4Is lower alkenyl, R1、R2M, n and r are as defined above.
(270) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a group of the formula:
Figure A9419071901502
(wherein A and R54As defined above), R4Is cycloalkyl-lower alkyl, R1、R2M, n and r are as defined above.
(271) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a group of the formula:
Figure A9419071901511
(wherein A and R54As defined above), R4Is naphthyl-lower alkyl, R1、R2M, n and r are as defined above.
(272) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a group of the formula:(wherein A and R54As defined above), R4Is lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, R1、R2M, n and r are as defined above.
(273) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a group of the formula:
Figure A9419071901513
(wherein A and R54As defined above), R4Is phenylsulfinyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(274) Quinoxalines of the formula (1)Derivatives or salts thereof, wherein R3Is a group of the formula:
Figure A9419071901521
(wherein A and R54As defined above), R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R1、R2M, n and r are as defined above.
(275) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a group of the formula:
Figure A9419071901522
(wherein A and R54As defined above), R4Is lower alkyl substituted by phenoxy, R1、R2M, n and r are as defined above.
(276) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a group of the formula:
Figure A9419071901523
(wherein A and R54As defined above), R4Is a group of the formula:(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(277) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a group of the formula:
Figure A9419071901532
(wherein A and R54As defined above), R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), R1、R2M, n and r are as defined above.
(278) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a group of the formula:(wherein A and R54As defined above), R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from the group consisting of oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, R1、R2M, n and r are as defined above.
(279) Quinoxaline derivatives of formula (1) or salts thereof, wherein R3Is a group of the formula:(wherein A and R54As defined above). R4Is a group of the formula:
Figure A9419071901542
(wherein each symbol is as defined above), R1、R2M, n and r are as defined above.
(280) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is a group of the formula:(wherein A, R5And p is as previously defined), m, n and r are as previously defined.
(281) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, lower alkoxy,A halogen atom, an amino group optionally having A substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, A lower alkoxy group substituted with A lower alkoxy group, A tetrazolyl group optionally having A lower alkyl substituent on the tetrazole ring, A hydroxyl group, A compound of the formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, and m, n and r are as defined above.
(282) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is lower alkenyl, and m, n and r are as defined above.
(283) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(284) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is naphthyl-lower alkyl, and m, n and r are as defined above.
(285) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is naphthyl-lower alkyl, and m, n and r are as defined above.
(286) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4At the phenyl partLower alkyl optionally substituted by phenylthio containing lower alkoxy substituents, and m, n and r are as defined above.
(287) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is a phenylsulfinyl-substituted lower alkyl group which may optionally have a lower alkoxy substituent on the phenyl moiety, and m, n and r are as defined above.
(288) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, and m, n and r are as previously defined.
(289) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is phenoxy-substituted loweralkyl, and m, n and r are as defined above.
(290) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is a group of the formula:(wherein each symbol is as defined above) and m, n and r are as defined above.
(291) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), m, n and r are as defined above.
(292) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is in 2, 3-A 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from oxo, hydroxy and siloxy containing lower alkyl on the dihydro-1H-indenyl ring, and m, n and r are as defined above.
(293) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3Is hydrogen or lower alkyl, R4Is a group of the formula:
Figure A9419071901571
(wherein each symbol is as defined above) and m, n and r are as defined above.
(294) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is a hydrogen atom, R3And R4Together with the nitrogen atom, form a 1, 2, 3, 4-tetrahydroisoquinolinyl group optionally containing lower alkoxy, and m, n and r are as defined above.
(295) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxyOr an amino group optionally having a lower alkyl substituent or an aminocarbonyl group optionally having a lower alkyl substituent, R2Is lower alkyl optionally having halogen substituents, R3Is hydrogen or lower alkyl, R4Is a group of the formula:
Figure A9419071901581
(wherein A, R5And p is as previously defined), m, n and r are as previously defined.
(296) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl optionally having halogen substituents, R3Is hydrogen or lower alkyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen, optionally containing substituents selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonylAmino of substituent, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent on tetrazolyl ring, hydroxy, or A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, and m, n and r are as defined above.
(297) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl optionally having halogen substituents, R3Is hydrogen or lower alkyl, R4Is lower alkenyl, and m, n and r are as defined above.
(298) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or amino optionally having lower alkyl substituentsRadical carbonyl, R2Is lower alkyl optionally having halogen substituents, R3Is hydrogen or lower alkyl, R4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(299) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl optionally having halogen substituents, R3Is hydrogen or lower alkyl, R4Is naphthyl-lower alkyl, and m, n and r are as defined above.
(300) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl optionally having halogen substituents, R3Is hydrogen or lower alkyl, R4Lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, and m, n and r are as defined above.
(301)Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl optionally having halogen substituents, R3Is hydrogen or lower alkyl, R4Is a phenylsulfinyl-substituted lower alkyl group which may optionally have a lower alkoxy substituent on the phenyl moiety, and m, n and r are as defined above.
(302) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl optionally having halogen substituents, R3Is hydrogen or lower alkyl, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, and m, n and r are as previously defined.
(303) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl optionally having halogen substituents, R3Is a hydrogen atom or lowerLower alkyl radical, R4Is phenoxy-substituted lower alkyl, and m, n and r are as defined above.
(304) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl optionally having halogen substituents, R3Is hydrogen or lower alkyl, R4Is a group of the formula
Figure A9419071901601
(wherein each symbol is as defined above) and m, n and rare as defined above.
(305) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl optionally having halogen substituentsRadical, R3Is hydrogen or lower alkyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), m, n and r are as defined above.
(306) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl optionally having halogen substituents, R3Is hydrogen or lower alkyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group which may optionally have a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, and m, n and r are as defined above.
(307) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl optionally having halogen substituents, R3Is a hydrogen atom or lowerLower alkyl radical, R4Is a group of the formula(wherein each symbol is as defined above) and m, n and r are as defined above.
(308) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl optionally having halogen substituents, R3And R4Together with the nitrogen atom, form a 1, 2, 3, 4-tetrahydroisoquinolinyl group optionally containing a lower alkoxy group, and m, n and r are as defined above.
(309) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula:(wherein A, R5And p is as previously defined), m, n and r are as previously defined.
(310) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen, optionally substituted by a substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonylAmino, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, and m, n and r are as defined above.
(311) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is lower alkenyl, and m, n and r are as defined above.
(312) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(313) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is naphthyl-lower alkyl, and m, n and r are as defined above.
(314) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, and m, n and r are as defined above.
(315) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3Is hydrogen or lower alkyl, R4In the phenyl moietyA phenylsulfinyl-substituted lower alkyl group which may optionally contain a lower alkoxy substituent, and m, n and r are as defined above.
(316) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, and m, n and r are as previously defined.
(317) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is phenoxy-substituted lower alkyl, and m, n and r are as defined above.
(318) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula:(wherein each code is as defined above)And m, n and r are as defined above.
(319) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), m, n and r are as defined above.
(320) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group which may optionally have a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, and m, n and r are as defined above.
(321) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula:
Figure A9419071901641
(wherein each symbol is as defined above) and m, n and r are as defined above.
(322) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is phenyl, R3And R4Together with the nitrogen atom, form a 1, 2, 3, 4-tetrahydroisoquinolinyl group optionally containing a lower alkoxy group, and m, n and r are as defined above.
(323) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or optionally having lower alkyl substituentsAminocarbonyl of lower alkyl substituents, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula:
Figure A9419071901651
(wherein A, R5And p is as previously defined), m, n and r are as previously defined.
(324) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, and m, n and r are as defined above.
(325) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is lower alkenyl, and m, n and r are as defined above.
(326) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(327) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or amino optionally having lower alkyl substituentsRadical carbonyl, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is naphthyl-lower alkyl, and m, n andr are as defined above.
(328) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, and m, n and r are as defined above.
(329) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is a phenylsulfinyl-substituted lower alkyl group which may optionally have a lower alkoxy substituent on the phenyl moiety, and m, n and r are as defined above.
(330) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, and m, n and r are as previously defined.
(331) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is phenoxy-substituted lower alkyl, and m, n and r are as defined above.
(332) Quinoxalinederivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl substituted by morpholinyl, R3Is a hydrogen atom or a lower alkyl group,R4is a group of the formula
Figure A9419071901671
(wherein each symbol is as defined above) and m, n and r are as defined above.
(333) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), m, n and r are as defined above.
(334) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group which may optionally have a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, and m, n and r are as defined above.
(335) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl substituted by morpholinyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula
Figure A9419071901672
(wherein each symbol is as defined above) and m, n and r are as defined above.
(336) Quinoxaline derivatives of formula (1)Or a salt thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is lower alkyl substituted by morpholinyl, R3And R4Together with the nitrogen atom, form a 1, 2, 3, 4-tetrahydroisoquinolinyl group optionally containing a lower alkoxy group, and m, n and r are as defined above.
(337) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula:
Figure A9419071901681
(wherein A, R5And p is as previously defined), m, n and r are as previously defined.
(338) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, and m, n and r are as defined above.
(339) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is lower alkenyl, and m, n and r are as defined above.
(340) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(341) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is naphthyl-lower alkyl, and m, n and r are as defined above.
(342) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, and m, n and r are as defined above.
(343 quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is a phenylsulfinyl-substituted lower alkyl group which may optionally have a lower alkoxy substituent on the phenyl moiety, and m, n and r are as defined above.
(344) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or amino optionally having lower alkyl substituentsRadical carbonyl, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is at phenylLower alkyl substituted by phenylsulfonyl which may optionally have lower alkoxy substituents in the moiety, and m, n and r are as defined above.
(345) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is phenoxy-substituted lower alkyl, and m, n and r are as defined above.
(346) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula:(wherein each symbol is as defined above) and m, n and r are as defined above.
(347) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), m, n and r are as defined above.
(348) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is imidazolyl-substituted lower alkyl, R3Is a hydrogen atom or a lower alkyl group,R4is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group which may optionally have a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, and m, n and r are as defined above.
(349) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is imidazolyl-substituted lower alkyl, R3Is hydrogen or lower alkyl, R4Is a group of the formula:
Figure A9419071901711
(wherein each symbol is as defined above) and m, n and r are as defined above.
(350) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents or aminocarbonyl optionally having lower alkyl substituents, R2Is imidazolyl-substituted lower alkyl, R3And R4Together with the nitrogen atom, form a 1, 2, 3, 4-tetrahydroisoquinolinyl group optionally containing a lower alkoxy group, and m, n and r are as defined above.
(351) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is hydrogen or lower alkyl, A is as defined above): r4Is a group of the formula
Figure A9419071901722
(wherein the group、R47And u is as defined above), R2M, n and r are as defined above.
(352) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lowerLower alkyl substituted by alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901724
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a group of the formula
Figure A9419071901731
(wherein A, R5And p is as defined above), R2M, n and r are as defined above.
(353) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901732
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, R2M, n and r are as defined above.
(354) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901741
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is lower alkenyl, R2M, n and r are as defined above.
(355) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901742
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is cycloalkyl-lower alkyl, R2M, n and r are as defined above.
(356) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, optionally having on the phenyl ringBenzoyl-substituted lower alkyl substituted by halogen, of formula-E-N (R)52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is naphthyl-lower alkyl, R2M, n and r are as defined above.
(357) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, R2M, n and r are as defined above.
(358) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901761
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4In the phenyl moiety mayLower alkyl substituted by phenylsulfinyl optionally having lower alkoxy substituents, R2M, n and r are as defined above.
(359) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, which is a pharmaceutically acceptable salt thereof, or52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901771
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, R2M, n and r are as defined above.
(360) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901772
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is lower alkyl substituted by phenoxy, R2M, n and r are as defined above.
(361) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkoxycarbonyloxyLower alkyl, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy substituted by a groupLower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally having a halogen substituent on the phenyl ring, a compound of formula-E-N (R)52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a group of the formula
Figure A9419071901782
(wherein the group
Figure A9419071901783
、R47And u is as defined above), R2M, n and r are as defined above.
(362) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkylsubstituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901791
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), R2M, n and r are as defined above.
(363) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkaneOxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally having a halogen substituent on the phenyl ring, a compound of formula-E-N (R)52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally having a substituent selected from the group consisting of oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, R2M, n and r are as defined above.
(364) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom orLower alkyl, R2Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a group of the formula(wherein the group、R47And u is as defined above), m, n and r are as defined above.
(365) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxyA carbonyl group, a lower alkanoyl substituted lower alkyl group, a benzoyl substituted lower alkyl group optionally having a halogen substituent on the phenyl ring, a compound of formula-E-N (R)52)(R53) Group (wherein E, R)52And R53As beforeThe above definitions), or a group of the formula:
Figure A9419071901811
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a group of the formula(wherein A, R5And p is as previously defined), m, n and r are as previously defined.
(366) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, and m, n and r are as defined above.
(367) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atomOr lower alkyl, R2Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is lower alkenyl, and m, n and r are as defined above.
(368) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonylLower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally having halogen substituent on phenyl ring, formula-E-N (R)52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(369) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogenatom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, benzyl optionally having halogen substituent on phenyl ringAcyl-substituted lower alkyl, of the formula-E-N (R)52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901832
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is naphthyl-lowLower alkyl, m, n and r are as defined above.
(370) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, and m, n and r are as defined above.
(371) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group,a is as defined above); r4Is a phenylsulfinyl-substituted lower alkyl group which may optionally have a lower alkoxy substituent on the phenyl moiety, and m, n and r are as defined above.
(372) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, and m, nand r are as previously defined.
(373) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom orLower alkyl, R2Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901861
(wherein R is54Is hydrogen or lower alkyl, A is as defined above): r4Is phenoxy-substituted lower alkyl, and m, n and r are as defined above.
(374) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or lowerAlkyl radical, R2Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901862
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a groupof the formula(wherein the group、R8And q is as defined above), m, n and r are as defined above.
(375) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is a hydrogen atom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), m, n and r are as defined above.
(376) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom orLower alkyl, R2Is hydrogenAtom, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or apharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group which may optionally have a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, and m, n and r are as defined above.
(377) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally having halogen substituent, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901891
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a group of the formula(wherein the group、R47And u is as defined above), m, n and r are as defined above.
(378) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is an optional toolLower alkyl with halogen substituents, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901894
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a group of the formula
Figure A9419071901901
(wherein A, R5And p is as previously defined), m, n and r are as previously defined.
(379) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally having halogen substituent, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and optionally halogenLower alkyl of the substituent, m, n and r are as defined above.
(380) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally having halogen substituent, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901911
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is lower alkenyl, and m, n and r are as defined above.
(381) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally having halogen substituent, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(382) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group，R2Is lower alkyl optionally having halogen substituent, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901922
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is naphthyl-lower alkyl, and m, n and r are as defined above.
(383) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally having halogen substituent, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkoxycarbonyloxy substituted lowerAlkyl, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally having halogen substituent on phenyl ring, formula-E-N (R)52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, and m, n and r are as defined above.
(384) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally having halogen substituent, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoylLower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally having halogen substituent on phenyl ring, formula-E-N (R)52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901932
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a phenylsulfinyl-substituted lower alkyl group which may optionally have a lower alkoxy substituent on the phenyl moiety, and m, n and r are as defined above.
(385) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally having halogen substituent, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, and m, n and r are as previously defined.
(386) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally having halogen substituent, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, benzoyl having optionally halogen substituent on phenyl ringLower alkyl of the generation, of the formula-E-N (R)52)(R53) Group (d) of(wherein E, R52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is phenoxy-substituted lower alkyl, and m, n and r are as defined above.
(387) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally having halogen substituent, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901952
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a group of the formula
Figure A9419071901953
(wherein the group
Figure A9419071901961
、R8And q is as defined above), m, n and r are as defined above.
(388) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally having halogen substituent, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901962
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is of the formula-A5-CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), m, n and r are as defined above.
(389) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl optionally having halogen substituent, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, optionally having halogen on the phenyl ringSubstituted benzoyl-substituted lower alkyl, of formula-E-N (R)52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is hydrogen or lower alkyl, A is as defined above) R4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group which may optionally have a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, and m, n and r are as defined above.
(390) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a saltthereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071901972
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a group of the formula
Figure A9419071901981
(wherein the group
Figure A9419071901982
、R47And u is as defined above), m, n and r are as defined above.
(391) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a group of the formula
Figure A9419071901984
(wherein A, R5And p is as previously defined), m, n and r are as previously defined.
(392) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, and m, n and r are as defined above.
(393) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoylLower alkyl of (a), benzoyl-substituted lower alkyl optionally having a halogen substituent on the phenyl ring, a compound of formula-E-N (R)52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is lower alkenyl, and m, n and r are as defined above.
(394) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(395) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071902011
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is naphthyl-lower alkyl, and m, n and r are as defined above.
(396) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, and m, n and r are as defined above.
(397) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E,R)52And R53As defined above), or a group of the formula:
Figure A9419071902022
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a phenylsulfinyl-substituted lower alkyl group which may optionally have a lower alkoxy substituent on the phenyl moiety, and m, n and r are as defined above.
(398) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom orLower alkyl, R2Is phenyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, which is a pharmaceutically acceptable salt thereof, or52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is phenylsulfonyl-substituted lower alkyl which may optionally contain lower alkoxy substituents on the phenyl moiety, and m, n and r are as previously defined.
(399) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonylLower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, or a pharmaceutically52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071902032
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is phenoxy-substituted lower alkyl, and m, n and r are as defined above.
(400) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a group of the formula
Figure A9419071902042
(wherein the group
Figure A9419071902043
、R8And q is as defined above), m, n and r are as defined above.
(401) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is lower alkyl substituted by lower alkanoyloxy, lowerAlkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoylSubstituted lower alkyl, benzoyl-substituted lower alkyl optionally having a halogen substituent on the phenyl ring, a compound of formula-E-N (R)52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071902051
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is of the formula-A5—CR42R43R44A group of (wherein A)5、R42、R43And R44As defined above), m, n and r are as defined above.
(402) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is phenyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071902052
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group which may optionally have a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, and m, n and r are as defined above.
(403) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, optionally having halogen substituent on phenyl ringBenzoyl-substituted lower alkyl of the formula-E-N (R)52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071902061
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a group of the formula
Figure A9419071902062
(wherein the group、R47And u is as defined above), m, n and r are as defined above.
(404) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom orLower alkyl, R2Is lower alkyl substituted by morpholinyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071902071
(wherein R is54Is hydrogen or lower alkyl, A is as defined above) R4Is a group of the formula
Figure A9419071902072
(wherein A, R5And p is as previously defined), m, n and r are as previously defined.
(405) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a salt thereof(R52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is phenyl-lower alkenyl which may optionally have substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined above), lower alkenyloxy, nitro and lower alkyl optionally having halogen substituents, and m, n and r are as defined above.
(406) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071902082
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is lower alkenyl, and m, n and r are as defined above.
(407) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonylLower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally having a halogen substituent on the phenyl ring, a compound of formula-E-N (R)52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071902091
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is cycloalkyl-lower alkyl, and m, n and r are as defined above.
(408) A quinoxaline derivative of formula (1) or a salt thereof, wherein R is1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Islower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071902101
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is naphthyl-lower alkyl, and m, n and r are as defined above.
(409) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, which is a salt thereof, or a pharmaceutically acceptable52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Lower alkyl substituted by phenylthio which may optionally contain lower alkoxy substituents in the phenyl moiety, and m, n and r are as defined above.
(410) Quinoxaline derivatives of formula (1) or saltsthereof, wherein R1Is a halogen atom or a lower alkyl group, R2Is lower alkyl substituted by morpholinyl, R3Is lower alkanoyloxy substitutedLower alkyl, lower alkoxycarbonyl, lower alkoxycarbonyloxy-substituted lower alkyl, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl-substituted lower alkyl, benzoyl-substituted lower alkyl optionally having halogen substituent on the phenyl ring, or a pharmaceutically acceptable salt thereof52)(R53) Group (wherein E, R)52And R53As defined above), or a group of the formula:
Figure A9419071902111
(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above); r4Is a phenylsulfinyl-substituted lower alkyl group which may optionally have a lower alkoxy substituent on the phenyl moiety, and m, n and r are as defined above.
(411) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:
Figure A9419071902112
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkyl substituted by phenylsulfonyl which may optionally bear lower alkoxy substituents on the phenyl moiety; m, n and r are as previously described.
(412) A quinoxaline derivative of formula (1) or a salt thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkyl substituted by phenoxy; m, n and r are as previously described.
(413) A quinoxaline derivative of formula (1) or a salt thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:
Figure A9419071902131
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:(wherein thegroup
Figure A9419071902133
、R8And q is as previously described); m, n and r are as previously described.
(414) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:
Figure A9419071902134
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula: -A5-CR42R43R44(wherein A is5、R42、R43And R44As previously described); m, n and r are as previously described.
(415) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:
Figure A9419071902141
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl optionally bearing a substituent selected from oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring; m, n and r are as previously described.
(416) Quinoxaline derivatives of formula (1)An organism or a salt thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, benzene optionally having halogen substituent on phenyl ringFormyl-substituted lower alkyl, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:
Figure A9419071902151
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:
Figure A9419071902152
(wherein the group
Figure A9419071902153
、R47And u is as previously described); m, n and r are as previously described.
(417) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:
Figure A9419071902161
(wherein, R54Is hydrogen or lower alkyl, A is as defined above) R4Is a group of the formula:
Figure A9419071902162
(wherein A, R5And p is as previously described); m, n and r are as previously described.
(418) Quinoxaline derivatives of formula (1) or salts thereof, wherein，R1Is a halogen atom or a lower alkyl group R2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:
Figure A9419071902163
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is phenyl-lower alkenyl, the phenyl moiety of which may optionally bear substituents selected from: lower alkoxy, lower alkoxy,A halogen atom, an amino group which may optionally have A substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, A lower alkoxy group substituted with A lower alkoxy group, A tetrazolyl group which may optionally have A lower alkyl substituent at the tetrazole moiety, A hydroxy group, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As described above), lower alkenyloxy, nitro and lower alkyl which may optionally have halogen substituents, m, n and r are as described above.
(419) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:
Figure A9419071902171
(wherein, R54Is hydrogen atom or lowerAlkyl, A is as previously described); r4M, n and r are lower alkenyl groups as described above.
(420) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, benzene optionally having halogen substituent on phenyl ringFormyl-substituted lower alkyl, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is cycloalkyl-lower alkyl; m, n and r are as previously described.
(421) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:
Figure A9419071902182
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is naphthyl-lower alkyl; m, n and r are as previously described.
(422) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom orA lower alkyl group; r2Lower alkyl substituted with imidazolyl; r3Is a lower alkanoyloxy groupLower alkyl substituted by lower alkoxycarbonyl, lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally bearing a halogen substituent on the phenyl ring, a group of formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:
Figure A9419071902191
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Lower alkyl substituted by phenylthio which may optionallybear lower alkoxy substituents on the phenyl moiety; m, n and r are as previously described.
(423) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:
Figure A9419071902192
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a phenylsulfinyl-substituted lower alkyl group which may optionally bear a lower alkoxy substituent on the phenyl moiety; m, n and r are as previously described.
(424) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl,Lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl which may optionally bear halogen substituents on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkyl substituted by phenylsulfonyl which may optionally bear lower alkoxy substituents on the phenyl moiety; m, n and r are as previously described.
(425) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E,R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkyl substituted by phenoxy; m, n and r are as previously described.
(426) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), orA group of formula (la):(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:(wherein the group，R8And q is as described above), m, n and r are as described above.
(427) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group R2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein, E, R52And R53As described above), or a group of the formula:
Figure A9419071902223
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula: -A5-CR42R43R44(wherein A is5、R42、R43And R44As previously described); m, n and r are as previously described.
(428) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a halogen atom or a lower alkyl group; r2Lower alkyl substituted with imidazolyl; r3Is lower alkanoyloxy substitutedLower alkyl, lower alkoxycarbonyl, lower alkoxycarbonyloxy-substituted lower alkyl, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl-substituted lower alkyl, benzoyl-substituted lower alkyl which may optionally bear halogen substituents on the phenyl ring, a group of the formula:-E-N (R)52)(R53) (wherein, E, R52And R53As described above) Or a group of the formula:
Figure A9419071902231
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl group which may optionally bear a substituent selected from oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring; m, n and r are as previously described.
(429) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is a hydrogen atom; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902241
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:
Figure A9419071902242
(wherein the group
Figure A9419071902243
、R47And u is as previously described); m, n and r are as previously described.
(430) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is a hydrogen atom; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, optionally substituted by halogen on phenyl ringBenzoyl-substituted lower alkyl, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:
Figure A9419071902251
(wherein A, R5And p is as previously described); m, n and r are as previously described.
(431) A quinoxaline derivative of formula (1) or a salt thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is a hydrogen atom; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is phenyl-lower alkenyl, the phenyl moiety of which may optionally bear substituents selected from: lower alkoxy, A halogen atom, amino optionally having A substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having A lower alkyl substituent on the tetrazole moiety, hydroxy, A compound of formulA-O-A4-CO-NR40R41Group (a) ofIn A4、R40And R41As described above), lower alkenyloxy, nitro and lower alkyl which may optionally have halogen substituents; m, n and r are as previously described.
(432) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lowLower alkoxy, amino optionally having lower alkyl substituents, or aminocarbonyl R optionally having lower alkyl substituents2Is a hydrogen atom; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902261
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkenyl; m, n and r are as previously described.
(433) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is a hydrogen atom; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53Such asAs described above), or a group of the formula:
Figure A9419071902271
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is cycloalkyl-lower alkyl; m, n and r are as previously described.
(434) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is a hydrogen atom; r3Is a lower alkanoyloxy groupLower alkyl substituted by lower alkoxycarbonyl, lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally bearing a halogen substituent on the phenyl ring, a group of formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is naphthyl-lower alkyl; m, n and r are as previously described.
(435) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a lower alkaneAn oxo group, an amino group which may optionally have a lower alkyl substituent, or an aminocarbonyl group which may optionally have a lower alkyl substituent; r2Is a hydrogen atom; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902281
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Lower alkyl substituted by phenylthio which may optionally bear lower alkoxy substituents on the phenyl moiety; m, n and r are as previously described.
(436) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is a hydrogen atom; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonylLower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4M, n and r are lower alkyl groups substituted by phenylsulfinyl which may optionally have lower alkoxy substituents on the phenyl moiety, as described previously.
(437) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is a hydrogen atom; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902292
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkyl substituted by phenylsulfonyl which may optionally bear lower alkoxy substituents on the phenyl moiety; m, n and r are as previously described.
(438) A quinoxaline derivative of formula (1) or a salt thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is a hydrogen atom; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonylLower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl which may optionally bear halogen substituents on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902301
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkyl substituted by phenoxy; m, n and r are as previously described.
(439) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is a hydrogen atom; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:(wherein the group
Figure A9419071902313
、R8And q is as previously described); m, n and r are as previously described.
(440) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is a hydrogen atom; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkylOxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl which may optionally bear halogen substituents on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula: -A5-CR42R43R44(wherein A is5、R42、R43And R44As previously described); m, n and r are as previously described.
(441) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is a hydrogen atom; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902321
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl optionally bearing a substituent selected from oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring; m, n and r are as previously described.
(442) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl which may optionally bear halogen substituents; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkoxycarbonyloxy substituted lowerAlkyl, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally bearing a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902331
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:
Figure A9419071902332
(wherein the group、R47And u is as previously described); m, n and r are as previously described.
(443) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl which may optionally bear halogen substituents; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:(wherein A, R5And p is as previously described); m, n and r are as previously described.
(444) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl which may optionally bear halogen substituents; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902343
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is phenyl-lower alkenyl, the phenyl moiety of which may optionally bear substituents selected from: lower alkoxy, A halogen atom, amino optionally having A substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having A lower alkyl substituent on the tetrazole moiety, hydroxy, A compound of formulA-O-A4—CO-NR40R41A group of (wherein A)4、R40And R41As described above), lower alkenyloxy, nitro and lower alkyl which may optionally have halogen substituents; m, n and r are as previously described.
(445) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl which may optionally bear halogen substituents; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkylsubstituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkenyl; m, n and r are as previously described.
(446) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted by lower alkyl, or amino optionally substituted by lower alkylAn aminocarbonyl group; r2Is lower alkyl which may optionally bear halogen substituents; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902361
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is cycloalkyl-lower alkyl; m, n and r are as previously described.
(447) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl which may optionally bear halogen substituents; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkyloxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally carry halogen substituents on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902362
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is naphthyl-lower alkyl; m, n and r are as previously described.
(448) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl which may optionally bear halogen substituents; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902371
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Lower alkyl substituted by phenylthio which may optionally bear lower alkoxy substituents on the phenyl moiety; m, n and r are as previously described.
(449) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl which may optionally bear halogen substituents; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, optionally having halogen on the phenyl ringSubstituted benzoyl-substituted lower alkyl, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902381
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a phenylsulfinyl-substituted lower alkyl group which may optionally bear a lower alkoxy substituent on the phenyl moiety; m, n and r are as previously described.
(450) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl which may optionally bear halogen substituents; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902382
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4At the phenyl partLower alkyl optionally substituted with phenylsulfonyl optionally substituted with lower alkoxy;m, n and r are as previously described.
(451) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl R which may optionally bear halogen substituents3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), orA group of the formula:
Figure A9419071902391
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is phenoxy-substituted lower alkyl; m, n and r are as previously described.
(452) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl which may optionally bear halogen substituents; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53)(wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:
Figure A9419071902402
(wherein the group、R8And q is as previously described); m, n and r are as previously described.
(453) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl which may optionally bear halogen substituents; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902411
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula: -A5-CR42R43R44(wherein A is5、R42、R43And R44As previously described); m, n and r are as previously described.
(454) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl which may optionally bear halogen substituents; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902412
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl optionally bearing a substituent selected from oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring; m, m,n and r are as previously described.
(455) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is phenyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonylLower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl which may optionally bear halogen substituents on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:(wherein the group、R47And u is as previously described); m, n and r are as previously described.
(456)Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is phenyl; r3Is lower alkyl substituted by lower alkanoyloxy,Lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally bearing a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902431
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:
Figure A9419071902432
(wherein A, R5And p is as previously described); m, n and r are as previously described.
(457) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is phenyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxyPhenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl which may optionally bear halogen substituents on the phenyl ring, a group of formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is phenyl-lower alkenyl, the phenyl moiety of which may optionally bear substituents selected from: lower alkoxy, A halogen atom, amino optionally having A substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having A lower alkyl substituent on the tetrazole moiety, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As described above), lower alkenyloxy, nitro and lower alkyl which may optionally have halogen substituents; m, n and r are as previously described.
(458) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is phenyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkenyl; m, n and r are as previously described.
(459) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is phenyl; r3Is lower alkyl substituted by lower alkanoyloxy, loweralkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902451
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is cycloalkyl-lower alkyl; m, n and r are as previously described.
(460) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is phenyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53Such asAs described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is naphthyl-lower alkyl; m, n and r are as previously described.
(461) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents, or amino optionally having lower alkyl substituentsAn alkylcarbonyl group; r2Is phenyl; r3Is lower alkyl substituted bylower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902462
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Lower alkyl substituted by phenylthio which may optionally bear lower alkoxy substituents on the phenyl moiety; m, n and r are as previously described.
(462) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is phenyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902471
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a phenylsulfinyl-substituted lower alkyl group which may optionally bear a lower alkoxy substituent on the phenyl moiety; m, n and r are as previously described.
(463) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is phenyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkyl substituted by phenylsulfonyl which may optionally bear lower alkoxy substituents on the phenyl moiety; m, n and r are as previously described.
(464) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is phenyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902482
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkyl substituted by phenoxy; m, n and r are as previously described.
(465) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a lower alkaneAn oxo group, an amino group which may optionally have a lower alkyl substituent, or an aminocarbonyl group which may optionally have a lower alkyl substituent; r2Is phenyl; r3Is lower alkyl substituted by lower alkanoyloxy, lowerLower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally bearing a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902491
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:(wherein the group、R8And q is as previously described); m, n and r are as previously described.
(466) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is phenyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonylLower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl which may optionally bear halogen substituents on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As describedabove), or a group of the formula:
Figure A9419071902501
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula: -A5-CR42R43R44(wherein A is5、R42、R43And R44As previously described); m, n and r are as previously described.
(467) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents, or optionally having lower alkyl substituentsAminocarbonyl with lower alkyl substituents; r2Is phenyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902502
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl optionally bearing a substituent selected from oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring; m, n and r are as previously described.
(468) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902511
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:
Figure A9419071902512
(wherein the group
Figure A9419071902513
、R47And u is as previously described); m, n and r are as defined aboveThe above-mentioned processes are described.
(469) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:
Figure A9419071902522
(wherein A, R5And p is as previously described); m, n and r are as previously described.
(470) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl substituted by morpholinyl; r3Lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, lower alkoxy substituted by lower alkoxy,phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl which may optionally bear halogen substituents on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902531
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is phenyl-lower alkenyl, the phenyl moiety of which may optionally bear substituents selected from: lower alkoxy, A halogen atom, amino optionally having A substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having A lower alkyl substituent on the tetrazole moiety, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As described above), lower alkenyloxy, nitro and lower alkyl which may optionally have halogen substituents; m, n and r are as previously described.
(471) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902541
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkenyl; m, n and r are as previously described.
(472) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally have halogen substituent on phenyl ring, lower alkyl substituted by lower alkoxycarbonyl, lower alkoxycarbonyl substituted by lower alkoxycarbonyl optionally having halogen substituent on phenyl ring, lower alkoxycarbonyl,A group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902542
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is cycloalkyl-lower alkyl; m, n and r are as previously described.
(473) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents, or amino optionally having lower alkyl substituentsA substituted aminocarbonyl group; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902551
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is naphthyl-lower alkyl; m, n and r are as previously described.
(474) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902552
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Lower alkyl substituted by phenylthio which may optionally bear lower alkoxy substituents on the phenyl moiety; m, n and r are as previously described.
(475) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902561
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a phenylsulfinyl-substituted lower alkyl group which may optionally bear a lower alkoxy substituent on the phenyl moiety; m, n and r are as previously described.
(476) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonylLower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl which may optionally carry halogen substituents on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkyl substituted by phenylsulfonyl which may optionally bear lower alkoxy substituents on the phenyl moiety; m, n and r are as previously described.
(477) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902572
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Lower alkyl substituted by phenoxy, m, n and r are as described previously.
(478) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl whichmay optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:
Figure A9419071902582
(wherein the group
Figure A9419071902583
、R8And q is as previously described); m, n and r are as previously described.
(479) Quinoxaline derivatives of formula (1 or salts thereof, wherein R1Is lower alkoxy, amino optionally having lower alkyl substituents, or amino optionally having lower alkyl substituentsA substituted aminocarbonyl group; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902591
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula: -A5-CR42R43R44(wherein A is5、R42、R43And R44As previously described); m, n and r are as previously described.
(480) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Is lower alkyl substituted by morpholinyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, benzene optionally having halogen substituent on phenyl ringFormyl-substituted lower alkyl, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a 2, 3-dihydro-1H-indenyl substituted lower alkyl optionally bearing a substituent selected from oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring; m, n and r are as previously described.
(481) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902602
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:
Figure A9419071902611
(wherein the group
Figure A9419071902612
、R47And u is as previously described); m, n and r are as previously described.
(482) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Lower alkyl substituted with imidazolyl; r3Lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkoxycarbonyloxyLower alkyl substituted by lower alkyl, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902613
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:
Figure A9419071902614
(wherein A, R5And p is as previously described); m, n and r are as previously described.
(483) A quinoxaline derivative of formula (1) or a salt thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is phenyl-lower alkenyl, the phenyl moiety of which may optionally bear substituents selected from: lower alkoxy, A halogen atom, amino optionally having A substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having A lower alkyl substituent on the tetrazole moiety, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As described above), lower alkenesOxy, nitro and lower alkyl which may optionally have halogen substituents; n, n and r are as previously described.
(484) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Lower alkyl substituted with imidazolyl; r3Is lower alkanoyloxyLower alkyl substituted by alkyl, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902631
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4M, n and r are lower alkenyl groups as described above.
(485) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902632
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Cycloalkyl-lower alkyl m, n and r are as previously described.
(486) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902641
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is naphthyl-lower alkyl; m, n and r are as previously described.
(487) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (whereinE、R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Lower alkyl substituted by phenylthio which may optionally bear lower alkoxy substituents on the phenyl moiety; m, n and r are as previously described.
(488) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902652
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a phenylsulfinyl-substituted lower alkyl group which may optionally bear a lower alkoxy substituent on the phenyl moiety; m, m,n and r are as previously described.
(489) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkyl substituted by phenylsulfonyl which may optionally bear lower alkoxy substituents on the phenyl moiety; m, n and r are as previously described.
(490) Quinoxaline derivatives of formula (1) or salts thereof, wherein,R1is lower alkoxy, amino optionally having lower alkyl substituents, or aminocarbonyl optionally having lower alkyl substituents: r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl,lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (whereinE、R52And R53As described above), or a group of the formula:
Figure A9419071902671
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is lower alkyl substituted by phenoxy; m, n and r are as previously described.
(491) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902672
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula:(wherein the group
Figure A9419071902682
、R8And q is as previously described); m, n and r are as previously described.
(492) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is lower alkoxy, amino optionally substituted with lower alkyl, or aminocarbonyl optionally substituted with lower alkyl; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902683
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is a group of the formula: -A5-CR42R43R44(wherein A is5、R42、R43And R44As previously described); m, n and r are as previously described.
(493) Quinoxaline derivatives of formula (1) or salts thereof, wherein R1Is a lower alkaneAn oxo group, an amino group which may optionally have a lower alkyl substituent, or an aminocarbonyl group which may optionally have a lower alkyl substituent; r2Lower alkyl substituted with imidazolyl; r3Is lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, lower alkyl substituted by lower alkoxycarbonyloxy, phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a group of the formula: -E-N (R)52)(R53) (wherein E, R52And R53As described above), or a group of the formula:
Figure A9419071902691
(wherein, R54Is hydrogen or lower alkyl, A is as defined above); r4Is optionally provided with a group selected from oxo, hydroxy on the 2, 3-dihydro-1H-indenyl ring2, 3-dihydro-1H-indenyl substituted lower alkyl containing a lower alkyl siloxy substituent; m, n and r are as previously described.
The compounds of the present invention also include compounds of the following formula (1): wherein m and n are both 1; or m is 1 and n is 0; or m is 0 and n is 1; or m and n are both 0. However, preferred compounds are those of formula (1) wherein m is 1 and n is 0.
Heterocyclic groups of the formula include, for example, pyridyl, thiazolyl, furyl, benzimidazolyl, benzothiazolyl, oxazolyl, quinolyl, indolyl, 1, 4-benzodioxanyl, 3, 4-dihydrofuro [2, 3-g]Quinolyl, 1, 2, 3, 4-tetrahydrofuro [2, 3-g]Quinolyl, furo [3, 2-c]]Pyridyl, furo [2, 3-g]Quinolyl, benzofuranyl, benzothienyl, 2, 3-dihydrobenzofuranyl, perhydrobenzofuranyl, imidazolylAzolyl, 1, 2, 3, 4-tetrazolyl, imidazo [1, 2-a]]Pyridyl, and the like.
Figure A9419071902701
Heterocyclic groups represented by the formula include, for example, 1, 2, 3, 4-tetrazolyl, thiazolyl, pyridyl, oxazolyl, 1, 2, 3, 5-oxathiadiazolyl, 1, 3, 4-triazolyl, 1, 2, 4-oxadiazolyl, 1, 2, 4-triazinyl, imidazolyl, 1, 3, 4-oxadiazolyl, pyrimidinyl, 1, 2, 3, 4-tetrazolyl, 3, 4-dihydrofuro [2, 3-g]]Quinolyl, 1, 2, 3, 4-tetrahydrofuro [2, 3-g]Quinolyl, naphtho [2, 1-b]]Furyl, oxazolyl, furo [2, 3-g]Quinolinyl and the like.
Figure A9419071902702
Heterocyclic groups represented by the following formula include, for example, thiazolyl, 1, 2, 3, 4-tetrazolyl, thiazolidinyl and the like.
Figure A9419071902703
Heterocyclic groups of the formula include, for example, benzofuranyl, benzothiazolyl, quinolonyl, 3, 4-dihydroquinolonyl, furo [3, 2-c]]Pyridyl, benzothienyl, and the like.
The compound of formula (1) of the present invention can be prepared by various methods, but is preferably prepared by the following method. Reaction scheme 1
Figure A9419071902711
[ wherein R1、R2、R3、R4R, m and n are as previously described]。
The reaction of the compound (2) and the compound (3) is carried out by a conventional amide bond-forming reaction. The reaction conditions for amide bond formation may be the same as those for conventional amide bond formation, for example:
(a) the mixed anhydride process, namely the following: reacting a carboxylic acid compound (2) with an alkyl haloformate to form a mixed anhydride, and then reacting the resulting mixed anhydride with an amine compound (3);
(b) the active ester method, namely the following method: the carboxylic acid compound (2) is converted into an active ester such as p-nitrophenyl ester, N-hydroxysuccinimide ester, 1-hydroxybenzotriazole ester, etc., and then the resulting active ester is reacted with an amine compound (3):
(c) carbodiimide method, i.e. the following method: condensing a carboxylic acid compound (2) with an amine compound (3) in the presence of an activating agent such as dicyclohexylcarbodiimide, carbonyldiimidazole or the like;
(d) other methods, namely the following methods: converting the carboxylic acid compound (2) into a carboxylic acid anhydride by treating with a dehydrating agent such as acetic anhydride, and then reacting the resulting acid anhydride with the amine compound (3); reacting an ester of the carboxylic acid compound (2) with a lower alcohol and an amine compound (3); reacting an acid halide compound (i.e., carboxylic acid halide) of the carboxylic acid compound (2) with the amine compound (3); the carboxylic acid compound (2) is activated with a phosphorus compound (e.g., triphenylphosphine, diethylphosphoryl chloride, etc.), and then the resultant compound is reacted with an amine compound (3): converting the carboxylic acid compound (2) into an N-carboxyamino anhydride with phosgene or trichloromethyl chloroformate, and then reacting the resulting compound with the amine compound (3); activating the carboxylic acid compound (2) with an acetylene compound (e.g., trimethylsilylethoxyacetylene, etc.) and then reacting the resulting compound with the amine compound (3), and so on.
The mixed acid anhydride used in the above-mentioned mixed acid anhydride method (a) is obtained by a known Schotten-Baumann reaction, and the product of the reaction is used directly for the reaction with the amine compound (3) without isolation from the reaction mixture to obtain the desired compound (1) of the present invention. The Sch _ tten-Baumann reaction is usually carried out in the presence of basic compounds. The basic compound is any conventional compound used in the Sch _ tten-Baumann reaction, including, for example, organic basic compounds such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methylmorpholine, 4-dimethylaminopyridine, 1, 5-diazabicyclo [4.3.0]non-5-ene (DBN), 1, 8-diazabicyclo [5.4.0]undec-7-ene (DBU), 1, 4-diazabicyclo [2.2.2]heptane (DABCO), etc.; inorganic basic compounds such as potassium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, and the like. The reaction is typically carried out at a temperature of from about-20 ℃ to about 100 ℃, preferably from 0 ℃ to about 50 ℃, and for a reaction time of from about 5 minutes to about 10 hours, preferably from 5 minutes to about 2 hours.
The reaction of the mixedacid anhydride thus obtained with the amine compound (3) is usually carried out at a temperature of-20 ℃ to about 150 ℃, preferably 10 ℃ to about 50 ℃ for 5 minutes to about 10 hours, preferably for about 5 minutes to 5 hours, and the mixed acid anhydride method may be carried out in a solvent or without a solvent. The solvent may be any conventional solvent commonly used in the mixed acid anhydride method, including, for example, halogenated hydrocarbons (e.g., dichloromethane, chloroform, dichloroethane, etc.), aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.), ethers (e.g., diethyl ether, dioxane, diisopropyl ether, tetrahydrofuran, dimethoxyethane, etc.), esters (e.g., methyl acetate, ethyl acetate, etc.), aprotic polar solvents (e.g., 1, 3, 3-tetramethylurea, N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, etc.), or a mixture of these solvents, and alkyl haloformates used in the mixed acid anhydride method include, for example, methyl chloroformate, methyl bromoformate, ethyl chloroformate, ethyl bromoformate, isobutyl chloroformate, etc. In the method, the carboxylic acid compound (2), the alkyl haloformate and the amine compound (3) are generally used in equimolar amounts, but about 1 to 1.5 moles of each of the alkyl haloformate and the amine compound (3) are preferably used per 1 mole of the carboxylic acid compound (2).
The active ester method (b) (for example, a method using N-hydroxysuccinimide ester) is carried out in the presence of a basic compound or in the absence of a basic compound in a suitable solvent which does not affect the reaction. In addition, a condensing agent such as dicyclohexylcarbodiimide, carbonyldiimidazole, 1-ethyl-3- (3' -dimethylaminopropyl) carbodiimide, or the like may be added to the reaction. The basic compound may be any of the basic compounds used in the above-mentioned Sch _ tten-Baumann reaction, as well as alkali metal carboxylates (e.g., sodium acetate, sodium benzoate,sodium formate, potassium acetate, lithium benzoate, cesium acetate, etc.) and alkali metal halides (e.g., potassium fluoride, cesium fluoride, etc.), and the like. The solvent includes, for example, halogenated hydrocarbons (e.g., dichloromethane, chloroform, dichloroethane, etc.), aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.), ethers (e.g., diethyl ether, dioxane, tetrahydrofuran, dimethoxyethane, etc.), esters (e.g., methyl acetate, ethyl acetate, etc.), aprotic polar solvents (e.g., N-dimethylformamide, dimethylsulfoxide, hexamethylphosphoramide, etc.), or a mixture of these solvents. The reaction temperature is 0 to 150 ℃, preferably 10 to 100 ℃, and the reaction time is 5 to 30 hours. The amine compound (3) and the N-hydroxysuccinimide ester are each used in at least equimolar amounts relative to 1 mole of the carboxylic acid compound (2), but it is preferable to use 1 to 2 moles of the amine compound (3) and the N-hydroxysuccinimide ester.
Further, the amide bond-forming reaction of scheme 1 can also be carried out by reacting the carboxylic acid compound (2) with the amine compound (3) in the presence of a condensing agent, for example, a phosphorus compound such as triphenylphosphine, triphenylphosphine-2, 2' -dipyridyl disulfide, diethyl chlorophosphate, diphenylphosphinochloride, phenyl-N-phenylphosphoramide chloride, diethyl cyanophosphate, bis (2-oxo-3-oxazolidinyl) phosphinic chloride, etc. The reaction is usually carried out in the presence of a solvent and a basic compound. In addition to the basic compounds used in the above-mentioned Sch _ tten-Baumann reaction, the basic compounds include, for example, sodium hydroxide, potassium hydroxide, etc. The solvent includes, for example, pyridine, acetone, acetonitrile or a mixture of two or more of the above solvents, in addition to, for example, the solvent used in the mixed anhydride method (a). The reaction is generally carried out at a temperature of from-20 ℃ to about 150 ℃, preferably from 0 ℃ to about 100 ℃, for a period of from about 5 minutes to about 30 hours. The condensing agent and the amine compound (3) are used in at least equimolar amounts, preferably 1 to 2 moles, per 1 mole of the carboxylic acid compound (2).
The amide bond-forming reaction may be carried out by reacting the amine compound (3) with the carboxylic acid compound (2) in the presence of a condensing agent. The reaction is carried out in a suitable solvent in the presence or absence of a catalyst. The solvent includes, for example, halogenated hydrocarbons (e.g., dichloromethane, dichloroethane, chloroform, methylchloride, etc.), acetonitrile, dimethylformamide, and the like. The catalyst includes, for example, organic bases such as dimethylaminopyridine, 4-piperidinopyridine and the like, salts such as pyridinium tosylate and the like, camphorsulfonic acid, mercuric oxide and the like. The condensing agent includes, for example, acetylene compounds such as trimethylsilylethoxyacetylene and the like. The condensing agent is used in an amount of 1 to 10 moles, preferably 2 to 6 moles, per 1 mole of the amine compound (3). The carboxylic acid compound (2) is usually used in at least an equimolar amount, preferably 1 to 2 moles, of the carboxylic acid compound (2) per 1 mole of the amine compound (3). The reaction is generally carried out at a temperature of from 0 to about 150 c, preferably from room temperature to about 100 c, for a period of from about 1 to about 10 hours.
In the case of the above-mentioned other process (d), in the case of the process of reacting a carboxylic acid halide with the amine compound (3), the reaction is usually carried out in a suitable solvent in the presence of a dehydrohalogenating agent which is any conventional basic compound including sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride and the like in addition to the basic compound used in the above-mentioned Sch _ tten-Baumann reaction. The solvent includes, for example, alcohols (such as methanol, ethanol, propanol, butanol, 3-methoxy-1-butanol, ethyl cellosolve, methyl cellosolve, etc.), pyridine, acetone, acetonitrile or a mixture of two or more of these solvents, the amounts of the amine compound (3) and carboxylic acid halide used are not critical, but the amine compound (3) is usually used in at least an equimolar amount, preferably about 1 to 5 moles of the amine compound (3) is used per 1 mole of the acid halide. The reaction is generally carried out at a temperature of from about-20 ℃ to about 180 ℃, preferably from about 0 ℃ to about 150 ℃, for from about 5 minutes to about 30 hours.
The carboxylic acid halide used in the above reaction can be prepared, for example, by reacting the carboxylic acid compound (2) with a halogenating agent in a solvent or under solvent-free conditions. The solvent may be any solvent which does not affect the reaction, for example, aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.), halogenated hydrocarbons (e.g., chloroform, dichloromethane, carbon tetrachloride, etc.), ethers (e.g., dioxane, tetrahydrofuran, diethyl ether, etc.), dimethylformamide, dimethylsulfoxide, etc. The halogenating agent can be any conventional reagent that converts the hydroxyl group in the carboxyl group to a halogen, such as thionyl chloride, phosphorus oxychloride, phosphorus oxybromide, phosphorus pentachloride, phosphorus pentabromide, and the like. The amounts of the carboxylic acid compound (2) and the halogenating agent are not critical, but when the reaction is carried out in the absence of a solvent, the halogenating agent is usually in excess relative to the carboxylic acid compound (2); when the reaction is carried out in a solvent, the halogenating agent is usually used in at least an equimolar amount, preferably 2 to 4 moles, per 1 mole of the carboxylic acid compound (2). The reaction temperature and the reaction time are not necessarily limited, but the reaction is usually carried out at a temperature of from room temperature to about 100 ℃, preferably from 50 to 80 ℃, for from about 30 minutes to about 6 hours.
In the method of reacting the amine compound (3) with the ester of the carboxylic acid compound (2) and the lower alcohol, the reaction is carried out in a suitable solvent or under solvent-free conditions. The solvent may be any solvent used for the reaction of the above carboxylic acid halide with the amine compound (3). The amine compound (3) is usually used in at least an equimolar amount, preferably 1 to 15 moles, of the amine compound (3) per 1 mole of the ester and lower ether of the carboxylic acid compound (2). The reaction is generally carried out at a temperature of from room temperature to 150 deg.C, preferably from room temperature to about 120 deg.C, for a period of from 1 to about 20 hours. Reaction scheme 2[ wherein R1、R2R, m and n are as defined above, X is a halogen atom: r3aIs hydrogen, lower alkyl, phenyl-lower alkoxycarbonyl, lower alkyl substituted by lower alkanoyloxy, lower alkanoyl, lower alkoxycarbonyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by lower alkoxycarbonyloxy, lower alkyl substituted by benzoyl which may optionally bear a halogen substituent on the phenyl ring, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, to obtain a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, orGroup (b): -E-NR52R53(wherein, R52And R53Same or different, each is hydrogen, lower alkyl, lower alkoxycarbonyl or phenyl, or R52And R53May be combined with the nitrogen atom to which they are attached to form a 5-or 6-membered saturated heterocyclic group with orwithout the insertion of an additional nitrogen atom or oxygen atom; e is lower alkylene, a group of the formula: -CO-, or a group of the formula:-CO-A- (wherein A is lower alkylene)), A group of the formulA:(wherein, R54Is a hydrogen atom or a lower alkyl group, A is as defined above), a group of the formula:(wherein A, R5And P is as previously described), phenyl-lower alkenyl optionally bearing substituents in the phenyl moiety selected from: lower alkoxy, A halogen atom, amino optionally having A substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having A lower alkyl substituent on the tetrazole moiety, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As described above), lower alkenyloxy, nitro and lower alkyl which may optionally have halogen substituents; or R3aIs lower alkenyl, cycloalkyl-lower alkyl, naphthyl-lower alkyl, lower alkyl substituted by phenylthio which may optionally bear lower alkoxy substituents on the phenyl moiety, lower alkyl substituted by phenylsulfinyl which may optionally bear lower alkoxy substituents on the phenyl moiety, lower alkyl substituted by phenylsulfonyl which may optionally bear lower alkoxy substituents on the phenyl moiety, lower alkyl substituted by phenoxy, a group of the formula:
Figure A9419071902781
(wherein the group
Figure A9419071902782
、R8And p is as previously described), a group of the formula: -A5-CR42R43R44(wherein A is5、R42、R43And R44As described above)2, 3-dihydro-1H-indenyl substituted lower alkyl optionally bearing a substituent selected from oxo, hydroxy and siloxy bearing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, or a group of the formula:(wherein the group
Figure A9419071902784
、R47And u is as previously described); r3bIs the above-mentioned R3aThose groups other than hydrogen atoms in the definition of (1); r3cAnd R3dEach is hydrogen atom or lower alkyl]
The reaction of compound (1a) and compound (4a) is usually carried out in a suitable inert solvent in the presence or absence of a basic compound. Inert solvents include, for example, aromatic hydrocarbons (e.g., benzene, methyl, xylene, etc.), ethers (e.g., tetrahydrofuran, dioxane, diglyme, etc.), alcohols (e.g., methanol, ethanol, isopropanol, butanol, etc.), ethyl acetate, acetone, acetonitrile, dimethyl sulfoxide, dimethylformamide, hexamethylphosphoramide, or mixtures of these solvents. The basic compound includes, for example, alkali metal carbonates (e.g., sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.), alkali metal hydroxides (e.g., sodium hydroxide, potassium hydroxide, etc.), sodium hydride, potassium, sodium amide, alkali metal alkoxides (e.g., sodium methoxide, sodium ethoxide, etc.), organic basic compounds (e.g., pyridine, N-ethyldiisopropylamine, dimethylaminopyridine, triethylamine, DBN, DBU, DABCO, etc.), etc. The amounts of compound (1a) and compound (4a) used are not critical, but compound (4a) is used in at least an equimolar amount, preferably 1 to 10 moles of compound (4a) per 1 mole of compound (1 a). The reaction is generally carried out at a temperature of from 0 to about 200 c, preferably from 0 to about 170 c, for from 30 minutes to 30 hours. Alkali metal halides such as sodium iodide, potassium iodide, etc. can be added into the reaction system. In addition, ammonium halides such as tetra-n-butylammonium iodide, tetra-n-butylammonium bromide, n-butyltriethylammonium iodide, tetraethylammonium iodide, tri-n-butylmethylammonium iodide, and the like may be added to the reaction system.
The reaction of the compound (1a) and the compound (4b) is usually carried out in a suitable solvent in the presence of a reducing agent or under the solvent-free condition. The solvent includes, for example, water, alcohols (e.g., methanol, ethanol, isopropanol, butanol, etc.), acetonitrile, formic acid, acetic acid, ethers (e.g., dioxane, diethyl ether, diglyme, tetrahydrofuran, etc.), aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.), or a mixture of these solvents. The reducing agent includes, for example, formic acid, alkali metal salts of fatty acids (e.g., sodium formate, etc.), hydrogenation reducing agents (e.g., sodium borohydride, sodium cyanoborohydride, lithium aluminum hydride, etc.), catalytic reducing agents (e.g., palladium black, palladium-carbon, platinum oxide, platinum black, raney nickel, etc.), and the like.
When formic acid is used as the reducing agent, the reaction is generally carried out at a temperature of from room temperature to about 200 deg.C, preferably from 50 to about 150 deg.C, for from 1 to about 10 hours. Formic acid is in excess relative to compound (1 a).
When a hydrogenating agent is used, the reaction is generally carried out at a temperature of from-30 to about 100 deg.C, preferably from 0 to about 70 deg.C, for a period of from 30 minutes to about 15 hours. The reducing agent is used in an amount of 1 to 20 moles, preferably 1 to 6 moles, per 1 mole of the compound (1 a). When lithium aluminum hydride is used as the reducing agent, the solvent is preferably selected from ethers (e.g., diethylether dioxane, tetrahydrofuran, diglyme, etc.) and aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.).
When a catalytic reducing agent is used, the reaction is generally carried out at a hydrogen pressure of 1 to 20 atm, preferably 1 to 10 atm, or in the presence of a hydrogen donor (such as formic acid, ammonium formate, cyclohexene, hydrazine hydrate, etc.) at-30 to about 100 ℃, preferably 0 to about 60 ℃ for 1 to 12 hours. The catalytic reducing agent is used in an amount of usually 0.1 to 40% by weight, preferably 1 to 20% by weight, based on the compound (1 a).
The compound (4b) is usually used in at least an equimolar amount to the compound (1a), and preferably 1 mol to an excess of the compound (4b) is used per 1 mol of the compound (1 a).
Reaction scheme 3[ wherein R1、R2、R3、R4R, m and n are as previously described]
The reaction for converting compound (1c) into compound (1d) and the reaction for converting compound (1e) into compound (1f) are carried out in a suitable solvent in the presence of an oxidizing agent. The solvent includes, for example, water, organic acids (e.g., formic acid, acetic acid, trifluoroacetic acid, etc.), alcohols (e.g., methanol, ethanol, etc.), halogenated hydrocarbons (e.g., chloroform, dichloromethane, etc.), or a mixture of these solvents. Oxidizing agents include, for example, peracids (e.g., performic acid, peracetic acid, pertrifluoroacetic acid, perbenzoic acid, m-chloroperbenzoic acid, p-carboxyperbenzoic acid, and the like), hydrogen peroxide, sodium metaperiodate, dichromic acid, dichromate salts (e.g., sodium dichromate, potassium dichromate, and the like), permanganic acid, permanganates (e.g., potassium permanganate, sodium permanganate, and the like), lead salts (e.g., lead tetraacetate, and the like), and the like. The oxidizing agent is used in at least an equimolar amount to the starting compound, preferably 1 to 2 moles per 1 mole of the starting compound. The above reaction is usually carried out at a temperature of-10 to 40 deg.C, preferably-10 to room temperature, for about 1 to 100 hours.
Reaction scheme 4[ wherein R1、R2、R3a、R8Group (b), group (b)
Figure A9419071902822
R, m, n, X and 1 are as previously described; r9aIs hydrogen, lower alkanoyl, lower alkyl, morpholinylcarbonyl-lower alkyl, cycloalkyl-carbonyl, phenyl-lower alkenylcarbonyl, lower alkylsulfonyl, aminocarbonyl which may optionally bear lower alkyl substituents, phenylsulfonyl which may optionally bear lower alkyl substituents on the phenyl moiety, phenyl-lower alkenyl which may optionally bear lower alkyl substituents on the phenyl moietyBenzoyl having 1 to 3 substituents selected from: a halogen atom, a lower alkoxy group, an amino group and a hydroxyl group which may optionally have a lower alkanoyl substituent, a lower alkanoyl group which may optionally be substituted with an amino group which may optionally have a lower alkanoyl substituent, a sulfonyl group which may optionally be substituted with an amino group which may optionally have a lower alkyl substituent, a phenyl-lower alkyl group, a phenyl group and an amino group which may optionally have a lower alkanoyl substituent; r10aIs lower alkanoyl, cycloalkylcarbonyl, phenyl-lower alkenylcarbonyl, benzoyl which may optionally bear in the phenyl moiety 1 to 3 substituents selected from: halogen atom, lower alkylAn oxo group, an amino group which may optionally have a lower alkanoyl substituent, and a hydroxy group, and a lower alkanoyl group which may optionally have an amino group substituted with a lower alkanoyl substituent; r10bIs lower alkyl, morpholinylcarbonyl-lower alkyl, lower alkenylsulfonyl, aminocarbonyl which may optionally bear lower alkyl substituents, phenylsulfonyl which may optionally bear lower alkyl substituents, phenyl-lower alkenyl, sulfonyl which may optionally bear amino substituents of lower alkyl substituents, or phenyl-lower alkyl; q' is 1 or 2; r10cAnd R10dEach is hydrogen atom or lower alkyl]。
The reaction of compound (1g) and compound (5) is carried out under the same reaction conditions as those for the reaction of compound (2) and compound (3) in the above-mentioned reaction scheme 1.
Wherein R is10aThe compound (1h) which is a lower alkanoyl group can be prepared by using a compound of the formula (R)11)2O (7) or R11X (8) (wherein R11Lower alkanoyl, X is as defined above) is obtained by subjecting compound (1g) to lower alkanoylation. The lower alkanoylation is carried out in the presence or absence of a basic compound. The basic compound includes, for example, alkali metals (e.g., sodium, potassium, etc.), hydroxides, carbonates, and bicarbonates of alkali metals, or organic basic compounds (e.g., N-dimethylaminopyridine, pyridine, piperidine, etc.), and the like. The reaction is carried out in a solvent or without a solvent. The solvent includes, for example, ketones (e.g., acetone, methyl ethyl ketone, etc.), ethers (e.g., diethyl ether, dioxane, etc.), aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.), water, pyridine, etc. Compound (7) or compound (8) is used in at least an equimolar amount to the starting compound (1g),it is preferable to use 1 mole to an excess of compound (7) or compound (8) per 1 mole of compound (1 g). The reaction is carried out at a temperature of 0 to 200 c, preferably 0 to 150 c, for about 5 minutes to about 5 days.
The reaction ofcompound (1g) with compound (6a) or compound (6b) is carried out under the same reaction conditions as those for the reaction of compound (1a) with compound (4a) or compound (4b) in scheme 2 above. Reaction scheme 5
Figure A9419071902841
[ wherein，R1、R2、R8、R3a、m、n、q′、R9、R10R and group
Figure A9419071902851
As previously described, R12Is lower alkyl]
The hydrolysis of the compound (1j) is carried out in a suitable solvent in the presence of an acid or a basic compound or under the solvent-free condition. The solvent includes, for example, water, lower alcohols (e.g., methanol, ethanol, isopropanol, etc.), ketones (e.g., acetone, methyl ethyl ketone, etc.), ethers (e.g., dioxane, tetrahydrofuran, ethylene glycol dimethyl ether, etc.), fatty acids (e.g., acetic acid, formic acid, etc.), dimethylformamide, or a mixture of these solvents. Acids include, for example, inorganic acids (e.g., hydrochloric acid, sulfuric acid, hydrobromic acid, and the like) and organic acids (e.g., formic acid, acetic acid, aromatic sulfonic acids, and the like). The basic compound includes, for example, an alkali metal salt (e.g., sodium carbonate, potassium carbonate, etc.), an alkali metal or alkaline earth metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, calcium hydroxide, etc.), and the like. The reaction is generally carried out at a temperature of from room temperature to about 200 deg.C, preferably from room temperature to about 150 deg.C, for a period of from 10 minutes to about 25 hours.
The reaction of compound (1k) with compound (9) is carried out under the same reaction conditions as those for the reaction of compound (2) with compound (3) in the above-mentioned reaction scheme 1.Reaction scheme 6Wherein R is1、R2、R3a、R8M, n, q', X and the groupAs described above; r13Is lower alkyl, phenyl-lower alkyl which may optionally bear an amino substituent (said amino group may optionally bear a lower alkanoyl substituent) in the phenyl moiety, carboxy-substituted lower alkyl, lower alkoxycarbonyl-substituted lower alkyl, lower alkoxy-substituted lower alkyl, lower alkenyl, lower alkanoyl, or morpholinylcarbonyl-lower alkyl; r14Is composed ofLower alkoxy, phenyl-lower alkoxy which may optionally bear an amino substituent in the phenyl moiety (said amino group may optionally bear a lower alkanoyl substituent), lower alkanoyloxy or lower alkoxy-substituted lower alkylOxy radical]。
When R is14In the case of phenyl-lower alkoxy, compound (10) is converted to compound (1m) by reducing compound (10). The reduction reaction is carried out by subjecting the compound (1m) to catalytic hydrogenation in a suitable solvent in the presence of a catalyst. The solvent includes, for example, water, acetic acid, alcohols (e.g., methanol, ethanol, isopropanol, etc.), hydrocarbons (e.g., hexane, cyclohexane, etc.), ethers (e.g., dioxane, tetrahydrofuran, diethyl ether, ethylene glycol dimethyl ether, etc.), esters (e.g., ethyl acetate, methyl acetate, etc.), aprotic polar solvents (e.g., dimethylformamide, etc.), or a mixture of these solvents. The catalyst is, for example, palladium black, palladium-carbon, platinum oxide, copper chromite, Raney nickel or the like, and is used in an amount of 0.02 to 1 part by weight per 1 part by weight of the compound (7). The reaction is generally carried out at a temperature of-20 to 100 c, preferably 0 to about 80 c, under a hydrogen pressure of 1 to 10 atmospheres for 0.5 to 20 hours.
When R is14In the case of lower alkoxy or lower alkoxy substituted with lower alkoxy, compound (10) is converted to compound (1m) by hydrolysis. The hydrolysis is carried out in the presence of an acid in a suitable solvent. The solvent includes, for example, water, lower alcohols (e.g., methanol, ethanol, isopropanol, etc.), ethers (e.g., dioxane, tetrahydrofuran, etc.), halogenated hydrocarbons (e.g., dichloromethane, chloroform, carbon tetrachloride, etc.), polar solvents (e.g., acetonitrile, etc.), or a mixture of these solvents. The acid includes, for example, inorganic acids (e.g., hydrochloric acid, sulfuric acid, hydrobromic acid, etc.), fatty acids (e.g., formic acid, acetic acid, etc.), lewis acids (e.g., boron trifluoride, aluminum chloride, boron tribromide, etc.), iodides (e.g., sodium iodide, potassium iodide, etc.), or a mixture of the above lewis acids and iodides, and the like. The reaction is generally carried out at a temperature of 0 to 150 c, preferably room temperature to 100 c, for 0.5 to about 50 hours.
When R is14In the case of a lower alkanoyloxy group, the reaction for converting compound (1o) into compound (1m) can be carried out in the same manner as in the hydrolysis of compound (1j) in the above-mentioned scheme 5.
By reaction with the compound (1g) and the compound (6) in the above reaction scheme 4Under the same reaction conditions of (1) and (1o) wherein R is13Compound (1m) which is a lower alkanoyl group can also be prepared by reacting compound (1m) with compound (7) under the same conditions as those in the reaction of compound (1g) with compound (7) in scheme 4 above. Reaction scheme 7[ wherein R1、R2、R3a、R5、R8M, n, q', A, X, r, -and groupsAs previously mentioned, p'is 1 or 2]
The halogenation reaction of compound (1p) or compound (1E) is carried out in the presence of a conventional halogenating agent. The halogenating agent can be any conventional halogenating agent, for example, a halogen atom (e.g., bromine, chlorine, etc.) or a halogenating agent such as iodine monochloride, sulfuryl chloride, N-halosuccinimide (e.g., N-bromosuccinimide, N-chlorosuccinimide, etc.). The halogenating agent is used in at least an equimolar amount of the compound (1p) or the compound (1E), preferably 1 to 1.5 moles per 1 mole of the compound (1p) or the compound (1E). The solvent includes, for example, halogenated hydrocarbons (such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride, etc.), acetic acid, propionic acid, water or a mixture of these solvents. The reaction is carried out at a temperature of from 0 ℃ to the boiling point of the solvent used, preferably from 0 to 100 ℃, for from 1 to about 10 hours. Reaction scheme 8[ wherein R1、R2、R3a、R8M, n, q', X, r, and the group
Figure A9419071902901
As previously described, R15Is lower alkyl with a hydroxy substituent, R16Is lower alkanoyl, R17And R18Each is lower alkyl, R19Is lower alkanoyloxy-substituted lower alkyl, R18aIs hydrogen or lower alkyl, R18cIs phenyl, R18bIs lower alkyl]
The reaction for converting compound (1r) into compound (1S) is carried out in a suitable solvent in the presence of an oxidizing agent. Oxidants include pyridinium chromates (e.g., pyridinium chlorochromate, pyridinium dichlorochromate, etc.), dimethyl sulfoxide-oxazole chloride, manganese dioxide, DDQ, chromic acid, chromites (e.g., sodium chromite, potassium chromite, etc.), permanganic acid, permanganates (e.g., potassium permanganate, sodium permanganate, etc.). The solvent includes, for example, water, organic acids (e.g., formic acid, acetic acid, trifluoroacetic acid, etc.), alcohols (e.g., methanol, ethanol, etc.), halogenated hydrocarbons (e.g., chloroform, dichloromethane, etc.), ethers (e.g., tetrahydrofuran, diethyl ether, dioxane, etc.), dimethyl sulfoxide, dimethylformamide or a mixture of these solvents. The oxidizing agent is generally used in at least an equimolar amount to the starting compound, preferably 1 to 30 moles per 1 mole of the starting compound. The reaction is carried out at a temperature of 0 to 150 c, preferably 0 to 100 c, for 1 to about 10 hours.
Compound (1r) is converted to compound (1S) by reacting compound (1r) with an oxidizing agent in a suitable solvent in the presence of a co-oxidizing agent. The solvent includes pyridine, ethers (e.g., dioxane, tetrahydrofuran, diethyl ether, etc.), aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.), halogenated hydrocarbons (e.g., dichloromethane, dichloroethane, chloroform, carbon tetrachloride, etc.), esters (e.g., ethyl acetate, etc.), water, alcohols (e.g., methanol, ethanol, isopropanol, tert-butanol, etc.), or a mixture of these solvents. The co-oxidant used herein includes, for example, N-oxides of organic amines such as pyridine N-oxide, N-ethyldiisopropylamine N-oxide, N-methylmorpholine N-oxide, trimethylamine N-oxide, triethylamine N-oxide and the like. The oxidizing agent includes, for example, tetra-n-propylamine perruthenate and the like. The co-oxidant is used in at least equimolar amounts to the starting compounds, preferably 1 to 5 moles of co-oxidant per 1 mole of starting compound. The oxidizing agent is used in catalytic amounts. The reaction is carried out at a temperature of-20 to 150 c, preferably 0 to 100 c, for 1 to about 20 hours. The reaction can be facilitated by adding a molecular sieve to the reactionsystem.
The compound (1s) is converted into the compound (1r) by performing a reduction reaction using a hydrogenating agent. Hydrogenating agents include, for example, lithium aluminum hydride, diborane, diisobutylaluminum hydride, sodium borohydride, lithium borohydride, tetrabutylammonium borohydride, calcium borohydride, aluminum hydride, and the like. At least 0.1 mole, preferably 0.1 to 15 moles, of hydrogenating agent is used per 1 mole of starting compound. The reaction is generally carried out in a suitable solvent at a temperature of-60 to 150 c, preferably-30 to 100 c, for a period of 10 minutes to about 20 hours. The solvent includes, for example, water, lower alcohols (e.g., methanol, ethanol, isopropanol, etc.), ethers (e.g., tetrahydrofuran, diethyl ether, diisopropyl ether, diglyme, etc.), aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.), or a mixture of these solvents.
The reaction of compound (1s) and compound (11) is carried out in a suitable solvent including any solvent used for the Grignard reaction, and examples of preferred solvents are ethers (e.g., diethyl ether, dioxane, tetrahydrofuran, etc.), aromatic hydrocarbons (e.g., benzene, toluene, etc.), saturated hydrocarbons (e.g., pentane, hexane, heptane, cyclohexane, etc.), etc. Compound (11) is generally used in at least an equimolar amount of compound (1s), and preferably 1 to 2 moles of compound (11) per 1 mole of compound (1 s). The reaction is carried out at a temperature of-70 ℃ to 100 ℃, preferably-30 ℃ to about 70 ℃ for 1 to about 50 hours.
Compound (1r) is converted into compound (1u) by reacting compound (1r) with compound (7) or compound (8) under the same conditions as those in the reaction of compound (1h) with compound (7) or compound (8) in the above-mentioned reaction scheme 4.
The reaction for converting compound (1u) into compound (1r) iscarried out under the same reaction conditions as those for the hydrolysis of compound (1j) in scheme 5 above.
The reaction of compound (1S) and compound (11a) is carried out in a suitable solvent in the presence of a basic compound. The basic compound includes, for example, inorganic bases such as metallic sodium, metallic potassium, sodium hydride, sodium amide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, and organic bases such as alkali metal alkoxides (e.g., sodium methoxide, sodium ethoxide, potassium tert-butoxide, etc.), alkyllithium, aryllithium, or lithium amide (e.g., methyllithium, N-butyllithium, phenyllithium, lithium diisopropylamide, etc.), pyridine, piperidine, quinoline, triethylamine, N-dimethylaniline, etc. The solvent may be any solvent which does not affect the reaction, for example, ethers (e.g., diethyl ether, dioxane, tetrahydrofuran, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether)Etc.), aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.), aliphatic hydrocarbons (e.g., N-hexane, heptane, cyclohexane, etc.), amines (e.g., pyridine, N-dimethylaniline, etc.), aprotic polar solvents (e.g., N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, etc.), alcohols (e.g., methanol, ethanol, isopropanol, etc.), or a mixture of these solvents. The reaction is generally carried out at a temperature of-80 ℃ to 150 ℃, preferably-80 ℃ to about 120 ℃, for 0.5 to about 15 hours. The compound (11a) is used in at least an equimolar amount of the compound (1s), and preferably 1 to 10 moles of the compound (11a) are used per 1 mole of the compound (1 s).Reaction scheme 9
Figure A9419071902931
[ wherein R1、R2、R3a、R5M, n, p', A, r and X are as previously described; r20Is lower alkyl, lower alkoxy-substituted lower alkyl, lower alkenyl, lower alkoxycarbonyl-substituted lower alkyl, hydroxy-substituted lower alkyl, carboxy-substituted lower alkyl, phenyl-lower alkyl which may optionally bear substituents selected from lower alkyl and lower alkoxy in the phenyl moiety, morpholinyl-substituted lower alkyl, or a group of the formula: -A1-CO-NR6R7(wherein A is1，R6And R7As previously described); r21Is lower alkoxy, lower alkoxy substituted by lower alkoxy, or phenyl-lower alkoxy which may optionally bear a substituent selected from the group consisting of lower alkyl and lower alkoxy in the phenyl moiety]
The reaction for converting compound (1x) into compound (1 x') is carried out under the same reaction conditions as those for converting compound (10) into compound (1m) in scheme 6 above.
The reaction of compound (1 x') with compound (12) is carried out under the same reaction conditions as those for the reaction of compound (1m) with compound (10) in scheme 6 above. Reaction scheme 10a
Figure A9419071902941
Reaction scheme 10b
Figure A9419071902942
[ wherein R1、R3a、R8、m、n、q′、R5P', r and groupsAs previously described, R22Is lower alkoxy substituted by lower alkoxycarbonyl, R23Is lower alkoxy substituted by carboxyl, R24Is morpholinylcarbonyl-lower alkoxy, R25Is a group of the formula: -O-A1-CO-NR6R7(wherein, A)1、R6And R7As described above)]
The reaction for converting compound (1y) into compound (1z) and the reaction for converting compound (1B) into compound (1C) are carried out under the same reaction conditions as those for the hydrolysis of compound (1j) in scheme 5 above.
The reaction of compound (1z) with compound (13) and the reaction of compound (1C) with compound (14) are carried out under the same reaction conditions as those for the reaction of compound (2) with compound (3) in the above-mentioned reaction scheme 1. Reaction scheme 11
Figure A9419071902952
[ wherein, R1、R2、R8、R3a、m、n、q′、R12、R5P', A, r and the groupsAs described above]
The reaction for converting compound (1j) to compound (1G) and the reaction for converting compound (1H) to compound (1I) are carried out under the same reaction conditions as those for the reaction for converting compound (1s) to compound (1r) in scheme 8 above. Reaction scheme 12[ wherein R1、R2、R3a、R5、A、m、n、p′、R12R and x are as defined above, B is lower alkylene]
The reaction for converting compound (1J) into compound (1K) is carried out under the same reaction conditions as those for the reaction for converting compound (1s) into compound (1r) in scheme 8 above.
Compound (1K) is converted to compound (1L) by reacting compound (1K) with a halogenating agent in a suitable solvent or in the absence of a solvent. The halogenating agent includes inorganic acids (e.g., hydrochloric acid, hydrobromic acid, etc.), N-diethyl-1, 2, 2-trichloroethylamide, phosphorus pentachloride, phosphorus pentabromide, phosphorus oxychloride, thionyl chloride, methanesulfonyl chloride, toluenesulfonyl chloride, etc., as well as basic compounds, carbon tetrachloride or carbon tetrabromide, and triphenylphosphine. The basic compound may be the same as the basic compound used for the reaction of the carboxylic acid halide and the amine compound in scheme 1 described above. The solvent includes, for example, ethers (e.g., dioxane, tetrahydrofuran, etc.), halogenated hydrocarbons (e.g., chloroform, dichloromethane, carbon tetrachloride, etc.), aromatic hydrocarbons (e.g., benzene, toluene, xylene, etc.), etc. When a phenyl-lower alkyl halide (e.g., tosyl chloride, etc.) and a basic compound are used as the halogenating agent, the halogenating agent is used in at least an equimolar amount to the compound (1K), and it is preferable to use 1 to 2 moles of the halogenating agent per 1 mole of the compound (1K). When other halogenating agents are used, the halogenating agent is used in at least an equimolar amount to the compound (1K), and it is preferred to use an excess amount of the halogenating agent. The reaction is generally carried out at a temperature of from room temperature to 150 deg.C, preferably from room temperature to 80 deg.C, for a period of from 1 to about 80 hours.
The reaction of compound (1L) with compound (13) is carried out under the same reaction conditions as those for the reaction of compound (1a) with compound (4a) in scheme 2 above.Reaction scheme 13Wherein R is1、R2、R3aR, m and n are as previously described; r26Is lower alkyl optionally substituted in the phenyl moiety by phenylthio with lower alkoxy substituents, R27Is phenylsulfinyl-substituted lower alkyl which may optionally bear lower alkoxy substituents on the phenyl moiety, R28Is lower alkyl substituted by phenylsulfonyl which may optionally bear lower alkoxy substituents on the phenyl moiety]
The reaction for converting compound (1N) into compound (1O) and the reaction for converting compound (1O) into compound (1P) are carried out under the same reaction conditions as those for the reaction for converting compound (1c) into compound (1d) in scheme 3 above.
By reaction with the conversion of compound 1(N) to compound (1O) except that at least 2 moles, preferably 2 to 4 moles, of oxidizing agent are used per 1 mole of compound (1N)The reaction for converting compound (1N) into compound (1P) is carried out under the same reaction conditions. Reaction scheme 14
Figure A9419071902991
[ wherein R1、R2、R3a、R5、m、n、p′、X、A、A1R and Y are as defined above, R6aIs a hydrogen atom, a lower alkyl group which may optionally have a hydroxyl substituent,Phenyl-lower alkyl, furyl-lower alkyl, or lower alkoxy-substituted lower alkyl which may optionally bear a lower alkoxy substituent in the phenyl moiety, R6bIs the above-mentioned R6aIn the definition of (1), a group other than a hydrogen atom, R6cAnd R6dEach is hydrogen or lower alkyl, R29Is hydrogen or lower alkyl, R30Is lower alkyl or a group of the formula: -A1CONR6R7(wherein A is1、R6And R7As described above), R30aAnd R30bEach is a hydrogen atom or a lower alkyl group, provided that when R30Is a group-A1CONR6R7When R is29Is a hydrogen atom.
The reaction of compound (1Q) with compound (15a) and the reaction of compound (1S) with compound (16a) are carried out under the same reaction conditions as those for the reaction of compound (1a) with compound (4a) in scheme 2 above. The reaction of compound (1Q) with compound (15b) and the reaction of compound (1S) with compound (16b) are carried out under the same reaction conditions as those for the reaction of compound (1a) with compound (4b) in scheme 2 above.
The starting compound (2) or (3) can be prepared by the following method. Reaction scheme 15
Figure A9419071903001
[ wherein R3bAs mentioned above, with the proviso that the radical R of the compound (3a)3bCH2The total number of carbon atoms of the acyclic part of (A) does not exceed 6]
Compound (17) is converted to compound (3a) by reacting compound (17) with hydrazine in a suitable solvent or by subjecting compound (17) to hydrolysis. The solvent used for the reaction of compound (17) and hydrazine includes, for example, water, the same solvent as used in the reaction of compound (2) and compound (3) in the above-mentioned reaction scheme 1. The reaction is usually carried out at a temperature of from room temperature to about 120 c, preferably from 0 to about 100 c, for from 0.5 to about 10 hours, with hydrazine being used at least in equimolar amounts to compound (17), preferably from 1 to 5 moles of hydrazine per 1 mole of compound (17).
The hydrolysis is carried out in the presence of an acid or basic compound in a suitable solvent or without a solvent. The solvent includes, for example, water, lower alcohols (e.g., methanol, ethanol, isopropanol, etc.), ketones (e.g., acetone, methyl ethyl ketone, etc.), ethers (e.g., dioxane, tetrahydrofuran, ethylene glycol dimethyl ether, etc.), fatty acids (e.g., acetic acid, formic acid, etc.), or a mixture of these solvents. The acid includes, for example, inorganic acids (e.g., hydrochloric acid, sulfuric acid, hydrobromic acid, etc.), organic acids (e.g., formic acid, acetic acid, aromatic sulfonic acids, etc.), and the like. The basic compound includes, for example, alkali metal carbonates (such as sodium carbonate, potassium carbonate, etc.), alkali metal or alkalineearth metal hydroxides (such as sodium hydroxide, potassium hydroxide, calcium hydroxide, etc.), and the like. The reaction is generally carried out at a temperature of from room temperature to about 200 deg.C, preferably from room temperature to about 150 deg.C, for a period of from 10 minutes to about 25 hours. Reaction scheme 16
Figure A9419071903011
[ wherein R31Is hydrogen atom, lower alkyl or lower alkenyl; r3eIs hydrogen atom, lower alkyl, a group of the formula: - (D) R' -R33(wherein D is lower alkylene: r' is0 or 1; r33Is a group of the formula:(wherein R is5And p is as previously described), lower alkanoyloxy-substituted lower alkyl, lower alkoxy-lower alkyl, lower alkanoyl-substituted lower alkyl, lower alkoxycarbonyloxy-substituted lower alkyl, benzoyl-substituted lower alkyl (which may optionally bear halogen substituents on the phenyl ring), a group of the formula: -E-N (R)52)(R53) (wherein R is52And R53As previously mentioned, E is lower alkylene), a group of the formula:
Figure A9419071903022
(wherein R is54Is hydrogen or lower alkyl, A is as defined above), cycloalkyl, naphthyl, a group of formula:(wherein R is8And q is as previously described, group
Figure A9419071903024
Is a five to fourteen-membered saturated or unsaturated heteromonocyclic, heterobicyclic, or heterotricyclic group having 1 to 4 heteroatoms selected from nitrogen atoms, oxygen atoms, and sulfur atoms), a phenyl group which may optionally bear a substituent selected from: lower alkoxy, halogen, optionally with a substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkeneAmino substituted by alkylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally substituted by lower alkyl in the tetrazole moiety, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As previously described), lower alkenyloxy, nitro and lower alkyl which may optionally bear halogen substituents, phenyl-lower alkenyl which may optionally bear substituents on the phenyl ring selected from: lower alkoxy, A halogen atom, amino optionally having A substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having A lower alkyl substituent on the tetrazole moiety, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As previously described), lower alkenyloxy, nitro and lower alkyl which may optionally bear halogen substituents, lower alkyl which may be substituted by phenylthio which may optionally bear lower alkoxy substituents on the phenyl ring, lower alkyl which may be substituted by phenylsulfinyl which may optionally bear lower alkoxy substituents on the phenyl ring, lower alkyl which may be substituted by phenylsulfonyl which may optionally bear lower alkoxy substituents on the phenyl ring, lower alkyl which is substituted by phenoxy, a group of the formula: -A5-CR42R43R44(wherein A is5、R42、R43And R44As previously described), a 2, 3-dihydro-1H-indenyl substituted lower alkyl group optionally bearing a substituent selected from oxo, hydroxy and siloxy bearing lower alkyl substituents on the 2, 3-dihydro-1H-indenyl ring, a group of the formula:(wherein the group
Figure A9419071903032
、R47And uis as previously described), a group of the formula:
Figure A9419071903033
(wherein, R47And u is as previously described, group
Figure A9419071903041
Is a five to fourteen membered unsaturated heteromonocyclic, heterobicyclic or heterotricyclic group having 1 to 4 heteroatoms selected from nitrogen atom, oxygen atom and sulfur atom); provided that when R is3eIs phenyl which may optionally bear substituents on the phenyl ring selected from: lower alkoxy, A halogen atom, amino optionally having A substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having A lower alkyl substituent on the tetrazole moiety, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As described above), lower alkenyloxy, nitro and lower alkyl which may optionally bear halogen substituents, or when R is3eIn the case of a group of the formula,then R31Is lower alkenyl, and with the proviso that also the radical (R) of compound (3b)3e)(R31) The total number of carbon atoms of the acyclic part of CH-is not more than 6, and R32Is lower alkanoyloxy]。
The reaction of compound (18) and compound (19) is carried out under the same reaction conditions as those for the reaction of compound (1a) and compound (4b) in scheme 2 above.
The starting compound (17) was prepared by the following method.Reaction scheme 17[ wherein R3b、R12And X is as previously described, M is an alkali metal (e.g., potassium, sodium, etc.), provided that the group-CH of compound (17)2R3bThe total number of carbon atoms in the middle non-cyclic part is not more than 6]。
The reaction for converting compound (20) into compound (21) is carried out in the same manner as the halogenation reaction of compound (1p) in scheme 7 above, but it is preferable to add a radical initiator (e.g., 2- (4-biphenyl) -5-phenyloxazole, azobisisobutyronitrile, perbenzoic acid, etc.) and an appropriate amount of water (e.g., 3 mol%) to the conversion reaction system.
The reaction of compound (21) and compound (22a) is carried out under the same conditions as those for the reaction of compound (1a) and compound (4b) in scheme 2 above.
The reaction for converting compound (23) into compound (24) is carried out under the same reaction conditions as those for the reaction for converting compound (1S) into compound (1r) in scheme 8 above.
The reaction of compound (24) and compound (22b) is carried out in a suitable solvent in the presence of an azodicarboxylic acid derivative and a phosphorus compound. Examples of the azodicarboxylic acid derivative are dialkyl azodicarboxylate (e.g., diethyl azodicarboxylate, dibutyl azodicarboxylate, etc.) and dialkyl azodiamide (e.g., 1' -azobiscarbonyldipiperidine, etc.), and examples of the phosphorus compound are trialkylphosphine (e.g., trimetaphosphine, etc.) and triarylphosphine (e.g., triphenylphosphine, etc.). The solvent may be a solvent other than a lower alcohol among the reaction solvents used for the compound (1a) and the compound (4a) in the above-mentioned reaction scheme 2. The azodicarboxylic acid derivative, the phosphorus compound and the compound (22) are used in at least equimolar amounts to the compound (24), preferably 1 to 1.5 moles of the azodicarboxylic acid derivative, the phosphorus compound and the compound (22) per 1 mole of the compound (24). The reaction is generally carried out at a temperature of from 0 to 100 deg.C, preferably from 0 to about 70 deg.C, for from 1 to about 15 hours.
The reaction for converting compound (25) into compound (24) is carried out under the same reaction conditions as those for the reaction for converting compound (1S) into compound (1r) in scheme 8 above.
The reaction of compound (26) and compound (22a) is carried out in a suitable solvent in the presence of formaldehyde and an acid. The solvent includes, for example, halogenated hydrocarbons (e.g., dichloromethane, dichloroethane, chloroform, carbon tetrachloride, etc.), water, alcohols (e.g., methanol, ethanol, isopropanol, etc.), alkanoic acids (e.g., acetic acid, propionic acid, etc.), acid anhydrides (e.g., acetic anhydride, etc.), polar solvents (e.g., acetone, dimethylformamide, etc.), or a mixture of these solvents. Acids includeSuch as inorganic acids, e.g., hydrogen chloride gas, hydrochloric acid, hydrobromic acid, and the like. The formaldehyde includes, for example, 20 to 40% by weight of an aqueous formaldehyde solution, a dimer of formaldehyde, a polymer of formaldehyde (i.e., paraformaldehyde), and the like. Compound (22a) is usually used in at least an equimolar amount of compound (26), and preferably 1 to 2 moles of compound (22a) are used per 1 mole of compound (26). Formaldehyde is generally used in at least an equimolar amount to compound (26), preferably in excess of formazan per 1 mole of compound (26)An aldehyde. The reaction is carried out at a temperature of 0 to about 200 deg.C, preferably room temperature to 150 deg.C, for 0.5 to about 24 hours. Reaction scheme 18 (27) (3c) [ wherein R3bAs described above]
The reaction for converting compound (27) into compound (3c) is carried out under the same reaction conditions as those forthe reaction for converting compound (1s) into compound (1r) in scheme 8 above. Reaction scheme 19 (28) (30) (3d) [ wherein R34Is a group of the formula:or a group of the formula: -NR36R37(wherein R is36And R37Each is phenyl-lower alkyl), R35Is phenylthio which may optionally bear a lower alkoxy substituent on the phenyl ring, A is as previously described]
The reaction of compound (28) and compound (29) is carried out under the same reaction conditions as those for the reaction of compound (1a) and compound (4a) in scheme 2 above.
When R of the compound (30)34In the case of a group of the formula,the reaction for converting compound (30) into compound (3d) is carried out under the same reaction conditions as those for the reaction for converting compound (17) into compound (3a) in scheme 15 above.
When R of the compound (30)34Is a group-NR36R37When the compound (10) (wherein R is as defined in the above reaction scheme 6)14Is phenyl-lowerLower alkoxy) to compound (1m) under the same reaction conditions as the reduction reaction to convert compound (30) to compound (3 d). Reaction scheme 20
Figure A9419071903082
[ wherein R1、R2、R12And r is as previously described]
The reaction of compound (31) and compound (32) is carried out in the presence of a basic compound. The basic compound includes basic compounds used in the reaction of the compound (1a) and the compound (4a) in the above-mentioned reaction scheme 2. Compound (32) is used inat least an equimolar amount to compound (31), preferably 1 to 5 moles of compound (32) per 1 mole of compound (31). The reaction is carried out at a temperature of 0 to 100 c, preferably 0 to about 70 c, for 1 hour to about 5 days.
The reaction for converting compound (33a) into compound (33b) is carried out in the presence of a halogenated phosphorus compound (e.g., phosphorus tribromide, phosphorus trichloride, etc.) in a suitable solvent. The solvent includes, for example, ethers (e.g., dioxane, tetrahydrofuran, etc.), halogenated hydrocarbons (e.g., chloroform, dichloromethane, carbon tetrachloride, etc.), and the like. 1 to 2 moles of halogenated phosphorus compound per 1 mole of compound (33a) are used. The reaction is generally carried out at a temperature of 0 to 100 c, preferably 0 to about 70 c, for 0.5 to 5 hours.
Compound (33a) is converted to compound (33c) by reacting compound (33a) with sodium hydrogensulfate in a suitable solvent in the presence of an acid. The solvent includes, for example, alcohols (e.g., methanol, ethanol, propanol, butanol, 3-methoxy-1-butanol, ethyl cellosolve, methyl cellosolve, etc.), water, etc. The acid includes, for example, inorganic acids such as hydrochloric acid and the like. Sodium bisulfate is used in at least an equimolar amount to the compound (33a), and preferably 1 to 5 moles of sodium bisulfate are used per 1 mole of the compound (33 a). The reaction is generally carried out at a temperature of from 0 to 100 c, preferably from 0 to about 70 c, for from 1 to about 10 hours.
The reaction for converting compound (33c) to compound (33d) is carried out under the same reaction conditions as those for the reaction for converting compound (1c) to compound (1d) in scheme 3 above.
In the same manner as in the above-mentioned reaction for converting Compound (33a) into Compound (33b)The reaction for converting the compound (33a) into the compound (33d) is carried out under conditions such that the halogenated phosphorus compound is replaced with a trialkyl phosphite (e.g., trimethyl phosphite) and the solvent used may be an alcohol such as 1-propanol at a reaction temperature of 0 to 150 deg.C, preferably 0 to 100 deg.C. Reaction scheme 21
Figure A9419071903101
[ wherein R1、R2、R12R, m and n are as previously described]
The hydrolysis reaction of the compound (33) is carried out under the same reaction conditions as those for the hydrolysis of the compound (1j) in the above scheme 5.
The esterification of the compound (2) was carried out by the following method: the starting compound is reacted with an alcohol (e.g., methanol, ethanol, isopropanol, etc.) in the presence of an inorganic acid (e.g., hydrochloric acid, sulfuric acid, etc.) and a halogenating agent (e.g., thionyl chloride, phosphorus oxychloride, phosphorus pentachloride, phosphorus trichloride, etc.) at a temperature of 0 to 150 c, preferably 50 to 100 c, for 5 minutes to about 10 hours.
Intermediate compound (24a) is prepared according to scheme 22 below.Reaction scheme 22
Figure A9419071903111
[ wherein R8Q' and R12As described above]
The reaction for converting compound (20a) into compound (20b) is carried out in a suitable solvent in the presence of an oxidizing agent. The solvent and the oxidizing agent used are the same as those used in the reaction for converting compound (1c) into compound (1d) in scheme 3 above, respectively. The oxidizing agent is usually in excess relative to the compound (20a), and the reaction is usually carried out at a temperature of from room temperature to 150 ℃ and preferably from room temperature to about 120 ℃for 1 to about 20 hours.
The reaction for converting compound (20b) into compound (20c) is carried out as follows: in the compound R12COOCOR12(wherein R is12As previously described), the compound (20b) is heated at a temperature of room temperature to about 200 c, preferably room temperature to 150 c, for 1 to 10 hours.
The reaction for converting compound (20c) into compound (24a) is carried out under the same reaction conditions as those for the hydrolysis of compound (1j) in scheme 5 above.
By reacting a compound of formula (I) wherein R5Or R8Reduction of the corresponding compound (1) which is nitro to prepare the compound in which R is5Or R8A compound which is an amino group.
The reduction reaction can be carried out as follows: for example, (a) in a suitable solvent, a catalyst is used, or (b) in an inert solvent, a mixture of a metal or metal salt and an acid, or a mixture of a metal or metal salt and an alkali metal hydroxide, alkali metal sulfite, or alkali metal ammonium salt is used as a reducing agent.
When the above-mentioned method (a) is employed, the solvent includes, for example, water, acetic acid, alcohols (e.g., methanol, ethanol, isopropanol, etc.), hydrocarbons (e.g., hexane, cyclohexane, etc.), ethers (e.g., dioxane, tetrahydrofuran, diethyl ether, diglyme, etc.), esters (e.g., ethyl acetate, methyl acetate, etc.), aprotic polar solvents (e.g., N-dimethylformamide, etc.), or a mixture of these solvents. Catalysts include, for example, palladium black, palladium-carbon, platinum oxide, copper chromite, raney nickel, and the like. 0.02 to 1 mol of catalyst is used per 1 mol of starting compound. The reaction is carried out at a temperature of-20 ℃ to 150 ℃, preferably 0 to 100 ℃, under a hydrogen pressure of 1 to 10 atmospheres for 0.5 to 10 hours. An acid (e.g., hydrochloric acid) may be added to the reaction system.
When the above method (b) is employed, the following are used as the reducing agent: a mixture of iron, zinc, tin or stannous chloride and an inorganic acid (e.g., hydrochloric acid, sulfuric acid, etc.), or a mixture of iron, iron sulfide, zinc or tin and an alkali metal hydroxide (e.g., sodium hydroxide, etc.), a sulfide (e.g., ammonium sulfide, etc.), aqueous ammonia, an ammonium salt (e.g., ammonium chloride, etc.). Inert solvents include, for example, water, methanol, ethanol, dioxane, acetic acid, and the like. The conditions for the reduction reaction may be selected according to the kind of the reducing agent used. For example, when a mixture of stannous chloride and hydrochloric acid is used as the reducing agent, the reaction is preferably carried out at a temperature of 0 ℃ to about room temperature for 0.5 to about 10 hours. The reducing agent can be used in at least equimolar amounts with respect to the starting compounds, generally from 1 to 5 mol per 1 mol of starting compoundA reducing agent. Reaction scheme 23[ wherein R1、R2、R3a、R8、R39M, n, q ', D, r' and groupsAs previously described, R48Is lower alkoxy, R49Is lower alkoxycarbonylR50And R51Same or different, each is hydrogen atom or lower alkyl]
The reaction of compound (1U) and compound (34) is carried out in a suitable solvent in the presence of a basic compound. The basic compound includes, for example, inorganic bases such as metallic sodium, metallic potassium, sodium hydride, sodium amide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate and the like, organic bases such as alkali metal alkoxides (e.g., sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like), alkyllithium, aryllithium or lithium amide (e.g., methyllithium, N-butyllithium, phenyllithium, lithium diisopropylamide and the like), pyridine, piperidine, quinoline, triethylamine, N-dimethylaniline and the like. The solvent may be any solvent which does not affect the reaction, and includes, for example, ethers (such as diethyl ether, dioxane, tetrahydrofuran, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, etc.), aromatic hydrocarbons (such as benzene, toluene, xylene, etc.), aliphatic hydrocarbons (such as N-hexane, heptane, cyclohexane, etc.), amines (such as pyridine, N-dimethylaniline, etc.), aprotic polar agents (such as N, N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, etc.), alcohols (such as methanol, ethanol, isopropanol, etc.), and the like. The reaction is generally carried out at a temperature of-80 to 150 deg.C, preferably-80 to about 120 deg.C, for 0.5 to about 15 hours.
The reaction for converting compound (1V) into compound (1W) can be carried out under the same reaction conditions as those for the hydrolysis of compound (1j) in scheme 5 above.
The reaction of compound (1W) with compound (35) is carried out under the same reaction conditions as those for the reaction of compound (2) with compound (3) in the above-mentioned reaction scheme 1.Reaction scheme 24
Figure A9419071903151
[ wherein R1、R2M, n, R and R3aAs previously described, R3c′Is phenyl-lower alkoxycarbonyl, lower alkanoylOr lower alkoxycarbonyl, phenoxycarbonyl or a group of the formula: -CO-A-NE52R53(wherein, A, R52、R53As described above)]
The reaction of compound (1a) and compound (38) is carried out under the same reaction conditions as those for the reaction of compound (2) and compound (3) in the above-mentioned reaction scheme 1. In the reaction, when the compound (38) is used in the form of an acid anhydride, the reaction of the carboxylic anhydride and the amine compound is carried out under the same reaction conditions as those of the reaction of the compound (2) and the compound (3) in the active ester method, that is, in the presence of a basic compound in a suitable solvent at a temperature of 0 to 150 ℃, preferably 10 to 100 ℃ for 5 to 30 hours, and the carboxylic anhydride compound is used at least in an equimolar amount to the compound (1a), preferably 1 to 2 moles of the carboxylic anhydride per 1 mole of the compound (1 a).
Wherein R is8The compound (1) which is a lower alkanoyl group can be prepared as follows: in which R is8The corresponding compound (1) which is cyano and the compound (11) of the following formula: r17MgX reaction (wherein R17And X is as previously described) and then hydrolyzing the resulting compound. The reaction of compound (1) and compound (11) is carried out under the same reaction conditions as those for the reaction of compound (1s) and compound (11) in scheme 8 above. Followed by reaction with the compounds of scheme 5(1j) The same conditions of hydrolysis followed the hydrolysis reaction. The reaction is preferably carried out in the presence of an acid.
Wherein R is5Is 1, 3-dioxolanyl which may optionally bear lower alkyl substituents or R8A compound which is a lower alkyl group substituted with a 1, 3-dioxolanyl group which may optionally have a lower alkyl substituent (1) by reacting a compound wherein R is5Is lower alkanoyl or R8A corresponding compound (1) which is a lower alkanoyl substituted lower alkyl group is reacted with a compound of the formula,
Figure A9419071903161
(wherein R is38Is lower alkyl, v is 0 or an integer from 1 to 3). The reaction is carried out in the presence of an acid in a suitable solvent. The solvent includes, for example, the solvents used in the reaction of the compound (1a) and the compound (4a) in the above-mentioned scheme 2, halogenated hydrocarbons (e.g., methylene chloride, ethylene dichloride)Alkanes, chloroform, etc.). The acid includes, for example, inorganic acids (e.g., hydrochloric acid, sulfuric acid, hydrobromic acid, etc.), organic acids (e.g., p-toluenesulfonic acid, etc.), and the like. Compound (36) is used in at least an equimolar amount to the starting compound, and preferably 1 to 10 moles of compound (36) are used per 1 mole of the starting compound. The reaction is generally carried out at a temperature of from room temperature to 150 deg.C, preferably from room temperature to about 100 deg.C, for a period of from 1 to about 24 hours.
Wherein R is5Is lower alkanoyl or R8Compounds which are lower alkanoyl substituted lower alkyl are prepared by reacting compounds (1) wherein R is5Is 1, 3-dioxolanyl which may optionally bear lower alkyl substituents or R8Is a lower alkyl group which may be substituted by a 1, 3-dioxolanyl group optionally having a lower alkyl substituent, by hydrolysis of the corresponding compound (1). The hydrolysis is carried out in the presence of an acid in a suitable solvent. The solvent includes, for example, water, lower alcohols (e.g., methanol, ethanol, isopropanol, etc.), ketones (e.g., acetone, methyl ethyl ketone, etc.), halogenated hydrocarbons (e.g., methylene chloride, dimethyl ketone, etc.)Ethyl chloride, chloroform, carbon tetrachloride, etc.) or mixtures of these solvents. The acid includes, for example, inorganic acids (e.g., hydrochloric acid, sulfuric acid, hydrobromic acid, etc.) and organic acids (e.g., p-toluenesulfonicacid, etc.). The reaction is carried out at a temperature of 0 to 70 deg.C, preferably 0 deg.C to room temperature, for 1 to about 10 hours.
Wherein R8 is tetrazolyl having a substituent selected from the group consisting of lower alkyl and lower alkoxy-lower alkyl, is prepared by reacting a compound (1) having the formula: in which R is8Corresponding compounds (1) which are tetrazolyl and formula R39X Compound (37) (wherein R39Which is lower alkyl or lower alkoxy-lower alkyl, and X is as described above) is reacted in the same manner as in the reaction of compound (10) with compound (4a) in the above-mentioned reaction scheme 2.
Wherein R is8A compound which is unsubstituted tetrazolyl by reacting a compound (1) wherein R is8For hydrolyzing a tetrazolyl compound (1) having a lower alkoxy-lower alkyl substituent under the same conditions as those in the above-mentioned Compound (10) (wherein R is14Lower alkoxy substituted by lower alkoxy) under the same conditions.
Wherein R is2Is morpholineThe compound (1) of lower alkyl substituted with an imidazolyl group or lower alkyl substituted with a lower imidazolyl group is produced by the following method: in which R is2The corresponding compound (1), which is a lower alkyl group having a halogen substituent, is reacted with morpholine or imidazole in the same manner as in the reaction of compound (1a) and compound (4a) in scheme 2 above.
Wherein R is2Compounds which are halogen-substituted methyl groups (1) by reacting compounds in which R is2The corresponding compound (1) which is a methyl group can be produced by the same reaction as the reaction for converting the compound (20) into the compound (21) in scheme 17 above. In addition, wherein R2The compound (1) which is a halogen-substituted methyl group in which the halogen atom is a fluorine atom is also produced by reacting a compound in which R is2The corresponding compound (1) which is a halogen-substituted methyl group in which the halogen atom is not a fluorine atom is reacted with silver fluoride.
Among the desired compounds (1) of the present invention, compounds having a basic group can be easily converted into their acid addition salts by treating with a pharmaceutically acceptable acid. Acids include, for example, inorganic acids (e.g., hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, and the like) and organic acids (e.g., oxalic acid, acetic acid, succinic acid, malonic acid, methanesulfonic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid, and the like). These salts have excellent antidiabetic activity as the free compound (1).
Further, among the desired compounds (1) of the present invention, a compound having an acidic group can be easily converted into a salt by treating with a pharmaceutically acceptable basic compound. The basic compound includes, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium bicarbonate, and the like.
The compounds required for each process step can be easily isolated and purified by conventional separation methods. Examples of the separation method are solvent extraction, dilution, recrystallization, column chromatography, preparative thin layer chromatography and the like.
In addition, the compound (1) of the present invention includes various stereoisomers and optical isomers, and these isomers are also useful as antidiabetics.
The desired compound (1) of the present invention and a salt thereof can be used as an antidiabetic agent and used in the form of a conventional pharmaceutical preparation. The formulations are prepared using conventional diluents or carriers. Examples of diluents or carriers are fillers, thickeners, binders, humectants, disintegrants, surfactants, lubricants, and the like. The dosage form of the pharmaceutical preparation may be selected according to the intended use, and representative dosage forms include tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories, injections (solutions, suspensions, etc.), and the like. To make tablets, the following carriers were used: for example, excipients (e.g., lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid, etc.), binders (e.g., water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, polyvinylpyrrolidone, etc.), disintegrants (e.g., dry starch, sodium alginate, agar powder, laminarin powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, glyceryl monostearate, starch, lactose, etc.), disintegration inhibitors (e.g., white sugar, glyceryl stearate, cacao butter, hydrogenated oil, etc.), absorption promoters (e.g., quaternary ammonium base, sodium lauryl sulfate, etc.), wetting agents (e.g., glycerin, starch, etc.), absorbents (e.g., starch, lactose, kaolin, bentonite, etc.), binders (e.g., water, ethanol, propanol, monosaccharide, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, colloidal silicates, etc.), lubricants (e.g., purified talc, stearates, boric acid powder, polyethylene glycol, etc.), and the like. Alternatively, the tablets may be formulated in the form of conventional coated tablets, such as sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets, or double-or multilayer tablets. Conventional carriers can be used for preparing pills, and include, for example, excipients (such as glucose, lactose, cacao butter, hydrogenated vegetable oil, kaolin, talc, etc.), binders (such as gum arabic powder, tragacanth powder, gelatin, ethanol, etc.), disintegrators (such as laminarin, agar, etc.), etc. Conventional carriers can be used for preparing suppositories, and include, for example, polyethylene glycol, cacao butter, higher alcohols, higher alcoholic sugars, gelatin, semisynthetic glycerides and the like. Capsules can be prepared by incorporating a compound of the present invention and the above-mentioned carrier into hard gelatin capsules or soft capsules according to a conventional method. In preparing injections, solutions, emulsions and suspensions are sterilized, preferably rendered isotonic with blood. In the preparation of such solutions, emulsions and suspensions, conventional diluents are used, such as water, ethanol, polyethylene glycol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters and the like. In this case, sodium chloride, glucose or glycerol may be added to the pharmaceutical formulation in an amount sufficient to render them isotonic. Conventional solubilizers, buffers and anesthetics can also be added to the pharmaceutical preparation. In addition, coloring agents, preservatives, perfumes, flavors, sweeteners and other agents may be optionally added as necessary.
The amount of the compound of the present invention to be added to the pharmaceutical preparation is not particularly limited, but may be selected from a wide range, but the amount thereof to be added is preferably in the range of 1 to 70% by weight.
The pharmaceutical preparation of the present invention containing the compound (1) or a salt thereof of the present invention as an active ingredient can be administered in any manner, and an appropriate administration manner can be determined depending on the type of preparation, age, sex and other conditions of patients, severity of diseases and the like. For example, tablets, pills, solutions, suspensions, emulsions, granules and capsules can be administered orally. The injection can be administered alone or together with conventional auxiliary liquids (e.g., glucose, amino acid solution) intravenously, or can be administered alone by intramuscular, intradermal, subcutaneous or intraperitoneal routes as required. Suppositories are administered by the intrarectal route.
The dosage of the pharmaceutical preparation of the present invention can be selected according to the use, age, sex and other conditions of the patient, severity of the disease, etc., but the dosage of the active compound of the present invention per kg body weight of the patient per day is usually in the range of about 0.2 to 200 mg.
Best Mode for Carrying Out The Invention
Examples
The present invention will be described in more detail below by way of examples of the preparation of antidiabetic agents, reference examples of the preparation process of the raw material compounds for preparing the compounds of the present invention, examples of the preparation process of the compounds of the present invention, and test examples of the activity of the compounds of the present invention.
Preparation example 1
Tablets were prepared from the following ingredients:
the amount of 2- (2-benzofuranylmethylaminocarbonyl) 5 mg-3-methylquinoxaline-4-oxide starch 132mg magnesium stearate 18mg lactose 45mg in total 200mg
Tablets each containing the above ingredients were prepared by a conventional method.
Preparation example 2
Film coated tablets were prepared from the following ingredients:
ingredient amounts of 2- [3- (4-methoxyphenyl) propylaminocarbon 150mg yl]-3-methylquinoxaline-4-oxide Avicel (trade name of microcrystalline cellulose manufactured by Asahi chemical industries, Ltd., Japan) 40g of corn starch 30g of magnesium stearate 2g of hydroxypropylmethylcellulose 10g of polyethylene glycol-60003 g of castor oil 40g of methanol 40g
The active compound of the invention, Avicel, corn starch and magnesium stearate were kneaded and tabletted with a conventional pestle (R10mm) for sugar coating. The thus-obtained tablets were coated with a film-coating agent consisting of hydroxypropylmethylcellulose, polyethylene glycol-6000, castor oil and methanol to prepare film-coated tablets.
Reference example 1
To a suspension of lithium aluminum hydride (0.93g) in diethyl ether (30ml) was added dropwise a solution of 2-ethoxycarbonyl-3-methylbenzofuran (5.0g) in anhydrous diethyl ether (10ml) under ice-cooling, and the mixture was stirred at room temperature for 30 minutes. The mixture was cooled and decomposed with saturated aqueous sodium sulfate solution. The mixture was filtered through celite and dried over anhydrous sodium sulfate. The residue was evaporated to remove the solvent to give 2-hydroxymethyl-3-methylbenzofuran (3.7g) as a white powder.
1H-NMR(CDCl3)δppm：1.82(1H，t，J＝6Hz)，2.27(3H，s)，4.76(2H，d，J＝6Hz)，7.20-7.55(4H，m)
Reference example 2
2-hydroxymethyl-3-methylbenzofuran (3.7g), triphenylphosphine (6.6g) and phthalimide (3.7g) were suspended in tetrahydrofuran (40ml), and a tetrahydrofuran (10ml) solution of diethyl azodicarboxylate (4.4g) was added dropwise thereto under ice-cooling. The mixture was stirred at room temperature overnight, the solvent was evaporated off, and the resulting residue was purified by silica gel column chromatography (solvent: dichloromethane), followed by crystallization from diethyl ether. The crystals were collected by filtration and dried to give 3-methyl-2-phthalimidomethylbenzofuran (4.6g) as a white powder.
1H-NMR(CDCl3)δppm：2.40(3H，s)，4.97(2H，s)，7.10-7.30(2H，m)，7.40(1H，d，J＝7Hz)，7.48(1H，d，J＝7Hz)，7.65-7.75(2H，m)，7.80-7.90(2H，m)
Reference example 3
3-methyl-2-phthalimidomethylbenzofuran (4.6g) was added to methanol (80ml), and hydrazine hydrate (1.2g) was added thereto, and then the mixture was refluxed for 3 hours. The mixture was evaporated to remove the solvent, a dilute aqueous solution of sodium hydroxide was added to the residue, and the mixture was extracted with chloroform. The chloroform layer was washed with saturated brine and was dried over anhydrous sodium sulfate. The solution was evaporated to remove the solvent to give 2-aminomethyl-3-methylbenzofuran (3.0g) as a colorless transparent liquid.
1H-NMR(CDCl3)δppm：1.55(2H，brs)，2.21(3H，s)，3.93(2H，s)，7.15-7.30(2H，m)，7.35-7.50(2H，m)
Reference example 4
To carbon tetrachloride (50ml) were added 2-methylbenzothiophene (4.0g), N-bromosuccinimide (4.8g) and azobisisobutyronitrile (0.3g), and the mixture was refluxed for 5 hours. After cooling, insoluble material was removed by filtration. The filtrate was concentrated to give 2-bromomethylbenzothiophene (6.7g) as a brown powder.
1H-NMR(CDCl3)δppm：4.79(2H，s)，7.30-7.45(2H，m)，7.36(1H，s)，7.70-7.65(2H，m)
Reference example 5
2-Bromomethylbenzothiophene (6.7g) was dissolved in dimethylformamide (40ml), potassium phthalimide (5.0g) was added thereto, and the mixture was stirred at 60 ℃ for 2 hours. The mixture was evaporated to remove dimethylformamide and the residue was extracted with chloroform. The extract was washed with water and saturated brine, dried over anhydrous sodium sulfate, and then the solvent was removed by evaporation. To the residue was added diethyl ether, and the precipitated crystals were collected by filtration and dried to give 2-phthalimidomethylbenzothiophene (4.5g) as a pale brown powder.
1H-NMR(CDCl3)δppm：5.10(2H，s)，7.20-7.40(3H，m)，7.70-7.80(4H，m)，7.80-7.95(2H，m)
Reference example 6
3-formylbenzofuran (4.3g) was dissolved in methanol (50ml), and sodium borohydride (1.1g) was slowly added thereto under ice-cooling. The mixture was stirred at the same temperature for 1 hour and methanol was evaporated off. The residue was extracted with chloroform, and the extract was washed with water and dried over anhydrous sodium sulfate. The solution was evaporated to remove the solvent to give 3-hydroxymethylbenzofuran (4.1g) as a pale yellow liquid.
1H-NMR(CDCl3)δppm：1.62(1H，t，J＝5Hz)，4.85(2H，d，J＝5Hz)，7.20-7.45(2H，m)，7.53(1H，d，J＝8Hz)，7.62(1H，s)，7.68(1H，d，J＝8Hz)
Reference example 7
A solution of ethyl 2-benzofuran acrylate (3.46g) in dry toluene was cooled to-50 ℃ and diisobutylaluminum hydride (1M in toluene, 37ml) was added dropwise thereto. The mixture was stirred at-20 ℃ for 1 hour, methanol (30ml) was added thereto, and the mixture was then stirred at room temperature overnight. The precipitate was removed by filtration and the filtrate was concentrated. The residue was dissolved in ethyl acetate, filtered through a magnesium silicate carrier, an activated magnesium silicate, and concentrated to give 2- (3-hydroxy-1-propenyl) benzofuran (2.6g) as a colorless liquid.
1H-NMR(CDCl3)δppm：4.39(2H，brs)，6.60(3H，m)，7.17-7.32(2H，m)，7.43(1H，d，J＝7Hz)，7.52(1H，d，J＝7Hz)
Reference example 8
Hydrogen chloride gas was blown into a mixture of benzothiophene (13.4g) and 37% aqueous formaldehyde solution (15ml) under ice-cooling for about 20 to 30 minutes. The mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into ice water and extracted with ether. The extract was washed with a saturated sodium bicarbonate solution and dried over anhydrous sodium sulfate. The solution was evaporated to remove the solvent, and the resulting residue and potassium phthalimide (18.5g) were dissolved in dimethylformamide (100 ml). The mixture was heated at 60 ℃ for 1.5 hours, and after cooling, the mixture was poured into ice water. The precipitated crystals were collected by filtration and washed with diisopropyl ether to give 3-phthalimidomethylbenzothiophene (13.4g) as pale brown crystals.
1H-NMR(CDCl3)δppm：5.08(2H，s)，7.3-7.5(2H，m)，7.61(1 H，s)，7.6-7.9(5H，m)，8.15(1H，d，J＝8Hz)
Reference example 9
2-Acetylbenzofuran (3.2g) was dissolved in methanol (60ml), and ammonium acetate (15g) and sodium cyanoborohydride (1.26g) were added thereto. The mixture was stirred at room temperature overnight, and a dilute aqueous hydrochloric acid solution was added thereto to make the solution acidic. The mixture was washed with ethyl acetate, the aqueous layer was basified with aqueous sodium hydroxide solution and extracted with chloroform. The chloroform layer was washed with water, dried over anhydrous sodium sulfate, and the chloroform was removed by evaporation to give 2- (1-aminoethyl) benzofuran (1.8g) as a colorless liquid.
1H-NMR(CDCl3)δppm：1.52(3H，d，J＝6Hz)，1.83(2H，brs)，4.20(1H，q，J＝6Hz)，6.50(1H，s)，7.15-7.30(2H，m)，7.43(1H，d，J＝8 Hz)，7.51(1 H，d，J＝8Hz)
Reference example 10
5-Ethyl-2-methylpyridine (25g) was dissolved in acetic acid (200ml), to which was added 30% aqueous hydrogen peroxide (25ml), and the mixture was heated at 100 ℃. After 4 hours, 30% aqueous hydrogen peroxide (25ml) was added to the mixture, and the resulting mixture was heated at the same temperature for 14 hours with stirring. After cooling, the mixture was concentrated by adding water, and this was repeated several times. The final residue was neutralized with saturated aqueous potassium carbonate solution and extracted with chloroform. The extract was dried over anhydrous potassium carbonate and the solvent was removed by evaporation. The resulting residue was dissolved in acetic anhydride (200ml), and the mixture was heated at 120 ℃ for 4 hours. The mixture was evaporated to remove the solvent, and saturated aqueous sodium bicarbonate solution was added thereto and extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and the solvent was removed by evaporation. The residue was dissolved in methanol (200ml), potassium carbonate (57g) was added thereto, and the mixture was stirred at room temperature for 12 hours. The mixture was evaporated to remove the solvent, and water was added thereto. The mixture was extracted with chloroform and dried over anhydrous potassium carbonate. The solution was evaporated to remove the solvent and the residue was purified by silica gel column chromatography (solvent: ethyl acetate: hexane ═ 1: 4) to give 5-ethyl-2-hydroxymethylpyridine (20.4 g). As a light brown liquid.
1H-NMR(CDCl3)δppm：1.26(3H，t，J＝8Hz)，2.66(2H，q，J＝8Hz)，3.67(1H，br)，4.73(2H，s)，7.18(1H，d，J＝8Hz)，7.52(1H，d，J＝8 Hz)，8.41(1H，s)
Reference example 11
4- (2-methyl-1, 3-dioxolan-2-yl) benzonitrile (1.9g) was dissolved in diethyl ether (20ml), to which was added lithium aluminum hydride (400mg) at 0 ℃. The mixture was allowed to react at room temperature for 14 hours, to which were added water (1ml) and 8M aqueous sodium hydroxide solution (3 ml). Magnesium sulfate was added to the mixture, and insoluble matter was removed by filtration. The filtrate was concentrated to give [4- (2-methyl-1, 3-dioxolan-2-yl) benzyl]amine (2.1g) as a colorless oil.
1H-NMR(CDCl3)δppm：7.45(2H，d，J＝8Hz)，7.29(2H，d，J＝8Hz)，4.04(2H，m)，3.87(2H，s)，3.77(2H，m)，1.77(2H，br)，1.65(3H，s)
Reference example 12
N-bromoethylphthalimide (13g) and p-methoxyphenylthiol (7.9g) were dissolved in dimethylformamide (70ml), to which was added potassium carbonate (10 g). The mixture was stirred at 70 ℃ overnight and the solvent was removed by evaporation. The residue was extracted with diethyl ether, washed with water and dried over anhydrous sodium sulfate. The solution was evaporated to remove ether and crystallized from n-hexane. The crystals were collected by filtration and dried to give N- [2- (4-methoxyphenylthio) ethyl]phthalimide (13.9g) as a white powder.
1H-NMR(CDCl3)δppm：3.14(2H，t，J＝7Hz)，3.75(3H，s)，3.89(2H，t，J＝7Hz)，6.80(2H，d，J＝8Hz)，7.42(2H，d，J＝8Hz)，7.65-7.75(2H，m)，7.75-7.90(2H，m)
Reference example 13
N- (2-chloroethyl) dibenzylamine hydrochloride (25g) and phenol (8.0g) were dissolved in dimethylformamide (100ml), and potassium carbonate (30g) was added thereto. The mixture was stirred at 70 ℃ for 6 hours and the dimethylformamide was removed by evaporation. The residue was extracted with diethyl ether, and the extract was washed with water and dried over anhydrous sodium sulfate. The solution was evaporated to remove ether to give N- (2-phenoxyethyl) dibenzylamine (25.5g) as a colorless oil.
1H-NMR(CDCl3)δppm：2.90(2H，t，J＝6Hz)，3.72(4H，s)，4.03(2H，t，J＝6Hz)，6.80(2H，d，J＝8Hz)，6.85-7.00(1H，m)，7.15-7.45(12H，m)
Reference example 14
N- (2-phenoxyethyl) dibenzylamine (25.5g) was dissolved in ethanol (500ml), to which 10% palladium on carbon (3.0g) was added. The mixture was hydrogenated at 50 ℃ under one atmosphere of hydrogen pressure. The catalyst was removed by filtration and the filtrate was evaporated to remove ethanol to give 2-phenoxyethylamine (11.0g) as a colorless oil.
1H-NMR(CDCl3)δppm：1.47(2H，brs)，3.08(2H，t，J＝5Hz)，4.01(2H，t，J＝5Hz)，6.85-7.00(3H，m)，7.25-7.35(2H，m)
Reference example 15
To triethylamine (1.5L) were added benzofuroxane (216g) and ethyl acetoacetate (207g), and the mixture was stirred at room temperature for 4 days. The precipitated crystals were collected by filtration, washed with water, dried and crystallized from ethyl acetate to give 2-ethoxycarbonyl-3-methylquinoxaline-1, 4-dioxide (115g) as pale yellow needles.
M.p.137—138℃。
Reference example 16
2-ethoxycarbonyl-3-methylquinoxaline-1, 4-dioxide (77g) is dissolved in concentrated hydrochloric acid (200ml) inethanol (3.5L), and a solution of sodium hydrogensulfite (200g) in water (1L) is added dropwise to the mixture at room temperature with stirring. The mixture was stirred at the same temperature for 4 hours, then the reaction mixture was neutralized with sodium bicarbonate and the ethanol was removed by evaporation. Water was added to the residue, and the precipitated crystals were collected by filtration, washed with water, dried and recrystallized from n-pentane to give 2-ethoxycarbonyl-3-methylquinoxaline (67g) as colorless needles.
M.p.74—75℃。
Reference example 17
2-ethoxycarbonyl-3-methylquinoxaline (64g) was dissolved in methylene chloride (700ml), and m-chloroperbenzoic acid (70g) was slowly added thereto under ice-cooling. The mixture was stirred at room temperature overnight, and the reaction solution was washed successively with a dilute aqueous solution of sodium thiosulfate, a saturated sodium bicarbonate solution and water, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation, and n-hexane was added to the residue. The precipitated crystals were collected by filtration, dried and recrystallized from n-hexane/diethyl ether to give 2-ethoxycarbonyl-3-methylquinoxaline-4-oxide (45g) as colorless needles.
M.p.91-93℃。
Reference example 18
2-ethoxycarbonyl-3-methylquinoxaline-1, 4-dioxide (105g) was dissolved in chloroform (500ml), and phosphorus tribromide (44ml) was slowly added dropwise thereto under ice-cooling. The mixture was stirred at room temperature for 1 hour and the solvent was removed by evaporation. The residue was poured into ice water and neutralized with potassium carbonate. The mixture was extracted with chloroform, washed with water and dried over anhydrous sodium sulfate. The solvent was removed by evaporation and the residue was purified by silica gel column chromatography (solvent: n-hexane: ethyl acetate 2: 1) and recrystallized from ethyl acetate/n-hexane to give 2-ethoxycarbonyl-3-methylquinoxaline-1-oxide (35g) as colorless prisms.
M.p.85-87℃。
Reference example 19
2-ethoxycarbonyl-3-methylquinoxaline-4-oxide (4.0g) was suspended in methanol (80ml) and a 5N aqueous sodium hydroxide solution (10ml), and the mixture was stirred at room temperature for 3 hours. The mixture was evaporated to remove the solvent and the residue was dissolved in water. The aqueous layer was washed with ethyl acetate and acidified with hydrochloric acid. The precipitated crystals were collected by filtration, washed with water and dried to give 2-carboxy-3-methylquinoxaline-4-oxide (3.2g) as a white powder.
M.p.143-145 deg.c (decomposition).
Reference example 20
2-Carboxyquinoxaline (2.0g) was dissolved in methanol (20ml), and thionyl chloride (1.3ml) was added dropwise thereto under ice-cooling. The mixture was refluxed for 15 minutes and the solvent was removed by evaporation. The residue was extracted with chloroform, and the extract was washed with a saturated aqueous sodium bicarbonate solution and dried over anhydrous sodium sulfate. The solvent was removed by evaporation, and the resulting 2-methoxycarbonylquinoxaline was dissolved in methylene chloride (40 ml). To the mixture was added m-chloroperbenzoic acid (2.9g) at room temperature with stirring, and the mixture was stirred at room temperature overnight. The reaction solution was washed with a dilute aqueous solution of sodium thiosulfate and a saturated sodium bicarbonate solution, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation, n-hexane was added to the residue, and the precipitated crystals were collected by filtration and dried to give 2-methoxycarbonylquinoxaline-4-oxide (2.0g) as a yellow powder.
M.p.154—155℃。
Reference example 21
2-ethoxycarbonyl-3-methylquinoxaline (2.2g) was dissolved in carbon tetrachloride (40ml), N-bromosuccinimide (2.7g) and perbenzoic acid (0.2g) were added thereto, and the mixture was refluxed for 8 hours. The mixture was evaporated to remove the solvent, and water was added thereto. The mixture was extracted with dichloromethane and the extracts were dried over anhydrous sodium sulfate and evaporated. The residue was dissolved in isopropanol (50ml), to which imidazole (2.8g) was added. The mixture was refluxed for 10 hours and the solvent was removed by evaporation. Water was added to the residue, and the mixture was extracted with chloroform and dried over anhydrous sodium sulfate. The solvent was removed by evaporation, and the residue was purified by silica gel column chromatography (solvent: dichloromethane: methanol: 16: 1) to give 2-ethoxycarbonyl-3- (1-imidazolyl) methylquinoxaline (1.33g) as a yellow powder.
1H-NMR(CDCl3)δppm：1.47(3H，t，J＝7Hz)，4.55(2H，q，J＝7Hz)，5.82(2H，s)，7.04(2H，d，J＝5Hz)，7.70(1H，s)，7.8-8.0(2H，m)，8.0-8.1(1H，m)，8.2-8.3(1H，m)
The compounds listed in Table 1 below were obtained from the appropriate starting compounds by the methods of reference examples 3, 9, 11 and 14.
TABLE 1
Figure A9419071903301
Figure A9419071903311
Figure A9419071903321
Figure A9419071903331
Figure A9419071903351
Figure A9419071903361
Figure A9419071903381
Figure A9419071903411
Figure A9419071903421
The compounds listed in Table 2 below were obtained from the appropriate starting compounds by the methods of reference examples 15 to 21.
TABLE 2
Figure A9419071903461
Figure A9419071903471
Figure A9419071903481
The compounds listed in Table 3 below were obtained from the appropriate starting compounds by the methods of reference examples 3, 9, 11 and 14.
TABLE 3
Figure A9419071903482
Figure A9419071903491
Figure A9419071903501
Figure A9419071903511
Figure A9419071903531
Figure A9419071903541
Figure A9419071903561
Figure A9419071903571
Figure A9419071903581
Figure A9419071903591
Figure A9419071903611
Figure A9419071903621
Figure A9419071903631
Figure A9419071903641
Figure A9419071903651
Figure A9419071903661
Figure A9419071903701
The compounds listed in Table 4 below were obtained from the appropriate starting compounds by the methods of reference examples 15 to 21.
TABLE 4
Figure A9419071903702
Figure A9419071903711
*：1H-NMR(CDCl3)ppm：
1.53(3H，t，J＝7Hz)，4.61(2H，d，J＝7Hz)，5.14(2H，s)，7.81-7.93(2H，m)，8.11(1H，m)，8.23(1H，m)
Example 1
2-ethoxycarbonyl-3-methylquinoxaline-4-oxide (1.5g) was mixed with 3-aminomethylbenzofuran (1.9g) under nitrogen and the mixture was stirred at 60 ℃ overnight. The reaction mixture was purified by silica gel column chromatography (solvent: n-hexane: ethyl acetate 3: 1) and recrystallized from ethanol to give 2- [ (3-benzofuranyl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (1.3g) as colorless needles.
M.p.143-144℃。
Example 2
2-carboxy-3-methylquinoxaline-4-oxide (0.8g) and 2-aminomethyl-5-dimethylaminobenzofuran (0.9g) were dissolved in dimethylformamide (10ml), and diethyl cyanophosphate (0.8g) and triethylamine (0.8g) were added dropwise thereto in this order under ice-cooling. The mixture was stirred at room temperature overnight, extracted with ethyl acetate and washed with water. The mixture was dried over anhydrous sodium sulfate and the solvent was removed by evaporation. The residue was purified by silica gel column chromatography (solvent: n-hexane: ethyl acetate 1: 1) and recrystallized from acetonitrile to give 2- [ (5-dimethylamino-2-benzofuranyl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (0.6g) as a yellow flake.
M.p.155-157℃
Example 3
2-Quinoxalinecarboxylic acid (0.5g) was dissolved in methylene chloride (10ml), and dicyclohexylcarbodiimide (0.7g) was added thereto. The mixture was stirred for 30 minutes, 2-aminomethylbenzofuran (0.5g) was added thereto, and the mixture was stirred overnight. The insoluble matter was removed by filtration, and the organic layer was washed with a saturated sodium bicarbonate solution and water, dried over anhydrous sodium sulfate, the solvent was removed by evaporation, and the residue was purified by silica gel column chromatography (solvent: n-hexane: ethyl acetate ═ 3: 1), and then recrystallized from n-hexane/ethyl acetate to give 2- [ (2-benzofuranyl) methylaminocarbonyl]quinoxaline (0.43g) as a colorless flaky substance.
M.p.155-156℃。
Example 4
2- [ (4-Morpholinocarbonylmethoxybenzyl) aminocarbonyl]-3-methyloxine (2.2g) was dissolved in methylene chloride (30ml), and m-chloroperbenzoic acid (1.3g) was added thereto at room temperature, and the mixture was stirred for 1 day. Chloroform was added to the mixture, and the organic layer was washed successively with an aqueous sodium thiosulfate solution, a saturated aqueous sodium hydrogencarbonate solution and water, and dried over anhydrous sodium sulfate. The mixture was evaporated to remove the solvent, and the residue was purified by silica gel column chromatography (solvent: ethyl acetate) and then recrystallized from acetonitrile to give 2- [ (4-morpholinocarbonylmethoxybenzyl) aminocarbonyl]-3-methylquinoxaline-4-oxide (1.5g) as colorless needles.
M.p.142-143℃。
The following compounds of the examples were prepared from the appropriate starting compounds by the method of example 4: 28-103, 125, 126, 128, 130-.
Example 5
2-Cinnamomylaminocarbonyl-3-methylquinoxaline (1.0g) was dissolved in dimethylformamide (15ml), and sodium hydride was added thereto under ice-cooling. The mixture was stirred at the same temperature for 30 minutes, methyl iodide (0.52g) was added thereto, and the mixture was stirred at room temperature for 2 hours. The mixture was poured into ice water and extracted with ether. The extract was washed with water and dried over anhydrous sodium sulfate. The solvent was removed by evaporation, and the residue was purified by silica gel column chromatography (solvent: N-hexane: ethyl acetate: 2: 1) to give 2- (N-cinnamyl-N-methylaminocarbonyl) -3-methylquinoxaline (0.8g) as a pale yellow liquid.
1H-NMR(CDCl3)δppm：2.78，2.79(3H，s)，2.92，3.24(3H，s)，3.98，4.43(2H，d，J＝6Hz)，6.10-6.40(1H，m)，6.40，6.70(1H，d，J＝16Hz)，7.20-7.50(5H，m)，7.70-7.85(2H，m)，8.00-8.15(2H，m)
The compounds 44, 66, 107, 110, 135, 138, 150, 151, 152, 153, 175, 176, 178, 186, 187, 191 and 192 of the following examples were prepared from the appropriate starting compounds by the method of example 5.
Example 6
2- [ (5-Aminobenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (0.4g) was suspended in pyridine (6ml), and acetic anhydride (0.26g) was added dropwise thereto under ice-cooling and stirring. The mixture was stirred at room temperature for one day and then poured into ice water. The precipitated crystals were collected by filtration, washed with water, and the crude crystals were recrystallized from acetonitrile to give 2- [ (5-acetylaminobenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (0.4g) as pale yellow needles.
M.p.183-184℃。
The compounds of examples 84 and 85 were prepared from the appropriate starting compounds by the method of example 6.
Example 7
2- [ (5-Aminobenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (0.8g) was dissolved in dimethylformamide (15ml), and potassium carbonate (0.5g) and N-chloroacetylmorpholine (0.37g) were added thereto. The mixture was stirred at 70 ℃ for 4 hours and the solvent was removed by evaporation. Water was added to the residue, and the mixture was extracted with chloroform, washed with water, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation, and the residue was purified by silica gel column chromatography (solvent: ethyl acetate), and the resultant was converted into its oxalate salt, followed by recrystallization from ethanol to give 2- [ (5-morpholinocarbonylmethylaminobenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (40mg) as a pale brown pellet.
M.p.159-167 deg.C (decomposition)
1H-NMR(CDCl3)δppm：3.09(3H，s)，3.40-3.55(2H，m)，3.55-3.85(6H，m)，3.90(2H，s)，4.78(2H，d，J＝6Hz)，6.60(1H，s)，6.65(1H，d，J＝7Hz)，6.67(1H，s)，7.28(1H，d，J＝7Hz)，7.75-7.85(2H，m)，8.05-8.15(1 H，m)，8.47(1H，brs)，8.50-8.60(1H，m)
Example 8
2- [ (5-Ethoxycarbonylbenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (4.2g) was added to a solution of sodium hydroxide (1.4g) in methanol (50ml) and water (14ml), and the mixture was stirred at room temperature overnight. The mixture was evaporated to remove methanol, and water was added to the resultant and acidified with hydrochloric acid. The precipitated crystals were collected by filtration, washed with water and dried to give 2- [ (5-carboxybenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (3.8g) as a white powder.
M.p.251-252 deg.c (decomposition).
Example 9
2- [ (6-methoxymethoxy-3-methylbenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (2.1g) was dissolved in tetrahydrofuran (20ml) and methanol (20ml), 6N hydrochloric acid (10ml) was added to the mixture, and the mixture was refluxed for 1 hour. The mixture was evaporated to remove the solvent, and the residue was extracted with chloroform. The extract was washed with saturated aqueous sodium hydrogencarbonate solution, water and brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation and the residue was recrystallized from dimethylformamide/water to give 2- [ (6-hydroxy-3-methylbenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (1.6g) as yellow needles.
M.p.222-223 ℃ (decomposition).
Example 10
2- [ (4-hydroxy-3-methylbenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (0.55g) was dissolved in dimethylformamide (4ml), potassium carbonate (0.41g) and methyl iodide (0.19ml) were added to the mixture, and the mixture was stirred at 60 ℃ for 4 hours. Water was added to the mixture, and the precipitated crystals were collected by filtration and washed with water. The crude crystals were recrystallized from ethyl acetate/n-hexane to give 2- [ (4-methoxy-3-methylbenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (0.41g) as yellow prisms.
M.p.196-197℃。
Example 11
2- [ (benzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (0.8g) was dissolved in chloroform (10ml), N-bromosuccinimide (0.47g) was added thereto, and the mixture was refluxed for 7 hours. The mixture was evaporated to remove the solvent, and the residue was purified by silica gel column chromatography (solvent: n-hexane: ethyl acetate: 2: 1) and then recrystallized from ethyl acetate/n-hexane to give 2- [ (3-bromobenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (0.44g) as colorless needles.
M.p.170-171℃。
The following compounds of the examples were prepared from the appropriate starting compounds by the method of example 11: 31. 34, 38, 88, 93, 98, 119, 124, 125, 131 and 139.
Example 12
2- [ (4-methoxybenzyl) aminocarbonyl]-3-methylquinoxaline (10.5g) was dissolved in anhydrous dichloromethane (150ml), to which was added dropwise a 1M solution of boron tribromide in dichloromethane (105ml) under ice-cooling. The mixture was stirred at room temperature for 2 days, cooled and then decomposed with methanol, and then the solvent was removed by evaporation. Water was added to the residue, the mixture was neutralized with sodium hydrogencarbonate, and the precipitated crystals were collected by filtration, washed with water and dried. The residue was recrystallized from ethanol to give 2- [ (4-hydroxybenzyl) aminocarbonyl]-3-methylquinoxaline (10.0g) as colorless needles.
M.p.211-214℃。
Example 13
2- { [5- (1-acetoxyethyl) benzofuran-2-yl]methylaminocarbonyl } -3-methyloxine-4-oxide (4.5g) was dissolved in methanol (90ml), to which potassium carbonate (1.8g) was added, and the mixture was stirred at room temperature overnight. The mixture was evaporated to remove the solvent and water was added to the residue. The mixture was extracted with chloroform, washed with water, and dried over anhydrous sodium sulfate. The mixture was evaporated to remove the solvent and the crude crystals were recrystallized from ethyl acetate/n-hexane to give 2- { [5- (1-hydroxyethyl) benzofuran-2-yl]methylaminocarbonyl } -3-methylquinoxaline-4-oxide (3.4g) as a colorless particulate.
M.p.112-114℃。
Example 14
2- { [5- (1-hydroxyethyl) benzofuran-2-yl]methylaminocarbonyl } -3-methylquinoxaline-4-oxide (0.8g) was dissolved in chloroform (30ml), manganese dioxide (3.6g) was added thereto, and the mixture was refluxed for 6 hours. The reaction was filtered through celite and concentrated. The residue was recrystallized from ethyl acetate/n-hexane to give 2- [ (5-acetylbenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (0.5g) as a pale yellow pellet.
M.p.205-206℃。
Example 15
2- [ (5-Acetylbenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide (0.7g) was dissolved in anhydrous tetrahydrofuran (20ml), and a 1M solution of methylmagnesium bromide in diethyl ether (2.5ml) was added dropwise thereto under ice-cooling. The mixture was stirred at room temperature for 3 hours and then poured into an ammonium chloride ice water solution. The mixture was extracted with chloroform, and the extract was washed with water and brine and dried over anhydrous sodium sulfate. The solvent was removed by evaporation and the residue was purified by silica gel column chromatography (solvent: n-hexane: ethyl acetate 1: 1) followed by recrystallization from n-hexane/ethyl acetate to give 2- { [5- (1-hydroxy-1-methylethyl) benzofuran-2-yl]methylaminocarbonyl } -3-methylquinoxaline-4-oxide (0.1g) as pale yellow prisms.
M.p.147-150℃。
Example 16
2- { [5- (5-tetrazolyl) benzofuran-2-yl]methylaminocarbonyl } -3-methylquinoxaline-4-oxide (1.4g) was dissolved in dimethylformamide (15ml), potassium carbonate (0.97g) and methyl iodide (0.44g) were added thereto, and the mixture was stirred at room temperature for 4 hours. The reaction solution was poured into ice water, and the precipitated crystals were collected by filtration and then recrystallized from dimethylformamide/ethanol to give 2- { [5- (2-methyl-5-tetrazolyl) benzofuran-2-yl]methylaminocarbonyl } -3-methylquinoxaline-4-oxide (0.48g) as a white powder.
M.p.206-209℃。
The compounds of examples 36 and 161-164 were prepared from the appropriate starting compounds by the method of example 16.
Example 17
2- [ (4-Methoxycarbonylmethoxybenzyl) aminocarbonyl]-3-methylquinoxaline (3.65g) was dissolved in methanol (50ml), to which was added 2N sodium hydroxide (6 ml). The mixture was stirred at room temperature for 2 hours. The mixture was evaporated to remove the solvent, and water was added to the resultant. The mixture was acidified with hydrochloric acid. The precipitated crystals were collected by filtration, washed with water and dried to give 2- [ (4-carboxymethoxybenzyl) aminocarbonyl]-3-methylquinoxaline (3.40g) as a white powder.
1H-NMR(DMSO-d6)δppm：2.83(3H，s)，4.48(2H，d，J＝6Hz)，4.66(2H，s)，6.91(2H，d，J＝9Hz)，7.33(2H，d，J＝9Hz)，7.8-8.0(2H，m)，8.0-8.2(2H，m)，9.33(1H，t，J＝6Hz)
The compound of example 49 was prepared from the appropriate starting compounds by the method of example 17.
Example 18
2- [ (4-Carboxymethoxybenzyl) aminocarbonyl]-3-methylquinoxaline (1.05g) was dissolved in dimethylformamide (10ml), furfuryl amine (0.35g) was added thereto, and then diethyl cyanophosphate (0.6g) and triethylamine (0.6g) were successively added dropwise thereto under ice-cooling. The mixture was stirred at room temperature overnight. And then poured into ice water. The precipitated crystals were collected by filtration and recrystallized from acetone/n-hexane to give 2- [ (4-furfurylaminocarbonylmethoxybenzyl) aminocarbonyl]-3-methylquinoxaline (0.92g) as a white powder.
M.p.175-176℃。
Example 19
2- [ (4-Methoxycarbonylmethoxybenzyl) aminocarbonyl]-3-methylquinoxaline (0.73g) and 2-methoxyethylamine (1.1ml) were dissolved in toluene (10ml), and the mixture was refluxed for 3 hours. The mixture was evaporated to remove the solvent, and the residue was recrystallized from ethyl acetate to give 2- { [4- (2-methoxyethylaminocarbonylmethoxy) benzyl]aminocarbonyl } -3-methylquinoxaline (0.95g) as a white powder.
M.p.138-140℃。
The compounds of the following examples were prepared from the appropriate starting compounds by the methods of examples 18 or 19: 46. 47, 66, 82, 83, 109, 110, 127, 138, 146-.
Example 20
2- [ (4-hydroxybenzyl) aminocarbonyl]-3-methylquinoxaline (1.8g) was dissolved in acetic acid (30ml) and chloroform (150ml), a solution of bromine (0.32ml) in acetic acid (5ml) was added dropwise thereto at room temperature, and the mixture was then stirred at the same temperature for 3 hours. The reaction solution was washed with a saturated sodium hydrogencarbonate solution and dried over anhydrous sodium sulfate. The solvent was removed by evaporation to give 2- [ (3-bromo-4-hydroxybenzyl) aminocarbonyl]-3-methylquinoxaline (1.0g) as a yellow powder.
The above-mentioned product was reacted with N-chloroacetylmorpholine by the method of example 10, followed by recrystallization from ethyl acetate/N-hexane to give 2- [ (3-bromo-4-morpholinocarbonylmethoxybenzyl) aminocarbonyl]-3-methylquinoxaline (0.6g) as colorless needles.
M.p.142-143℃。
The compounds of the following examples were prepared from the appropriate starting compounds by the methods of examples 10 or 20: 45. 51, 56, 58-60, 64-66, 78, 79, 82-83, 87, 106, 108, 110, 116, 117, 120, 121, 123, 126, 127, 138, 140-.
Example 21
2- [ (4-methoxycarbonylbenzyl) aminocarbonyl]-3-methylquinoxaline (0.75g) was dissolved in tetrahydrofuran (40ml), and lithium aluminum hydride (0.17g) was added dropwise thereto under ice-cooling and stirring. The mixture was stirred at the same temperature for 3 hours, and then a 10% aqueous solution of sodium hydroxide (0.3ml) and water (0.3ml) were successively added thereto and decomposed. The mixture was filtered through celite, and the filtrate was dried over anhydrous sodium sulfate. The solvent was removed by evaporation to give 2- [ (4-hydroxymethylbenzyl) aminocarbonyl]-3-methylquinoxaline (0.44g) as a yellow powder.
1H-NMR(CDCl3)δppm：1.75(1H，t，J＝6Hz)，4.70(4H，d，J＝6Hz)，7.3-7.5(4H，m)，7.7-7.9(2H，m)，8.0-8.1(2H，m)，8.39(1H，brs)
Example 22
Lithium aluminum hydride (1.9g) was suspended in tetrahydrofuran (100ml), and a solution of 2- [ (4-methoxycarbonylmethoxybenzyl) aminocarbonyl]-3-methylquinoxaline (9.5g) in tetrahydrofuran (50ml) was slowly added dropwise thereto under ice-cooling. After the addition was completed, the mixture was stirred at the same temperature for 30 minutes and then at room temperature for 2 hours. After completion of the reaction, ethyl acetate was added to the reaction mixture under ice-cooling, followed by addition of a saturated aqueous ammonium chloride solution. The insoluble matter was removed by filtration, and the filtrate was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate and the solvent was removed by evaporation. The residue was purified by silica gel column chromatography (solvent: ethyl acetate: n-hexane ═ 1: 4) to give 2- { [4- (2-hydroxyethoxy) benzyl]aminocarbonyl } -3-methylquinoxaline (1.0g) as a yellow liquid.
1H-NMR(CDCl3)δppm：2.25(1H，br)，3.17(3H，s)，3.9-4.1(4H，m)，4.63(2H，d，J＝6Hz)，6.92(2H，d，J＝7Hz)，7.34(2H，d，J＝7Hz)，7.7-7.9(2H，m)，8.0-8.1(2H，m)，8.34(1H，br)
Example 23
2- { [4- (2-hydroxyethoxy) benzyl]aminocarbonyl } -3-methylquinoxaline (0.2g) and triphenylphosphine (0.17g) were dissolved in carbon tetrachloride (10ml) and the mixture was refluxed for 1.5 hours. After the reaction was completed, the mixture was evaporated to remove the solvent, and the residue was purified by silica gel column chromatography (solvent: ethyl acetate: n-hexane ═ 1: 2) to give 2- { [4- (2-chloroethoxy) benzyl]aminocarbonyl } -3-methylquinoxaline (0.10g) as a yellow liquid.
1H-NMR(CDCl3)δppm：3.17(3H，s)，3.82(2H，t，J＝6Hz)，4.24(2H，t，J＝6Hz)，4.64(2H，d，J＝6Hz)，6.93(2H，d，J＝9Hz)，7.35(2H，d，J＝9Hz)，7.7-7.9(2H，m)，8.0-8.1(2H，m)，8.33(1H，br)
Example 24
2- { [ (4-chloroethoxy) benzyl]aminocarbonyl } -3-methylquinoxaline (100mg) and morpholine (0.21ml) were dissolved in dimethylformamide (10ml), and thereto were added sodium iodide (1.2g) and potassium carbonate (300mg), followed by heating the mixture at 60 ℃ for 7.5 hours. After completion of the reaction, the mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation, and the residue was purified by silica gel column chromatography (solvent: ethyl acetate: n-hexane ═ 2: 3) to give a yellow liquid, which was dissolved in ethanol, and then an ethanol-hydrochloric acid solution was added thereto and concentrated to dryness. The precipitated crystals were recrystallized from ethanol/diethyl ether to give 2-{ [4- (2-morpholinoethoxy) benzyl]aminocarbonyl } -3-methylquinoxaline hydrochloride (70mg) as a yellow powder.
M.p.155-158 deg.C (decomposition)
The compound of example 203 was prepared from the appropriate starting compounds by the method of example 24.
Example 25
2- { [4- (2-methyl-1, 3-dioxolan-2-yl) benzyl]aminocarbonyl } -3-methylquinoxaline-4-oxide (1.3g) was dissolved in acetone (20ml) and methylene chloride (10ml), p-toluenesulfonic acid (60mg) was added thereto, and the mixture was stirred at room temperature for 5 hours. The mixture was evaporated to remove the solvent and the residue was extracted with ethyl acetate. The extract was washed with a saturated aqueous sodium bicarbonate solution and dried over anhydrous sodium sulfate. The solvent was removed by evaporation, and the residue was recrystallized from ethanol to give 2- [ (4-acetylbenzyl) aminocarbonyl]-3-methylquinoxaline-4-oxide (1.0g) as pale yellow needles.
M.p.165-167℃。
Example 26
2- [2- (4-Methoxyphenylthio) ethylamino carbonyl]-3-methylquinoxaline-4-oxide (2.4g) was dissolved in methylene chloride (40ml), m-chloroperbenzoic acid (1.4g) was slowly added thereto under ice-cooling, and then the mixture was stirred at the same temperature for 1 hour. The reaction solution was washed with an aqueous sodium thiosulfate solution, a saturated sodium bicarbonate solution and water, and dried over anhydrous sodium sulfate. The mixture was evaporated to remove the solvent, and the residue was purified by silica gel column chromatography (solvent: ethyl acetate) and then recrystallized from ethanol to give 2- [2- (4-methoxyphenylsulfinyl) ethylaminocarbonyl]-3-methylquinoxaline-4-oxide (1.8g) as colorless needles.
M.p.156-157℃。
The compounds of examples 212 and 217 and 220 were prepared from the appropriate starting compounds by the method of example 26.
Example 27
2- [2- (4-Methoxyphenylthio) ethylamino carbonyl]-3-methylquinoxaline-4-oxide (2.4g) was dissolved in methylene chloride (40ml), and m-chloroperbenzoic acid (2.8g) was slowly added thereto under ice-cooling. The mixture was allowed to react at the same temperature for 1 hour, and the reaction solution was washed with an aqueous sodium thiosulfate solution, a saturated sodium bicarbonate solution and water, and dried over anhydrous sodium sulfate. The mixture was evaporated to remove the solvent, and the residue was recrystallized from ethanol to give 2- [2- (4-methoxyphenylsulfonyl) ethylaminocarbonyl]-3-methylquinoxaline-4-oxide (2.1g) as colorless needles.
M.p.148-150℃。
The compounds of examples 218 and 220 were prepared from the appropriate starting compounds by the method of example 27.
The compounds listed in Table 5 below were prepared from the appropriate starting compounds by the methods of examples 1, 2 or 3.
TABLE 5
Figure A9419071903851
Example 28 structure:
Figure A9419071903852
R1：H R2：CH3m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 154-157 form: free example 29 structure:
Figure A9419071903853
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 169-170 morphology: freeEXAMPLE 30 Structure
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 143-144 mode: free example 31 structure:
Figure A9419071903862
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 121-128 modes: free example 32 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: orange pellet recrystallization solvent: ethanol M.p. (° c): 173- "174 pattern: freeExample 33 structure:
Figure A9419071903871
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow pellet recrystallization solvent: dimethylformamide/water M.p. (° c): 192-: free example 34 structure:
Figure A9419071903872
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow powder recrystallization solvent: ethanol/water M.p. (° c): 180-182 mode: free example 35 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless pellets recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 149-151 mode: freeExample 36 structure:
Figure A9419071903881
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 171- "177 form: free example 37 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: pale yellow prismatic recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 210-212 (decomposition) mode: free example 38 structure:
Figure A9419071903883
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless flake recrystallization solvent: acetonitrile M.p. (° c): 215-217 (decomposition) mode: free
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: acetonitrile M.p. (° c): 183-184 mode: free example 40 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: yellow powder recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 182-183 mode: free example 41 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: light red needle recrystallization solvent: ethanol M.p. (° c):173- "174 pattern: freeExample 42 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: yellow pellet recrystallization solvent: acetonitrile M.p. (° c) l.214-215 (decomposed) form: free example 43 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 187-189 mode: free example 44 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: yellow flake recrystallization solvent: acetonitrile M.p. (° c): 155-157 type: freeExample 45 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: acetonitrile M.p. (° c): 159-160 mode: free
Figure A9419071903912
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder recrystallization solvent: 2-propanol M.p. (° c): 183-184 mode: free
Figure A9419071903913
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle-likeRecrystallization solvent of substance: 2-propanol M.p. (° c): 146-148 modes: freeExample 48 structure:
Figure A9419071903921
R1：H R2：CH3
m: 1 n: 0 crystal form: pale yellow prismatic recrystallization solvent: acetonitrile M.p. (° c): 168-169 form: free example 49 structure:
Figure A9419071903922
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless bell recrystallization solvent: ethanol/water M.p. (° c): 202-204 mode: free example 50 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder M.p. (° c): 251-252 (decomposition) mode: freeExample 51 structure:
Figure A9419071903931
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 120-122 mode: free
Figure A9419071903932
R1：H R2：CH3
m: 1 n: 0 crystal form: light brown pellet recrystallization solvent: ethanol M.p. (° c): 159-167 (decomposition) state: oxalate example 53 structure:
Figure A9419071903933
R1：H R2：CH3
m: 1 n: 0 crystal form: solvent for recrystallization of yellow needles: dimethylformamide/water M.p. (° c): 222-: freeExample 54 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 156-158 mode: free
Figure A9419071903942
R1：H R2：CH3
m: 1 n: 0 crystal form: yellow pellet recrystallization solvent: dimethylformamide/water M.p. (° c): 237-: free example 56 structure:
Figure A9419071903943
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder M.p. (° c): 130-132 mode: free
Figure A9419071903951
R1：H R2：CH3
m: 1 n: 0 crystal form: yellow prism recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 196-: free
Figure A9419071903952
R1：H R2：CH3
m: 1 n: 0 crystal form: yellow flake recrystallization solvent: ethanol M.p. (° c): 123-124 mode: free
Figure A9419071903953
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 177-178 morphology: freeExample 60 structure:
Figure A9419071903961
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: dimethylformamide M.p. (° c): 155-156 mode: free example 61 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: dimethylformamide/water M.p. (° c): 220-221 mode: free example 62 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 170-171 mode: freeExample 63 structure:
Figure A9419071903971
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 125-126 morphology: free example 64 structure:
Figure A9419071903972
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder M.p. (° c): 166-168 morphology: examples of liberation65 structure:
Figure A9419071903973
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder M.p. (° c): 114-116 mode: freeExample 66 structure:
Figure A9419071903981
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder recrystallization solvent: acetonitrile M.p. (° c): 184-186 mode: free example 67 structure:
Figure A9419071903982
R1：H R2：CH3
m: 1 n: 0 crystal form: white pellet recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 160-161 mode: free example 68 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow powder recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 70-72 forms: free
Figure A9419071903991
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless pellets recrystallization solvent: ethanol M.p. (° c): 89-90 forms: free
Figure A9419071903992
R1：H R2：CH3
m: 1 n: 0 crystal form: recrystallization solution of colorless granulesPreparation: n-hexane/ethyl acetate M.p. (° c): 112-114 mode: free example 71 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: pale yellow rod recrystallization solvent: acetonitrile M.p. (° c): 184-185 morphology: freeExample 72 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 153-155 mode: free example 73 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 160-162 mode: free example 74 structure:
Figure A9419071904003
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 143-144 mode: freeExample 75 structure:
Figure A9419071904011
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 199->210 morphology: free
R1：H R2：CH3
m: 1 n: 0 crystal form: yellow powder recrystallization solvent: dimethylformamide/ethanol M.p. (° c): 256-258 (decomposition) mode: free
Figure A9419071904013
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow pellet recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 205-206 morphology: freeExample 78 construction:
Figure A9419071904021
R1：H R2：CH3
m: 1 n:0 crystal form: light yellow powder recrystallization solvent: ethanol M.p. (° c): 154-155 mode: free example 79 structure:
Figure A9419071904022
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless prismatic crystal recrystallization solvent: ethanol M.p. (° c): 169-170 morphology: free example 80 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: brown powder recrystallization solvent: ethanol M.p. (° c): 133-135 mode: freeExample 81 structure:
R1：H R2：CH3
m: 11 n: 0 crystal form: light yellow flakes recrystallization solvent: ethanol M.p. (° c): 112-114 mode: free
Figure A9419071904032
R1：H R2：CH3
m: 1 n: 0 crystal form: pale yellow rod recrystallization solvent: dimethylformamide/ethanol M.p. (° c): 189-190 mode: free
Figure A9419071904033
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow powder recrystallization solvent: dimethylformamide/ethanol M.p. (° c): 177-178 morphology: free
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder recrystallization solvent: dimethylformamide/water M.p. (° c): 230-232 morphology: free
Figure A9419071904042
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder recrystallization solvent: ethyl acetate M.p. (° c): 218-220 mode: free example 86 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: dimethylformamide/water M.p. (° c): 214-215 mode: freeExample 87 structure:
Figure A9419071904051
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder M.p. (° c): 146-147 morphology: free example 88 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless flake recrystallization solvent: dimethylformamide/water M.p. (° c): 180-181: free example 89 structure:
Figure A9419071904053
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: chloroform/n-hexane M.p. (° c): 186-188 morphology: free
R1：H R2：CH3
m: 1 n: 0 crystal form: yellow powder recrystallization solvent: ether/n-hexane M.p. (° c): 80-83 form: free example 91 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: brown prismatic recrystallization solvent: acetone/n-hexane M.p. (° c): 179-180 morphology: free example 92 structure:
Figure A9419071904063
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder recrystallization solvent: ethanol M.p. (° c): 206-207 configuration: free
Figure A9419071904071
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 139-141 morphology: free
R1：H R2：CH3
m: 1 n: 0 crystal form: pale yellow prismatic recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 147-150 mode: free example 95 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder recrystallization solvent: ethanol M.p. (° c): 133-134 morphology: free
Figure A9419071904081
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder recrystallization solvent: dimethylformamide/ethanol M.p. (° c): 206-209 morphology: free
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 117-119 morphology: free example 98 structure:
Figure A9419071904083
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow powder recrystallization solvent: ethanol M.p. (° c): 200-202 (decomposition) mode: freeExample 99 structure:
Figure A9419071904091
R1：H R2：CH3
m: 1 n: 0 crystal form: light brown needle recrystallization solvent: acetone/n-hexane M.p. (° c): 199-200 mode: free example 100 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 167-&168 forms: free example 101 structure:
R1：H R2：CH3
m: 0 n: 1 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 152-153 morphology: freeExample 102 structure:
R1：H R2：CH3
m: 1 n: 1 crystal form: yellow powder recrystallization solvent: ethanol M.p. (° c): 130-133 (decomposition) form: free example 103 structure:
Figure A9419071904102
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 143-144 mode: free example 104 structure:
Figure A9419071904103
R1：H R2：CH3
m: 0 n: 0 crystal form: light brown needle recrystallization solvent: diisopropyl ether/n-hexane morphology: freeExample 105 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: light brown prismatic recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 122-124: free example 106 structure:
Figure A9419071904112
R1：H R2：CH3
m: 0 n: 0 crystal form: light yellow needle morphology: free example 107 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: light yellow needle morphology: freeExample 108 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 99-100 forms: free example 109 structure:
Figure A9419071904122
R1：H R2：CH3
m: 0 n: 0 crystal form: white powder recrystallization solvent: ethyl acetate M.p. (° c): 124-125 morphology: free
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless flake recrystallization solvent: ethanol/water M.p. (° c): 139-140 mode: freeExample 111 structure:
Figure A9419071904131
R1：H R2：CH3
m: 0 n: 0 crystal form: light brown oil morphology: free example 112 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form:red powder recrystallization solvent: diisopropyl ether/n-hexane M.p. (° c): 148-150 mode: free example 113 structure:
Figure A9419071904133
R1：H R2：CH3
m: 0 n: 0 crystal form: yellow prism recrystallization solvent: n-hexane M.p. (° c): 105-106 morphology: freeExample 114 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 135-136 morphology: free example 115 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: light yellow powder recrystallization solvent: diisopropyl ether/n-hexane M.p. (° c): 121-122 mode: free example 116 structure:
Figure A9419071904143
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: diisopropyl ether M.p. (° c): 88-89 form: freeExample 117 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: light yellow needle recrystallization solvent: diethyl ether M.p. (° c): 129-130 mode: free example 118 structure:
Figure A9419071904152
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/diethyl ether M.p. (° c): 106-107 mode: free example 119 structure:
Figure A9419071904153
R1：H R2：CH3
m: 0 n: 0 crystal form: yellow pellet recrystallization solvent: diisopropyl ether/n-hexane M.p. (° c): 118-119 morphology: freeExample 120 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: light yellow needle recrystallization solvent: diisopropyl ether/n-hexane M.p. (° c): 101-102 mode: free example 121 structure:
Figure A9419071904162
R1：H R2：CH3
m: 0 n: 0 crystal form: yellow pellet recrystallization solvent: diisopropyl ether/n-hexane M.p. (° c): 118-119 morphology: free example 122 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: orange powder recrystallization solvent: diisopropyl ether/n-hexane M.p. (° c): 184-185 morphology: free
Example 123 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: yellow flake recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 148-150 mode: free example 124 structure:
Figure A9419071904172
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: diisopropyl ether M.p. (° c): 124-125 morphology: free example 125 structure:
Figure A9419071904173
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless flake recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 122-123 mode: freeExample 126 structure:
Figure A9419071904181
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 115-116 mode: free example 127 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: acetonitrile M.p. (° c): 142-143 mode: free example 128 structure:
Figure A9419071904183
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 99-100 forms: freeExample 129 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: light yellow pellet recrystallization solvent: methanol/water M.p deg.C): 102-103 mode: free example 130 structure:
Figure A9419071904192
R1：H R2：CH3
m: 1 n: 0 crystal form: solvent for recrystallization of yellow needles: ethanol M.p. (° c): 211-213 mode: free example 131 structure:
Figure A9419071904193
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 123-124 mode: freeExample 132 structure:
Figure A9419071904201
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 146-147 morphology: free example 133 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: orange needle recrystallization solvent: ethanol M.p. (° c): 246-248 (decomposition) state: free example 134 structure:
Figure A9419071904203
R1：H R2：CH3
m: 1 n: 0 crystal form: orange powder recrystallization solvent: ethanol M.p. (° c): 188-: freeExample 135 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: orange powder recrystallization solutionPreparation: acetone form: oxalate example 136 structure:
Figure A9419071904212
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 211-214 mode: free example 137 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: yellow pellet recrystallization solvent: ethyl acetate M.p. (° c): 187-&lt192-&gt forms: freeExample 138 structure:
Figure A9419071904221
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate M.p. (° c): 190-: free example 139 structure:
Figure A9419071904222
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: diisopropyl ether M.p. (° c): 147-&gt148 forms: free example 140 structure:
Figure A9419071904223
R1：H R2：CH3
m: 0 n: 0 crystal form: light yellow powder recrystallization solvent: diisopropyl ether M.p. (° c): 116-117 mode: freeExample 141 structure:
Figure A9419071904231
R1：H R2：CH3
m: 1 n: 0 crystal form: orange colourPowder recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 120-122 mode: free example 142 structure:
Figure A9419071904232
R1：H R2：CH3
m: 0 n: 0 crystal form: solvent for recrystallization of yellow needles: ethyl acetate/n-hexane M.p. (° c): 127-128 modes: free example 143 structure:
Figure A9419071904233
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 128-130 mode: freeExample 144 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 123-124 mode: free example 145 structure:
Figure A9419071904242
R1：H R2：CH3
m: 1 n: 0 crystal form: yellow prism recrystallization solvent: isopropanol/diisopropyl ether M.p. (° c): 171-: free example 146 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow pellet recrystallization solvent: isopropyl/diisopropyl ether M.p. (° c): 176-177 morphology: freeExample 147 structure:
Figure A9419071904251
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless flake recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 148-149 modes: free example 148 structure:
Figure A9419071904252
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 119-120 mode: free example 149 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: white powder M.p. (° c): 135-137 form: freeExample 150 structure:
Figure A9419071904261
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 118-119 morphology: free example 151 structure:
Figure A9419071904262
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless prismatic crystal recrystallization solvent: acetone M.p. (° c): 135-137 form: free example 152 structure:
Figure A9419071904263
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: acetone/n-hexane M.p. (° c): 196 and 198: freeExample 153 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless flake recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 133-134 morphology: free example 154 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: dimethylformamide M.p. (° c): 225-226 morphology: free example 155 structure:
Figure A9419071904273
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 98-100 form: freeExample 156 structure:
Figure A9419071904281
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow powder recrystallization solvent: ethyl acetate M.p. (° c): 100-101 mode: free example 157 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 144-145 morphology: free example 158 structure:
Figure A9419071904283
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 133-134 morphology: freeExample 159 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow powder M.p. (° c): 83-87 forms: free example 160 structure:
Figure A9419071904292
R1：H R2：CH3
m: 0 n: 0 crystal form: white powder recrystallization solvent: acetone/n-hexane M.p. (° c): 175-176 mode: free example 161 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder recrystallization solvent: ethanol/diethyl ether M.p. (° c): 246-247 (decomposition) form: hydrochloride saltExample 162 structure:
Figure A9419071904301
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless flake recrystallization solvent: methanol/ether M.p. (° c): 214-215 mode: hydrochloride salt example 163 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder M.p. (° c): 212-215 (decomposition) mode: hydrochloride salt example 164 structure:
Figure A9419071904303
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 139-141 morphology: freeExample 165 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless pellets recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 170-171 mode: free example 166 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless pellets recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 152-153 morphology: free example 167 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 165-166 morphology: freeExample 168 structure:
Figure A9419071904321
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 142-143 mode: free example 169structure:
Figure A9419071904322
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder M.p. (° c): 134-135 mode: free example 170 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless flake recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 126-128 morphology: free formIs/are as followsExample 171 structure:
Figure A9419071904331
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 126-128 morphology: free example 172 structure:
Figure A9419071904332
R1：H R2：CH3
m: 0 n: 0 crystal form: white powder recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 106-107 mode: free example 173 structure:
Figure A9419071904333
m: 1 n: 0 crystal form: colorless prismatic crystal recrystallization solvent: acetone/n-hexane M.p. (° c): 167-&169 forms: freeExample 174 structure:
Figure A9419071904341
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 129-130 mode: free example 175 structure:
Figure A9419071904342
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 135-136 morphology: free example 176 structure:
Figure A9419071904343
R1：H R2：CH3
m: 0 n: 0 crystal form: white powder recrystallization solvent: ethyl acetate M.p. (° c): 138-140 modes: freeExample 177 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate M.p. (° c): 140-141 morphology: free example 178 structure:
Figure A9419071904352
R1：H R2：CH3
m: 1 n: 0 crystal form: solvent for recrystallization of yellow needles: ethyl acetate/n-hexane M.p. (° c): 146-147 morphology: free example 179 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 154-155 mode: freeExample 180 structure:
Figure A9419071904361
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 155-156 mode: free example 181 structure:
Figure A9419071904362
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/diethyl ether M.p. (° c): 67-69 forms: free example 182 structure:
Figure A9419071904363
R1：H R2：CH3
m: 1 n: 0 crystal form: brown powder recrystallization solvent: ethyl acetate M.p. (° c): 132-133 form: freeExample 183 Structure:
Figure A9419071904371
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 174-175 morphology: free example 184 structure:
Figure A9419071904372
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 156-158 mode: free example 185 structure:
Figure A9419071904373
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 102-103 mode: freeExample 186 structure:
Figure A9419071904381
R1：H R2：CH3
m: 0 n: 0 crystal form: yellow oil morphology: free example 187 structure:
Figure A9419071904382
R1：H R2：CH3
m: 1 n: 0 crystal form: yellow oil morphology: free
Figure A9419071904383
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 123-124 mode: free
Figure A9419071904391
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 149-151 mode: free
Figure A9419071904392
R1：H R2：CH3
m: 0 n: 0 crystal form: yellow powder morphology: free
Figure A9419071904393
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless prismatic crystal recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 122-123 mode: free
Figure A9419071904401
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder recrystallization solvent: methanol/ether M.p. (° c): 110-112 mode: free
Figure A9419071904402
R1：H R2：CH3
m: 0 n: 0 crystal form: solvent for recrystallization of yellow needles: dimethylformamide/water M.p. (° c): 193-195 modes: free example 194 structure:
Figure A9419071904403
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: diisopropyl ether M.p. (° c): 152-153 morphology: freeExample 195 structure:
Figure A9419071904411
R1：H R2：CH3
m: 0 n: 0 crystal form: white powder recrystallization solvent: ethyl acetate M.p. (° c): 164-165 morphology: free example 196 structure:
Figure A9419071904412
R1：H R2：CH3
m: 1 n: 0 crystal form: yellow pellet recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 144-145 morphology: free example 197 structure:
Figure A9419071904413
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 195-196 morphology: freeExample 198 architecture:
Figure A9419071904421
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 105-107 mode: free
Figure A9419071904422
R1：H R2：CH3
m: 1 n: 0 crystal form: recrystallization solvent of pale yellow flaky matter: ethanol M.p. (° c): 159-160 mode: free example 200 structure:
Figure A9419071904423
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 165-167: freeExample 201 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 195-196 morphology: free example 202 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: yellow powder recrystallization solvent: ethanol/diethyl ether M.p. (° c): 155-: hydrochloride salt example 203 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: yellow pellet recrystallization solvent: ethanol/diethyl ether M.p. (° c): 116-118 morphology: hydrochloride saltExample 204 structure:
Figure A9419071904441
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 118-120 mode: free example 205 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanolM.p. (° c): 56-58 forms: free example 206 structure:
Figure A9419071904443
R1：H R2：CH3
m: 0 n: 0 crystal form: light brown prismatic recrystallization solvent: isopropanol/water M.p. (° c): 133-134 morphology: freeExample 207 structure:
Figure A9419071904451
R1：H R2：CH3
m: 1 n: 0 crystal form: white powder recrystallization solvent: ethyl acetate M.p. (° c): 170-171 mode: free example 208 structure:
Figure A9419071904452
R1：H R2：CH3
m: 0 n: 0 crystal form: light yellow oil morphology: free example 209 structure:
Figure A9419071904453
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless oil form: freeExample 210 structure:
Figure A9419071904461
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): forms 76 to 77: free example 211 structure:
Figure A9419071904462
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 156-157 forms: free example 212 structure:
Figure A9419071904463
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 148-150 mode: freeExample 213 structure:
Figure A9419071904471
R1：H R2：CH3
m: 1 n: 0 crystal form: pale yellow prismatic recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 113-114 mode: free example 214 structure:
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: ethanol/water M.p. (° c): 115-116 mode: free example 215 structure:
Figure A9419071904473
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: ethanol/water M.p. (° c): 87-88 form: freeExample 216 structure:
Figure A9419071904481
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 107-109 mode: free example 217 structure:
Figure A9419071904482
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: ethanol/water M.p. (° c): 132-133 mode: free example 218 structure:
Figure A9419071904483
R1：H R2：CH3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 162-163 mode: freeExample 219 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 156-157 forms: free example 220 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 181-182 form: free example 221 structure:
Figure A9419071904493
R1：H R2：CF3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 155-157 type: freeExample 222 structure:
R1：H R2：CF3
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 115-116 mode: free example 223
Figure A9419071904502
m: 0 n: 0 crystal form: colorless pellets recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 150-151 mode: free example 224 structure:
R1：H R2：H
m: 1 n: 0 crystalform: recrystallization solvent of pale yellow flaky matter: ethanol M.p. (° c): 126 form: freeExample 225 architecture:
R1：H R2：H
m: 0 n: 0 crystal form: colorless flake recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 155-156 mode: free example 226 structure:
Figure A9419071904512
R1：H R2：H
m: 1 n: 0 crystal form: light brown flake recrystallization solvent: acetonitrile M.p. (° c): 211-213 mode: free example 227 structure:
Figure A9419071904513
Figure A9419071904514
m: 0 n: 0 crystal form: brown pellet recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 169-171 form: freeExample 228 structure:
Figure A9419071904521
R1：H R2：-CH(CH3)2
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 114-116 mode: free example 229 structure:
Figure A9419071904522
R1：H R2：-C2H5
m: 1 n: 0 crystal form: colorless prismatic crystal recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 114-115 morphology: free example 230 structure:
R1：H R2：-C2H5
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 87-89 forms: freeExample 231 structure:
Figure A9419071904531
R1：H R2：-CH(CH3)2
m: 0 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane M.p. (° c): 67-68 forms: free example 232 structure:
R1：H R2：-C2H5
m: 0 n: 0 crystal form: pale yellow prismatic recrystallization solvent: n-hexane M.p. (° c): 82-83 form: free example 233
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 157-158 form: freeExample 234 structure:
Figure A9419071904541
R1：H R2：H
m: 0 n: 0 crystal form: solvent for recrystallization of yellow needles: n-hexane/ethyl acetate M.p. (° c): 92-93 forms: free example 235
Figure A9419071904542
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 173- "174 pattern: free example 236
R1：7-Cl R2：CH3
m: 1 n: 0 crystal form: colorless flake recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 160-161 mode: freeExample 237
Figure A9419071904551
Crystal form: white powder recrystallization solvent: ethanol/diethyl ether M.p. (° c): 156-158 (decomposition) mode: oxalate salt example 238
Figure A9419071904552
m: 0 n: 0 crystal form: light yellow powder recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 118-119 morphology: free example 239 structure:
Figure A9419071904553
R1：H R2：CH3
m: 1 n: 0 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 116-118 morphology: freeExample 240 structure:
R1：H R2：CH3
m: 1 n: 0 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 112-113 mode: free example 241 structure:
Figure A9419071904562
R1：H R2：CH3
m: 0 n: 0 crystal form: white powder form: free example 242 structure:
Figure A9419071904563
R1：H R2：CH3
m: 0 n: 0 crystal form: yellow powder morphology: freeExample 243 structure:
Figure A9419071904571
R1：H R2：CH3
m: 0 n: 0 crystal form: white powder form: free example 244
R1：H R2：CH3
m: 0 n: 0 crystal form: yellow colourPowder morphology: free example 245
Figure A9419071904573
R1：H R2：CH3
m: 0 n: 0 crystal form: yellow oil morphology: free example 246 structure:
Figure A9419071904574
R1：H R2：CH3
m: 0 n: 0 crystal form: yellow oil morphology: freeNMR analysis:
example numbering 1H-NMRδppm：
186 (CDCl3)；1.11(3H，t，J＝7Hz)，1.20(3H，t，J＝7Hz)，3.17(3H，s)，3.3- 3.5(4H，m)，4.6-4.7(4H，m)，6.89(1H，d，J＝8Hz)，7.00(2H，m)，7.30 (1H，d，J＝8Hz)，7.7-7.9(2H，m)，8.0-8.1(2H，m)，8.40(1H，brs)
187 (CDCl3)；1.12(3H，t，J＝7Hz)，1.21(3H，t，J＝7Hz)，3.10(3H，s)，3.3- 3.5(4H，m)，4.66(2H，d，J＝7Hz)，4.68(2H，s)，6.88(1H，d，J＝8Hz)， 7.0-7.1(2H，m)，7.29(1H，d，J＝8Hz)，7.7-7.9(2H，m)，8.0-8.1(1H， m)，8.39(1H，br)，8.5-8.6(1H，m)
190 (CDCl3)；3.17(3H，s)，3.61(3H，s)，4.63(2H，d，J＝6Hz)，4.99(2H，s)， 6.9-7.0(4H，m)，7.3-7.4(4H，m)，7.7-7.9(2H，m)，8.0-8.1(2H，m)， 8.31(1H，brs)
208 (CDCl3)；2.78，2.79(3H，s)，2.92，3.24(3H，s)，3.98，4.43(2H，d，J＝6 Hz)，6.10-6.40(1H，m)，6.40，6.70(1H，d，J＝16Hz)，7.20-7.50(5H， m)，7.70-7.85(2H，m)，8.00-8.15(2H，m)，
209 (CDCl3)；8.56(1H，m)，8.20(1H，brt，J＝6Hz)，8.06(1H，m)，7.77 (2H，m)，7.21(4H，m)，6.51(1H，s)，4.22(2H，d，J＝6Hz)，3.07(3H，s)， 2.90(1H，sept，J＝7Hz)，1.98(3H，s)，1.25(6H，d，J＝7Hz)
245 (CDCl3)；2.25(1H，br)，3.17(3H，s)，3.9-4.1(4H，m)，4.63(2H，d，J＝6 Hz)，6.92(2H，d，J＝7Hz)，7.34(2H，d，J＝7Hz)，7.7-7.9(2H，m)，8.0- 8.1(2H，m)，8.34(1H，br)
52 (CDCl3)；3.09(3H，s)，3.40-3.55(2H，m)，3.55-3.85(6H，m)，3.90 (2H，s)，4.78(2H，d，J＝6Hz)，6.60(1H，s)，6.65(1H，d，J＝7Hz)，6.67 (1H，s)，7.28(1H，d，J＝7Hz)，7.75-7.85(2H，m)，8.05-8.15(1H，m)， 8.47(1H，brs)，8.50-8.60(1H，m)
104 (CDCl3)；8.05(3H，m)，7.78(2H，m)，7.25(5H，m)，3.56(2H，q，J＝7 Hz)，3.14(3H，s)，2.77(2H，t，J＝7Hz)，2.04(2H，qui，J＝7Hz)
106 (CDCl3)；8.05(3H，m)，7.78(2H，m)，7.15(2H，d，J＝9Hz)，6.84(2H， d，J＝9Hz)，3.76(3H，s)，3.54(2H，q，J＝7Hz)，3.14(3H，s)，2.72(2H， t，J＝7Hz)，2.00(2H，qui，J＝7Hz)
107 (CDCl3)；8.03(3H，m)，7.79(2H，m)，7.11(2H，d，J＝9Hz)，6.69(2H， d，J＝9Hz)，3.54(2H，q，J＝7Hz)，3.14(3H，s)，2.88(6H，s)，2.69(2H， t，J＝7Hz)，1.99(2H，qui，J＝7Hz)
111 (CDCl3)；1.62(3H，s)，1.69(3H，s)，1.77(3H，s)，2.0-2.2(4H，m)，3.15 (3H，s)，4.12(2H，t，J＝6Hz)，5.11(1H，br)，5.36(1H，br)，7.7-8.2(4H， m)，7.92(1H，br)
135 (DMSO-d6)；1.75-1.90(2H，m)，2.54(2H，t，J＝7Hz)，2.63(3H，s)， 2.83(6H，s)，3.25-3.35(2H，m)，6.67(2H，d，J＝9Hz)，7.06(2H，d， J＝9Hz)，7.85-7.96(2H，m)，8.10-8.20(1H，m)，8.40-8.50(1H，m)， 8.87(1H，brs)
246 (CDCl3)；3.17(3H，s)，3.82(2H，t，J＝6Hz)，4.24(2H，t，J＝6Hz)，4.64 (2H，d，J＝6Hz)，6.93(2H，d，J＝9Hz)，7.35(2H，d，J＝9Hz)，7.7-7.9 (2H，m)，8.0-8.1(2H，m)，8.33(1H，br)
241 (DMSO-d6)；2.83(3H，s)，4.48(2H，d，J＝6Hz)，4.66(2H，s)，6.91 (2H，d，J＝9Hz)，7.33(2H，d，J＝9Hz)，7.8-8.0(2H，m)，8.0-8.2(2H， m)，9.33(1H，t，J＝6Hz)
242 (CDCl3)；3.17(3H，s)，4.61(2H，d，J＝6Hz)，5.91(1H，brs)，7.00(1H， d，J＝8Hz)，7.26(1H，dd，J＝2Hz，J＝8Hz)，7.52(1H，d，J＝2Hz)，7.7- 7.9(2H，m)，8.0-8.1(2H，m)，8.40(1H，brs)
243 (CDCl3)；3.17(3H，s)，3.92(3H，s)，4.77(2H，d，J＝6Hz)，7.48(2H，d， J＝8Hz)，7.7-7.9(2H，m)，8.0-8.1(2H，m)，8.04(2H，d，J＝8Hz)， 8.51(1H，brs)
244 (CDCl3)；1.75(1H，t，J＝6Hz)，4.70(4H，d，J＝6Hz)，7.3-7.5(4H，m)， 7.7-7.9(2H，m)，8.0-8.1(2H，m)，8.39(1H，brs)
The compounds listed in Table 6 were prepared in the same manner asin examples 1 to 4 using the appropriate starting compounds.
TABLE 6
Figure A9419071904601
Example 247 structure:
Figure A9419071904602
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: ethanol M.p. (° c): 206-208 morphology: free example 248 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: ethanol M.p. (° c): 142-144 modes: freeExample 249 structure:
Figure A9419071904611
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: ethyl acetate M.p. (° c): 213-214 mode: free example 250
Figure A9419071904612
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless pellets recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 160-162 mode: free example 251 structure:
Figure A9419071904613
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light brown powder M.p. (° c): 235-236 (decomposition) morphology: freeExample 252
Figure A9419071904621
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light brown powder recrystallization solvent: ethanol M.p. (° c): 198-200 mode: free
Figure A9419071904622
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow pellet recrystallization solvent: 2-propanol M.p. (° c): 140-141 morphology: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 185-190 mode: free
Figure A9419071904631
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: acetonitrile M.p. (° c): 197-198 mode: free
Figure A9419071904632
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow pellet recrystallization solvent: dimethylformamide/water M.p. (° c): 255-256 (decomposition) mode: free
Figure A9419071904633
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: ethanol M.p. (° c): 230-231 (decomposed) form: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light brown powder recrystallization solvent: ethanol M.p. (° c): 142-146 mode: free example 259 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: ethanol/water M.p. (° c): 227-228 morphology: free example 260 structure:
Figure A9419071904643
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powder recrystallization solvent: dimethylformamide/water M.p. (° c): 248-250 (decomposition) mode: free
R1：H R2：CH3
m: 0 n: 0 r:1 crystal form: white powder recrystallization solvent: ethyl acetate M.p. (° c): 234-236 forms: free example 262
Figure A9419071904652
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 193-194 mode: free
Figure A9419071904653
R1：H R2：CH3
m：1 n: 0 r:1 crystal form: white powder recrystallization solvent: ethanol M.p. (° c): 166-167: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: acetonitrile M.p. (° c): 212-213 mode: free example 265 structure:
Figure A9419071904662
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: ethanol M.p. (° c): 246-247 (decomposition) form: free example 266 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 197-198 mode: freeExample 267 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow amorphous morphology: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: acetonitrile M.p. (° c): 235-236 (decomposition) morphology: free example 269 structure:
Figure A9419071904673
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 143-147 mode: free
Figure A9419071904681
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 175-: free example 271 structure:
Figure A9419071904682
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: acetonitrile M.p. (° c): 226-227 mode: free
Figure A9419071904683
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow pellet recrystallization solvent: ethanol M.p. (° c): 139-144 morphology: freeExample 273 structure:
Figure A9419071904691
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow pellet recrystallization solvent: ethanol M.p. (° c): 184-187 mode: free example 274 structure:
Figure A9419071904692
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: acetonitrile M.p. (° c): 183-185 morphology: free example 275
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: diethyl ether M.p. (° c): 118-120 mode: freeExample 276 structure:
Figure A9419071904701
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: acetonitrile M.p. (° c): 217-218 mode: free example 277 structure:
Figure A9419071904702
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: acetonitrile M.p. (° c): 213-214 mode: free example 278 structure:
Figure A9419071904703
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless prismatic crystal recrystallization solvent: ethanol M.p. (° c): 138-140 modes: freeExample 279 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 121-122 mode: free example 280 structure:
Figure A9419071904712
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless and colorlessNeedle recrystallization solvent: acetonitrile M.p. (° c): 247-248: free example 281
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow pellet recrystallization solvent: ethanol M.p. (° c): 178-180 morphology: freeExample 282 structure:
Figure A9419071904721
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless pellets recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 190-191 morphology: free
Figure A9419071904722
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: ethyl acetate M.p. (° c): 238-240 (decomposition) mode: free example 284
Figure A9419071904723
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: acetonitrile M.p. (° c): 221-222 mode: freeExample 285 structure:
Figure A9419071904731
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: n-hexane/ethyl acetate M.p. (° c): 137-138 morphology: free example 286
Figure A9419071904732
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 144-145 morphology: free example 287 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: solvent for recrystallization of yellow needles: ethanol M.p. (° c): 70-73 form: freeExample 288 structure:
Figure A9419071904741
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: acetonitrile M.p. (° c): 189-190 mode: free
Figure A9419071904742
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 145-147 morphology: free
Figure A9419071904743
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 134-135 mode: freeExample 291 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless pellets recrystallization solvent: ethanol M.p. (° c): 174-176 mode: free example 292 structure:
Figure A9419071904752
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 160-162 mode: free example 293 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 196-: freeExample 294
Figure A9419071904761
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 156-160 modes: free example 295
Figure A9419071904762
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder M.p. (° c): 129-131 morphology: free
Figure A9419071904763
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: solvent for recrystallization of yellow needles: n-hexane/ethyl acetate M.p. (° c): 113-115 form: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless pellets recrystallization solvent: ethanol M.p. (° c): 187-191 modes: swimming deviceExample 295 structure from:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless pellets recrystallization solvent: ethanol M.p. (° c): 145-146 mode: free example 299 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: acetonitrile M.p. (° c): 184-186 mode: freeExample 300
Figure A9419071904781
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: acetonitrile M.p. (° c): 162-163 mode: free example 301 structure:
Figure A9419071904782
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 179-180 morphology: free example 302 structure:
Figure A9419071904783
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light brown pellet recrystallization solvent: ethanol M.p. (° c): 120-122 mode: freeExample 303
R1：H R2：CH3
m：1 n: 0 r:1 crystal form: light yellow pellet recrystallization solvent: ethanol M.p. (° c): 103-105 mode: free example 304
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 123-125 morphology: free example 305 structure:
Figure A9419071904793
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder form: freeExample 306 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder form: free example 307 structure:
Figure A9419071904802
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: diethyl ether M.p. (° c): 103-105 mode: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powder recrystallization solvent: ethanol M.p. (° c): 191-193 mode: free
R1：H R2：CH3
m：1 n: 0 r:1 crystal form: white powder recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 141.5-143 forms: free
Figure A9419071904812
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: pale yellow prismatic recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 162-163 mode: free
Figure A9419071904813
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: pale yellow prismatic recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 178-179 morphology: free
Figure A9419071904821
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: ethanol M.p. (° c): 230-&231 modes: free
Figure A9419071904822
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: ethanol M.p. (° c): 124.5-125 morphology: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: dichloromethane/diethyl ether M.p. (° c): 198-200 mode: freeExample 315 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: dichloromethane/ethanol morphology: free example 316 structure:
Figure A9419071904832
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: dichloromethane/ethanol M.p. (° c): 193.5-196 morphology: free
Figure A9419071904833
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white flake recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 203.5-207.5 forms: free
Figure A9419071904841
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 162-163 mode: free
Figure A9419071904842
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 191-193 mode: free example 320 structure:
Figure A9419071904843
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 119-120 mode: freeExample 321
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: recrystallization solvent of pale yellow flaky matter: dichloromethane/diethyl ether M.p. (° c): 86-88 morphology: free example 322 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white flake recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 140-142 modes: free example 323 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 115-117 mode: freeExample 324 structure:
Figure A9419071904861
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 129-133 morphology: free example 325 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: dichloromethane/diethyl ether M.p. (° c): 177-179 modes: free example 326 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 144-146 mode: freeExample 327 structure:
Figure A9419071904871
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powder morphology: free example 328 structure:
Figure A9419071904872
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white amorphous morphology: free
Figure A9419071904873
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 173- "174 pattern: freeExample 330
Figure A9419071904881
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 173- "175 morphology: free example 331
Figure A9419071904882
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 193-196 morphology: free example 332 structure:
Figure A9419071904883
R1：HR2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 100-101 mode: freeExample 333
Figure A9419071904891
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 151-152 modes: free example 334
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: ethyl acetate M.p. (° c): 141-142 mode: free example 335 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white amorphous morphology: freeExample 336
Figure A9419071904901
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 143.5-145 forms: free example 337 structure:
Figure A9419071904902
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 217-219 morphology: free example 338
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light brown powder recrystallization solvent: ethanol M.p. (° c): 166-168 morphology: free
Figure A9419071904911
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powder recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 223-228 mode: free example 340
Figure A9419071904912
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powder recrystallization solvent: dichloromethane/diethyl ether M.p. (° c): 228-230 modes: free
Figure A9419071904913
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 150-151 mode: freeExample 342 structure:
Figure A9419071904921
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: ethanol M.p. (° c): 237- "239 form: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle-like article rejoiningCrystal solvent: dichloromethane/n-hexane M.p. (° c): 180-205 mode: free
Figure A9419071904923
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: methanol/dichloromethane/n-hexane M.p. (° c): 240-243 mode: freeExample 345 structure:
Figure A9419071904931
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white flake recrystallization solvent: methanol/dichloromethane/n-hexane M.p. (° c): 182.5-186 forms: free example 346 structure:
Figure A9419071904932
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow amorphous form: free example 347 structure:
Figure A9419071904933
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white amorphous morphology: freeExample 348 structure:
Figure A9419071904941
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow oil morphology: free example 349
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form:white flake recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 178.5-180 form: free example 350
R1：H R2：-CH2F
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 153-155 mode: freeExample 351
R1：H R2：-CH2F
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 126-131 morphology: free example 352 structure:
R1：H R2：-CH2F
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 111-114 morphology: free example 353 structure:
Figure A9419071904953
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless oil form: freeExample 354 Structure:
Figure A9419071904961
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow amorphous form: free example 355 Structure:
Figure A9419071904962
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow amorphous morphology: free example 356
Figure A9419071904963
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 124.5-128 forms: free
Figure A9419071904971
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 129-132 mode: free
Figure A9419071904972
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white needle recrystallization solvent: dichloromethane/n-hexane M.p. (° c): 149-150 mode: free example 359
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow pellet recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 151-153 modes: freeExample 360
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: dimethylformamide/water M.p. (° c): 237-: free example 361
Figure A9419071904982
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: recrystallization solvent of pale yellow flaky matter: ethyl acetate M.p. (° c): 160-161 mode: free example 362 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate M.p. (° c): 169-170 morphology: freeExample 363
Figure A9419071904991
R1：H R2：CH3
m: 1 n:0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate M.p. (° c): 190-191 forms: free example 364 structure:
Figure A9419071904992
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 180-181: free example 365 structure:
Figure A9419071904993
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: acetone M.p. (° c): 173- "174 pattern: freeExample 366 structure:
Figure A9419071905001
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: dimethyl formamideWater M.p. (° c): 203-204 mode: free
Figure A9419071905002
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow pellet recrystallization solvent: dimethylformamide/water M.p. (° c): 250-251 mode: free example 368 structure:
Figure A9419071905003
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: solvent for recrystallization of yellow needles: dimethylformamide/water M.p. (° c): 246-247 mode: freeExample 369 Structure:
Figure A9419071905011
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: dimethylformamide/water M.p. (° c): 247-248: free example 370
Figure A9419071905012
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate M.p. (° c): 160-161 mode: free example 371 structure:
Figure A9419071905013
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: pale yellow prismatic recrystallization solvent: dimethylformamide/water M.p. (° c): 214-215 mode: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless prismatic crystal recrystallization solvent: acetone M.p. (° c): 202-203 mode: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: methanol M.p. (° c): 254-255 morphology: free
Figure A9419071905023
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: dimethylformamide/water M.p. (° c): 201-203 mode: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow pellet recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 161-162 mode: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: solvent for recrystallization of yellow needles: dimethylformamide/water M.p. (° c): 197-198 mode: free
Figure A9419071905033
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow pellet recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 171-172 mode: free
Figure A9419071905041
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate M.p. (° c): 108-109 morphology: free example 379 structure:
Figure A9419071905042
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow pellet recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 117-120 mode: free example 380 structure:
Figure A9419071905043
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow amorphous M.p. (° c): 97-100 form: free
Figure A9419071905051
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: ethyl acetate/n-hexane M.p. (° c):148-149 modes: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powder recrystallization solvent: acetone/n-hexane M.p. (° c): 156-157 forms: free example 383
Figure A9419071905053
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow pellet recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 159-160 mode: free
Figure A9419071905061
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: acetone/n-hexane M.p. (° c): 177-178 morphology: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 181-182 form: free example 386 structure:
Figure A9419071905063
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 196-: freeExample 387 structure:
Figure A9419071905071
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 186-187 modes: free
Figure A9419071905072
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: chloroform/n-hexane M.p. (° c): 175-176 mode: free
Figure A9419071905073
R1：H R2：CH3
m：1 n：0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate M.p. (° c): 136-138 morphology: freeExample 390 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 173- "174 pattern: free example 391
Figure A9419071905082
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless flake recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 186-187 modes: free
Figure A9419071905083
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: recrystallization solvent of pale yellow flaky matter: dimethylformamide/water M.p. (° c): 197-198 mode: free
Figure A9419071905091
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow flake recrystallization solvent: dimethylformamide/water M.p. (° c): 230-&231 modes: free
Figure A9419071905092
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: solvent for recrystallization of yellow needles: dimethylformamide/water M.p. (° c): 225-226 morphology: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 196-: free
Figure A9419071905101
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 160-161 mode: free
Figure A9419071905102
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow pellet recrystallization solvent: dimethylformamide/water M.p. (° c): 218-220 (decomposition) mode: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 168-169 form: freeExample 399
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow prism recrystallization solvent: ethanol M.p. (° c): 202-203 mode: free example 400 structure:
Figure A9419071905112
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent:ethyl acetate M.p. (° c): 159-160 mode: free example 401 structure:
Figure A9419071905113
R1：6-and7-CH3R2：CH3
m: 1 n: 0 r: 2, crystal form: brown needle recrystallization solvent: chloroform/n-hexane M.p. (° c): 207-208 morphology: freeExample 402
R1：6-and7-CH3R2：CH3
m: 1 n: 0 r: 2, crystal form: brown flake recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 189-190 mode: free example 403 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powder morphology: free example 404 structure:
Figure A9419071905123
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powder morphology: freeExample 405 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: orange powder morphology: free example 406 structure:
Figure A9419071905132
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: orange powder morphology: free example 407 structure:
Figure A9419071905133
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder form: freeExample 408 structure:
Figure A9419071905141
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder form: free example 409 structure:
Figure A9419071905142
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: brown prismatic recrystallization solvent: ethanol/dimethylformamide M.p. (° c): 179-180 morphology: free example 410
Figure A9419071905143
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: pale yellow prismatic recrystallization solvent: ethanol/dimethylformamide M.p. (° c): 231-233 type: free
Figure A9419071905151
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 203-204 mode: free example 412
Figure A9419071905152
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 129-130 mode: free example 413
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: pale yellow prismatic recrystallization solvent: ethanol M.p. (° c): 177-178 morphology: freeExample 414
Figure A9419071905161
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powder recrystallization solvent: ethanol M.p. (° c): 120-122 mode: free example 415
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 142-143 mode: free
Figure A9419071905163
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: ethanol/dimethylformamide M.p. (° c): 189-190 mode: freeExample 417
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powder recrystallization solvent: dimethylformamide M.p. (° c): 236-237 mode: free example 418 structure:
Figure A9419071905172
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: pale yellow prismatic recrystallization solvent: dimethylformamide M.p. (° c): 229-230 mode: free example 419 structure:
Figure A9419071905173
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powder recrystallization solvent: ethanol/dimethylformamide M.p. (° c): 233-234 mode: freeExample 420
Figure A9419071905181
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: brown flakes recrystallization solvent: ethanol/dimethylformamide M.p. (° c): 196-: free example 421 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: solvent for recrystallization of yellow needles: ethanol M.p. (° c): 163-165 morphology: free example 422
Figure A9419071905183
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 213-214 mode: freeExample 423 structure:
Figure A9419071905191
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powderRecrystallization solvent: ethanol/dimethylformamide M.p. (° c): 220-221 mode: free example 424 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powder recrystallization solvent: dimethylformamide M.p. (° c): 214-215 mode: freeExample 425
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: dimethylformamide M.p. (° c): 244 (decomposed) form: free example 426
Figure A9419071905202
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: ethyl acetate M.p. (° c): 186-188 morphology: free example 427 structure:
Figure A9419071905203
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 174-175 morphology: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow powder recrystallization solvent: dimethylformamide M.p. (° c): 202-203 mode: free example 429
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 167-&168 forms: free example 430
Figure A9419071905213
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: ethanol M.p. (° c): 174-175 morphology: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 209-210 mode: free example 432 structure:
Figure A9419071905222
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder M.p. (° c): 198-199 modes: free
Figure A9419071905223
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: dimethylformamide M.p. (° c): 91-93 modes: free
Figure A9419071905231
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: ethanol M.p. (° c): 212-213 mode: free example 435 structure:
Figure A9419071905232
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless prismatic crystal recrystallization solvent: dimethylformamide M.p. (° c): 237-: free example 436
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: dimethylformamide/ethanol M.p. (° c): 209-209.5 form: freeExample 437
Figure A9419071905241
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 198.5-199 forms: free example 438
Figure A9419071905242
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 193.5-194 morphology: free example 439 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder M.p. (° c): form 211: freeExample 440
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: solvent for recrystallization of yellow needles: ethanol M.p. (° c): 137-138 morphology: free example 441
R1：H R2：CH3
m: 0 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 155.5-156 form: free examples 442
Figure A9419071905253
R1：H R2：CH3
m: 1 n: 1 r:1 crystal form: pale yellow prismatic recrystallization solvent: ethanol M.p. (° c): 219-220 morphology: free
Figure A9419071905261
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 117-118 mode: free
Figure A9419071905262
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: ether/n-hexane M.p. (° c): 127-129 mode: free example 445
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: acetonitrile M.p. (° c): 212-213 (decomposition) mode: free
Figure A9419071905271
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: second stepNitrile M.p. (° c): 197-198 mode: free example 447
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 198-199 modes: free
Figure A9419071905273
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow pellet recrystallization solvent: ethanol M.p. (° c): 155-156 mode: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: diethyl ether M.p. (° c): 100-105 mode: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethanol M.p. (° c): 215-216 (decomposition) mode: free
Figure A9419071905283
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless pellets recrystallization solvent: diethyl ether M.p. (° c): 103-105 mode: free
Figure A9419071905291
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow colourPellet recrystallization solvent: diethyl ether M.p. (° c): 124-126 mode: free
Figure A9419071905292
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow pellet recrystallization solvent: diethyl ether M.p. (° c): 124-125 morphology: free
Figure A9419071905293
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: n-hexane/diethyl ether M.p. (° c): 119-121 morphology: free
Figure A9419071905301
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow pellet recrystallization solvent: diethyl ether M.p. (° c): 100-101 mode: free example 456
Figure A9419071905302
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow powder recrystallization solvent: diethyl ether M.p. (° c): 122-124: free example 457
Figure A9419071905303
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: diethyl ether M.p. (° c): 107-109 mode: freeExample 458 structure:
Figure A9419071905311
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: red powder morphology: free example 459 structure:
Figure A9419071905312
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 125-129 mode: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: ethanol M.p. (° c): 154-157 form: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: dichloromethane/ethanol M.p. (° c): 206-208 morphology: free
Figure A9419071905322
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: dichloromethane/ethanol M.p. (° c): 205-208 morphology: free example 463
Figure A9419071905323
R1：7-OCH3R2：CH3
m: 1 n: 0 r:1 crystal form: brown pellet recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 196-: freeExample 464
Figure A9419071905331
R1：7-N(C2H5)2R2：CH3
m: 1 n: 0 r:1 crystal form: red needle recrystallization solvent: ethyl acetate M.p. (° c): 202-204 mode: free example 465
Figure A9419071905332
R1：6-CON(C2H5)2R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: isopropyl alcohol M.p. (° c): 160-162 mode: free
Figure A9419071905333
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 172-: freeExample 467
Figure A9419071905341
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow pellet recrystallization solvent: ethanol/water M.p. (° c): 141-142 mode: free example 468
Figure A9419071905342
R1：H R2：CH3
m: 1n: 0 r:1 crystal form: yellow flake recrystallization solvent: acetone/n-hexane M.p. (° c): 148-150 mode: free example 469 structure:
R1：H R2：CH3
m：1 n：0 r:1 crystal form: yellow pellet recrystallization solvent: acetonitrile M.p. (° c): 221-223 mode: freeExample 470
Figure A9419071905351
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: acetonitrile M.p. (° c): 207-208 morphology: free
Figure A9419071905352
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: dimethylformamide/water M.p. (° c): 205-206 morphology: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 171-172 mode: freeExample 473 structure:
Figure A9419071905361
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: solvent for recrystallization of yellow needles: ethyl acetate/n-hexane M.p. (° c): 179-180 morphology: free example 474 structure:
Figure A9419071905362
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: acetonitrile M.p. (° c): 188-189 modes: freeExample 475
Figure A9419071905371
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: acetonitrile/water M.p. (° c): 174-175 morphology: free
Figure A9419071905372
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 187-188 morphology: free example 477 structure:
Figure A9419071905373
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless needle recrystallization solvent: ethyl acetate/n-hexane M.p. (° c): 183-184 mode: freeExample 478 structure:
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: solvent for recrystallization of yellow needles: ethyl acetate/diisopropyl ether M.p. (° c): 181-182 form: free example 479 structure:
Figure A9419071905382
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow needle recrystallization solvent: diethyl ether M.p. (° c): 109.5-110.5 form: free
NMR analysis:
example numbering1H-NMRδppm：
267 (CDCl3，250MHz)：2.75(6H，s)，3.08(3H，s)，4.78(2H，s)，4.80(2H， d，J＝8Hz)，6.67(1H，s)，7.14(1H，d，J＝9Hz)，7.15-7.20(5H，m)，7.35 (1H，d，J＝9Hz)，7.45(1H，s)，7.75-7.90(2H，m)，8.10(1H，m)，8.45- 8.60(2H，m)
305 (DMSO-d6，250MHz)：2.69(3H，s)，4.72(2H，d，J＝6Hz)，6.51(1H，d， J＝16Hz)，6.88(1H，s)，7.55-7.75(3H，m)，7.85-8.00(3H，m)，8.16 (1H，m)，8.50(1H，m)，9.58(1H，t，J＝6Hz)
306 (DMSO-d6，250MHz)：2.65(3H，s)，4.69(2H，d，J＝6Hz)，7.68(1H，d， J＝9Hz)，7.80-8.00(3H，m)，8.12(1H，s)，8.15(1H，m)，8.45(1H，m)， 8.55(1H，s)，9.49(1H，t，J＝6Hz)，12.91(1H，br)
315 (CDCl3，250MHz)：2.17(3H；s)，2.42(3H，s)，3.11(3H，s)，4.39(2H，t， J＝7Hz)，6.47(1H，t，J＝8Hz)，6.62(1H，s)，7.07(1H，d，J＝8Hz)，7.28 (1H，s)，7.30(1H，d，J＝8Hz)，7.78-7.83(2H，m)，8.05-8.15(2H，m)， 8.60(1H，m)
327 (DMSO-d6，250MHz)：1.99(3H，s)，2.69(3H，s)，4.18(2H，t，J＝7Hz)， 5.94(1H，t，J＝7Hz)，7.59-7.70(3H，m)，7.83(1H，s)，7.89-7.95(2H， m)，8.18(1H，m)，8.48(1H，m)，9.17(1H，t，J＝7Hz)
328 (CDCl3，250MHz)：1.29(6H，br)，2.25(3H，s)，3.11(3H，s)，3.60(4H， br)，4.34(2H，t，J＝7Hz)，5.93(1H，t，J＝7Hz)，7.30(1H，s)，7.48(2H， s)，7.68(1H，s)，7.79-7.83(2H，m)，8.05-8.15(2H，m)，8.62(1H，m)
335 (CDCl3，250MHz)：3.00(3H，s)，3.17(2H，t，J＝7Hz)，3.71(2H，q，J＝7 Hz)，3.85(3H，s)，6.90(1H，d，J＝8Hz)，6.92(1H，d，J＝8Hz)，7.27- 7.36(2H，m)，7.70-7.81(2H，m)，7.97(1H，m)，8.27(1H，brt，J＝7Hz)， 8.55(1H，m)，9.3(1H，br)
343 (CDCl3，250MHz)：2.57(3H，s)，3.11(3H，s)，3.51(3H，s)，4.85(2H， d，J＝6Hz)，5.34(2H，s)，7.17(1H，d，J＝8Hz)，7.29(1H，dd，J＝8Hz， 2.5Hz)，7.78-7.82(2H，m)，8.06(1H，m)，8.28(1H，br)，8.36(1H，d， J＝2.5Hz)，8.60(1H，m)
346 (CDCl3，250MHz)：2.17(3H，s)，3.09(3H，s)，3.63-3.69(8H，m)，4.31 (2H，t，J＝7Hz)，4.71(2H，s)，5.92(1H，t，J＝7Hz)，6.85(1H，dd，J＝8 Hz，2Hz)，7.02(1H，t，J＝2Hz)，7.08(1H，d，J＝8Hz)，7.26(1H，t，J＝8 Hz)，7.76-7.83(2H，m)，8.05-8.12(2H，m)，8.58(1H，m)
347 (CDCl3，250MHz)：1.14(3H，t，J＝7Hz)，1.22(3H，t，J＝7Hz)，2.17 (3H，s)，3.10(3H，s)，3.40(4H，q，J＝7Hz)，4.31(2H，t，J＝7Hz)，4.69 (2H，s)，5.92(1H，t，J＝7Hz)，6.86(1H，d，J＝8Hz)，7.05(1H，s)，7.06 (1H，d，J＝8Hz)，7.25(1H，t，J＝8Hz)，7.79-7.83(2H，m)，8.08-8.12 (2H，m)，8.60(1H，m)
348 (CDCl3，250MHz)：1.83(3H，s)，2.18(3H，s)，3.10(3H，s)，4.31(2H，t， J＝7Hz)，4.45(2H，s)，4.99(1H，s)，5.10(1H，s)，5.93(1H，t，J＝7Hz)， 6.84(1H，d，J＝8Hz)，7.00(1H，s)，7.03(1H，d，J＝8Hz)，7.24(1H，t， J＝8Hz)，7.78-7.82(2H，m)，8.07-8.11(2H，m)，8.60(1H，m)
353 (CDCl3，250MHz)：2.18(3H，s)，3.10(3H，s)，3.49(3H，s)，4.31(2H，t， J＝7Hz)，5.19(2H，s)，5.93(1H，t，J＝7Hz)，6.95(1H，d，J＝8Hz)，7.08 (1H，d，J＝8Hz)，7.10(1H，s)，7.25(1H，t，J＝8Hz)，7.77-7.84(2H，m)， 8.06-8.11(2H，m)，8.60(1H，m)
354 (CDCl3，250MHz)：0.87(3H，t，J＝7Hz)，1.78-2.05(2H，m)，2.06(3H， s)，3.10(3H，s)，4.82(2H，d，J＝6Hz)，5.72(1H，t，J＝8Hz)，6.72(1H， s)，7.26(1H，dd，J＝8Hz，2Hz)，7.44(1H，d，J＝8Hz)，7.52(1H，d，J＝2 Hz)，7.77-7.83(2H，m)，8.08(1H，m)，8.48(1H，br)，8.58(1H，m)
355 (CDCl3，250MHz)：0.91(3H，t，J＝7Hz)，1.82(2H，m)，3.10(3H，s)， 4.69(1H，br)，4.82(2H，d，J＝6Hz)，6.71(1H，s)，7.25(1H，d，J＝8Hz)， 7.41(1H，d，J＝8Hz)，7.51(1H，s)，7.78-7.82(2H，m)，8.07(1H，m)， 8.51(1H，br)，8.58(1H，m)
357 (CDCl3，250MHz)：3.09(3H，s)，3.41(3H，s)，4.89(2H，d，J＝7Hz)， 7.06(1H，d，J＝2Hz)，7.14(1H，dd，J＝8Hz，2Hz)，7.43(1H，d，J＝8 Hz)，7.75-7.82(2H，m)，8.07(1H，m)，8.53-8.59(2H，m)
358 (CDCl3，250MHz)：3.07(3H，s)，3.35(3H，s)，4.82(2H，d，J＝7Hz)， 6.68(1H，s)，7.03(1H，dd，J＝8Hz，2Hz)，7.17(1H，d，J＝2Hz)，7.41 (1H，d，J＝8Hz)，7.74-7.82(2H，m)，8.06(1H，m)，8.52-8.57(2H，m)
403 (CDCl3，250MHz)：3.10(3H，s)，3.73(2H，br)，4.82(2H，d，J＝6Hz)， 6.64(1H，d，J＝7Hz)，6.69(1H，s)，6.9-7.1(2H，m)，7.7-7.9(2H，m)， 8.0-8.1(1H，m)，8.44(1H，br)，8.5-8.6(1H，m)
404 (CDCl3，250MHz)：3.11(3H，s)，3.91(2H，brs)，4.81(2H，d，J＝6Hz)， 6.51(1H，d，J＝8Hz)，6.68(1H，s)，6.93(1H，d，J＝8Hz)，7.12(1H，dd， J＝8Hz，8Hz)，7.7-7.9(2H，m)，8.0-8.2(1H，m)，8.48(1H，brs)，8.5-8.7 (1H，m)
405 (DMSO-d6，250MHz)：2.67(3H，s)，4.60(2H，d，J＝6Hz)，5.14(1H， s)，6.53(1H，d，J＝8Hz)，6.58(1H，s)，6.67(1H，s)，7.21(1H，d，J＝8 Hz)，7.8-8.0(2H，m)，8.1-8.2(1H，m)，8.4-8.5(1H，m)，9.40(1H，br)
406 (DMSO-d6，250MHz)：2.44(3H，s)，2.64(3H，s)，4.50(2H，d，J＝6 Hz)，4.78(2H，s)，6.51(1H，d，J＝8Hz)，6.80(1H，s)，7.12(1H，d，J＝8 Hz)，7.8-8.0(2H，m)，8.1-8.2(1H，m)，8.4-8.5(1H，m)，9.21(1H，t，J＝6 Hz)
407 (CDCl3，250MHz)：0.20(3H，s)，0.22(3H，s)，0.95(9H，s)，2.6-2.8 (2H，m)，3.09(3H，s)，3.1-3.3(1H，m)，3.6-3.8(2H，m)，5.07(1H，d， J＝6Hz)，7.2-7.3(4H，m)，7.7-7.9(2H，m)，8.0-8.2(2H，m)，8.5-8.7 (1H，m)
408 (CDCl3，250MHz)：2.6-2.8(1H，br)，2.9-3.1(2H，m)，3.06(3H，s)，3.6- 4.0(3H，m)，5.15(1H，t，J＝5Hz)，7.1-7.3(3H，m)，7.4-7.5(1H，m)，7.7- 7.9(2H，m)，8.0-8.1(1H，m)，8.45(1H，brs)，8.5-8.7(1H，m)
444 Mixtures of rotamers (CDCl3)：1.14，1.29(9H，s)，1.66，2.20(3H，brs)，2.62，2.66(3H，s)， 4.28，4.59(2H，d，J＝7.2Hz)，5.45，5.73(2H，s)，6.38，6.52(1H，t， J＝7.2Hz)，6.57，6.71(1H，s)，7.15-7.35(2H，m)，7.4-7.5(1H，m)，7.5- 7.6(1H，m)，7.76-7.87(2H，m)，8.05-8.15(1H，m)，8.55-8.65(1H，m)
455 Mixtures of rotamers (CDCl3)：1.06，1.19(3H，t，J＝7Hz)，1.72，2.19(3H，s)，2.27，2.47(2H， q，J＝7Hz)，2.65，2.66(3H，s)，4.28，4.59(2H，d，J＝7Hz)，5.44，5.73 (2H，s)，6.34，6.49(1H，t，J＝7Hz)，6.56，6.71(1H，s)，7.15-7.35(2H， m)，7.43(2H，d，J＝8Hz)，7.53(1H，d，J＝8Hz)，7.70-7.85(2H，m)， 8.07(1H，m)，8.60(1H，m)
456 Mixtures of rotamers (CDCl3)：1.70，2.20(3H，s)，2.66(3H，s)，3.22，3.55(3H，s)，4.19，4.58 (2H，d，J＝7Hz)，4.68，5.12(2H，s)，6.43，6.51(1H，t，J＝7Hz)，6.55， 6.70(1H，s)，7.13-7.30(2H，m)，7.40-7.60(2H，m)，7.70-7.85(2H，m)， 8.10(1H，m)，8.60(1H，m)
457 Mixtures of rotamers (CDCl3)：1.74，2.20(3H，s)，2.00，2.17(3H，s)，2.66，2.67(3H，s)， 4.29，4.59(2H，d，J＝7Hz)，5.42，5.71(2H，s)，6.35，6.49(1H，t，J＝7 Hz)，6.58，6.71(1H，s)，7.16-7.33(2H，m)，7.40-7.60(2H，m)，7.75- 7.86(2H，m)，8.07(1H，m)，8.61(1H，m)
458 (DMSO-d6)：2.14(3H，s)，2.70(3H，s)，4.23(2H，t，J＝6Hz)，6.43(1H， t，J＝6Hz)，7.08(1H，s)，7.63(1H，d，J＝9Hz)，7.80-8.00(3H，m)，8.20 (1H，m)，8.23(1H，s)，8.48(1H，m)，9.26(1H，br)
479 Mixtures of rotamers (CDCl3)：1.23，1.33(3H，t，J＝7.0Hz)，1.74，2.21(3H，brs)，2.66，2.67 (3H，s)，4.08，4.25(2H，q，J＝7.0Hz)，4.30，4.62(2H，d，J＝7.5Hz)， 5.48，5.75(2H，s)，6.36，6.49(1H，t，J＝7.5Hz)，6.57，6.71(1H，s)， 7.15-7.35(2H，m)，7.4-7.6(2H，m)，7.75-7.85(2H，m)，8.05-8.15(1H， m)，8.55-8.65(1H，m)
Example 480
2- { [ 3-methyl-3- (benzofuran-2-yl) -2-propenyl]aminocarbonyl } -3-methylquinoxaline-4-oxide (0.6g) was dissolved in methylene chloride (40ml), and 4-dimethylaminopyridine (0.5g) and di-tert-butyl dicarbonate (0.6g) were added thereto. The mixture was stirred at room temperature for 1 day. The reaction solution was washed with dilute hydrochloric acid and brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation and the residue was purified by silica gel column chromatography (solvent: N-hexane: ethyl acetate 3: 1) and then recrystallized from N-hexane/diethyl ether to give 2- { N-tert-butoxycarbonyl-N- [ 3-methyl-3- (benzofuran-2-yl) -2-propenyl]aminocarbonyl } -3-methylquinoxaline-4-oxide (0.6g) as a white powder.
M.p.119-121℃。
The compounds of examples 443, 444, 451 and 453 were prepared from the appropriate starting compounds by the method of example 480.
Example 481
2- { [ 3-methyl-3- (benzofuran-2-yl) -2-propenyl]aminocarbonyl } -3-methylquinoxaline-4-oxide (1.0g) was suspended in tetrahydrofuran (50ml), followed by addition of sodium hydride (180mg) thereto under an argon atmosphere. The mixture was stirred at room temperature for 40 minutes. To the mixture was added dropwise ethyl chloroformate (440mg) under ice-cooling, and the mixture was stirred at room temperature overnight. The reaction solution was poured into ice water and extracted with dichloromethane. The extract was washed with water and saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation. The residue was purified by silica gel column chromatography (solvent: dichloromethane: methanol 400: 1). Then recrystallized from ether to give 2- { N-ethoxycarbonyl-N- [ 3-methyl-3- (benzofuran-2-yl) -2-propenyl]aminocarbonyl } -3-methylquinoxaline-4-oxide (0.77g) as a pale yellow granule.
M.p.124-125℃。
The compounds of examples 443, 444, 451, 452 and 454 were prepared from the appropriate starting compounds by the method of example 481.
Example 482
2- { [ 3-methyl-3- (benzofuran-2-yl) -2-propenyl]aminocarbonyl } -3-methylquinoxaline-4-oxide (1.0g) was suspended in dimethylformamide (10ml), and sodium hydride (180mg) was added thereto under ice-cooling, and then the mixture was stirred at room temperature for 15 minutes. Methoxymethyl chloride (320mg) was added dropwise to the mixture under ice-cooling, and the mixture was stirred at room temperature overnight. The reaction mixture was poured into ice water and extracted with ethyl acetate. The extract was washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation and the residue was purified by silica gel column chromatography (solvent: N-hexane: ethyl acetate 4: 1) and then recrystallized from ether to give 2- { N-methoxymethyl-N- [ 3-methyl-3- (benzofuran-2-yl) -2-propenyl]aminocarbonyl } -3-methylquinoxaline-4-oxide (0.23g) as a pale yellow powder which was a mixture of rotamers.
M.p.122-124℃
1H-NMR(CDCl3)δppm：1.70，2.20(3H，s)，2.66(3H，s)，3.22，3.55(3H，s)，4.19，4.58(2H，d，J＝7Hz)，4.68，5.12(2H，s)，6.43，6.51(1H，t，J＝7Hz)，6.55，6.70(1H，s)，7.13-7.30(2H，m)，7.40-7.60(2H，m)，7.70-7.85(2H，m)，8.10(1H，m)，8.60(1H，m)
The compounds of examples 443, 444, 451, 455, 457 and 479 are prepared from the appropriate starting compounds by the method of example 482.
Example 483
To a suspension of sodium hydride (92mg) in dimethylformamide (20ml) was added 2- { [ 3-methyl-3- (benzofuran-2-yl) -2-propenyl]aminocarbonyl } -3-methylquinoxaline-4-oxide (746mg), and the mixture was stirred at room temperature for 30 minutes. Chloromethyl pivalate (322. mu.l) and a catalytic amount of tetra-n-butylammonium iodide were added to the mixture, and the mixture was stirred for 1 hour. The reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and brine, and then dried. The solvent was removed by evaporation and the residue was purified by silica gel column chromatography and then recrystallized from ether/N-hexane to give 2- { N-pivaloyloxymethyl-N- [ 3-methyl-3- (benzofuran-2-yl) -2-propenyl]aminocarbonyl } -3-methylquinoxaline-4-oxide (300mg) as pale yellow needles which was a mixture of rotamers.
M.p.127-129℃
1H-NMR(CDCl3)δppm：1.14，1.29(9H，s)，1.66，2.20(3H，brs)，2.62，2.66(3H，s)，4.28，4.59(2H，d，J＝7.2Hz)，5.45，5.73(2H，s)，6.38，6.52(1H，t，J＝7.2Hz)，6.57，6.71(1H，s)，7.15-7.35(2H，m)，7.4-7.5(1H，m)，7.5-7.6(1H，m)，7.76-7.87(2H，m)，8.05-8.15(1H，m)，8.55-8.65(1H，m)
The compounds of examples 443, 451-457 and 479 were prepared from the appropriate starting compounds by the method of example 483.
The compounds listed in Table 7 below were obtained from the appropriate starting compounds by the methods of examples 1 to 4.
TABLE 7
Figure A9419071905461
Example 484 structure:
Figure A9419071905462
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: white powder recrystallization solvent: diethyl ether M.p. (° c): 129-134 morphology: free example 485
Figure A9419071905463
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: yellow pellet recrystallization solvent: diethyl ether M.p. (° c): 126-127 mode: freeExample 486
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: light yellow pellet recrystallization solvent: diethyl ether M.p. (° c): 170-172 mode: free
R1：H R2：CH3
m: 1 n: 0 r:1 crystal form: colorless pellets recrystallization solvent: ethanol M.p. (° c): 140-141 morphology: free
Examples Numbering 1H-NMRδppm：
485 Mixtures of rotamers (CDCl3)：1.86，1.87(3H，s)，2.06，2.40(3H，s)，2.50，2.61(3H，s)， 4.91，5.08(2H，s)，5.48，5.71(2H，s)，7.26-7.40(1H，m)，7.50-7.60 (1H，m)，7.65-7.75(1H，m)，7.75-7.86(2H，m)，7.98-8.15(1H，m)， 8.55-8.65(1H，m)
487 Mixtures of rotamers (CDCl3)：1.98，2.11(3H，s)，2.15，2.53(3H，s)，2.64，2.69(3H，s)， 4.60，4.80(2H，s)，5.55，5.72(2H，s)，7.40-7.50(3H，m)，7.70-7.80 (2H，m)，7.85-8.10(3H，m)，8.55-8.65(1H，m)
Pharmacological experiments
Experiment: glucose uptake assay in L6 cells
L6 cells (obtained from rat striated muscle) were precultured in Minimal Essential Medium (MEM) containing 10% FCS and then plated onto 48-well plates such that each well contained 4X 10 cells4And (4) cells. The plates were cultured in 2% FCS to differentiate L6 cells into myocytes. After 6 days, the test compound is added to the culture mixture, the culture solution is removed the next day, and then [2], [ solution]is added thereto3H]-2-removingThe plates were allowed to react at 37 ℃ for 10 minutes with oxygen glucose. After the reaction was completed, the plate was washed twice with cold phosphate buffered saline solution, and then the cells were hydrolyzed with 0.1% sodium lauryl sulfate, and the radioactivity of the resultant was measured. Glucose uptake was estimated by comparing the radioactivity in the wells with the test compound to the radioactivity in the wells without test compound (control), and expressed as a percentage (%). The results are shown in Table 8.
TABLE 8
Test compounds Dosage (mol) Glucose uptake (％) Test compounds Dosage (mol) Glucose uptake (％)
Example 29 10-5 201 Example 30 10-5 210
Example 33 10-5 120 Example 39 10-5 159
EXAMPLE 41 10-5 181 Example 44 10-5 176
Example 45 10-6 147 Example 46 10-6 217
Example 47 10-5 148 Example 60 10-6 166
Example 61 10-6 154 Example 62 10-6 223
Example 66 10-5 154 Example 69 10-6 194
Example 73 10-6 168 Example 75 10-6 249
Example 77 10-6 245 Example 83 10-5 153
Example 85 10-6 177 Example 92 10-6 201
Example 93 10-6 240 Example 94 10-6 188
Example 96 10-6 200 Example 97 10-6 136
Example 99 10-6 154 Example 103 10-5 198
Example 105 10-5 186 Example 107 10-6 206
Example 109 10-5 222 Example 110 10-5 209
Example 112 10-5 159 Example 113 10-5 123
Example 117 10-5 226 Example 119 10-5 158
Example 122 10-5 199 Example 125 10-5 188
Example 126 10-5 212 Example 130 10-5 161
Example 132 10-6 187 Example 134 10-5 125
Example 136 10-5 129 Example 143 10-5 210
Example 145 10-5 136 Example 147 10-5 138
Example 150 10-6 203 Example 151 10-6 156
Example 148 10-6 183 Example 153 10-5 191
Example 154 10-5 163 Example 155 10-5 212
Example 156 10-6 155 Example 159 10-5 152
Example 162 10-5 187 Example 166 10-5 168
Example 170 10-6 165 Example 171 10-5 163
Example 175 10-5 123 Example 177 10-6 178
Example 179 10-6 200 Example 181 10-6 223
Example 182 10-5 150 Example 183 10-5 212
Example 185 10-6 169 Example 190 10-6 193
Example 193 10-6 121 Example 199 10-6 165
Example 200 10-6 142 Example 201 10-6 207
Example 203 10-6 239 Example 204 10-6 192
Example 208 10-5 125 Example 210 10-5 145
Example 212 10-5 121 Example 213 10-5 146
Example 215 10-5 186 Example 221 10-6 120
Example 224 10-5 135 Example 229 10-5 149
Example 238 10-5 144 Example 383 10-6 168
Example 428 10-6 128 Example 446 10-6 183
Example 459 10-6 127 Example 460 10-6 158
Example 470 10-6 204

Claims (33)

1. A quinoxaline derivative of the formula:
Figure A9419071900021
wherein R is1Is hydrogen atom, halogen atom, lower alkyl, lower alkoxy, optionally having lower alkyl
Amino of a substituent or aminocarbonyl optionally having a lower alkyl substituent; r2Is hydrogen atom, lower alkyl optionally having halogen substituent, phenyl, morpholinyl
Lower alkyl ofOr lower alkyl substituted with imidazolyl; n is 0; m is 0 or 1; r is 1 or 2; r3And R4Which may be the same or different, are each a) a hydrogen atom, b) a lower alkyl group; c)
phenyl lower alkoxycarbonyl, d) lower alkanoyloxy-substituted lower alkyl, e) lower
A lower alkanoyl group; f) lower alkoxycarbonyl, g) lower alkoxy-lower alkyl, h)
Phenoxycarbonyl, i) lower alkanoyl substituted lower alkyl, j) lower alkoxycarbonyloxy
Substituted lower alkyl, k) benzoyl optionally containing halogen substituents on the phenyl ring
Lower alkyl substituted by 1) formula-E-N (R)52)(R53) A group of (1), whereinR52And R53Identical or different, are each a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl group or a phenyl group, or R52And R53A5-or6-membered saturated heterocyclic group which may form together with the nitrogen atom to which they are attached, with or without the insertion of an additional nitrogen atom or oxygen atom, E is lower alkylene, A group of the formulA-CO-or A group of the formulA-CO-A-wherein A is lower alkylene, m) A group of the formulA;wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above, n) a group of the formula,
Figure A9419071900032
wherein A is as defined above;
p is an integer of 1 to 3;
R5lower alkoxy substituted by lower alkoxy, optionally having lower alkoxy
Amino, halogen, nitro, hydroxy, optionally with hydroxy substituents, or substituted by lower alkyl groups
Lower alkyl of substituent, lower alkenyloxy, lower alkoxy substituted by carboxyl, lower alkyl substituted by lower alkenyl, lower alkoxy substituted by lower alkoxy
Lower alkoxy substituted by lower alkoxycarbonyl, lower alkoxy substituted by halogen
Lower alkoxy, hydroxy-substituted lower alkoxy, optionally with substituents on the phenyl moiety
Phenyl-lower alkoxy substituted by lower alkyl and lower alkoxy, optionally with
1, 3-dioxolanyl, lower alkanoyl, morpholinyl with lower alkyl substituents
Substituted lower alkoxy, morpholinyl substituted lower alkyl, morpholinylcarbonyl or of formula
-Y-A1-CONR6R7Group (wherein A)1Is lower alkylene, Y is of the formula
-O-group or-NH-group, R6And R7Identical or different, each
Is a hydrogen atom, a lower alkyl group optionally having a hydroxy substituent, on the phenyl moiety
Is selected from phenyl-lower alkyl with lower alkoxy substituent, furyl substituted lower alkyl
Lower alkyl, or lower alkyl substituted by lower alkoxy, or R6And R7And
with or without additional nitrogen or oxygen atoms being formed together by adjacent nitrogen atoms to which they are attached
An interrupted 5-or 6-membered saturated heterocyclic group, said heterocyclic group optionally having 1-
3 substituents selected from hydroxy, lower alkyl and phenyl-lower alkyl), o) phenyl-lower alkenyl, which optionally contains in its phenyl moiety a substituent selected from the group consisting of
A substituent of (1); lower alkoxy, halogen, optionally with a substituent selected from lower alkanoyl
And phenyl-lower alkenylcarbonyl-substituted amino, lower alkoxy
Tetrazole of lower alkoxy, optionally containing lower alkyl substituents on the tetrazole moiety
A radical, A hydroxyl radical, of the formulA-O-A4-CO-NR40R41A group of (wherein A)4Is composed of
Lower alkylene, R40And R41Identical or different, each being a hydrogen atom or lower
Lower alkyl, or R40And R41With and their phasesAdjacent nitrogen atoms to which they are attached together
With or without additional nitrogen or oxygen atoms inserted in 5-or 6-membered saturated
Heterocyclyl), lower alkenyloxy, nitro and optionally halogen-containing substituents
A lower alkyl group; p) analkenyl group; q) cycloalkyl-lower alkyl; r) naphthyl-lower alkyl; s) lower optionally substituted in the phenyl moiety by phenylthio having lower alkoxy substituents
An alkyl group; t) Phenylsulfinyl substitution optionally having lower alkoxy substituent(s) in the phenyl moiety
Lower alkyl of (a); u) phenylsulfonyl optionally substituted in the phenyl moiety with lower alkoxy substituents
A lower alkyl group; v) phenoxy-substituted lower alkyl; w) a group of the formula:wherein q is an integer of 1 to 3, formulaIs lower alkyl which is substituted by a 5-to 14-membered saturated or unsaturated heteromonocyclic, heterobicyclic or heterotricyclic group containing 1 to 4 heteroatoms selected from N, O and S, R8Substituted on the above heterocyclic group and is hydrogen atom, oxo group, lower alkyl optionally having a hydroxy substituent, halogen atom, nitro group, lower alkoxy group, cyano group, lower alkoxycarbonyl group, phenyl-lower alkoxy optionally having an amino substituent (the amino substituent optionally having a lower alkanoyl substituent), lower alkoxy substituted by carboxy group, lower alkoxy substituted by lower alkoxycarbonyl group, hydroxy group, lower alkoxy substituted by lower alkoxy group, lower alkenyloxy group, lower alkyl substituted by lower alkanoyloxy group, lower alkyl substituted by halogen group, lower alkanoyl group, or is phenyl optionally having a substituent selected from the group consisting of lower alkyl group, lower alkoxy substituted by lower alkoxy group, hydroxy group, halogen atom and lower alkoxy group on the phenyl moiety, or is lower alkenyloxyLower alkyl sulfinyl, optionally having a substituent selected from the group consisting of lower alkyl sulfonyl and lower alkanoylLower alkyl substituted with amino of the substituent, lower alkylthio, lower alkylsulfonyl, lower alkanoyloxy, lower alkyl substituted with 1, 3-dioxolan optionally having lower alkyl substituent, lower alkyl substituted with lower alkanoyl, lower alkyl substituted with aminocarbonyl optionally having lower alkyl substituent, lower alkenyl substituted with lower alkoxycarbonyl, lower alkenyl substituted with aminocarbonyl optionally having lower alkyl substituent, lower alkenyl substituted with carboxyl, benzoyl, lower alkoxy-lower alkyl, a group of the formula(wherein s is an integer of 1 to 3, formulaThe radical being a 5-or 6-membered saturated or unsaturated heterocyclic radical containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, R45A lower alkyl group, a lower alkoxy-substituted lower alkyl group, a phenyl group or an oxo group) bonded to the heterocyclic group, a group of the formula
Figure A9419071900063
(wherein t is an integer of 1 to 3, formula
Figure A9419071900064
The radicals being 5-to 6-membered saturated or unsaturated by 1 to 4 heteroatoms selected from N, O and S
Lower alkyl substituted by heterocyclic radical, R46Bonded to said heterocyclic radical and being hydrogen atom
Lower alkyl or oxo), or of the formula- (C ═ O)1NR9R10Group (it)
Wherein 1 is 0 or 1, R9And R10Are different or identical and are each a hydrogen atom,
Lower alkanoyl, lower alkyl, morpholinylcarbonyl-lower alkyl, cycloalkylcarbonyl,
Phenyl-lower alkenylcarbonyl, lower alkylsulfonyl, optionally with lower alkyl
Substituted aminocarbonyl, benzene optionally having lower alkyl substituents in the phenyl moiety
Phenylsulfonyl, phenyl-lower alkenyl, or each optionally containing in the phenyl moiety
Having 1 to 3 substituents selected from halogen atoms, lower alkoxy groups, optionally having lower alkanoyl substituents
Benzoyl groups being substituted by amino groups and hydroxy groups, or each being optionally substituted
Lower alkanoyl substituted with amino group having lower alkanoyl substituent, optionally having lower
Amino-substituted sulphonyl, phenyl-lower alkyl, phenyl or nitro of alkyl substituents
Optionally amino with a lower alkanoyl substituent, or R9And R10With and their phases
Adjacent nitrogen atoms bound together with or without interposition of other nitrogen or oxygen atoms
5-or 6-membered saturated heterocyclic group of (a); x) formula-A5-CR42R45R44A group of (wherein A)5Is a lower alkylene group or a lower alkylene group,
R42and R43Together form a group of the formula ═ O or ═ N-OH or lower alkylenedioxy
Radical, R44Is phenyl optionally containing lower alkoxy substituents in the phenyl moiety): y) optionally having a ring selected from oxo, hydroxy, on the 2, 3-dihydro-1H-indenyl
Or 2, 3-dihydro-1H-substituted siloxy group having lower alkyl group
Indenyl-substituted lower alkyl; z) a group of the formula
Figure A9419071900071
Wherein u is an integer of 1 to 3, formula
Figure A9419071900081
The group being lower alkenyl substituted by a 5-to 14-membered saturated or unsaturated heteromonocyclic, heterobicyclic or heterotricyclic group containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, R47Bonded to the heterocyclic group and is a hydrogen atom, a halogen-substituted lower alkyl group, an oxo group, a halogen atom, a lower alkoxy group, a lower alkyl group, a lower alkoxycarbonyl group, a carboxyl group, an aminocarbonyl group optionally having a lower alkyl substituent, an amino group optionally having a lower alkanoyl substituent, an amino group optionally having a substituent selected from a lower alkoxy group and a halogen atom in the phenyl moietyPhenyl as a substituent, or a group of the formula:(whereinR45And s is as previously defined); or R3And R4May form a 1, 2, 3, 4-tetrahydroisoquinoline together with the adjacent nitrogen atom to which they are bonded
Quinolinyl, said heterocyclyl optionally containing lower alkoxy substituents.
Provided that when R is1Is a hydrogen atom, R2Is methyl, R3R is a hydrogen atom and m is 04Is not 2- (imidazol-2-yl) ethyl, 2- (indol-3-yl) ethyl or cyclobutyl.
2. The quinoxaline derivative or a salt thereof according to claim 1, wherein m is 1.
3. The quinoxaline derivative or a salt thereof according to claim 1, wherein m is 0.
4. The quinoxaline derivative or salt thereof according to claim 1, wherein R is1Is a hydrogen atom.
5. The quinoxaline derivative or salt thereof according to claim 1, wherein R is1Is a halogen atom,Lower alkyl, lower alkoxy, amino optionally having lower alkyl substituents, or aminocarbonyl optionally having lower alkyl substituents.
6. The quinoxaline derivative or salt thereof according to claim 4, wherein R is2Is a lower alkyl group optionally having halogen substituents.
7. The quinoxaline derivative or salt thereof according to claim 4, wherein R is2Is a hydrogen atom, a phenyl group, a lower alkyl group substituted with a morpholinyl group or a lower alkyl group substituted with an imidazolyl group.
8. The quinoxaline derivative or salt thereof according to claim 5, wherein R2Is a lower alkyl group optionally having halogen substituents.
9. The quinoxaline derivative or salt thereof according to claim 5, wherein R2Is a hydrogen atom, a phenyl group, a lower alkyl group substituted with a morpholinyl group or a lower alkyl group substituted with an imidazolyl group.
10. The quinoxaline derivative or salt thereof according to claim 6, wherein R3Is a hydrogen atom, a lower alkyl group substituted with a lower alkanoyloxy group, a lower alkoxycarbonyl group, or a lower alkyl group substituted with a lower alkoxycarbonyloxy group, R4Is a group of the formula:
Figure A9419071900091
(wherein the group
Figure A9419071900092
R8And q is as defined in claim 1) or a group of the formula
Figure A9419071900093
(wherein the groupR47And u is as defined in claim 1).
11. The quinoxaline derivative or salt thereof according to claim 6, wherein R3Is hydrogen atom, lower alkyl substituted by lower alkanoyloxy, lower alkoxycarbonyl, or lower alkyl substituted by lower alkoxycarbonyloxy, R4Is a group of the formula
Figure A9419071900102
(wherein A, R5And p is as defined in claim 1), phenyl-lower alkenyl optionally having substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted with lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4Is lower alkylene, R40And R41Identical or different and are each a hydrogen atom or a lower alkyl group, or R40And R41With adjacent nitrogen bound to themThe atoms together form a 5-or 6-membered saturated heterocyclic group with or without the interposition of other nitrogen or oxygen atoms), a lower alkenyloxy group, a nitro group, and a lower alkyl group optionally containing a halogen substituent, or R4Is alkenyl, cycloalkyl-lower alkyl, naphthyl-lower alkyl, phenylthio-substituted lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, phenylsulfinyl-substituted lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, phenylsulfonyl-substituted lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, phenoxy-substituted lower alkyl, formula-A5-CR42R43R44A group of (wherein A)5Is lower alkylene, R42And R43Taken together to form a group of the formula: o or N-OH or lower alkylenedioxy, R44Is phenyl optionally having a lower alkoxy substituent on the phenyl moiety), a 2, 3-dihydro-1H-indenyl substituted lower alkyl optionally having a siloxy substituent selected from oxo, hydroxy and lower alkyl containing groups on the 2, 3-dihydro-1H-indenyl ring.
12. The quinoxaline derivative or salt thereof according to claim 6, wherein R is3Is phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally having halogen substituent on phenyl ring, a compound of formula-E-N (R)52)(R53) Group (wherein R)52And R53Identical or different and are each a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl group or a phenyl group, or R52And R53Together with the nitrogen atom to which they are bonded form A5-or 6-membered saturated heterocyclic group with or without the insertion of another nitrogen atom or oxygen atom, E is lower alkylene, A group of the formulA-CO-or A group of the formulA-CO-A (wherein A is lower alkylene)) or A group of the formulA(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above), and R4Is a group of the formula
Figure A9419071900112
(wherein A, R5And p is as defined in claim 1), optionally with a phenyl moietyPhenyl-lower alkenyl selected from the following substituents: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted with lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4Is lower alkylene, R40And R41Identical or different and are each a hydrogen atom or a lower alkyl group, or R40And R41Together with the adjacent nitrogen atom to which they are bonded form a 5-or 6-membered saturated heterocyclic group with or without the interposition of other nitrogen atoms or oxygen atoms), a lower alkenyloxy group, a nitro group, and a lower alkyl group optionally having a halogen substituent, or R4Is alkenyl, cycloalkyl-lower alkyl, naphthyl-lower alkyl, phenylthio-substituted lower alkyl optionally having lower alkoxy substituents in the phenyl moiety, phenylsulfinyl-substituted lower alkyl optionally having lower alkoxy substituents in the phenyl moiety, phenylsulfonyl-substituted lower alkyl optionally having lower alkoxy substituents in the phenyl moiety, phenoxy-substituted lower alkyl, or a group of the formula
Figure A9419071900121
(wherein the group
Figure A9419071900122
R8And q is as defined in claim 1), formula-A5-CR42R43R44A group of (wherein A)3Is lower alkylene, R42And R43Taken together to form a group of the formula: o or N-OH or lower alkylenedioxy, R44Is phenyl optionally having a lower alkoxy substituent on the phenyl moiety), a 2, 3-dihydro-1H-indenyl-substituted lower alkyl optionally having a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, or a group of the formula
Figure A9419071900131
(wherein the group
Figure A9419071900132
，R47And u is as defined in claim 1).
13. The quinoxaline derivative or salt thereof according to claim 6, wherein R is3And R4And together with the adjacent nitrogen atom to which they are bonded form a 1, 2, 3, 4-tetrahydroisoquinolinyl group, said heterocyclic group optionally having a lower alkoxy substituent.
14. The quinoxaline derivative or salt thereof according to claim 7, wherein R is3Is a hydrogen atom, a lower alkyl group substituted with a lower alkanoyloxy group, a lower alkoxycarbonyl group, or a lower alkyl group substituted with a lower alkoxycarbonyloxy group, and R4Is a group of the formula
Figure A9419071900133
(wherein the group
Figure A9419071900134
，R8And q is as defined in claim 1) or a group of the formula
Figure A9419071900135
(wherein the group，R47And u is as defined in claim 1).
15. The quinoxaline derivative or salt thereof according to claim 7, wherein R is3Is a hydrogen atom, a lower alkyl group, a lower alkanoyloxy-substituted lower alkyl group, a lower alkoxycarbonyl group or a lower alkoxycarbonyloxy-substituted lower alkyl group, and R4Is a group of the formula
Figure A9419071900141
(wherein A, R5And p is as defined in claim 1), phenyl-lower alkenyl optionally having substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting oflower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted by lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41Of (2) aGroup (wherein A)4Is lower alkylene, R40And R41Identical or different and are each a hydrogen atom or a lower alkyl group, or R40And R41Together with the adjacent nitrogen atom to which they are bonded form a 5-or 6-membered saturated heterocyclic group with or without the interposition of other nitrogen atoms or oxygen atoms), a lower alkenyloxy group, a nitro group, and a lower alkyl group optionally having a halogen substituent, or R4Is alkenyl, cycloalkyl-lower alkyl, naphthyl-lower alkyl, phenylthio-substituted lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, phenylsulfinyl-substituted lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, phenylsulfonyl-substituted lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, phenoxy-substituted lower alkyl, formula-A5-CR42R43R44A group of (wherein A)5Is lower alkylene, R42And R43Taken together to form a group of the formula: o or N-OH or lower alkylenedioxy, R44Is phenyl optionally having lower alkoxy substituents on the phenyl moiety), optionally having a siloxy group selected from oxo, hydroxy and lower alkyl containing groups on the 2, 3-dihydro-1H-indenyl ring2, 3-dihydro-1H-indenyl substituted lower alkyl as a substituent.
16. The quinoxaline derivative or salt thereof according to claim 7, wherein R is3Is phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally having halogen substituent on phenyl ring, a compound of formula-E-N (R)52)(R53) Group (wherein R)52And R53Identical or different and are each a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl group or a phenyl group, or R52And R53Together with the nitrogen atom to which they are bonded form A5-or 6-membered saturated heterocyclic group with or without the insertion of other nitrogen atoms or oxygen atoms, E is lower alkylene, A group of the formulA-CO-or A group of the formulA-CO-A (wherein A is lower alkylene)) orGroup of formula (II)(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above), and R4Is a group of the formula(wherein A, R5And p is as defined in claim 1), phenyl-lower alkenyl optionally having substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lowerLower alkoxy substituted by alkoxy, tetrazolyl optionally having lower alkyl substituent on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4Is lower alkylene, R40And R41Identical or different and are each a hydrogen atom or a lower alkyl group, or R40And R41Together with the adjacent nitrogen atom to which they are bonded form a 5-or 6-membered saturated heterocyclic group with or without the interposition of other nitrogen atoms or oxygen atoms), a lower alkenyloxy group, a nitro group, and a lower alkyl group optionally having a halogen substituent, or R4Is alkenyl, cycloalkyl-lower alkyl, naphthyl-lower alkyl, phenylthio-substituted lower alkyl optionally having lower alkoxy substituents in the phenyl moiety, phenylsulfinyl-substituted lower alkyl optionally having lower alkoxy substituents in the phenyl moiety, phenylsulfonyl-substituted lower alkyl optionally having lower alkoxy substituents in the phenyl moiety, phenoxy-substituted lower alkyl, or a group of the formula(wherein the group
Figure A9419071900162
，R8And q is as defined in claim 1), formula-A5-CR42R43R44A group of (wherein A)5Is lower alkylene, R42And R43Taken together to form a group of the formula: o or N-OH or lower alkylenedioxy, R44Is phenyl optionally having lower alkoxy substituents on the phenyl moiety), optionally having a substituent selected from oxo, hydroxy, on the 2, 3-dihydro-1H-indenyl ring2, 3-dihydro-1H-indenyl-substituted lower alkyl with a lower alkyl-containing siloxy substituent, or a group of the formula
Figure A9419071900171
(wherein the group，R47And u is as defined in claim 1).
17. The quinoxaline derivative or salt thereof according to claim 7, wherein R is3And R4Together with the adjacent nitrogen atom to which they are bonded, form a 1, 2, 3, 4-tetrahydroisoquinolinyl group, said heterocyclic group optionally having a lower alkoxy substituent.
18. The quinoxaline derivative or salt thereof according to claim 8, wherein R is3Is a hydrogen atom, a lower alkyl group substituted with a lower alkanoyloxy group, a lower alkoxycarbonyl group, or a lower alkyl group substituted with a lower alkoxycarbonyloxy group, R4Is a group of the formula:
Figure A9419071900173
(wherein the group、R8And q is as defined in claim 1) or a group of the formula
Figure A9419071900175
(wherein the group
Figure A9419071900176
、R47And u is as defined in claim 1).
19. The quinoxaline derivative or salt thereof according to claim 8, wherein R is3Is a hydrogen atom, a lower alkyl group, a lower alkanoyloxy-substituted lower alkyl group, a lower alkoxycarbonyl group or a lower alkoxycarbonyloxy-substituted lower alkyl group, and R4Is a group of the formula(wherein A, R5And p is as defined in claim 1), phenyl-lower alkenyl optionally having substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, optionally having substituent(s) selected from lower alkanoyl and phenyl-lower alkenylcarbonylAmino, lower alkoxy substituted lower alkoxy, tetrazolyl optionally having lower alkyl substituent on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4Is lower alkylene, R40And R41Identical or different and are each a hydrogen atom or a lower alkyl group, or R40And R41Together with the adjacent nitrogen atom to which they are bonded form a 5-or 6-membered saturated heterocyclic group with or without the interposition of other nitrogen atoms or oxygen atoms), a lower alkenyloxy group, a nitro group, and a lower alkyl group optionally having a halogen substituent, or R4Is alkenyl, cycloalkyl-lower alkyl, naphthyl-lower alkyl, phenylthio-substituted lower alkyl optionally having lower alkoxy substituents onthe phenyl moiety, phenylsulfinyl-substituted lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, phenylsulfonyl-substituted lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, phenoxy-substituted lower alkyl, formula-A5-CR42R43R44A group of (wherein A)5Is lower alkylene, R42And R43Taken together to form a group of the formula: o or N-OH or lower alkylenedioxy, R44Is phenyl optionally having lower alkoxy substituents on the phenyl moiety), optionally having a siloxy group selected from oxo, hydroxy and lower alkyl containing groups on the 2, 3-dihydro-1H-indenyl ring2, 3-dihydro-1H-indenyl substituted lower alkyl as a substituent.
20. The quinoxaline derivative or salt thereof according to claim 8, wherein R is3Is phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally having halogen substituent on phenyl ring, a compound of formula-E-N (R)52)(R53) Group (wherein R)52And R53Identical or different and are each a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl group or a phenyl group, or R52And R53With nitrogen bound to themThe atoms together forming A5-or 6-membered saturated heterocyclic group with or without the interposition of A further nitrogen atom or oxygen atom, E being lower alkylene, A group of the formulA-CO-or A group of the formulA-CO-A (wherein A is lower alkylene)) or A group of the formulA(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above), and R4Is a group of the formula
Figure A9419071900192
(wherein A, R5And p is as defined in claim 1), phenyl-lower alkenyl optionally having substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lowerLower alkoxy substituted by alkoxy, tetrazolyl optionally having lower alkyl substituent on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4Is lower alkylene, R40And R41Identical or different and are each a hydrogen atom or a lower alkyl group, or R40And R41Together with the adjacent nitrogen atom to which they are bonded form a 5-or 6-membered saturated heterocyclic group with or without the interposition of other nitrogen atoms or oxygen atoms), a lower alkenyloxy group, a nitro group, and a lower alkyl group optionally having a halogen substituent, or R4Is alkenyl, cycloalkyl-lower alkyl, naphthyl-lower alkyl, phenylthio-substituted lower alkyl optionally having lower alkoxy substituents in the phenyl moiety, phenylsulfinyl-substituted lower alkyl optionally having lower alkoxy substituents in the phenyl moiety, phenylsulfonyl-substituted lower alkyl optionally having lower alkoxy substituents in the phenyl moiety, phenoxy-substituted lower alkyl, or a group of the formula
Figure A9419071900201
(wherein the group，R8And q is as defined in claim 1), formula-A5-CR42R43R44A group of (wherein A)5Is lower alkylene, R42And R43Taken together to form a group of the formula: is ═ iO or ═ N-OH or lower alkylenedioxy, R44Is phenyl optionally having a lower alkoxy substituent on the phenyl moiety), a 2, 3-dihydro-1H-indenyl-substituted lower alkyl optionally having a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, or a group of the formula
Figure A9419071900211
(wherein the group，R47And u is as defined in claim 1).
21. The quinoxaline derivative or salt thereof according to claim 8, wherein R is3And R4Together with the adjacent nitrogen atom to which they are bonded, form a 1, 2, 3, 4-tetrahydroisoquinolinyl group, said heterocyclic group optionally having a lower alkoxy substituent.
22. The quinoxaline derivative or salt thereof according to claim 9, wherein R is3Is a hydrogen atom, a lower alkyl group substituted with a lower alkanoyloxy group, a lower alkoxycarbonyl group, or a lower alkyl group substituted with a lower alkoxycarbonyloxy group, R4Is a group of the formula:(wherein the group
Figure A9419071900214
、R8And q is as defined in claim 1) or a group of the formula
Figure A9419071900215
(wherein the group
Figure A9419071900216
、R47And u is as defined in claim 1).
23. The quinoxaline derivative or salt thereof according to claim 9, wherein R is3Is a hydrogen atom, a lower alkyl group, a lower alkanoyloxy-substituted lower alkyl group, a lower alkoxycarbonyl group, or a lower alkoxycarbonyloxy-substituted lower alkyl group, and R4Is a group of the formula(wherein A, R5And p is as defined in claim 1) inPhenyl-lower alkenyl optionally having substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted with lower alkoxy, tetrazolyl optionally having lower alkyl substituent(s) on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4Is lower alkylene, R40And R41Identical or different and are each a hydrogen atom or a lower alkyl group, or R40And R41Together with the adjacent nitrogen atom to which they are bonded form a 5-or 6-membered saturated heterocyclic group with or without the interposition of other nitrogen atoms or oxygen atoms), a lower alkenyloxy group, a nitro group, and a lower alkyl group optionally having a halogen substituent, or R4Is alkenyl, cycloalkyl-lower alkyl, naphthyl-lower alkyl, phenylthio-substituted lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, phenylsulfinyl-substituted lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, phenylsulfonyl-substituted lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, phenoxy-substituted lower alkyl, formula-A5-CR42R43R44A group of (wherein A)3Is lower alkylene, R42And R43Taken together to form a group of the formula: o or N-OH or lower alkylenedioxy, R44Is phenyl optionally having lower alkoxy substituents on the phenyl moiety), optionally having a siloxy group selected from oxo, hydroxy and lower alkyl containing groups on the 2, 3-dihydro-1H-indenyl ring2, 3-dihydro-1H-indenyl substituted lower alkyl as a substituent.
24. The quinoxaline derivative or salt thereof according to claim 9, wherein R is3Is phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkanoyl substituted lower alkyl, benzoyl substituted lower alkyl optionally having halogen substituent on phenyl ring, a compound of formula-E-N (R)52)(R53) Group (a) ofIn R52And R53Identical or different and are each a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl group or a phenyl group, or R52And R53Together with the nitrogen atom to which they are bonded form A5-or 6-membered saturated heterocyclic group with or without the insertion of another nitrogen atom or oxygen atom, E is lower alkylene, A group of the formulA-CO-or A group of the formulA-CO-A (wherein A is lower alkylene)) or A group of the formulA(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above), and R4Is a group of the formula(wherein A, R5And p is as defined in claim 1), phenyl-lower alkenyl optionally having substituents on the phenyl moiety selected from: lower alkoxy, halogen atom, amino optionally having substituent(s) selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lowerLower alkoxy substituted by alkoxy, tetrazolyl optionally having lower alkyl substituent on the tetrazole ring, hydroxy, A compound of formulA-O-A4-CO-NR40R41A group of (wherein A)4Is lower alkylene, R40And R41Identical or different and are each a hydrogen atom or a lower alkyl group, or R40And R41Together with the adjacent nitrogen atom to which they are bonded form a 5-or 6-membered saturated heterocyclic group with or without the interposition of other nitrogen atoms or oxygen atoms), a lower alkenyloxy group, a nitro group, and a lower alkyl group optionally having a halogen substituent, or R4Is alkenyl, cycloalkyl-lower alkyl, naphthyl-lower alkyl, phenylthio-substituted lower alkyl optionally having lower alkoxy substituents in the phenyl moiety, phenylsulfinyl-substituted lower alkyl optionally having lower alkoxy substituents in the phenyl moiety, phenylsulfonyl-substituted lower alkyl optionally having lower alkoxy substituents in the phenyl moiety, phenoxy-substituted lower alkyl, or a group of the formula
Figure A9419071900241
(wherein the group
Figure A9419071900242
，R8And q is as defined in claim 1) Of the formula-A5-CR42R43R44A group of (wherein A)5Is lower alkylene, R42And R43Taken together to form a group of the formula: o or N-OH or lower alkylenedioxy, R44Is phenyl optionally having a lower alkoxy substituent on the phenyl moiety), a 2, 3-dihydro-1H-indenyl-substituted lower alkyl optionally having a substituent selected from oxo, hydroxy and lower alkyl-containing siloxy on the 2, 3-dihydro-1H-indenyl ring, or a group of the formula
Figure A9419071900251
(wherein the group
Figure A9419071900252
，R47And u is as defined in claim 1).
25. The quinoxaline derivative or salt thereof according to claim 9, wherein R is3And R4Together with the adjacent nitrogen atom to which they are bonded, form a 1, 2, 3, 4-tetrahydroisoquinolinyl group, said heterocyclic group optionally having a lower alkoxy substituent.
26. The quinoxaline derivative or salt thereof according to claim 10, wherein in the formula
Figure A9419071900253
In the group of (A) is represented byThe saturated or unsaturated heterocyclic group in the 5-to 14-membered saturated or unsaturated heterocyclic group-substituted lower alkyl group represented by (A) is selected from: benzofuranyl, benzothienyl, indolyl, 2, 3-dihydrobenzofuranyl, perhydrobenzofuranyl, quinolinyl, benzimidazolyl, benzothiazolyl, imidazo [1, 2-a]]Pyridyl, 1, 4-benzodioxan, furo [3, 2-c]Pyridyl, 1, 2, 3, 4-tetrahydrofuro [2, 3-g]Quinolyl, furo [2, 3-g]]Quinolyl, 3, 4-dihydrofuro [2, 3-g]Quinolinyl, thiazolyl, pyridyl, furanyl, imidazolyl, 1, 2, 3, 4-tetrazolyl, and oxazolyl.
27. The quinoxaline derivative or salt thereof according to claim 26, wherein the compound is represented by formula (la)
Figure A9419071900261
The saturated or unsaturated heterocyclic group in the 5-to 14-membered saturated or unsaturated heterocyclic group-substituted lower alkyl group represented is a benzofuranyl group or an oxazolyl group.
28. The quinoxaline derivative or salt thereof according to claim 10, wherein in the formula
Figure A9419071900262
In the group of (A) is represented by
Figure A9419071900263
The saturated or unsaturated heterocyclic group in the 5-to 14-membered saturated or unsaturated heterocyclic group-substituted lower alkenyl group represented by (A) is selected from the group consisting of benzofuranyl, benzothienyl, quinolonyl, 3, 4-dihydroquinolonyl, benzothienyl, furo [3, 2-c]]Pyridyl, furo [2, 3-g]Quinolyl, 3, 4-dihydrofuro [2, 3-g]Quinolyl, 1, 2, 3, 4-tetrahydrofuro [2, 3-g]Quinolyl, naphtho [2, 1-b]]Furyl and oxazolyl.
29. The quinoxaline derivative or salt thereof according to claim 28, wherein the compound is represented by formula (la)The saturated or unsaturated heterocyclic group in the 5-to 14-membered saturated or unsaturated heterocyclic group-substituted lower alkenyl group represented is a benzofuranyl group.
30. The quinoxaline derivative or a salt thereof according to claim 1, which is selected from the group consisting of 2- [3- (benzofuran-2-yl) -2-butenylaminocarbonyl]-3-methylquinoxaline-4-oxide, 2- [ (3-methyl-7-trifluoromethylbenzofuran-2-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide, 2- [ (2-phenyl-5-methyloxazol-4-yl) methylaminocarbonyl]-3-methylquinoxaline-4-oxide, 2- { [5- (2, 5-dimethylthiazol-4-yl) benzofuran-3-yl]methylaminocarbonyl) -3-methylquinoxaline-4-oxide, a salt thereof, a pharmaceutically acceptable carrier, 2- {3- [5- (2-methyl-1, 2, 3, 4-tetrazol-5-yl) benzofuran-2-yl]-2-butenylaminocarbonyl } -3-methylquinoxaline-4-oxide, 2- [ 5-benzofuran-2-yl) -2, 4-hexadienylaminocarbonyl]-3-methylquinoxaline-4-oxide, 2- {3- [5- (2, 5-dimethylthiazol-4-yl) benzofuran-2-yl]-2-butenylaminocarbonyl } -3-methylquinoxaline-4-oxide, 2- {3- [5- (thiazol-2-yl) benzofuran-2-yl]-2-methylquinoxaline-4-oxide -butenylaminocarbonyl } -3-methylquinoxaline-4-oxide, 2- [3- (5, 7-difluorobenzofuran-2-yl) -2-butenylaminocarbonyl]-3-methylquinoxaline-4-oxide, 2- { N- [3- (benzofuran-2-yl) -2-butenyl]-N-methoxycarbonylaminocarbonyl } -3-methylquinoxaline-4-oxide, 2- { N- [3- (benzofuran-2-yl) -2-butenyl]-N-propionyloxymethylaminocarbonyl } -3-methylquinoxaline-4-oxide, 2- (methyl-2-yl) -2-methylquinoxaline-4-oxide, 2- { N- [3- (benzofuran-3-yl) -2-butenyl]-N-acetoxymethylaminocarbonyl } -3-methylquinoxaline-4-oxide,2- { N- [3- (benzofuran-2-yl) -2-butenyl-N-ethoxycarbonyloxymethylaminocarbonyl } -3-methylquinoxaline-4-oxide, 2- { N- [3- (methyl-7-trifluoromethylbenzofuran-2-yl) methyl]-N-acetoxymethylaminocarbonyl } -3-methylquinoxaline-4-oxide, and 2- { N- [ 2-phenyl-5-methyloxazol-4-yl) methyl]- N-acetoxymethylaminocarbonyl) -3-methylquinoxaline-4-oxide: or a salt thereof.
31. An antidiabetic agent comprising the compound of claim 1 as an active ingredient.
32. An antidiabetic agent comprising a quinoxaline derivative of the formula or a pharmaceutically acceptable salt thereof as an active ingredient,
Figure A9419071900281
wherein R is1Is hydrogen atom, halogen atom, lower alkyl, lower alkoxy, optionally having lower alkyl
Amino of a substituent or aminocarbonyl optionally having a lower alkyl substituent; r2Is hydrogen atom, lower alkyl optionally having halogen substituent, phenyl, morpholinyl
Lower alkyl or imidazolyl-substituted lower alkyl of (a); m and n are each 0 or 1; r is 1 or 2R3And R4Which may be the same or different, are each a) a hydrogen atom, b) a lower alkyl group; c)
phenyl lower alkoxycarbonyl, d) lower alkanoyloxy-substituted lower alkyl, e) lower
A lower alkanoyl group; f) lower alkoxycarbonyl, g) lower alkoxy-lower alkyl, h)
Phenoxycarbonyl, i) lower alkanoyl substituted lower alkyl, j) lower alkoxycarbonyloxy
Substituted lower alkyl, k) benzoyl optionally containing halogen substituents on the phenyl ring
Lower alkyl substituted by 1) formula-E-N (R)52)(R53) A group of (1), wherein
R52And R53Identical or different, each being a hydrogen atom, a lower alkyl group, a lower alkoxy group
Carbonyl or phenyl, or R52And R53May be formed with the nitrogen atom to which they are attachedOr A5-or 6-membered saturated heterocyclic group with no additional nitrogen or oxygen atoms inserted, E is lower alkylene, A group of the formulA-CO-or A group of the formulA-CO-A (wherein A is lower alkylene), m) A group of the formulA:
Figure A9419071900291
wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above, n) a group of the formula,
Figure A9419071900292
wherein A is as defined above;
p is an integer of 1 to 3;
R5is hydrogen atom, lower alkoxy substituted by lower alkoxy, or
Selected from amino having lower alkyl substituent, halogen atom, nitro, hydroxy, optionally having
Lower alkyl with hydroxy substituent, lower alkenyloxy, lower alkyl substituted by carboxyl
Oxy, lower alkoxy substituted by lower alkoxycarbonyl, halogen
Substituted lower alkoxy, hydroxy substituted lower alkoxy, on the phenyl moiety
Is selected from phenyl-lower alkoxy having a substituent selected from lower alkyl and lower alkoxy,
1, 3-dioxolanyl optionally having a lower alkyl substituent, a lower alkanoyl group,
Lower alkoxy substituted by morpholinyl, lower alkyl substituted by morpholinyl, morpholinylcarbonyl
Or formula-Y-A1-CONR6R7Group (wherein A)1Is lower alkylene, Y
Is a group of the formula-O-or a group of the formula-NH-, R6And R7The same or different, and the like,
each is a hydrogen atom, a lower alkyl group optionally having a hydroxy substituent, in the phenyl moiety
Optionally substituted with phenyl-lower alkyl, furyl having lower alkoxy substituents thereon
Lower alkyl, or lower alkyl substituted by lower alkoxy, or R6And R7
With or without additional nitrogen atoms formed together with the adjacent nitrogen atoms to which they are attached or
A 5-or 6-membered saturated heterocyclic group interrupted by an oxygen atom, said heterocyclic group optionally having
1-3 substituents selected from hydroxy, lower alkyl and phenyl-lower alkyl), o) phenyl-lower alkenyl, which optionally contains in its phenyl moiety a substituent selected from the group consisting of
The substituent (b): lower alkoxy, halogen, optionally with a substituent selected from lower alkanoyl
And phenyl-lower alkenylcarbonyl-substituted amino, lower alkoxy
Tetrazole of lower alkoxy, optionally containing lower alkyl substituents on the tetrazole moiety
A radical, A hydroxyl radical, of the formulA-O-A4-CO-NR40R41A group of (wherein A)4Is composed of
Lower alkylene, R40And R41Identical or different, each being a hydrogen atom or lower
Lower alkyl, or R40And R41Together with the adjacent nitrogen atom to which they are attached
With or without additional nitrogen or oxygen atoms inserted in 5-or 6-membered saturated
Heterocyclyl), lower alkenyloxy, nitro and optionally halogen-containing substituents
A lower alkyl group; p) an alkenyl group; q) cycloalkyl-lower alkyl; r) naphthyl-lower alkyl; s) lower optionally substituted in the phenyl moiety by phenylthio having lower alkoxy substituents
An alkyl group; t) Phenylsulfinyl substitution optionally having lower alkoxy substituent(s) in the phenyl moiety
Lower alkyl of (a); u) phenylsulfonyl optionally substituted in the phenyl moiety with lower alkoxy substituents
A lower alkyl group; v) phenoxy-substituted lower alkyl; w) a group of the formula:wherein q is an integer of 1 to 3, formulaIs lower alkyl which is substituted by a 5-to 14-membered saturated or unsaturated heteromonocyclic, heterobicyclic or heterotricyclic group containing 1 to 4 heteroatoms selected from N, O and S, R8Substituted on the above heterocyclic group and is a hydrogen atom, oxo group, lower alkyl optionally having a hydroxy substituent, halogen atom, nitro group, lower alkoxy group, cyano group, lower alkoxycarbonyl group, phenyl-lower alkoxy optionally having an amino substituent (the amino substituent optionally having a lower alkanoyl substituent), lower alkoxy substituted by carboxy group, lower alkoxy substituted by lower alkoxycarbonyl, hydroxy group, lower alkoxy substituted by lower alkoxy, lower alkenyloxy group, lower alkyl substituted by lower alkanoyloxy group, lower alkyl substituted by halogen group, lower alkanoyl group, or is phenyl optionally having a substituent selected from the group consisting of lower alkyl, lower alkoxy substituted by lower alkoxy, hydroxy group, halogen atom and lower alkoxy group on the phenyl moiety, oris lower alkenyl group, morpholinylcarbonyl-lower alkoxy group, lower alkoxycarbonyl group, lower alkoxy group, lower alkoxycarbonyl group, lower, Lower alkylsulfinyl, optionally havingLower alkyl substituted by amino selected from lower alkylsulfonyl and lower alkanoyl substituents, lower alkylthio, lower alkylsulfonyl, lower alkanoyloxy, lower alkyl substituted by 1, 3-dioxolanyl optionally having lower alkyl substituent, lower alkanoyl substituted lower alkylLower alkyl, aminocarbonyl-substituted lower alkyl optionally having lower alkyl substituent(s), lower alkoxycarbonyl-substituted lower alkenyl, aminocarbonyl-substituted lower alkenyl optionally having lower alkyl substituent(s), carboxy-substituted lower alkenyl, benzoyl, lower alkoxy-lower alkyl, a group of the formula(wherein s is an integer of 1 to 3, formula
Figure A9419071900322
The radical being a 5-or 6-membered saturated or unsaturated heterocyclic radical containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, R45A lower alkyl group, a lower alkoxy-substituted lower alkyl group, a phenyl group or an oxo group) bonded to the heterocyclic group, a group of the formula
Figure A9419071900323
(wherein t is an integer of 1 to 3, formula
Figure A9419071900324
The radicals being 1 toLower alkyl substituted by 5-to 6-membered saturated or unsaturated heterocyclyl having 4 heteroatoms selected from N, O and S, R46Bonded to said heterocyclyl and is hydrogen atom, lower alkyl or oxo), or of the formula- (C ═ O)1NR9R10Group (wherein l is 0 or 1, R9And R10Different or the same, and each is a hydrogen atom, a lower alkanoyl group, a lower alkyl group, a morpholinocarbonyl-lower alkyl group, a cycloalkylcarbonyl group, a phenyl-lower alkenylcarbonyl group, a lower alkylsulfonyl group, an aminocarbonyl group optionally having a lower alkyl substituent, a phenylsulfonyl group optionally having a lower alkyl substituent on the phenyl moiety, a phenyl-lower alkenyl group, or each is a benzoyl group optionally having 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkoxy group, an amino group optionally having a lower alkanoyl substituent and a hydroxyl group on the phenyl moiety, or each is a lower alkanoyl group optionally having an amino substituent on the lower alkanoyl substituent, an amino-substituted sulfonyl group optionally having a lower alkanoyl substituent, a phenyl-lower alkyl group, a phenyl group or an amino group optionally having a lower alkanoyl substituent, or R9And R10With or combined with themAdjacent nitrogen atoms together form a 5-or 6-membered saturated heterocyclic group with or without the interposition of other nitrogen atoms or oxygen atoms); x) formula-A5-CR42R43R44A group of (wherein A)5Is lower alkylene, R42And R43Together form a group of the formula ═ O or ═ N-OH or lower alkylenedioxy, R44Is phenyl optionally containing lower alkoxy substituents in the phenyl moiety): y) a 2, 3-dihydro-1H-indenyl substituted lower alkyl optionally having a substituent selected from oxo, hydroxy or siloxy with lower alkyl on the 2, 3-dihydro-1H-indenyl ring: z) a group of the formula
Figure A9419071900331
Wherein u is an integer of 1 to 3, formula
Figure A9419071900341
The group being lower alkenyl substituted by a 5-to 14-membered saturated or unsaturated heteromonocyclic, heterobicyclic or heterotricyclic group containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, R47Bonded to the heterocyclic group and is a hydrogen atom, a halogen-substituted lower alkyl group, an oxo group, a halogen atom, a lower alkoxy group, a lower alkyl group, a lower alkoxycarbonyl group, a carboxyl group, an aminocarbonyl group optionally having a lower alkyl substituent, an amino group optionally having a lower alkanoyl substituent, a phenyl group optionally having a substituent selected from the group consisting of a lower alkoxy group and a halogen atom in the phenyl moiety, or a group of the formula:(wherein
Figure A9419071900343
、R45And s is as previously defined); or R3And R4May form a 1, 2, 3, 4-tetrahydroisoquinoline together with the adjacent nitrogen atom to which they are bonded
Quinolinyl, said heterocyclyl optionally containing lower alkoxy substituents.
33. A method for producing the quinoxaline derivative according to claim 1, which comprises:
a) reacting a compound of formula (2) or a reactive derivative thereof with a compound of formula HNR3R4(wherein R is3And R4As defined in claim 1) ofThe reaction of the amine is carried out,(2) (wherein R is1、R2M, n and r are as defined in claim 1);
b) reacting a quinoxaline compound of formula (Ia) with R3bX or R3cCOR3d(wherein R is3bAnd R3aSame, except that R3bNot being a hydrogen atom, R3cAnd R3dEach being a hydrogen atom or a lower alkyl group) compound,
Figure A9419071900352
(1a) (wherein R is3aIs hydrogen atom, lower alkyl, phenyl-lower alkoxycarbonyl, lower alkyl substituted by lower alkanoyloxy, lower alkanoyl, lower alkoxycarbonyl, lower alkoxy-lower alkyl, phenoxycarbonyl, lower alkyl substituted by lower alkanoyl, lower alkyl substituted by lower alkoxycarbonyloxy, lower alkyl substituted by benzoyl optionally having halogen substituent on phenyl ring, or a pharmaceutically acceptable salt thereof, or a pharmaceutically52)(R53) Group (wherein R)52And R53Same or differentSame, each is a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl group or a phenyl group, or R52And R53Together with the adjacent nitrogen atom to which they are bonded form A5-or 6-membered saturated heterocyclic group with or without the interposition of another nitrogen atom or oxygen atom, E is lower alkylene, A group of the formulA-CO-or A group of the formulA-CO-A-wherein A is lower alkylene, A group of the formulA:(wherein R is54Is a hydrogen atom or a lower alkyl group, A is as defined above), a group of the formula:
Figure A9419071900362
(wherein A, R5And p is as defined in claim 1), or is phenyl-lower alkenyl optionally containing substituents on the phenyl moiety selected from: lower alkoxy, a halogen atom, amino optionally having a substituent selected from the group consisting of lower alkanoyl and phenyl-lower alkenylcarbonyl, lower alkoxy substituted with lower alkoxy, tetrazolyl optionally having a lower alkyl substituent on the tetrazolyl moiety, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, a,Hydroxy, formulA-O-A4-CO-NR40R41A group of (wherein A)4、R40And R41As defined in claim 1), lower alkenyloxy, nitro and
lower alkyl optionally having halogen substituent(s), or alkenyl, cycloalkyl-lower alkyl, naphthyl-lower alkyl, phenylthio-substituted lower alkyl optionally having lower alkoxy substituent(s) on the phenyl moiety, phenylsulfinyl-substituted lower alkyl optionally having lower alkoxy substituent(s) on the phenyl moiety, phenylsulfonyl-substituted lower alkyl optionally having lower alkoxy substituent(s) on the phenyl moiety, phenoxy-substituted lower alkyl, lower alkyl optionally having lower alkoxy substituent(s) on the phenyl moiety, lower alkyl optionally having lower alkoxy substituent(s) on the phenyl moietyAnd (3) clustering:
Figure A9419071900371
(wherein the group
Figure A9419071900372
、R8And q is as defined in claim 1), formula-A5-CR42R43R44Group (wherein A)5、R42、R43And R44As defined in claim 1), a 2, 3-dihydro-1H-indenyl substituted lower alkyl optionally having a substituent selected from oxo, hydroxy and siloxy containing lower alkyl on the 2, 3-dihydro-1H-indenyl ring, or is a group of the formula:
Figure A9419071900373
(wherein the group
Figure A9419071900374
，R47And u is as defined in claim 1), and R is1、R2M, n and r are as defined in claim 1) to give a compound of formula (1b),
Figure A9419071900375
(1b)(wherein R is1、R2M, n and R are as defined in claim 1, R3aAnd R3bAs defined above);
c) oxidizing the quinoxaline compound of formula (1c) with an oxidizing agent to convert it to a compound of formula (1d),
(1c) (wherein R is1、R2、R3、R4N and r are as defined in claim 1),
(1d) (wherein R is1、R2、R3、R4N and r are as defined in claim 1), d) oxidizing the quinoxaline compound of formula (1N) with an oxidizing agent to convert it into a compound of formula (10) and further into a compound of formula (1P)
Figure A9419071900391
(1N) (wherein R28Is lower alkoxy substituted by phenylthio optionally having lower alkoxy substituents on the phenyl moiety, R1、R2M, n and R are as defined in claim 1, R3aAs defined above),
Figure A9419071900392
(1O) (wherein R27Is phenylsulfinyl-substituted lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, R1、R2M, n and R are as defined in claim 1, R3aAs defined above),
(1P) (wherein R28Is phenylsulfonyl-substituted lower alkyl optionally having lower alkoxy substituents on the phenyl moiety, R1、R2M, n and R are as defined in claim 1, R3aAs defined above), e) oxidizing the quinoxaline compound of formula (1N) with an oxidizing agent to convert it to a compound of formula (1P),
Figure A9419071900402
(1N) (wherein R1、R2M, n and R are as defined in claim 1, R3aAnd R26As defined above),
Figure A9419071900411
(1P) (wherein R1、R2M, n and R are as defined in claim 1, R3aAnd R28As defined above), or f) reacting a compound of formula (1a) with formula R3cOH Compound (wherein R3cAs defined above) to give a compound of formula (1Y),
Figure A9419071900412
(1a) (wherein R is1、R2M, n and R are as defined in claim 1, R3aAs defined above),
(1Y) (wherein R1、R2M, n and R are as defined in claim 1, R3aAs defined above, R3c′Is phenyl-lower alkoxycarbonyl, lower alkanoyl, lower alkoxycarbonyl, phenoxycarbonyl or of the formulA-CO-A-NR52R53Group (wherein A, R)52And R53As defined above)).
CN94190719A 1993-09-28 1994-09-22 Quinoxaline derivative as antidiabetic agent Pending CN1114834A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP24114093 1993-09-28
JP241140/93 1993-09-28
JP114639/94 1994-04-28
JP11463994 1994-04-28

Publications (1)

Publication Number Publication Date
CN1114834A true CN1114834A (en) 1996-01-10

Family

ID=26453355

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94190719A Pending CN1114834A (en) 1993-09-28 1994-09-22 Quinoxaline derivative as antidiabetic agent

Country Status (7)

Country Link
EP (1) EP0670831A1 (en)
KR (1) KR100196356B1 (en)
CN (1) CN1114834A (en)
AU (1) AU674613B2 (en)
CA (1) CA2150345A1 (en)
TW (1) TW284760B (en)
WO (1) WO1995009159A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100460397C (en) * 2006-11-07 2009-02-11 浙江大学 Sulfur-containing quinoxaline dioxide, method for producing same and their application
CN104086491A (en) * 2014-07-09 2014-10-08 广西师范大学 Method for preparing 2,3-disubstituted quinoxaline derivatives

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088062C (en) * 1994-11-23 2002-07-24 纽罗根公司 Certain 4 -aminomethyl -2 -substituted imidazole derivatives and 2 -aminomethyl -4 -substituted imidazole derivatives, new classes of dopamine receptor subtype specific ligands
WO1998055454A2 (en) * 1997-06-05 1998-12-10 Takeda Chemical Industries, Ltd. Benzofurans and benzothophenes as suppressors of neurodegeneration
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
ES2131020B1 (en) * 1997-10-13 2000-03-01 Lacer Sa DERIVATIVES OF BENZOFURANO, DIHIDROBENZOFUNARO, DIHIDROBENZOPIRANO AND BENZOPIRANO AS ANTIDEPRESSIVE AGENTS.
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
AP1538A (en) 1999-01-11 2006-01-10 Agouron Pharma Tricyclic inhibitors of poly (adp-ribose) polymerases.
ECSP003637A (en) 1999-08-31 2002-03-25 Agouron Pharma TRICYCLE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES
US6969730B2 (en) * 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
FR2822463B1 (en) 2001-03-21 2004-07-30 Lipha BICYCLIC GUANIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
MXPA03000966A (en) * 2002-02-28 2003-09-04 Pfizer Prod Inc Antidiabetic agents.
US7153889B2 (en) 2002-11-12 2006-12-26 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
US20050148586A1 (en) * 2004-01-06 2005-07-07 Beavers Mary P. Quinoxalinones
PL1720836T3 (en) 2004-02-25 2014-09-30 Lilly Co Eli 6-substituted 2,3,4,5-tetrahydro-1h-benzo [d]azepines as 5-ht2c receptor agonists
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7145005B2 (en) 2004-05-12 2006-12-05 Abbott Laboratories 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
ATE432926T1 (en) * 2004-07-26 2009-06-15 Lilly Co Eli OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR ACTIVE INGREDIENTS, THEIR PRODUCTION AND THERAPEUTIC USE
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
TWI385169B (en) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd Heterocyclic substituted pyridine derivatives and antifungal agent containing same
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
US8183264B2 (en) 2006-09-21 2012-05-22 Eisai R&D Managment Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
EP2091944B1 (en) 2006-11-17 2011-05-18 Pfizer Inc. Substituted bicyclocarboxyamide compounds
CN102702185A (en) 2007-04-27 2012-10-03 卫材R&D管理有限公司 Heterocycle-substituted pyridine derivative's salt or crystal thereof
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
EP2344446A4 (en) 2008-10-17 2012-04-04 Akaal Pharma Pty Ltd S1p receptors modulators
EP2344484B1 (en) * 2008-10-17 2016-06-08 Akaal Pharma Pty Ltd S1p receptors modulators and use thereof
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
US8501804B2 (en) 2008-10-27 2013-08-06 Takeda Pharmaceutical Company Limited Bicyclic compound
EA201690153A1 (en) 2013-07-03 2016-06-30 Кариофарм Терапевтикс, Инк. SUBSTITUTED PETROPHORANE AND BENZOXAZOLYL COMPOUNDS AND THEIR APPLICATIONS
WO2017117447A1 (en) * 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
US20240109899A1 (en) * 2021-02-04 2024-04-04 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
CR20230576A (en) 2021-06-14 2024-04-05 Scorpion Therapeutics Inc Urea derivatives which can be used to treat cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3717M (en) * 1964-04-17 1965-11-29 Rhone Poulenc Sa New quinoxaline derivatives and drugs containing them.
US3819633A (en) * 1970-04-01 1974-06-25 Erba Carlo Spa (iso)quinolyl sulfonylureas having antidiabetic activity
IL39384A0 (en) * 1971-05-17 1972-07-26 Ciba Geigy Ag New quinoxaline derivatives,their manufacture and pharmaceutical compositions containing them
SE405853B (en) * 1972-05-01 1979-01-08 Pfizer PROCEDURE FOR THE PREPARATION OF 2-KINOXALINCARBOXAMIDE-1,4-DIOXIDES
AU9049391A (en) * 1990-12-20 1992-07-22 Warner-Lambert Company 2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity
NO179904C (en) * 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Condensed heterocyclic compounds and their use

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100460397C (en) * 2006-11-07 2009-02-11 浙江大学 Sulfur-containing quinoxaline dioxide, method for producing same and their application
CN104086491A (en) * 2014-07-09 2014-10-08 广西师范大学 Method for preparing 2,3-disubstituted quinoxaline derivatives
CN104086491B (en) * 2014-07-09 2016-04-06 广西师范大学 The preparation method of 2,3-bis-substituted quinoxaline derivative

Also Published As

Publication number Publication date
KR950704269A (en) 1995-11-17
EP0670831A1 (en) 1995-09-13
TW284760B (en) 1996-09-01
CA2150345A1 (en) 1995-04-06
KR100196356B1 (en) 1999-06-15
AU7666094A (en) 1995-04-18
WO1995009159A1 (en) 1995-04-06
AU674613B2 (en) 1997-01-02

Similar Documents

Publication Publication Date Title
CN1114834A (en) Quinoxaline derivative as antidiabetic agent
CN1230431C (en) Arylmethy lamine derivatives for use as tryptase inhibitors
CN1186326C (en) Propane-1,3-dione derivatives
CN1138546C (en) Certain 1, 4, 5 -tri- substituted imidazole compounds useful as cytokine
CN1046506C (en) Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
CN1286815C (en) Novel 4-anilinoquinoline-3-carboxamides compound
CN1137884C (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
CN1070856C (en) Thiazole derivative
CN1183114C (en) Quinoline derivatives and quinazoline derivatives
CN1061036C (en) Substituted pyrazolyl benzenesulfonamides for treating inflammation
CN1930144A (en) 3-'4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
CN1646495A (en) Amine compounds and use thereof
CN1059723A (en) Hete rocyclic derivatives
CN1633296A (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CN1394205A (en) Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
CN1816529A (en) Pyrazole-amide compounds useful as kinase inhibitors
CN1823063A (en) Quinoline derivatives as phosphodiesterase inhibitors
CN1688549A (en) Compound having TGF-beta inhibitory activity and medicinal composition containing the same
CN1313280A (en) Benzheterocyclic derivatives
CN1805929A (en) Phosphodiesterase 4 inhibitors
CN1046529A (en) Carbostyril derivative
CN1342145A (en) Fused-ring compounds and use thereof as drugs
CN1503673A (en) antiinflammation agents
CN1038586C (en) Pyrazine derivatives and process for preparing same
CN1809559A (en) Pyrazole derivatives as phosphodiesterase 4 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned